# 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. _Endorsed by the European Stroke Organisation (ESO)_

Isabelle C Van Gelder,

Isabelle C Van Gelder[](javascript:;)

(Chairperson)

(

Netherlands

)

Corresponding author: Isabelle C. Van Gelder, Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. Tel: +31 50 361 1327. Email: [i.c.van.gelder@umcg.nl](mailto:i.c.van.gelder@umcg.nl)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-7579-1201](https://orcid.org/0000-0002-7579-1201)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Isabelle+C+Van+Gelder)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Van Gelder I)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Van Gelder Isabelle C%22)

Michiel Rienstra,

Michiel Rienstra

(Task Force Co-ordinator)

(

Netherlands

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-2581-070X](https://orcid.org/0000-0002-2581-070X)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Michiel+Rienstra)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Rienstra M)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Rienstra Michiel%22)

Karina V Bunting,

Karina V Bunting

(Task Force Co-ordinator)

(

United Kingdom

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-4602-4377](https://orcid.org/0000-0003-4602-4377)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Karina+V+Bunting)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Bunting K)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Bunting Karina V%22)

Ruben Casado-Arroyo,

Ruben Casado-Arroyo

(

Belgium

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-3876-6074](https://orcid.org/0000-0002-3876-6074)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Ruben+Casado-Arroyo)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Casado-Arroyo R)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Casado-Arroyo Ruben%22)

Valeria Caso,

Valeria Caso

(

Italy

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-2020-8891](https://orcid.org/0000-0002-2020-8891)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Valeria+Caso)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Caso V)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Caso Valeria%22)

Harry J G M Crijns,

Harry J G M Crijns

(

Netherlands

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-1073-5337](https://orcid.org/0000-0003-1073-5337)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Harry+J+G+M+Crijns)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Crijns H)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Crijns Harry J G M%22)

Tom J R De Potter,

Tom J R De Potter

(

Belgium

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-1424-114X](https://orcid.org/0000-0003-1424-114X)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Tom+J+R+De+Potter)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=De Potter T)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22De Potter Tom J R%22)

Jeremy Dwight,

Jeremy Dwight

(

United Kingdom

)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Jeremy+Dwight)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Dwight J)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Dwight Jeremy%22)

Luigina Guasti,

Luigina Guasti

(

Italy

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-4524-4864](https://orcid.org/0000-0002-4524-4864)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Luigina+Guasti)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Guasti L)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Guasti Luigina%22)

Thorsten Hanke,

Thorsten Hanke

(

Germany

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-8481-4700](https://orcid.org/0000-0002-8481-4700)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Thorsten+Hanke)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Hanke T)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Hanke Thorsten%22)

[... Show more](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#)

Tiny Jaarsma,

Tiny Jaarsma

(

Sweden

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-4197-4026](https://orcid.org/0000-0002-4197-4026)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Tiny+Jaarsma)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Jaarsma T)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Jaarsma Tiny%22)

Maddalena Lettino,

Maddalena Lettino

(

Italy

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-0146-9196](https://orcid.org/0000-0003-0146-9196)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Maddalena+Lettino)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Lettino M)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Lettino Maddalena%22)

Maja-Lisa Løchen,

Maja-Lisa Løchen

(

Norway

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-8532-6573](https://orcid.org/0000-0002-8532-6573)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Maja-Lisa+L%c3%b8chen)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Løchen M)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Løchen Maja-Lisa%22)

R Thomas Lumbers,

R Thomas Lumbers

(

United Kingdom

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-9077-4741](https://orcid.org/0000-0002-9077-4741)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=R+Thomas+Lumbers)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Lumbers R)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Lumbers R Thomas%22)

Bart Maesen,

Bart Maesen

(

Netherlands

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0001-8622-1450](https://orcid.org/0000-0001-8622-1450)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Bart+Maesen)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Maesen B)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Maesen Bart%22)

Inge Mølgaard,

Inge Mølgaard

(

Denmark

)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Inge+M%c3%b8lgaard)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Mølgaard I)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Mølgaard Inge%22)

Giuseppe M C Rosano,

Giuseppe M C Rosano

(

United Kingdom

)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Giuseppe+M+C+Rosano)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Rosano G)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Rosano Giuseppe M C%22)

Prashanthan Sanders,

Prashanthan Sanders

(

Australia

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-3803-8429](https://orcid.org/0000-0003-3803-8429)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Prashanthan+Sanders)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Sanders P)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Sanders Prashanthan%22)

Renate B Schnabel,

Renate B Schnabel

(

Germany

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0001-7170-9509](https://orcid.org/0000-0001-7170-9509)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Renate+B+Schnabel)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Schnabel R)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Schnabel Renate B%22)

Piotr Suwalski,

Piotr Suwalski

(

Poland

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0003-2670-4164](https://orcid.org/0000-0003-2670-4164)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Piotr+Suwalski)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Suwalski P)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Suwalski Piotr%22)

Emma Svennberg,

Emma Svennberg

(

Sweden

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-6413-0870](https://orcid.org/0000-0002-6413-0870)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Emma+Svennberg)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Svennberg E)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Svennberg Emma%22)

Juan Tamargo,

Juan Tamargo

(

Spain

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-7979-7758](https://orcid.org/0000-0002-7979-7758)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Juan+Tamargo)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Tamargo J)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Tamargo Juan%22)

Otilia Tica,

Otilia Tica

(

Romania

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-6019-122X](https://orcid.org/0000-0002-6019-122X)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Otilia+Tica)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Tica O)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Tica Otilia%22)

Vassil Traykov,

Vassil Traykov

(

Bulgaria

)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-9523-6416](https://orcid.org/0000-0002-9523-6416)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Vassil+Traykov)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Traykov V)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Traykov Vassil%22)

Stylianos Tzeis,

Stylianos Tzeis

(

Greece

)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Stylianos+Tzeis)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Tzeis S)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Tzeis Stylianos%22)

Dipak Kotecha,

Dipak Kotecha[](javascript:;)

(Chairperson)

(

United Kingdom

)

Corresponding author: Dipak Kotecha, Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom & NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. Tel: +44 121 371 8124. Email: [d.kotecha@bham.ac.uk](mailto:d.kotecha@bham.ac.uk)

  [![ORCID logo](https://academic.oup.com//oup.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png)  https://orcid.org/0000-0002-2570-9812](https://orcid.org/0000-0002-2570-9812)

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=Dipak+Kotecha)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Kotecha D)

[Google Scholar](http://scholar.google.com/scholar?q=author:%22Kotecha Dipak%22)

ESC Scientific Document Group

ESC Scientific Document Group

Search for other works by this author on:

[Oxford Academic](https://academic.oup.com/eurheartj/search-results?f_Authors=ESC+Scientific+Document+Group+)

[PubMed](http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=ESC Scientific Document Group )

[Google Scholar](http://scholar.google.com/scholar?q=author:%22ESC Scientific Document Group %22)

Isabelle C Van Gelder and Dipak Kotecha Chairpersons contributed equally to the document and are joint corresponding authors.

Michiel Rienstra and Karina V Bunting Task Force Co-ordinators contributed equally to the document.

**Author/Task Force Member affiliations are listed in author information.**

Representing European Stroke Organisation (ESO).

Representing European Association for Cardio-Thoracic Surgery (EACTS).

**ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.**

**ESC subspecialty communities having participated in the development of this document:**

**Associations:** Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

**Councils:** Council for Cardiology Practice, Council of Cardio-Oncology, Council on Cardiovascular Genomics, Council on Stroke.

**Working Groups:** Cardiac Cellular Electrophysiology, Cardiovascular Pharmacotherapy, E-Cardiology, Thrombosis.

**Patient Forum**

  ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176il3.jpeg?Expires=1728478928&Signature=SCxXno2RCVJu9VT~QIHm21GGcsbgpf7A~ElUn6~pr8zCjIU-QidKZHdjrvQDai0RYadQPJjrI0oMTT42q-s-OQQsniNpJQ4k8KcXpAgH3p9U9tnzJROx0pxjH-0D3TqPOP5bk2HpFgUP7rp-QEI8Uu40259fNWqs~jZHO596ISdu2CO7dZjouSDQ1OBujUArZRsZWyXBuCUld0iPWoGziVHbr2c0H3sXEBPahLI~sJdaYxBtKQoMrUKERe0SLg7L5EZsY1ows-nVI0DWLQRjJ5e9m17mwu1KfvURMeUQDv-2oTpTVSnoE6HPBwC-z5AqWTfluCCTXhcG6wUjWx6Jpw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  **All experts involved in the development of these guidelines have submitted declarations of interest which are reported in a supplementary document to the guidelines. See the _European Heart Journal_ online or [www.escardio.org/guidelines](https://www.escardio.org/Guidelines) for supplementary documents as well as evidence tables.**

**Disclaimer.** The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.

**Permissions.** The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the _European Heart Journal_ and the party authorized to handle such permissions on behalf of the ESC ([journals.permissions@oup.com](mailto:journals.permissions@oup.com)).

[Author Notes](javascript:;)

_European Heart Journal_, ehae176, [https://doi.org/10.1093/eurheartj/ehae176](https://doi.org/10.1093/eurheartj/ehae176)

Published:

30 August 2024

$(document).ready(function () { $('.article-top-widget').on('click', '.ati-toggle-trigger', function () { $(this).find('.icon-general-add, .icon-minus').toggleClass('icon-minus icon-general-add'); $(this).siblings('.ati-toggle-content').toggleClass('hide'); }); // In Chrome, an anchor tag with target="\_blank" and a "mailto:" href opens a new tab/window as well as the email client // I suspect this behavior will be corrected in the future // Remove the target="\_blank" $('ul.wi-affiliationList').find('a\[href^="mailto:"\]').each(function () { $(this).removeAttr('target'); }); });

- [![pdf](https://academic.oup.com//oup.silverchair-cdn.com/UI/app/svg/pdf.svg)PDF](https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehae176/58970727/ehae176.pdf)
- [Split View](javascript:;)
- [

Views



](javascript:;)

- [Article contents](javascript:;)
- [Figures & tables](javascript:;)
- [Supplementary Data](javascript:;)
- [Cite](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#)

### Cite

Isabelle C Van Gelder, Michiel Rienstra, Karina V Bunting, Ruben Casado-Arroyo, Valeria Caso, Harry J G M Crijns, Tom J R De Potter, Jeremy Dwight, Luigina Guasti, Thorsten Hanke, Tiny Jaarsma, Maddalena Lettino, Maja-Lisa Løchen, R Thomas Lumbers, Bart Maesen, Inge Mølgaard, Giuseppe M C Rosano, Prashanthan Sanders, Renate B Schnabel, Piotr Suwalski, Emma Svennberg, Juan Tamargo, Otilia Tica, Vassil Traykov, Stylianos Tzeis, Dipak Kotecha, ESC Scientific Document Group , 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. _Endorsed by the European Stroke Organisation (ESO)_, _European Heart Journal_, 2024;, ehae176, [https://doi.org/10.1093/eurheartj/ehae176](https://doi.org/10.1093/eurheartj/ehae176)

Select Format Select format .ris (Mendeley, Papers, Zotero) .enw (EndNote) .bibtex (BibTex) .txt (Medlars, RefWorks) Download citation

[Close](javascript:;)

- [_Permissions Icon_ Permissions](https://s100.copyright.com/AppDispatchServlet?publisherName=OUP&publication=1522-9645&title=2024%20ESC%20Guidelines%20for%20the%20management%20of%20atrial%20fibrillation%20developed%20in%20collaboration%20with%20the%20European%20Association%20for%20Cardio-Thoracic%20Surgery%20%28EACTS%29%20Developed%20by%20the%20task%20force%20for%20the%20management%20of%20atrial%20fibrillation%20of%20the%20European%20Society%20of%20Cardiology%20%28ESC%29%2C%20with%20the%20special%20contribution%20of%20the%20European%20Heart%20Rhythm%20Association%20%28EHRA%29%20of%20the%20ESC.%20Endorsed%20by%20the%20European%20Stroke%20Organisation%20%28ESO%29&publicationDate=2024-08-30&volumeNum=&issueNum=&author=Van%20Gelder%2C%20Isabelle%20C%3B%20Rienstra%2C%20Michiel&startPage=1&endPage=101&contentId=10.1093%2Feurheartj%2Fehae176&oa=&copyright=%C2%A9%20The%20European%20Society%20of%20Cardiology%202024.%20All%20rights%20reserved.%20For%20permissions%2C%20please%20email%3A%20journals.permissions%40oup.com.&orderBeanReset=True)

- [_Share Icon_ Share](javascript:;)
- [Facebook](javascript:;)
- [Twitter](javascript:;)
- [LinkedIn](javascript:;)
- [Email](javascript:;)

Navbar Search Filter European Heart JournalESC Publications Cardiovascular MedicineBooksJournalsOxford Academic Mobile Enter search term[Search](javascript:;)

[Close](javascript:;)

Navbar Search Filter European Heart JournalESC Publications Cardiovascular MedicineBooksJournalsOxford Academic Enter search term[Search](javascript:;)

[Advanced Search](https://academic.oup.com/eurheartj/advanced-search?page=1&fl_SiteID=5375&SearchSourceType=1)

[Search Menu](javascript:;)

[Guidelines](javascript:;), [Atrial fibrillation](javascript:;), [AF-CARE](javascript:;), [Comorbidity](javascript:;), [Risk factors](javascript:;), [Anticoagulation](javascript:;), [Rate control](javascript:;), [Rhythm control](javascript:;), [Cardioversion](javascript:;), [Antiarrhythmic drugs](javascript:;), [Catheter ablation](javascript:;), [AF surgery](javascript:;), [Evaluation](javascript:;), [Stroke](javascript:;), [Thromboembolism](javascript:;)

Topic:

- [anticoagulation](javascript:;)
- [atrial fibrillation](javascript:;)
- [electric countershock](javascript:;)
- [thromboembolism](javascript:;)
- [cardiac ablation](javascript:;)
- [hemorrhage](javascript:;)
- [cerebrovascular accident](javascript:;)
- [ischemic stroke](javascript:;)
- [heart failure](javascript:;)
- [advisory committees](javascript:;)
- [comorbidity](javascript:;)
- [surgical procedures, operative](javascript:;)
- [diagnosis](javascript:;)
- [guidelines](javascript:;)
- [vitamin k antagonists](javascript:;)
- [ablation](javascript:;)
- [risk of excessive or recurrent bleeding](javascript:;)
- [european society of cardiology](javascript:;)
- [rhythm](javascript:;)
- [direct oral anticoagulants](javascript:;)

## Table of contents

- 1\. Preamble 6

- 2\. Introduction 8

-  2.1. What is new 9

- 3\. Definitions and clinical impact 13

-  3.1. Definition and classification of AF 13

-  3.2. Diagnostic criteria for AF 14

-  3.3. Symptoms attributable to AF 15

-  3.4. Diagnostic evaluation of new AF 15

-  3.5. Adverse events associated with AF 16

-  3.6. Atrial flutter 17

- 4\. Patient pathways and management of AF 17

-  4.1. Patient-centred, multidisciplinary AF management 17

-   4.1.1. The patient at the heart of care 17

-   4.1.2. Education and shared decision-making 18

-   4.1.3. Education of healthcare professionals 19

-   4.1.4. Inclusive management of AF 19

-  4.2. Principles of AF-CARE 19

- 5\. \[C\] Comorbidity and risk factor management 25

-  5.1. Hypertension 26

-  5.2. Heart failure 26

-  5.3. Type 2 diabetes mellitus 27

-  5.4. Obesity 27

-  5.5. Obstructive sleep apnoea 27

-  5.6. Physical inactivity 27

-  5.7. Alcohol excess 28

- 6\. \[A\] Avoid stroke and thromboembolism 28

-  6.1. Initiating oral anticoagulation 28

-   6.1.1. Decision support for anticoagulation in AF 28

-  6.2. Oral anticoagulants 30

-   6.2.1. Direct oral anticoagulants 31

-   6.2.2. Vitamin K antagonists 32

-   6.2.3. Clinical vs. device-detected subclinical AF 32

-  6.3. Antiplatelet drugs and combinations with anticoagulants 33

-  6.4. Residual ischaemic stroke risk despite anticoagulation 33

-  6.5. Percutaneous left atrial appendage occlusion 33

-  6.6. Surgical left atrial appendage occlusion 34

-  6.7. Bleeding risk 35

-   6.7.1. Assessment of bleeding risk 35

-   6.7.2. Management of bleeding on anticoagulant therapy 35

- 7\. \[R\] Reduce symptoms by rate and rhythm control 38

-  7.1. Management of heart rate in patients with AF 38

-   7.1.1. Indications and target heart rate 39

-   7.1.2. Heart rate control in the acute setting 39

-   7.1.3. Long-term heart rate control 39

-   7.1.4. Atrioventricular node ablation and pacemaker implantation 40

-  7.2. Rhythm control strategies in patients with AF 40

-   7.2.1. General principles and anticoagulation 40

-   7.2.2. Electrical cardioversion 43

-   7.2.3. Pharmacological cardioversion 43

-   7.2.4. Antiarrhythmic drugs 44

-   7.2.5. Catheter ablation 45

-   7.2.6. Anticoagulation in patients undergoing catheter ablation 46

-   7.2.7. Endoscopic and hybrid AF ablation 47

-   7.2.8. AF ablation during cardiac surgery 48

-   7.2.9. Atrial tachycardia after pulmonary vein isolation 48

- 8\. \[E\] Evaluation and dynamic reassessment 48

-  8.1. Implementation of dynamic care 49

-  8.2. Improving treatment adherence 49

-  8.3. Cardiac imaging 49

-  8.4. Patient-reported outcome measures 50

- 9\. The AF-CARE pathway in specific clinical settings 51

-  9.1. AF-CARE in unstable patients 51

-  9.2. AF-CARE in acute and chronic coronary syndromes 51

-  9.3. AF-CARE in vascular disease 53

-  9.4. AF-CARE in acute stroke or intracranial haemorrhage 53

-   9.4.1. Management of acute ischaemic stroke 53

-   9.4.2. Introduction or re-introduction of anticoagulation after ischaemic stroke 54

-   9.4.3. Introduction or re-introduction of anticoagulation after haemorrhagic stroke 54

-  9.5. AF-CARE for trigger-induced AF 54

-  9.6. AF-CARE in post-operative patients 55

-  9.7. AF-CARE in embolic stroke of unknown source 55

-  9.8. AF-CARE during pregnancy 56

-  9.9. AF-CARE in congenital heart disease 57

-  9.10. AF-CARE in endocrine disorders 57

-  9.11. AF-CARE in inherited cardiomyopathies and primary arrhythmia syndromes 57

-  9.12. AF-CARE in cancer 58

-  9.13. AF-CARE in older, multimorbid, or frail patients 58

-  9.14. AF-CARE in atrial flutter 58

- 10\. Screening and prevention of AF 58

-  10.1. Epidemiology of AF 58

-  10.2. Screening tools for AF 59

-  10.3. Screening strategies for AF 60

-   10.3.1. Single timepoint screening ‘snapshot’ 61

-   10.3.2. Prolonged screening 61

-  10.4. Factors associated with incident AF 62

-  10.5. Primary prevention of AF 62

-   10.5.1. Hypertension 63

-   10.5.2. Heart failure 63

-   10.5.3. Type 2 diabetes mellitus 63

-   10.5.4. Obesity 63

-   10.5.5. Sleep apnoea syndrome 63

-   10.5.6. Physical activity 63

-   10.5.7. Alcohol intake 64

- 11\. Key messages 64

- 12\. Gaps in evidence 64

- 13\. ‘What to do’ and ‘What not to do’ messages from the guidelines 66

- 14\. Evidence tables 69

- 15\. Data availability statement 69

- 16\. Author information 69

- 17\. Appendix 70

- 18\. References 71


## Tables of Recommendations

- Recommendation Table 1 — Recommendations for the diagnosis of AF (see also Evidence Table 1) 15

- Recommendation Table 2 — Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2) 15

- Recommendation Table 3 — Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3) 15

- Recommendation Table 4 — Recommendations for patient-centred care and education (see also Evidence Table 4) 19

- Recommendation Table 5 — Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5) 26

- Recommendation Table 6 — Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6) 29

- Recommendation Table 7 — Recommendations for oral anticoagulation in AF (see also Evidence Table 7) 31

- Recommendation Table 8 — Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8) 33

- Recommendation Table 9 — Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9) 33

- Recommendation Table 10 — Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10) 34

- Recommendation Table 11 — Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11) 35

- Recommendation Table 12 — Recommendations for assessment of bleeding risk (see also Evidence Table 12) 35

- Recommendation Table 13 — Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13) 38

- Recommendation Table 14 — Recommendations for heart rate control in patients with AF (see also Evidence Table 14) 38

- Recommendation Table 15 — Recommendations for general concepts in rhythm control (see also Evidence Table 15) 42

- Recommendation Table 16 — Recommendations for electrical cardioversion of AF (see also Evidence Table 16) 43

- Recommendation Table 17 — Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17) 43

- Recommendation Table 18 — Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18) 45

- Recommendation Table 19 — Recommendations for catheter ablation of AF (see also Evidence Table 19) 46

- Recommendation Table 20 — Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20) 47

- Recommendation Table 21 — Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21) 47

- Recommendation Table 22 — Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22) 48

- Recommendation Table 23 — Recommendations to improve patient experience (see also Evidence Table 23) 51

- Recommendation Table 24 — Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24) 53

- Recommendation Table 25 — Recommendations for trigger-induced AF (see also Evidence Table 25) 55

- Recommendation Table 26 — Recommendations for management of post-operative AF (see also Evidence Table 26) 55

- Recommendation Table 27 — Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27) 56

- Recommendation Table 28 — Recommendations for patients with AF during pregnancy (see also Evidence Table 28) 56

- Recommendation Table 29 — Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29) 57

- Recommendation Table 30 — Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30) 58

- Recommendation Table 31 — Recommendations for screening for AF (see also Evidence Table 31) 61

- Recommendation Table 32 — Recommendations for primary prevention of AF (see also Evidence Table 32) 63


## List of tables

- Table 1 Classes of recommendations 7

- Table 2 Levels of evidence 7

- Table 3 New recommendations 9

- Table 4 Revised recommendations 12

- Table 5 Definitions and classifications for the temporal pattern of AF 14

- Table 6 Other clinical concepts relevant to AF 14

- Table 7 The modified European Heart Rhythm Association (mEHRA) symptom classification 16

- Table 8 Diagnostic work-up for patients with AF 17

- Table 9 Achieving patient-centred AF management 18

- Table 10 Updated definitions for the CHA2DS2-VA score 29

- Table 11 Recommended doses for direct oral anticoagulant therapy 32

- Table 12 Drugs for rate control in AF 39

- Table 13 Antiarrhythmic drugs for sinus rhythm restoration 44

- Table 14 Non-cardiac conditions associated with trigger-induced AF 54

- Table 15 Tools for AF screening 60

- Table 16 Factors associated with incident AF 62

- Table 17 ‘What to do’ and ‘what not to do’ 66


## List of figures

- Figure 1 Impacts and outcomes associated with clinical AF. AF, atrial fibrillation 16

- Figure 2 Multidisciplinary approach to AF management 18

- Figure 3 Central illustration. Patient pathway for AF-CARE (see Figures 4, 5, 6, and 7 for the \[R\] pathways for first-diagnosed, paroxysmal, persistent and permanent AF) 20

- Figure 4 \[R\] Pathway for patients with first-diagnosed AF 21

- Figure 5 \[R\] Pathway for patients with paroxysmal AF 22

- Figure 6 \[R\] Pathway for patients with persistent AF 23

- Figure 7 \[R\] Pathway for patients with permanent AF 24

- Figure 8 Management of key comorbidities to reduce AF recurrence 25

- Figure 9 Common drug interactions with oral anticoagulants 30

- Figure 10 Modifying the risk of bleeding associated with OAC 36

- Figure 11 Management of oral anticoagulant-related bleeding in patients with AF 37

- Figure 12 Approaches for cardioversion in patients with AF 41

- Figure 13 Relevance of echocardiography in the AF-CARE pathway 50

- Figure 14 Antithrombotic therapy in patients with AF and acute or chronic coronary syndromes 52

- Figure 15 Non-invasive diagnostic methods for AF screening 59

- Figure 16 Approaches to screening for AF 61


## Abbreviations and acronyms

 - AAD

Antiarrhythmic drugs

 - ACE

Angiotensin-converting enzyme

 - ACEi

Angiotensin-converting enzyme inhibitor

 - ACS

Acute coronary syndromes

 - ACTIVE W

Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (trial)

 - AF

Atrial fibrillation

 - AF-CARE

Atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment

 - AFEQT

Atrial Fibrillation Effect on QualiTy-of-Life (questionnaire)

 - AFFIRM

Atrial Fibrillation Follow-up Investigation of Rhythm Management (trial)

 - AFL

Atrial flutter

 - AFQLQ

Atrial Fibrillation Quality of Life Questionnaire

 - AF-QoL

Atrial Fibrillation Quality of Life (questionnaire)

 - AFSS

Atrial Fibrillation Severity Scale

 - AI

Artificial intelligence

 - APACHE-AF

Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation (trial)

 - APAF-CRT

Ablate and Pace for Atrial Fibrillation—cardiac resynchronization therapy

 - ARB

Angiotensin receptor blocker

 - ARTESiA

Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (trial)

 - AT

Atrial tachycardia

 - ATHENA

A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg twice daily for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (trial)

 - AUGUSTUS

An open-label, 2 × 2 factorial, randomized controlled, clinical trial to evaluate the safety of apixaban vs. vitamin k antagonist and aspirin vs. aspirin placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention

 - AVERROES

Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (trial)

 - AVN

Atrioventricular node

 - b.p.m.

Beats per minute

 - BMI

Body mass index

 - BNP

B-type natriuretic peptide

 - BP

Blood pressure

 - C<sub>2</sub>HEST

Coronary artery disease or chronic obstructive pulmonary disease (1 point each); hypertension (1 point); elderly (age ≥75 years, 2 points); systolic heart failure (2 points); thyroid disease (hyperthyroidism, 1 point)

 - CABANA

Catheter Ablation versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (trial)

 - CAD

Coronary artery disease

 - CASTLE-AF

Catheter Ablation versus Standard Conventional Treatment in Patients With Left Ventricle (LV) Dysfunction and AF (trial)

 - CASTLE-HTx

Catheter Ablation for Atrial Fibrillation in Patients With End-Stage Heart Failure and Eligibility for Heart Transplantation (trial)

 - CCS

Chronic coronary syndrome

 - CHADS<sub>2</sub>

Congestive heart failure, hypertension, age >75 years, diabetes; previous stroke (2 points)

 - CHA<sub>2</sub>DS<sub>2</sub>\-VA

Congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years (score)

 - CHA<sub>2</sub>DS<sub>2</sub>\-VASc

Congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke or TIA or thromboembolism (2 points), vascular disease, age 65–74 years, sex category

 - CKD

Chronic kidney disease

 - CMR

Cardiac magnetic resonance

 - COMPASS

Cardiovascular Outcomes for People Using Anticoagulation Strategies (trial)

 - CPAP

Continuous positive airway pressure

 - CrCl

Creatinine clearance

 - CRT

Cardiac resynchronization therapy

 - CT

Computed tomography

 - CTA

Computed tomography angiography

 - CTI

Cavo-tricuspid isthmus

 - DAPT

Dual antiplatelet therapy

 - DOAC

Direct oral anticoagulant

 - EAST-AFNET 4

Early treatment of Atrial fibrillation for Stroke prevention Trial

 - ECG

Electrocardiogram

 - ECV

Electrical cardioversion

 - EHRA

European Heart Rhythm Association

 - ELAN

Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (trial)

 - ESUS

Embolic stroke of undetermined source

 - FFP

Fresh frozen plasma

 - GI

Gastrointestinal

 - GWAS

Genome-wide association studies

 - HAS-BLED

Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly (score)

 - HAVOC

Hypertension, age, valvular heart disease, peripheral vascular disease, obesity, congestive heart failure, and coronary artery disease

 - HbA1c

Haemoglobin A1c (glycated or glycosylated haemoglobin)

 - HCM

Hypertrophic cardiomyopathy

 - HF

Heart failure

 - HFmrEF

Heart failure with mildly reduced ejection fraction

 - HFpEF

Heart failure with preserved ejection fraction

 - HFrEF

Heart failure with reduced ejection fraction

 - HR

Hazard ratio

 - i.v.

Intravenous

 - ICH

Intracranial haemorrhage

 - ICHOM

International Consortium for Health Outcomes Measurement

 - IMT

Intima-media thickness

 - INR

International normalized ratio (of prothrombin time)

 - LA

Left atrium

 - LAA

Left atrial appendage

 - LAAO

Left atrial appendage occlusion

 - LAAOS III

Left Atrial Appendage Occlusion Study

 - LEGACY

Long-Term Effect of Goal directed weight management on Atrial Fibrillation Cohort: a 5 Year follow-up study

 - LMWH

Low molecular weight heparin

 - LOOP

Atrial Fibrillation Detected by Continuous ECG Monitoring (trial)

 - LV

Left ventricle

 - LVEF

Left ventricular ejection fraction

 - LVH

Left ventricular hypertrophy

 - mEHRA

Modified European Heart Rhythm Association score

 - MI

Myocardial infarction

 - MRI

Magnetic resonance imaging

 - NOAH

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (trial)

 - NSAID

Non-steroidal anti-inflammatory drug

 - NT-proBNP

N-terminal pro-B-type natriuretic peptide

 - NYHA

New York Heart Association

 - OAC

Oral anticoagulant(s)

 - OR

Odds ratio

 - OSA

Obstructive sleep apnoea

 - PAD

Peripheral arterial disease

 - PCC

Prothrombin complex concentrate

 - PCI

Percutaneous intervention

 - PFO

Patent foramen ovale

 - POAF

Post-operative atrial fibrillation

 - PPG

Photoplethysmography

 - PROM

Patient-reported outcome measure

 - PVD

Peripheral vascular disease

 - PVI

Pulmonary vein isolation

 - QLAF

Quality of Life in Atrial Fibrillation (questionnaire)

 - QRS

Q wave, R wave, and S wave, the ‘QRS complex’ represents ventricular depolarization

 - RACE 7 ACWAS

Rate Control versus Electrical Cardioversion Trial 7—Acute Cardioversion versus Wait and See (trial)

 - RACE I

RAte Control versus Electrical cardioversion study

 - RACE II

Rate Control Efficacy in Permanent Atrial Fibrillation (trial)

 - RACE 3

Routine versus Aggressive upstream rhythm Control for prevention of Early AF in heart failure (trial)

 - RACE 4

IntegRAted Chronic Care Program at Specialized AF Clinic Versus Usual CarE in Patients with Atrial Fibrillation (trial)

 - RATE-AF

RAte control Therapy Evaluation in permanent Atrial Fibrillation (trial)

 - RCT

Randomized controlled trial

 - RR

Relative risk

 - SAVE

Sleep Apnea cardioVascular Endpoints (trial)

 - SBP

Systolic blood pressure

 - SGLT2

Sodium-glucose cotransporter-2

 - SIC-AF

Successful Intravenous Cardioversion for Atrial Fibrillation

 - SORT-AF

Supervised Obesity Reduction Trial for AF Ablation Patients (trial)

 - SoSTART

Start or STop Anticoagulants Randomised Trial

 - SR

Sinus rhythm

 - STEEER-AF

Stroke prevention and rhythm control Therapy: Evaluation of an Educational programme of the European Society of Cardiology in a cluster-Randomised trial in patients with Atrial Fibrillation (trial)

 - STEMI

ST-segment elevation myocardial infarction

 - STROKESTOP

Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden (trial)

 - TE

Thromboembolism

 - TIA

Transient ischaemic attack

 - TIMING

Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation (trial)

 - TOE

Transoesophageal echocardiography

 - TSH

Thyroid-stimulating hormone

 - TTE

Transthoracic echocardiogram

 - TTR

Time in therapeutic range

 - UFH

Unfractionated heparin

 - VKA

Vitamin K antagonist


## 1\. Preamble

Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use by health professionals and the European Society of Cardiology (ESC) makes its Guidelines freely available.

ESC Guidelines do not override the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient or the patient's caregiver where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession.

ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated when warranted by new evidence. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website ([https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines](https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines)). This guideline updates and replaces the previous version from 2020.

The Members of this task force were selected by the ESC to include professionals involved with the medical care of patients with this pathology as well as patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from across the whole of the ESC region and from relevant ESC Subspecialty Communities. Consideration was given to diversity and inclusion, notably with respect to gender and country of origin. The task force performed a critical review and evaluation of the published literature on diagnostic and therapeutic approaches including assessment of the risk–benefit ratio. The strength of every recommendation and the level of evidence supporting them were weighed and scored according to predefined scales as outlined in _[Tables 1](javascript:;) and [2](javascript:;)_ below. Patient-reported outcome measures (PROMs) and patient-reported experience measures were also evaluated as the basis for recommendations and/or discussion in these guidelines. The task force followed ESC voting procedures and all approved recommendations were subject to a vote and achieved at least 75% agreement among voting members. Members of the task force with declared interests on specific topics were asked to abstain from voting on related recommendations.

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules which can be found on the ESC website ([http://www.escardio.org/guidelines](http://www.escardio.org/guidelines)) and have been compiled in a report published in a supplementary document with the guidelines. Funding for the development of ESC Guidelines is derived entirely from the ESC with no involvement of the healthcare industry.

Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884123)

Classes of recommendations

![Classes of recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il1.jpeg?Expires=1728478928&Signature=TXNDe10I9wudNHyUYMQO4DJUEdaCdZ5NeMOccA-iyPe~qP17F7V7ycDl5A16ItRuSNSVljoQqmjPcXfC4B~-at1C9hOyFP8Gne3s~uq9RFiGRJ89f6FPUEqYGIVeT0xO9aGW9fccY3KcPCK9rSqEFzydmF0nSQcylLKp0umLrwr773jsrV6acRT1m9EtRVTHkIT5jL5bPsrTWujxH1TKiuOTZI6hYFnu3wPiNKcNDCT~GEjrICVMUDY9Z1AL-R8eMWyx2h2Gw6e9RPvdhQTDBPrxhRF7iq~jNeeHlg3Pd7RfU6p22gbjxQYEFz9U~KjASINBb1AtJgBqcBYrGJcK6Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884123)

Classes of recommendations

![Classes of recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il1.jpeg?Expires=1728478928&Signature=TXNDe10I9wudNHyUYMQO4DJUEdaCdZ5NeMOccA-iyPe~qP17F7V7ycDl5A16ItRuSNSVljoQqmjPcXfC4B~-at1C9hOyFP8Gne3s~uq9RFiGRJ89f6FPUEqYGIVeT0xO9aGW9fccY3KcPCK9rSqEFzydmF0nSQcylLKp0umLrwr773jsrV6acRT1m9EtRVTHkIT5jL5bPsrTWujxH1TKiuOTZI6hYFnu3wPiNKcNDCT~GEjrICVMUDY9Z1AL-R8eMWyx2h2Gw6e9RPvdhQTDBPrxhRF7iq~jNeeHlg3Pd7RfU6p22gbjxQYEFz9U~KjASINBb1AtJgBqcBYrGJcK6Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884124)

Levels of evidence

![Levels of evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il2.jpeg?Expires=1728478928&Signature=TSQj3ZVy2fApwN1OxMNSKOGpnoHY7tVJ8~RYU845GvT6itutpvO87QXuF8~CxGduA~eui1t1ODfyksWH8xEcPxetEaMUNgiRjEdcrqmukTHLlZx4pmQTq-NDKbKHfTdr50PSLCJyOHhrCc-RpSiyVtiycITDIObzneLp2lFCM4ZmrSKM0NpM72UpqvSvDfKNBwMZcethwAIYJfpOUoC~JVp4ff-nUmadO0fVcgUPw2ziNa62XUIta5Hib2U3moBzTNfDQe9uAzx3608nRSG-~9I4tL9pfiBKkUcYVzxgWC0vwVWton~DJdnhBwE45Z~GeaclJdYgE1ZsTLR2A4MVbg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884124)

Levels of evidence

![Levels of evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il2.jpeg?Expires=1728478928&Signature=TSQj3ZVy2fApwN1OxMNSKOGpnoHY7tVJ8~RYU845GvT6itutpvO87QXuF8~CxGduA~eui1t1ODfyksWH8xEcPxetEaMUNgiRjEdcrqmukTHLlZx4pmQTq-NDKbKHfTdr50PSLCJyOHhrCc-RpSiyVtiycITDIObzneLp2lFCM4ZmrSKM0NpM72UpqvSvDfKNBwMZcethwAIYJfpOUoC~JVp4ff-nUmadO0fVcgUPw2ziNa62XUIta5Hib2U3moBzTNfDQe9uAzx3608nRSG-~9I4tL9pfiBKkUcYVzxgWC0vwVWton~DJdnhBwE45Z~GeaclJdYgE1ZsTLR2A4MVbg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

The ESC Clinical Practice Guidelines (CPG) Committee supervises and co-ordinates the preparation of new guidelines and is responsible for the approval process. In addition to review by the CPG Committee, ESC Guidelines undergo multiple rounds of double-blind peer review by external experts, including members from across the whole of the ESC region, all National Cardiac Societies of the ESC and from relevant ESC Subspecialty Communities. After appropriate revisions, the guidelines are signed off by all the experts in the task force. The finalized document is signed off by the CPG Committee for publication in the _European Heart Journal_.

ESC Guidelines are based on analyses of published evidence, chiefly on clinical trials and meta-analyses of trials, but potentially including other types of studies. Evidence tables summarizing key information from relevant studies are generated early in the guideline development process to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and reinforce transparency in the guidelines development process. The tables are published in their own section of ESC Guidelines and reference specific recommendation tables.

Off-label use of medication may be presented in this guideline if a sufficient level of evidence shows that it can be considered medically appropriate for a given condition. However, the final decisions concerning an individual patient must be made by the responsible health professional giving special consideration to:

- The specific situation of the patient. Unless otherwise provided for by national regulations, off-label use of medication should be limited to situations where it is in the patient's interest with regard to the quality, safety, and efficacy of care, and only after the patient has been informed and has provided consent.

- Country-specific health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.


## 2\. Introduction

Atrial fibrillation (AF) is one of the most commonly encountered heart conditions, with a broad impact on all health services across primary and secondary care. The prevalence of AF is expected to double in the next few decades as a consequence of the ageing population, an increasing burden of comorbidities, improved awareness, and new technologies for detection.

The effects of AF are variable across individual patients; however, morbidity from AF remains highly concerning. Patients with AF can suffer from a variety of symptoms and poor quality of life. Stroke and heart failure as consequences of AF are now well appreciated by healthcare professionals, but AF is also linked to a range of other thromboembolic outcomes. These include subclinical cerebral damage (potentially leading to vascular dementia), and thromboembolism to every other organ, all of which contribute to the higher risk of mortality associated with AF.

The typical drivers of AF onset and progression are a range of comorbidities and associated risk factors. To achieve optimal care for patients with AF, it is now widely accepted that these comorbidities and risk factors must be managed early and in a dynamic way. Failure to do so contributes to recurrent cycles of AF, treatment failure, poor patient outcomes, and a waste of healthcare resources. In this iteration of the European Society of Cardiology (ESC) practice guidelines on AF, the task force has consolidated and evolved past approaches to develop the AF-CARE framework (Atrial Fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment). Comorbidities and risk factors is placed as the initial and central component of patient management. This should be considered first as it applies to all patients with AF, regardless of their thromboembolic risk factors or any symptoms that might warrant intervention. This is followed by considering how best to \[A\] avoid stroke and thromboembolism, and then the options available to reduce symptoms, and in some cases improve prognosis, through \[R\] rate and rhythm control. \[E\] Evaluation and reassessment should be individualized for every patient, with a dynamic approach that accounts for how AF and its associated conditions change over time.

Patient empowerment is critical in any long-term medical problem to achieve better outcomes, encourage adherence, and to seek timely guidance on changes in clinical status. A patient-centred, shared decision-making approach will facilitate the choice of management that suits each individual patient, particularly in AF where some therapies and interventions improve clinical outcomes, and others are focused on addressing symptoms and quality of life. Education and awareness are essential, not only for patients but also healthcare professionals in order to constrain the impact of AF on patients and healthcare services.

With this in mind, the task force have created a range of patient pathways that cover the major aspects of AF-CARE. At present, these remain based on the time-orientated classification of AF (first-diagnosed, paroxysmal, persistent, and permanent), but ongoing research may allow for pathology-based classifications and a future of personalized medicine. Clinical practice guidelines can only cover common scenarios with an evidence base, and so there remains a need for healthcare professionals to care for patients within a local multidisciplinary team. While guideline-adherent care has repeatedly been shown to improve patient outcomes, the actual implementation of guidelines is often poor in many healthcare settings. This has been demonstrated in the ESC's first randomized controlled trial (RCT), STEEER-AF (Stroke prevention and rhythm control Therapy: Evaluation of an Educational programme of the European Society of Cardiology in a cluster-Randomised trial in patients with Atrial Fibrillation), which has sought to improve guideline adherence in parallel to guideline production. The task force developing the 2024 AF Guidelines have made implementation a key goal by focusing on the underpinning evidence and using a consistent writing style for each recommendation (the intervention proposed, the population it should be applied to, and the potential value to the patient, followed by any exceptions). _[Tables 3](javascript:;)_ and _[4](javascript:;)_ below outline new recommendations and those with important revisions. These initiatives have been designed to make the _2024 ESC Guidelines for the management of AF_ easier to read, follow, and implement, with the aim of improving the lives of patients with AF. A patient version of these guidelines is also available at [http://www.escardio.org/Guidelines/guidelines-for-patients](http://www.escardio.org/Guidelines/guidelines-for-patients).

### 2.1. What is new

Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884136)

New recommendations

![New recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t3.jpeg?Expires=1728478928&Signature=U8JMswTWpQMT-~TwXGLCksmjBcz8l~YeCZka1lmirzyN5GHK-6zqNQbAp4eThHHnz9zr1XrT5y2Q2X6Yx751PQfzdIaFC4XiP4a4CSI0bNGESMSNwHstsQC6wirZnj5Tf8XgitsHyj-esqAWoITehcobEcHftkAwFCcPqlclhuOgMo4~oXG3vEP7MGAnoc-Op5pQ854d0AzZl3~s3740LkeuL0yzRwYGpshA6vtFRq5rUn1rs4KUJIeP-vc84pt-5FhQUTmd0k4am2BV7i9WvpMFf62-jVg-33qJerdVZlzui8L~2ffkAhDFTt9AuD6oL1wYEkyeDE7zOhwnAq1j4A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884136)

New recommendations

![New recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t3.jpeg?Expires=1728478928&Signature=U8JMswTWpQMT-~TwXGLCksmjBcz8l~YeCZka1lmirzyN5GHK-6zqNQbAp4eThHHnz9zr1XrT5y2Q2X6Yx751PQfzdIaFC4XiP4a4CSI0bNGESMSNwHstsQC6wirZnj5Tf8XgitsHyj-esqAWoITehcobEcHftkAwFCcPqlclhuOgMo4~oXG3vEP7MGAnoc-Op5pQ854d0AzZl3~s3740LkeuL0yzRwYGpshA6vtFRq5rUn1rs4KUJIeP-vc84pt-5FhQUTmd0k4am2BV7i9WvpMFf62-jVg-33qJerdVZlzui8L~2ffkAhDFTt9AuD6oL1wYEkyeDE7zOhwnAq1j4A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884137)

Revised recommendations

![Revised recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t4.jpeg?Expires=1728478928&Signature=hnhYtEceR6fr~eWR9wCtN-ZrxpUo0wn1l4emYTSK8tgasPlB963uBCTiV9sRPSFHOPVkeIMjaK6SPhVnZy5p6sxHPkjyFOnuS6oLXRqoj1~Oypj~cwO7M0zHBN6Zw1AJopqTrzk1RNRbUJHxORCmCmNCs3x0v1heW50GwQLRMcyFXY1-0LCdWbdclJsBcgAgTUOFIC2T6cUJLeaEc4GIbura6uCufXFfOyJy7dxa36CCtYVanX9qcFqr8a0LC2OjM3lEWgjJwZTFZtbObeDYw2tstFEjlX11rgaH5SBOkHoyJ7bhZmQsWVy5P4VvyawpkuTUj1TNmXaeSZp~vZCM1A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884137)

Revised recommendations

![Revised recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t4.jpeg?Expires=1728478928&Signature=hnhYtEceR6fr~eWR9wCtN-ZrxpUo0wn1l4emYTSK8tgasPlB963uBCTiV9sRPSFHOPVkeIMjaK6SPhVnZy5p6sxHPkjyFOnuS6oLXRqoj1~Oypj~cwO7M0zHBN6Zw1AJopqTrzk1RNRbUJHxORCmCmNCs3x0v1heW50GwQLRMcyFXY1-0LCdWbdclJsBcgAgTUOFIC2T6cUJLeaEc4GIbura6uCufXFfOyJy7dxa36CCtYVanX9qcFqr8a0LC2OjM3lEWgjJwZTFZtbObeDYw2tstFEjlX11rgaH5SBOkHoyJ7bhZmQsWVy5P4VvyawpkuTUj1TNmXaeSZp~vZCM1A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 3\. Definitions and clinical impact

### 3.1. Definition and classification of AF

Atrial fibrillation is one of the most common heart rhythm disorders. A supraventricular arrhythmia with uncoordinated atrial activation, AF results in a loss of effective atrial contraction (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478928&Signature=LeTi7xCg0DZMpxCixcN6zSZvbi-PIvNWtpQuMSNg3jTFo8H4ms8EdOwIz-bBU3hicL-g0WFc2z-3hGi7f5RQTiQxNAc0o~B24kGKyUCRc5yGbgWOUG1zxo3NtCpkehEK9uF3PBD9iuFkoXlXU1E~wfDrGbUjBWjPxPP8CZ-lR2Fydkj4P3oWN6sTT4DCuy~TytQjp9~PKREiFqdHHPiStM-4Fy3MWzbgC5~9Xln9cYxRbp7UtP6suHz92PgRwSMrGD~15IVutLq-xYXjbh9pAdsHfgnn8avOhC5PjDkZ7lI1Kb~rjZuGEbuXIKnmQuoGlyNG6axlhUJpIXHUBaWHJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) for pathophysiology). AF is reflected on the surface electrocardiogram (ECG) by the absence of discernible and regular P waves, and irregular activation of the ventricles. This results in no specific pattern to RR intervals, in the absence of an atrioventricular block. The definition of AF by temporal pattern is presented in _[Table 5](javascript:;)_. It should be noted that these categories reflect observed episodes of AF and do not suggest the underlying pathophysiological process. Some patients may progress consecutively through these categories, while others may need periodic reclassification due to their individual clinical status. Over time, some patients with AF develop atrial and ventricular damage, which can make attempts at rhythm control futile. For this reason, or when patients and physicians make a joint decision for rate control, AF is classified as permanent (the most common ‘type’ of AF in historical registries).<sup><span class="xrefLink" id="jumplink-ehae176-B1"></span><a href="javascript:;" reveal-id="ehae176-B1" data-open="ehae176-B1" class="link link-ref link-reveal xref-bibr">1</a></sup> Despite many limitations, this task force have retained this temporal approach because most trials in patients with AF have used these definitions. Classifying AF by underlying drivers could inform management, but the evidence in support of the clinical use of such classification is currently lacking.

Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884141)

Definitions and classifications for the temporal pattern of AF

| Temporal classification .  | Definition .  |
| --- | --- |
| **First-diagnosed AF** | AF that has not been diagnosed before, regardless of symptom status, temporal pattern, or duration. |
| **Paroxysmal AF** | AF which terminates spontaneously within 7 days or with the assistance of an intervention. Evidence suggests that most self-terminating paroxysms last <48 h.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> |
| **Persistent AF** | AF episodes which are not self-terminating. Many intervention trials have used 7 days as a cut-off for defining persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a>,<span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> Long-standing persistent AF is arbitrarily defined as continuous AF of at least 12 months' duration but where rhythm control is still a treatment option in selected patients, distinguishing it from permanent AF. |
| **Permanent AF** | AF for which no further attempts at restoration of sinus rhythm are planned, after a shared decision between the patient and physician. |

| Temporal classification .  | Definition .  |
| --- | --- |
| **First-diagnosed AF** | AF that has not been diagnosed before, regardless of symptom status, temporal pattern, or duration. |
| **Paroxysmal AF** | AF which terminates spontaneously within 7 days or with the assistance of an intervention. Evidence suggests that most self-terminating paroxysms last <48 h.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> |
| **Persistent AF** | AF episodes which are not self-terminating. Many intervention trials have used 7 days as a cut-off for defining persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a>,<span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> Long-standing persistent AF is arbitrarily defined as continuous AF of at least 12 months' duration but where rhythm control is still a treatment option in selected patients, distinguishing it from permanent AF. |
| **Permanent AF** | AF for which no further attempts at restoration of sinus rhythm are planned, after a shared decision between the patient and physician. |

AF, atrial fibrillation.

© ESC 2024

Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884141)

Definitions and classifications for the temporal pattern of AF

| Temporal classification .  | Definition .  |
| --- | --- |
| **First-diagnosed AF** | AF that has not been diagnosed before, regardless of symptom status, temporal pattern, or duration. |
| **Paroxysmal AF** | AF which terminates spontaneously within 7 days or with the assistance of an intervention. Evidence suggests that most self-terminating paroxysms last <48 h.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> |
| **Persistent AF** | AF episodes which are not self-terminating. Many intervention trials have used 7 days as a cut-off for defining persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a>,<span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> Long-standing persistent AF is arbitrarily defined as continuous AF of at least 12 months' duration but where rhythm control is still a treatment option in selected patients, distinguishing it from permanent AF. |
| **Permanent AF** | AF for which no further attempts at restoration of sinus rhythm are planned, after a shared decision between the patient and physician. |

| Temporal classification .  | Definition .  |
| --- | --- |
| **First-diagnosed AF** | AF that has not been diagnosed before, regardless of symptom status, temporal pattern, or duration. |
| **Paroxysmal AF** | AF which terminates spontaneously within 7 days or with the assistance of an intervention. Evidence suggests that most self-terminating paroxysms last <48 h.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> |
| **Persistent AF** | AF episodes which are not self-terminating. Many intervention trials have used 7 days as a cut-off for defining persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a>,<span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> Long-standing persistent AF is arbitrarily defined as continuous AF of at least 12 months' duration but where rhythm control is still a treatment option in selected patients, distinguishing it from permanent AF. |
| **Permanent AF** | AF for which no further attempts at restoration of sinus rhythm are planned, after a shared decision between the patient and physician. |

AF, atrial fibrillation.

© ESC 2024

Several other classifications have been applied to patients with AF, many of which have limited evidence to support them. The definition of AF is a developing field and ongoing research may allow for pathology-based strategies that could facilitate personalized management in the future. _[Table 6](javascript:;)_ presents some commonly used concepts in current clinical practice. Due to the lack of supporting evidence (particularly for the time periods stated), this task force have edited and updated these definitions by consensus.

Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884143)

Other clinical concepts relevant to AF

| Clinical concept .  | Definition .  |
| --- | --- |
| **Clinical AF** | Symptomatic or asymptomatic AF that is clearly documented by an ECG (12-lead ECG or other ECG devices). The minimum duration to establish the diagnosis of clinical AF for ambulatory ECG is not clear and depends on the clinical context. Periods of 30 s or more may indicate clinical concern, and trigger further monitoring or risk stratification for thromboembolism. |
| **Device-detected subclinical AF** | Device-detected subclinical AF refers to asymptomatic episodes of AF detected on continuous monitoring devices. These devices include implanted cardiac electronic devices, for which most atrial high-rate episodes<sup><span class="xrefLink" id="jumplink-tblfn108"></span><a href="javascript:;" reveal-id="tblfn108" data-open="tblfn108" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> may be AF, as well as consumer-based wearable monitors. Confirmation is needed by a competent professional reviewing intracardiac electrograms or an ECG-recorded rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> Device-detected subclinical AF is a predictor of future clinical AF.<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a></sup> |
| **AF burden** | The overall time spent in AF during a clearly specified and reported period of monitoring, expressed as a percentage of time. |
| **Recent-onset AF** | There is accumulating data on the value of the term recent-onset AF in decision-making for acute pharmacological or electrical cardioversion of AF. The cut-off time interval to define this entity has not yet been established.<sup><span class="xrefLink" id="jumplink-ehae176-B8 ehae176-B9 ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B8 ehae176-B9 ehae176-B10" data-open="ehae176-B8 ehae176-B9 ehae176-B10" class="link link-ref link-reveal xref-bibr">8–10</a></sup> |
| **Trigger-induced AF** | New AF episode in close proximity to a precipitating and potentially reversible factor.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> |
| **Early AF** | The time since diagnosis that qualifies for early AF is dissociated from any underlying atrial cardiomyopathy and is not well defined, broadly ranging from 3 to 24 months.<sup><span class="xrefLink" id="jumplink-ehae176-B15 ehae176-B16 ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B15 ehae176-B16 ehae176-B17" data-open="ehae176-B15 ehae176-B16 ehae176-B17" class="link link-ref link-reveal xref-bibr">15–17</a></sup> The definition of early AF also does not necessarily determine early timing of intervention. |
| **Self-terminating AF** | Paroxysmal AF which terminates spontaneously.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> This definition may be of value for decisions on acute rhythm control taken jointly by the patient and healthcare provider. |
| **Non-self-terminating AF** | Atrial fibrillation which does not terminate spontaneously and, if needed, termination can be achieved only with an intervention. |
| **Atrial cardiomyopathy** | A combination of structural, electrical, or functional changes in the atria that leads to clinical impact (e.g. progression/recurrence of AF, limited effectiveness of AF therapy, and/or development of heart failure).<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a>,<span class="xrefLink" id="jumplink-ehae176-B19"></span><a href="javascript:;" reveal-id="ehae176-B19" data-open="ehae176-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Atrial cardiomyopathy includes inflammatory and prothrombotic remodelling of the atria, neurohormonal activation (thereby affecting the ventricles), and fibrosis of myocardial tissue.<sup><span class="xrefLink" id="jumplink-ehae176-B20"></span><a href="javascript:;" reveal-id="ehae176-B20" data-open="ehae176-B20" class="link link-ref link-reveal xref-bibr">20</a></sup> |

| Clinical concept .  | Definition .  |
| --- | --- |
| **Clinical AF** | Symptomatic or asymptomatic AF that is clearly documented by an ECG (12-lead ECG or other ECG devices). The minimum duration to establish the diagnosis of clinical AF for ambulatory ECG is not clear and depends on the clinical context. Periods of 30 s or more may indicate clinical concern, and trigger further monitoring or risk stratification for thromboembolism. |
| **Device-detected subclinical AF** | Device-detected subclinical AF refers to asymptomatic episodes of AF detected on continuous monitoring devices. These devices include implanted cardiac electronic devices, for which most atrial high-rate episodes<sup><span class="xrefLink" id="jumplink-tblfn108"></span><a href="javascript:;" reveal-id="tblfn108" data-open="tblfn108" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> may be AF, as well as consumer-based wearable monitors. Confirmation is needed by a competent professional reviewing intracardiac electrograms or an ECG-recorded rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> Device-detected subclinical AF is a predictor of future clinical AF.<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a></sup> |
| **AF burden** | The overall time spent in AF during a clearly specified and reported period of monitoring, expressed as a percentage of time. |
| **Recent-onset AF** | There is accumulating data on the value of the term recent-onset AF in decision-making for acute pharmacological or electrical cardioversion of AF. The cut-off time interval to define this entity has not yet been established.<sup><span class="xrefLink" id="jumplink-ehae176-B8 ehae176-B9 ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B8 ehae176-B9 ehae176-B10" data-open="ehae176-B8 ehae176-B9 ehae176-B10" class="link link-ref link-reveal xref-bibr">8–10</a></sup> |
| **Trigger-induced AF** | New AF episode in close proximity to a precipitating and potentially reversible factor.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> |
| **Early AF** | The time since diagnosis that qualifies for early AF is dissociated from any underlying atrial cardiomyopathy and is not well defined, broadly ranging from 3 to 24 months.<sup><span class="xrefLink" id="jumplink-ehae176-B15 ehae176-B16 ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B15 ehae176-B16 ehae176-B17" data-open="ehae176-B15 ehae176-B16 ehae176-B17" class="link link-ref link-reveal xref-bibr">15–17</a></sup> The definition of early AF also does not necessarily determine early timing of intervention. |
| **Self-terminating AF** | Paroxysmal AF which terminates spontaneously.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> This definition may be of value for decisions on acute rhythm control taken jointly by the patient and healthcare provider. |
| **Non-self-terminating AF** | Atrial fibrillation which does not terminate spontaneously and, if needed, termination can be achieved only with an intervention. |
| **Atrial cardiomyopathy** | A combination of structural, electrical, or functional changes in the atria that leads to clinical impact (e.g. progression/recurrence of AF, limited effectiveness of AF therapy, and/or development of heart failure).<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a>,<span class="xrefLink" id="jumplink-ehae176-B19"></span><a href="javascript:;" reveal-id="ehae176-B19" data-open="ehae176-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Atrial cardiomyopathy includes inflammatory and prothrombotic remodelling of the atria, neurohormonal activation (thereby affecting the ventricles), and fibrosis of myocardial tissue.<sup><span class="xrefLink" id="jumplink-ehae176-B20"></span><a href="javascript:;" reveal-id="ehae176-B20" data-open="ehae176-B20" class="link link-ref link-reveal xref-bibr">20</a></sup> |

AF, atrial fibrillation; b.p.m., beats per minute; ECG, electrocardiogram.

<sup>a</sup>Atrial high-rate episodes are defined as episodes generally lasting more than 5 min with an atrial lead rate ≥170 b.p.m.,<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a>,<span class="xrefLink" id="jumplink-ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24"></span><a href="javascript:;" reveal-id="ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24" data-open="ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24" class="link link-ref link-reveal xref-bibr">21–24</a></sup> detected by implanted cardiac devices that allow for automated continuous monitoring and storage of atrial rhythm. Atrial high-rate episodes need to be visually inspected because some may be electrical artefacts or false positives.

© ESC 2024

Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884143)

Other clinical concepts relevant to AF

| Clinical concept .  | Definition .  |
| --- | --- |
| **Clinical AF** | Symptomatic or asymptomatic AF that is clearly documented by an ECG (12-lead ECG or other ECG devices). The minimum duration to establish the diagnosis of clinical AF for ambulatory ECG is not clear and depends on the clinical context. Periods of 30 s or more may indicate clinical concern, and trigger further monitoring or risk stratification for thromboembolism. |
| **Device-detected subclinical AF** | Device-detected subclinical AF refers to asymptomatic episodes of AF detected on continuous monitoring devices. These devices include implanted cardiac electronic devices, for which most atrial high-rate episodes<sup><span class="xrefLink" id="jumplink-tblfn108"></span><a href="javascript:;" reveal-id="tblfn108" data-open="tblfn108" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> may be AF, as well as consumer-based wearable monitors. Confirmation is needed by a competent professional reviewing intracardiac electrograms or an ECG-recorded rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> Device-detected subclinical AF is a predictor of future clinical AF.<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a></sup> |
| **AF burden** | The overall time spent in AF during a clearly specified and reported period of monitoring, expressed as a percentage of time. |
| **Recent-onset AF** | There is accumulating data on the value of the term recent-onset AF in decision-making for acute pharmacological or electrical cardioversion of AF. The cut-off time interval to define this entity has not yet been established.<sup><span class="xrefLink" id="jumplink-ehae176-B8 ehae176-B9 ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B8 ehae176-B9 ehae176-B10" data-open="ehae176-B8 ehae176-B9 ehae176-B10" class="link link-ref link-reveal xref-bibr">8–10</a></sup> |
| **Trigger-induced AF** | New AF episode in close proximity to a precipitating and potentially reversible factor.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> |
| **Early AF** | The time since diagnosis that qualifies for early AF is dissociated from any underlying atrial cardiomyopathy and is not well defined, broadly ranging from 3 to 24 months.<sup><span class="xrefLink" id="jumplink-ehae176-B15 ehae176-B16 ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B15 ehae176-B16 ehae176-B17" data-open="ehae176-B15 ehae176-B16 ehae176-B17" class="link link-ref link-reveal xref-bibr">15–17</a></sup> The definition of early AF also does not necessarily determine early timing of intervention. |
| **Self-terminating AF** | Paroxysmal AF which terminates spontaneously.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> This definition may be of value for decisions on acute rhythm control taken jointly by the patient and healthcare provider. |
| **Non-self-terminating AF** | Atrial fibrillation which does not terminate spontaneously and, if needed, termination can be achieved only with an intervention. |
| **Atrial cardiomyopathy** | A combination of structural, electrical, or functional changes in the atria that leads to clinical impact (e.g. progression/recurrence of AF, limited effectiveness of AF therapy, and/or development of heart failure).<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a>,<span class="xrefLink" id="jumplink-ehae176-B19"></span><a href="javascript:;" reveal-id="ehae176-B19" data-open="ehae176-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Atrial cardiomyopathy includes inflammatory and prothrombotic remodelling of the atria, neurohormonal activation (thereby affecting the ventricles), and fibrosis of myocardial tissue.<sup><span class="xrefLink" id="jumplink-ehae176-B20"></span><a href="javascript:;" reveal-id="ehae176-B20" data-open="ehae176-B20" class="link link-ref link-reveal xref-bibr">20</a></sup> |

| Clinical concept .  | Definition .  |
| --- | --- |
| **Clinical AF** | Symptomatic or asymptomatic AF that is clearly documented by an ECG (12-lead ECG or other ECG devices). The minimum duration to establish the diagnosis of clinical AF for ambulatory ECG is not clear and depends on the clinical context. Periods of 30 s or more may indicate clinical concern, and trigger further monitoring or risk stratification for thromboembolism. |
| **Device-detected subclinical AF** | Device-detected subclinical AF refers to asymptomatic episodes of AF detected on continuous monitoring devices. These devices include implanted cardiac electronic devices, for which most atrial high-rate episodes<sup><span class="xrefLink" id="jumplink-tblfn108"></span><a href="javascript:;" reveal-id="tblfn108" data-open="tblfn108" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> may be AF, as well as consumer-based wearable monitors. Confirmation is needed by a competent professional reviewing intracardiac electrograms or an ECG-recorded rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> Device-detected subclinical AF is a predictor of future clinical AF.<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a></sup> |
| **AF burden** | The overall time spent in AF during a clearly specified and reported period of monitoring, expressed as a percentage of time. |
| **Recent-onset AF** | There is accumulating data on the value of the term recent-onset AF in decision-making for acute pharmacological or electrical cardioversion of AF. The cut-off time interval to define this entity has not yet been established.<sup><span class="xrefLink" id="jumplink-ehae176-B8 ehae176-B9 ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B8 ehae176-B9 ehae176-B10" data-open="ehae176-B8 ehae176-B9 ehae176-B10" class="link link-ref link-reveal xref-bibr">8–10</a></sup> |
| **Trigger-induced AF** | New AF episode in close proximity to a precipitating and potentially reversible factor.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> |
| **Early AF** | The time since diagnosis that qualifies for early AF is dissociated from any underlying atrial cardiomyopathy and is not well defined, broadly ranging from 3 to 24 months.<sup><span class="xrefLink" id="jumplink-ehae176-B15 ehae176-B16 ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B15 ehae176-B16 ehae176-B17" data-open="ehae176-B15 ehae176-B16 ehae176-B17" class="link link-ref link-reveal xref-bibr">15–17</a></sup> The definition of early AF also does not necessarily determine early timing of intervention. |
| **Self-terminating AF** | Paroxysmal AF which terminates spontaneously.<sup><span class="xrefLink" id="jumplink-ehae176-B2"></span><a href="javascript:;" reveal-id="ehae176-B2" data-open="ehae176-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> This definition may be of value for decisions on acute rhythm control taken jointly by the patient and healthcare provider. |
| **Non-self-terminating AF** | Atrial fibrillation which does not terminate spontaneously and, if needed, termination can be achieved only with an intervention. |
| **Atrial cardiomyopathy** | A combination of structural, electrical, or functional changes in the atria that leads to clinical impact (e.g. progression/recurrence of AF, limited effectiveness of AF therapy, and/or development of heart failure).<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a>,<span class="xrefLink" id="jumplink-ehae176-B19"></span><a href="javascript:;" reveal-id="ehae176-B19" data-open="ehae176-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> Atrial cardiomyopathy includes inflammatory and prothrombotic remodelling of the atria, neurohormonal activation (thereby affecting the ventricles), and fibrosis of myocardial tissue.<sup><span class="xrefLink" id="jumplink-ehae176-B20"></span><a href="javascript:;" reveal-id="ehae176-B20" data-open="ehae176-B20" class="link link-ref link-reveal xref-bibr">20</a></sup> |

AF, atrial fibrillation; b.p.m., beats per minute; ECG, electrocardiogram.

<sup>a</sup>Atrial high-rate episodes are defined as episodes generally lasting more than 5 min with an atrial lead rate ≥170 b.p.m.,<sup><span class="xrefLink" id="jumplink-ehae176-B7"></span><a href="javascript:;" reveal-id="ehae176-B7" data-open="ehae176-B7" class="link link-ref link-reveal xref-bibr">7</a>,<span class="xrefLink" id="jumplink-ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24"></span><a href="javascript:;" reveal-id="ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24" data-open="ehae176-B21 ehae176-B22 ehae176-B23 ehae176-B24" class="link link-ref link-reveal xref-bibr">21–24</a></sup> detected by implanted cardiac devices that allow for automated continuous monitoring and storage of atrial rhythm. Atrial high-rate episodes need to be visually inspected because some may be electrical artefacts or false positives.

© ESC 2024

### 3.2. Diagnostic criteria for AF

In many patients, the diagnosis of AF is straightforward, e.g. typical symptoms associated with characteristic features on a standard 12-lead ECG that indicate the need for AF management. Diagnosis becomes more challenging in the context of asymptomatic episodes or AF detected on longer-term monitoring devices, particularly those that do not provide an ECG (see _Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s9)_). To guard against inappropriate diagnosis of AF, this task force continues to recommend that ECG documentation is required to initiate risk stratification and AF management. In current practice, ECG confirmation can include multiple options: not only where AF persists across a standard 12-lead ECG, but also single- and multiple-lead devices that provide an ECG (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478928&Signature=sYPSkc059rzSsSo6~r0xwLGmW-M0Rv7xwul7KcNwszjWMC8gVHVAwqMgkRxMRKYpzAKJLAhzP~U7wa5MVlCzK~iOm9uxrzZKH13uwuC58sd05TSq5sbB~z6MBP6fy-oOgfv8gGq6D-ZIjwcugiuOUUCtl5pzaYUqbngt-M9BeQtwmHgyFPgiyBzYXocwwtv7P8k-BvoWZx3OnbHs5m4LJ6ZaY3RiAMKV0Y13OH5Q~1IcGmBJVu9UzD6dQISR2PTy-AcQ0~zoK-k8Oy9SaHeT8NiHRuo7y5UTRFOGupYBPqABrtWs-Gjjqd2ykJdFQsvptIUiPfLT80TOsS5d5PcSFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478928&Signature=sYPSkc059rzSsSo6~r0xwLGmW-M0Rv7xwul7KcNwszjWMC8gVHVAwqMgkRxMRKYpzAKJLAhzP~U7wa5MVlCzK~iOm9uxrzZKH13uwuC58sd05TSq5sbB~z6MBP6fy-oOgfv8gGq6D-ZIjwcugiuOUUCtl5pzaYUqbngt-M9BeQtwmHgyFPgiyBzYXocwwtv7P8k-BvoWZx3OnbHs5m4LJ6ZaY3RiAMKV0Y13OH5Q~1IcGmBJVu9UzD6dQISR2PTy-AcQ0~zoK-k8Oy9SaHeT8NiHRuo7y5UTRFOGupYBPqABrtWs-Gjjqd2ykJdFQsvptIUiPfLT80TOsS5d5PcSFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). This does not include non-ECG wearables and other devices that typically use photoplethysmography. Note that many pivotal AF trials required two or more ECGs documenting AF, or an established AF diagnosis before randomization.<sup><span class="xrefLink" id="jumplink-ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28 ehae176-B29"></span><a href="javascript:;" reveal-id="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28 ehae176-B29" data-open="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28 ehae176-B29" class="link link-ref link-reveal xref-bibr">25–29</a></sup> The time period of AF required for diagnosis on monitoring devices is not clear cut. A standard 12-lead ECG measures 10 s, while 30 s or more on single-lead or multiple-lead ECG devices has generally been the consensus opinion, albeit with limited evidence.

Recommendation Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884146)

Recommendations for the diagnosis of AF (see also Evidence Table 1)

![Recommendations for the diagnosis of AF (see also Evidence Table 1)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt1.jpeg?Expires=1728478928&Signature=qIvzt8ZBjGo7OgMOoW3GYixmRdLGPolrdxCKv3DXaGo5TscrcY72byyuUGEMYQgS~r343uNWP8ctEiWq9ExA2XkKnirX46Zc-y6ogVz9YRC0cgGEOvhg7bGBtlqrK-hqyhCOamsCcONucCkKsZeMdufKbeRENIcpGkHI8U0ePtYjBKRushruAznkv8QPT3BZDPCLx~NQWrvfZRnViwN7tm1i-UfYQULxSRe--Hh~HbKwn37jiWba-SAjviFmAWu2mDpesj3b1VXdbml-F6q8rsGRa52WvmpdbiI5pUVglBbn1Kobntwh~QwV1Gfg7foRNP8RvkwouGBzQtFk4mdlhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884146)

Recommendations for the diagnosis of AF (see also Evidence Table 1)

![Recommendations for the diagnosis of AF (see also Evidence Table 1)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt1.jpeg?Expires=1728478928&Signature=qIvzt8ZBjGo7OgMOoW3GYixmRdLGPolrdxCKv3DXaGo5TscrcY72byyuUGEMYQgS~r343uNWP8ctEiWq9ExA2XkKnirX46Zc-y6ogVz9YRC0cgGEOvhg7bGBtlqrK-hqyhCOamsCcONucCkKsZeMdufKbeRENIcpGkHI8U0ePtYjBKRushruAznkv8QPT3BZDPCLx~NQWrvfZRnViwN7tm1i-UfYQULxSRe--Hh~HbKwn37jiWba-SAjviFmAWu2mDpesj3b1VXdbml-F6q8rsGRa52WvmpdbiI5pUVglBbn1Kobntwh~QwV1Gfg7foRNP8RvkwouGBzQtFk4mdlhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 3.3. Symptoms attributable to AF

Symptoms related to episodes of AF are variable and broad, and not just typical palpitations (_[Figure 1](javascript:;)_). Asymptomatic episodes of AF can occur,<sup><span class="xrefLink" id="jumplink-ehae176-B30"></span><a href="javascript:;" reveal-id="ehae176-B30" data-open="ehae176-B30" class="link link-ref link-reveal xref-bibr">30</a></sup> although 90% of patients with AF describe symptoms with variable severity.<sup><span class="xrefLink" id="jumplink-ehae176-B31"></span><a href="javascript:;" reveal-id="ehae176-B31" data-open="ehae176-B31" class="link link-ref link-reveal xref-bibr">31</a></sup> Even in symptomatic patients, some episodes of AF may remain asymptomatic.<sup><span class="xrefLink" id="jumplink-ehae176-B32"></span><a href="javascript:;" reveal-id="ehae176-B32" data-open="ehae176-B32" class="link link-ref link-reveal xref-bibr">32</a>,<span class="xrefLink" id="jumplink-ehae176-B33"></span><a href="javascript:;" reveal-id="ehae176-B33" data-open="ehae176-B33" class="link link-ref link-reveal xref-bibr">33</a></sup> The presence or absence of symptoms is not related to incident stroke, systemic embolism, or mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B34"></span><a href="javascript:;" reveal-id="ehae176-B34" data-open="ehae176-B34" class="link link-ref link-reveal xref-bibr">34</a></sup> However, symptoms do impact on patient quality of life.<sup><span class="xrefLink" id="jumplink-ehae176-B35"></span><a href="javascript:;" reveal-id="ehae176-B35" data-open="ehae176-B35" class="link link-ref link-reveal xref-bibr">35</a>,<span class="xrefLink" id="jumplink-ehae176-B36"></span><a href="javascript:;" reveal-id="ehae176-B36" data-open="ehae176-B36" class="link link-ref link-reveal xref-bibr">36</a></sup> Cardiac-specific AF symptoms such as palpitations are less common than non-specific symptoms such as fatigue, but they significantly impair quality of life.<sup><span class="xrefLink" id="jumplink-ehae176-B36"></span><a href="javascript:;" reveal-id="ehae176-B36" data-open="ehae176-B36" class="link link-ref link-reveal xref-bibr">36</a>,<span class="xrefLink" id="jumplink-ehae176-B37"></span><a href="javascript:;" reveal-id="ehae176-B37" data-open="ehae176-B37" class="link link-ref link-reveal xref-bibr">37</a></sup> Although women are often underrepresented in clinical trials of AF,<sup><span class="xrefLink" id="jumplink-ehae176-B38 ehae176-B39 ehae176-B40"></span><a href="javascript:;" reveal-id="ehae176-B38 ehae176-B39 ehae176-B40" data-open="ehae176-B38 ehae176-B39 ehae176-B40" class="link link-ref link-reveal xref-bibr">38–40</a></sup> the available literature suggests that women with AF appear to be more symptomatic and have poorer quality of life.<sup><span class="xrefLink" id="jumplink-ehae176-B41"></span><a href="javascript:;" reveal-id="ehae176-B41" data-open="ehae176-B41" class="link link-ref link-reveal xref-bibr">41</a>,<span class="xrefLink" id="jumplink-ehae176-B42"></span><a href="javascript:;" reveal-id="ehae176-B42" data-open="ehae176-B42" class="link link-ref link-reveal xref-bibr">42</a></sup> Patients with AF report a higher burden of anxiety and severity of depression (odds ratio \[OR\], 1.08; 95% confidence interval \[CI\], 1.02–1.15; _P_ = .009) as compared with the general population,<sup><span class="xrefLink" id="jumplink-ehae176-B43"></span><a href="javascript:;" reveal-id="ehae176-B43" data-open="ehae176-B43" class="link link-ref link-reveal xref-bibr">43</a>,<span class="xrefLink" id="jumplink-ehae176-B44"></span><a href="javascript:;" reveal-id="ehae176-B44" data-open="ehae176-B44" class="link link-ref link-reveal xref-bibr">44</a></sup> with higher prevalence of these symptoms in women with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B45"></span><a href="javascript:;" reveal-id="ehae176-B45" data-open="ehae176-B45" class="link link-ref link-reveal xref-bibr">45</a></sup>

![Impacts and outcomes associated with clinical AF. AF, atrial fibrillation.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f1.jpeg?Expires=1728478928&Signature=YWjr8zklr79On2DKd-gb0WuudFUGHH4X5jVncMS7ibxtHn2jcbqXdbvPDhD0SJdNJg4OSMsXGzUm0gNwX0q8IJBdHUwPkjVVBgduWfoySf5EClkVsjFCNMWwEWpdArRInrqVe~wuM22n0hHcVa57BYMZXXuiijYzoPA9URSoHaZ1N9ScPBya3fwLYOyvLT1HTGElC5-~rMVfXYd4l554MRZiPeZS18InJxUpslHD0s-twh0Rp7nEhXnEwQY5WiornUMP3uenckOj9Fc5IZFXiQHy3yB2cPt78vbDtaGRL3Ikz8SZgfaI3afieAwtTp0IRxMRX~6-xp5R4~vuU~HQpQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 1

Impacts and outcomes associated with clinical AF. AF, atrial fibrillation.

[Open in new tab](https://academic.oup.com/view-large/figure/479884149/ehae176f1.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f1.jpeg?Expires=1728478928&Signature=kukWaFslF7PHgOSNyhxuS76BnKdynvTlV3~tmUO-~ERjqHA7VqcUGhEi0pv7OCdwZ5tA0E0U8y5NJEPS4lLW7Q53fnKYfXkkXkh6qUzd0cFN1~aYtRldhhLn2LMq8V58xfLj0dkaHkHNhLJ8MXvbQEPJ-bcQ~kvwHNTZNqzkrcbJl6bMmWneZE~Fv5RwgZeK8XUL6uwqm9-Y3Lu~U6ggkT1xpszzcg4SkaEWjmk7MzZWxBiTkOYmV2DYDEaJdu8cYLJB2DTkA1skjg-mG8wnzr6F-lwM3ZL6yh-7lHUZkhnSzlrkB7SuG7gk9ZNOw0xJeqyIYExcyCHBS3o7siOseQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884149&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Assessment of AF-related symptoms should be recorded initially, after a change in treatment, or before and after intervention. The modified European Heart Rhythm Association score (mEHRA) symptom classification (_[Table 7](javascript:;)_) is similar to the New York Heart Association (NYHA) functional class for heart failure. It correlates with quality of life scores in clinical trials, is associated with clinical progress and events, and may be a valuable starting point in routine practice to assess the burden and impact of symptoms together with the patient.<sup><span class="xrefLink" id="jumplink-ehae176-B46 ehae176-B47 ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B46 ehae176-B47 ehae176-B48" data-open="ehae176-B46 ehae176-B47 ehae176-B48" class="link link-ref link-reveal xref-bibr">46–48</a></sup> Note that symptoms may also relate to associated comorbidities and not just the AF component. The patient-related effects of symptoms from AF over time can alternatively be evaluated using patient-reported outcome measures (see _Section [8.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s7.4)_).

Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884151)

The modified European Heart Rhythm Association (mEHRA) symptom classification

| Score .  | Symptoms .  | Description .  |
| --- | --- | --- |
| 1 | None | AF does not cause any symptoms |
| 2a | Mild | Normal daily activity not affected by symptoms related to AF |
| 2b | Moderate | Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms |
| 3 | Severe | Normal daily activity affected by symptoms related to AF |
| 4 | Disabling | Normal daily activity discontinued |

| Score .  | Symptoms .  | Description .  |
| --- | --- | --- |
| 1 | None | AF does not cause any symptoms |
| 2a | Mild | Normal daily activity not affected by symptoms related to AF |
| 2b | Moderate | Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms |
| 3 | Severe | Normal daily activity affected by symptoms related to AF |
| 4 | Disabling | Normal daily activity discontinued |

AF, atrial fibrillation.

© ESC 2024

Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884151)

The modified European Heart Rhythm Association (mEHRA) symptom classification

| Score .  | Symptoms .  | Description .  |
| --- | --- | --- |
| 1 | None | AF does not cause any symptoms |
| 2a | Mild | Normal daily activity not affected by symptoms related to AF |
| 2b | Moderate | Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms |
| 3 | Severe | Normal daily activity affected by symptoms related to AF |
| 4 | Disabling | Normal daily activity discontinued |

| Score .  | Symptoms .  | Description .  |
| --- | --- | --- |
| 1 | None | AF does not cause any symptoms |
| 2a | Mild | Normal daily activity not affected by symptoms related to AF |
| 2b | Moderate | Normal daily activity not affected by symptoms related to AF, but patient troubled by symptoms |
| 3 | Severe | Normal daily activity affected by symptoms related to AF |
| 4 | Disabling | Normal daily activity discontinued |

AF, atrial fibrillation.

© ESC 2024

Recommendation Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884152)

Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2)

![Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt2.jpeg?Expires=1728478928&Signature=LXtIApkOVtTPeieHwCjLGrwzJ6XP-r5ZpTyT1Mh6F2UZpfYLnuImwsJ0lj~9xb7md-JRWDYQZY-C8k~UTUNpZyLWsgmgFqknD2sea3oqszVxmTVOFT3p~DS0ps8CERTo7shIVBO2xxdHDvydnvvOwOZGCqyKI6TVK0z60~2et8jJqrQH4mZtS2XcOqUlYRCC2iIUyHWYYy3bsivLQP45Jez68Y95eC~TQV3ebxPTNLIaKse8Vlva1NGvgQd9-lEz3~Jm~Y7zjW6ctz-EZwS2zgKlKeLTzYT2RxLbIsR-djgp30y4IRmV2~Iicf98jxO5dPpMH~uMWUrrtTQ-5NXRtg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884152)

Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2)

![Recommendations for symptom evaluation in patients with AF (see also Evidence Table 2)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt2.jpeg?Expires=1728478928&Signature=LXtIApkOVtTPeieHwCjLGrwzJ6XP-r5ZpTyT1Mh6F2UZpfYLnuImwsJ0lj~9xb7md-JRWDYQZY-C8k~UTUNpZyLWsgmgFqknD2sea3oqszVxmTVOFT3p~DS0ps8CERTo7shIVBO2xxdHDvydnvvOwOZGCqyKI6TVK0z60~2et8jJqrQH4mZtS2XcOqUlYRCC2iIUyHWYYy3bsivLQP45Jez68Y95eC~TQV3ebxPTNLIaKse8Vlva1NGvgQd9-lEz3~Jm~Y7zjW6ctz-EZwS2zgKlKeLTzYT2RxLbIsR-djgp30y4IRmV2~Iicf98jxO5dPpMH~uMWUrrtTQ-5NXRtg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 3.4. Diagnostic evaluation of new AF

All patients with AF should be offered a comprehensive diagnostic assessment and review of medical history to identify risk factors and/or comorbidities needing active treatment. _[Table 8](javascript:;)_ displays the essential diagnostic work-up for a patient with AF.

Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884155)

Diagnostic work-up for patients with AF

| All patients .  | Selected patients .  |
| --- | --- |
| 
- Medical history to determine AF pattern, relevant family history, and comorbidities, and to assess risk factors for thromboembolism and bleeding


 | 

- Ambulatory ECG monitoring for assessing AF burden and ventricular rate control

- Exercise ECG to evaluate rate control or effects of class IC antiarrhythmic drugs


 |
| 

- 12-lead ECG


 | 

- Further blood tests for investigation of cardiovascular disease and refinement of stroke/bleeding risk (e.g. NT-proBNP, troponin)


 |
| 

- Assess symptoms and functional impairment


 | 

- Transoesophageal echocardiography for left atrial thrombus and valvular disease assessment


 |
| 

- Collect generic or AF-specific patient-reported outcome measures


 | 

- Coronary CT, angiography, or ischaemia imaging for suspected CAD


 |
| 

- Blood tests (full blood count, kidney function, serum electrolytes, liver function, glucose/HbA1c, and thyroid function)


 | 

- CMR for evaluation of atrial and ventricular cardiomyopathies, and to plan interventional procedures


 |
| 

- Transthoracic echocardiography where this will guide AF-CARE management decisions


 | 

- Brain imaging and cognitive function assessment for cerebrovascular disease and dementia risk


 |

| All patients .  | Selected patients .  |
| --- | --- |
| 
- Medical history to determine AF pattern, relevant family history, and comorbidities, and to assess risk factors for thromboembolism and bleeding


 | 

- Ambulatory ECG monitoring for assessing AF burden and ventricular rate control

- Exercise ECG to evaluate rate control or effects of class IC antiarrhythmic drugs


 |
| 

- 12-lead ECG


 | 

- Further blood tests for investigation of cardiovascular disease and refinement of stroke/bleeding risk (e.g. NT-proBNP, troponin)


 |
| 

- Assess symptoms and functional impairment


 | 

- Transoesophageal echocardiography for left atrial thrombus and valvular disease assessment


 |
| 

- Collect generic or AF-specific patient-reported outcome measures


 | 

- Coronary CT, angiography, or ischaemia imaging for suspected CAD


 |
| 

- Blood tests (full blood count, kidney function, serum electrolytes, liver function, glucose/HbA1c, and thyroid function)


 | 

- CMR for evaluation of atrial and ventricular cardiomyopathies, and to plan interventional procedures


 |
| 

- Transthoracic echocardiography where this will guide AF-CARE management decisions


 | 

- Brain imaging and cognitive function assessment for cerebrovascular disease and dementia risk


 |

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CAD, coronary artery disease; CMR, cardiac magnetic resonance; CT, computed tomography; CTA, computed tomography angiography; ECG, electrocardiogram; HbA1c, glycated haemoglobin; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

© ESC 2024

Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884155)

Diagnostic work-up for patients with AF

| All patients .  | Selected patients .  |
| --- | --- |
| 
- Medical history to determine AF pattern, relevant family history, and comorbidities, and to assess risk factors for thromboembolism and bleeding


 | 

- Ambulatory ECG monitoring for assessing AF burden and ventricular rate control

- Exercise ECG to evaluate rate control or effects of class IC antiarrhythmic drugs


 |
| 

- 12-lead ECG


 | 

- Further blood tests for investigation of cardiovascular disease and refinement of stroke/bleeding risk (e.g. NT-proBNP, troponin)


 |
| 

- Assess symptoms and functional impairment


 | 

- Transoesophageal echocardiography for left atrial thrombus and valvular disease assessment


 |
| 

- Collect generic or AF-specific patient-reported outcome measures


 | 

- Coronary CT, angiography, or ischaemia imaging for suspected CAD


 |
| 

- Blood tests (full blood count, kidney function, serum electrolytes, liver function, glucose/HbA1c, and thyroid function)


 | 

- CMR for evaluation of atrial and ventricular cardiomyopathies, and to plan interventional procedures


 |
| 

- Transthoracic echocardiography where this will guide AF-CARE management decisions


 | 

- Brain imaging and cognitive function assessment for cerebrovascular disease and dementia risk


 |

| All patients .  | Selected patients .  |
| --- | --- |
| 
- Medical history to determine AF pattern, relevant family history, and comorbidities, and to assess risk factors for thromboembolism and bleeding


 | 

- Ambulatory ECG monitoring for assessing AF burden and ventricular rate control

- Exercise ECG to evaluate rate control or effects of class IC antiarrhythmic drugs


 |
| 

- 12-lead ECG


 | 

- Further blood tests for investigation of cardiovascular disease and refinement of stroke/bleeding risk (e.g. NT-proBNP, troponin)


 |
| 

- Assess symptoms and functional impairment


 | 

- Transoesophageal echocardiography for left atrial thrombus and valvular disease assessment


 |
| 

- Collect generic or AF-specific patient-reported outcome measures


 | 

- Coronary CT, angiography, or ischaemia imaging for suspected CAD


 |
| 

- Blood tests (full blood count, kidney function, serum electrolytes, liver function, glucose/HbA1c, and thyroid function)


 | 

- CMR for evaluation of atrial and ventricular cardiomyopathies, and to plan interventional procedures


 |
| 

- Transthoracic echocardiography where this will guide AF-CARE management decisions


 | 

- Brain imaging and cognitive function assessment for cerebrovascular disease and dementia risk


 |

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CAD, coronary artery disease; CMR, cardiac magnetic resonance; CT, computed tomography; CTA, computed tomography angiography; ECG, electrocardiogram; HbA1c, glycated haemoglobin; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

© ESC 2024

A 12-lead ECG is warranted in all AF patients to confirm rhythm, determine ventricular rate, and look for signs of structural heart disease, conduction defects, or ischaemia.<sup><span class="xrefLink" id="jumplink-ehae176-B56"></span><a href="javascript:;" reveal-id="ehae176-B56" data-open="ehae176-B56" class="link link-ref link-reveal xref-bibr">56</a></sup> Blood tests should be carried out (kidney function, serum electrolytes, liver function, full blood count, glucose/glycated haemoglobin \[HbA1c\], and thyroid tests) to detect any concomitant conditions that may exacerbate AF or increase the risk of bleeding and/or thromboembolism.<sup><span class="xrefLink" id="jumplink-ehae176-B57"></span><a href="javascript:;" reveal-id="ehae176-B57" data-open="ehae176-B57" class="link link-ref link-reveal xref-bibr">57</a>,<span class="xrefLink" id="jumplink-ehae176-B58"></span><a href="javascript:;" reveal-id="ehae176-B58" data-open="ehae176-B58" class="link link-ref link-reveal xref-bibr">58</a></sup>

Other investigations will depend on individualized assessment and the planned treatment strategy.<sup><span class="xrefLink" id="jumplink-ehae176-B59 ehae176-B60 ehae176-B61 ehae176-B62 ehae176-B63 ehae176-B64 ehae176-B65"></span><a href="javascript:;" reveal-id="ehae176-B59 ehae176-B60 ehae176-B61 ehae176-B62 ehae176-B63 ehae176-B64 ehae176-B65" data-open="ehae176-B59 ehae176-B60 ehae176-B61 ehae176-B62 ehae176-B63 ehae176-B64 ehae176-B65" class="link link-ref link-reveal xref-bibr">59–65</a></sup> A transthoracic echocardiogram (TTE) should be carried out in the initial work-up, where this will guide management decisions, or in patients where there is a change in cardiovascular signs or symptoms. The task force recognizes that accessibility to TTE might be limited or delayed in the primary care setting, but this should not delay initiation of oral anticoagulation (OAC) or other components of AF-CARE where indicated.<sup><span class="xrefLink" id="jumplink-ehae176-B66"></span><a href="javascript:;" reveal-id="ehae176-B66" data-open="ehae176-B66" class="link link-ref link-reveal xref-bibr">66</a></sup> Further details on TTE and reassessment (e.g. if elevated heart rate limits diagnostic imaging, or where there is a change in clinical status) are presented in _Section [8.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s7.3)_. Additional imaging using different modalities may be required to assist with comorbidity and AF-related management (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478928&Signature=LeTi7xCg0DZMpxCixcN6zSZvbi-PIvNWtpQuMSNg3jTFo8H4ms8EdOwIz-bBU3hicL-g0WFc2z-3hGi7f5RQTiQxNAc0o~B24kGKyUCRc5yGbgWOUG1zxo3NtCpkehEK9uF3PBD9iuFkoXlXU1E~wfDrGbUjBWjPxPP8CZ-lR2Fydkj4P3oWN6sTT4DCuy~TytQjp9~PKREiFqdHHPiStM-4Fy3MWzbgC5~9Xln9cYxRbp7UtP6suHz92PgRwSMrGD~15IVutLq-xYXjbh9pAdsHfgnn8avOhC5PjDkZ7lI1Kb~rjZuGEbuXIKnmQuoGlyNG6axlhUJpIXHUBaWHJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Figure S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478928&Signature=LeTi7xCg0DZMpxCixcN6zSZvbi-PIvNWtpQuMSNg3jTFo8H4ms8EdOwIz-bBU3hicL-g0WFc2z-3hGi7f5RQTiQxNAc0o~B24kGKyUCRc5yGbgWOUG1zxo3NtCpkehEK9uF3PBD9iuFkoXlXU1E~wfDrGbUjBWjPxPP8CZ-lR2Fydkj4P3oWN6sTT4DCuy~TytQjp9~PKREiFqdHHPiStM-4Fy3MWzbgC5~9Xln9cYxRbp7UtP6suHz92PgRwSMrGD~15IVutLq-xYXjbh9pAdsHfgnn8avOhC5PjDkZ7lI1Kb~rjZuGEbuXIKnmQuoGlyNG6axlhUJpIXHUBaWHJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Recommendation Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884158)

Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3)

![Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt3.jpeg?Expires=1728478929&Signature=EfdShtJaDlxcCuPE0Zi-FW39qmdZNeURqbuPUJ-A58kS22S4suXk98KhhdXu9x~dAFRsGC7guqA~CrltkZVcplBo4ygthqZ-v5A5Rag38d4G0~GxWaIeeQOC~RITMZqhU641RYNk6nIFeXYfrgSTWxC3InW9lxTdSxB4S-RxWPg1ogiCL9ZodPmrTGIgKmKgICiLnA7Xdo7QyCorEkbX~C2~x-n-Rf72MiY-UyOM2gAH0wMHK8xjW5wAIu4MwH~3xdMY8jjAvFAXhBZ28Rphnm5c4uJsVPdmZoQBiNAgbSS0WQ02pn3bvAxZj9AGfLxFdvIkWaZ6hWnRCMGCBzcZ9Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884158)

Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3)

![Recommendations for diagnostic evaluation in patients with new AF (see also Evidence Table 3)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt3.jpeg?Expires=1728478929&Signature=EfdShtJaDlxcCuPE0Zi-FW39qmdZNeURqbuPUJ-A58kS22S4suXk98KhhdXu9x~dAFRsGC7guqA~CrltkZVcplBo4ygthqZ-v5A5Rag38d4G0~GxWaIeeQOC~RITMZqhU641RYNk6nIFeXYfrgSTWxC3InW9lxTdSxB4S-RxWPg1ogiCL9ZodPmrTGIgKmKgICiLnA7Xdo7QyCorEkbX~C2~x-n-Rf72MiY-UyOM2gAH0wMHK8xjW5wAIu4MwH~3xdMY8jjAvFAXhBZ28Rphnm5c4uJsVPdmZoQBiNAgbSS0WQ02pn3bvAxZj9AGfLxFdvIkWaZ6hWnRCMGCBzcZ9Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 3.5. Adverse events associated with AF

Atrial fibrillation is associated with a range of serious adverse events (_[Figure 1](javascript:;)_) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Patients with AF also have high rates of hospitalization and complications from coexisting medical conditions. The most common non-fatal outcome in those with AF is heart failure, occurring in around half of patients over time. Patients with AF have a four- to five-fold increase in the relative risk (RR) of heart failure compared with those without AF, as demonstrated in two meta-analyses (RR, 4.62; 95% CI, 3.13–6.83 and RR, 4.99; 95% CI, 3.0–8.22).<sup><span class="xrefLink" id="jumplink-ehae176-B68"></span><a href="javascript:;" reveal-id="ehae176-B68" data-open="ehae176-B68" class="link link-ref link-reveal xref-bibr">68</a>,<span class="xrefLink" id="jumplink-ehae176-B69"></span><a href="javascript:;" reveal-id="ehae176-B69" data-open="ehae176-B69" class="link link-ref link-reveal xref-bibr">69</a></sup> The next most common adverse impacts from AF are ischaemic stroke (RR, 2.3; 95% CI, 1.84–2.94), ischaemic heart disease (RR, 1.61; 95% CI, 1.38–1.87), and other thromboembolic events.<sup><span class="xrefLink" id="jumplink-ehae176-B69 ehae176-B70 ehae176-B71"></span><a href="javascript:;" reveal-id="ehae176-B69 ehae176-B70 ehae176-B71" data-open="ehae176-B69 ehae176-B70 ehae176-B71" class="link link-ref link-reveal xref-bibr">69–71</a></sup> The latter typically include arterial thromboembolic events (preferred to the term systemic), although venous thromboembolism is also associated with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B72"></span><a href="javascript:;" reveal-id="ehae176-B72" data-open="ehae176-B72" class="link link-ref link-reveal xref-bibr">72</a>,<span class="xrefLink" id="jumplink-ehae176-B73"></span><a href="javascript:;" reveal-id="ehae176-B73" data-open="ehae176-B73" class="link link-ref link-reveal xref-bibr">73</a></sup> Patients with AF also have an increased risk of cognitive impairment (adjusted hazard ratio \[HR\], 1.39; 95% CI, 1.25–1.53)<sup><span class="xrefLink" id="jumplink-ehae176-B74"></span><a href="javascript:;" reveal-id="ehae176-B74" data-open="ehae176-B74" class="link link-ref link-reveal xref-bibr">74</a></sup> and dementia (OR, 1.6; 95% CI, 1.3–2.0).<sup><span class="xrefLink" id="jumplink-ehae176-B75 ehae176-B76 ehae176-B77"></span><a href="javascript:;" reveal-id="ehae176-B75 ehae176-B76 ehae176-B77" data-open="ehae176-B75 ehae176-B76 ehae176-B77" class="link link-ref link-reveal xref-bibr">75–77</a></sup> It should be noted that most of the observational studies on adverse events have a mix of patients taking and not taking OAC. When carefully controlling for the confounding effects of stroke, comorbidities, and OAC, AF exposure was still significantly associated with vascular dementia (HR, 1.68; 95% CI, 1.33–2.12; _P_ < .001), but not Alzheimer's disease (HR, 0.85; 95% CI, 0.70–1.03; _P_ = .09).<sup><span class="xrefLink" id="jumplink-ehae176-B78"></span><a href="javascript:;" reveal-id="ehae176-B78" data-open="ehae176-B78" class="link link-ref link-reveal xref-bibr">78</a></sup>

Hospital admission rates due to AF vary widely depending on the population studied, and may be skewed by selection bias. In a Dutch RCT including first-diagnosed AF patients (mean age 64 years), cardiovascular hospitalization rates were 7.0% to 9.4% per year.<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a></sup> An Australian study identified 473 501 hospitalizations for AF during 15 years of follow-up (300 million person-years), with a relative increase in AF hospitalizations of 203% over the study period, in contrast to an increase for all hospitalizations of 71%. The age-specific incidence of hospital admission increased particularly in the older age groups.<sup><span class="xrefLink" id="jumplink-ehae176-B80"></span><a href="javascript:;" reveal-id="ehae176-B80" data-open="ehae176-B80" class="link link-ref link-reveal xref-bibr">80</a></sup>

Atrial fibrillation is also associated with increased mortality. In 2017, AF contributed to over 250 000 deaths globally, with an age-standardized mortality rate of 4.0 per 100 000 people (95% uncertainty interval 3.9–4.2).<sup><span class="xrefLink" id="jumplink-ehae176-B81"></span><a href="javascript:;" reveal-id="ehae176-B81" data-open="ehae176-B81" class="link link-ref link-reveal xref-bibr">81</a></sup> The most frequent cause of death in patients with AF is heart failure related,<sup><span class="xrefLink" id="jumplink-ehae176-B70"></span><a href="javascript:;" reveal-id="ehae176-B70" data-open="ehae176-B70" class="link link-ref link-reveal xref-bibr">70</a></sup> with complex relationships to cardiovascular and non-cardiovascular disease.<sup><span class="xrefLink" id="jumplink-ehae176-B82"></span><a href="javascript:;" reveal-id="ehae176-B82" data-open="ehae176-B82" class="link link-ref link-reveal xref-bibr">82</a></sup> There is up to a two-fold increased risk of all-cause mortality (RR, 1.95; 95% CI, 1.50–2.54),<sup><span class="xrefLink" id="jumplink-ehae176-B68"></span><a href="javascript:;" reveal-id="ehae176-B68" data-open="ehae176-B68" class="link link-ref link-reveal xref-bibr">68</a></sup> and cardiovascular mortality (RR, 2.03; 95% CI, 1.79–2.30)<sup><span class="xrefLink" id="jumplink-ehae176-B69"></span><a href="javascript:;" reveal-id="ehae176-B69" data-open="ehae176-B69" class="link link-ref link-reveal xref-bibr">69</a></sup> in AF compared with sinus rhythm. Even in the absence of major thromboembolic risk factors, the incidence of death is 15.5 per 1000 person-years in those with AF exposure, compared with 9.4 per 1000 person-years without (adjusted HR, 1.44; 95% CI, 1.38–1.50; _P_ < .001).<sup><span class="xrefLink" id="jumplink-ehae176-B78"></span><a href="javascript:;" reveal-id="ehae176-B78" data-open="ehae176-B78" class="link link-ref link-reveal xref-bibr">78</a></sup> Patients with OAC-related bleeding have higher mortality, including both minor and major bleeding (as defined by the International Society on Thrombosis and Haemostasis scale).<sup><span class="xrefLink" id="jumplink-ehae176-B83"></span><a href="javascript:;" reveal-id="ehae176-B83" data-open="ehae176-B83" class="link link-ref link-reveal xref-bibr">83</a></sup> Despite OAC, patients with AF remain at high residual risk of death, highlighting the importance of attention to concomitant disease.<sup><span class="xrefLink" id="jumplink-ehae176-B84"></span><a href="javascript:;" reveal-id="ehae176-B84" data-open="ehae176-B84" class="link link-ref link-reveal xref-bibr">84</a></sup>

### 3.6. Atrial flutter

Atrial flutter (AFL) is the among the most common atrial tachyarrhythmias, with an overall incidence rate of 88 per 100 000 person-years, rising to 317 per 100 000 person-years in people over 50 years of age.<sup><span class="xrefLink" id="jumplink-ehae176-B85"></span><a href="javascript:;" reveal-id="ehae176-B85" data-open="ehae176-B85" class="link link-ref link-reveal xref-bibr">85</a></sup> Risk factors for AFL and AF are similar, and more than half of all patients with AFL will develop AF.<sup><span class="xrefLink" id="jumplink-ehae176-B85"></span><a href="javascript:;" reveal-id="ehae176-B85" data-open="ehae176-B85" class="link link-ref link-reveal xref-bibr">85</a></sup> Observational studies suggest that thromboembolic risk is elevated in AFL.<sup><span class="xrefLink" id="jumplink-ehae176-B86"></span><a href="javascript:;" reveal-id="ehae176-B86" data-open="ehae176-B86" class="link link-ref link-reveal xref-bibr">86</a></sup> In direct comparison of AFL with AF, some studies suggest a similar risk of stroke and others a lower risk in AFL,<sup><span class="xrefLink" id="jumplink-ehae176-B87 ehae176-B88 ehae176-B89 ehae176-B90"></span><a href="javascript:;" reveal-id="ehae176-B87 ehae176-B88 ehae176-B89 ehae176-B90" data-open="ehae176-B87 ehae176-B88 ehae176-B89 ehae176-B90" class="link link-ref link-reveal xref-bibr">87–90</a></sup> possibly due to different comorbidity burdens and the impact of confounders such as AFL/AF ablation and anticoagulation (more frequently stopped in AFL).<sup><span class="xrefLink" id="jumplink-ehae176-B91"></span><a href="javascript:;" reveal-id="ehae176-B91" data-open="ehae176-B91" class="link link-ref link-reveal xref-bibr">91</a></sup>

## 4\. Patient pathways and management of AF

### 4.1. Patient-centred, multidisciplinary AF management

#### 4.1.1. The patient at the heart of care

A patient-centred and integrated approach to AF management means working with a model of care that respects the patient's experience, values, needs, and preferences for planning, co-ordination, and delivery of care. A central component of this model is the therapeutic relationship between the patient and the multidisciplinary team of healthcare professionals (_[Figure 2](javascript:;)_). In patient-centred AF management, patients are seen not as passive recipients of health services, but as active participants who work as partners alongside healthcare professionals. Patient-centred AF management requires integration of all aspects of AF management. This includes symptom control, lifestyle recommendations, psychosocial support, and management of comorbidities, alongside optimal medical treatment consisting of pharmacotherapy, cardioversion, and interventional or surgical ablation (_[Table 9](javascript:;)_). Services should be designed to ensure that all patients have access to an organized model of AF management, including tertiary care specialist services when indicated (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_, _[Evidence Table 4 and Additional Evidence Table S3](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). It is equally important to maintain pathways for patients to promptly re-engage with specialist services when their condition alters.

![Multidisciplinary approach to AF management.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f2.jpeg?Expires=1728478929&Signature=iU~wifyyfffuDkYi5XpTS93o5bcRLQve~r~jPobGiQpJEbc1-2pb-8SieWnasO9WRuXeej-nK5L-i3HzzkGyDPXEd~dyy15A0NWG~6MuzNtuz1xIy602QQSmaZf4ao5OiTFDe5Shq6sUZKnlbyyV0XW0ohLuTskm8sEqY3z0zKIxlD0GhoIt0VDUPG5BpcxYBuK06fNHPnyU5r3mh-hVPYgiVqqNniwx1pjaID7RIXvYxxvuZzC3AncXwGB~tvPHm3QSp1gniIh3NadbTEoITJjA-UH4zk6AkCMjzk43Jo447jxeTZMQRbBl8GDPVoaqvCfUa8u9JRZlM~495RloiA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 2

Multidisciplinary approach to AF management.

Principal caregivers are involved in the community and hospital settings to provide optimal, patient-centred care for patients living with AF. AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment.

[Open in new tab](https://academic.oup.com/view-large/figure/479884169/ehae176f2.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f2.jpeg?Expires=1728478929&Signature=ZrRmmgCz0QFElKi0UptaeQKnU1Oa5~My0BOyg6-q~9YbizJY7qjv2l0fETKyDQSriFn3fI2GCQ~iduS6Q5h54NRfjrcP5pP5oJ8m~ZWTwRNgX~D8ELXlo9OK4ss9M~FPZjgtuBoBRTle-VOpcyeTbbYbxPAaoIJGxL86CC8chyNu08gDMOFqqaHqHMRjU-XjhpYhayJnb5omBptvoDRo0S9Uam7K4yrLEzAEi4xqQLuv6ADUZAxLuhWj2igs1T320YIXaqhPZaPI5MV0t6TDfOjixnOGtnVd9Ot9RDq1Y-dL5ORXfP-W9h6PCfhetN9quYu-H0MH7oNE7euu6Vb9lQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884169&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884170)

Achieving patient-centred AF management

| Components of patient-centred AF management: .  |
| --- |
| 
- Optimal treatment according to the AF-CARE pathway, which includes:


 |
|   ∘ \[C\] Comorbidity and risk factor management |
|   ∘ \[A\] Avoid stroke and thromboembolism |
|   ∘ \[R\] Reduce symptoms by rate and rhythm control |
|   ∘ \[E\] Evaluation and dynamic reassessment |
| 

- Lifestyle recommendations


 |
| 

- Psychosocial support


 |
| 

- Education and awareness for patients, family members, and caregivers


 |
| 

- Seamless co-ordination between primary care and specialized AF care


 |
| **How to implement patient-centred AF management:** |
| 

- Shared decision-making


 |
| 

- Multidisciplinary team approach


 |
| 

- Patient education and empowerment, with emphasis on self-care


 |
| 

- Structured educational programmes for healthcare professionals


 |
| 

- Technology support (e-Health, m-Health, telemedicine)<sup><span class="xrefLink" id="jumplink-tblfn112"></span><a href="javascript:;" reveal-id="tblfn112" data-open="tblfn112" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup>


 |

| Components of patient-centred AF management: .  |
| --- |
| 
- Optimal treatment according to the AF-CARE pathway, which includes:


 |
|   ∘ \[C\] Comorbidity and risk factor management |
|   ∘ \[A\] Avoid stroke and thromboembolism |
|   ∘ \[R\] Reduce symptoms by rate and rhythm control |
|   ∘ \[E\] Evaluation and dynamic reassessment |
| 

- Lifestyle recommendations


 |
| 

- Psychosocial support


 |
| 

- Education and awareness for patients, family members, and caregivers


 |
| 

- Seamless co-ordination between primary care and specialized AF care


 |
| **How to implement patient-centred AF management:** |
| 

- Shared decision-making


 |
| 

- Multidisciplinary team approach


 |
| 

- Patient education and empowerment, with emphasis on self-care


 |
| 

- Structured educational programmes for healthcare professionals


 |
| 

- Technology support (e-Health, m-Health, telemedicine)<sup><span class="xrefLink" id="jumplink-tblfn112"></span><a href="javascript:;" reveal-id="tblfn112" data-open="tblfn112" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup>


 |

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment.

<sup>a</sup>e-Health refers to healthcare services provided using electronic methods; m-Health, refers to healthcare services supported by mobile devices; and telemedicine refers to remote diagnosis or treatment supported by telecommunications technology.

© ESC 2024

Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884170)

Achieving patient-centred AF management

| Components of patient-centred AF management: .  |
| --- |
| 
- Optimal treatment according to the AF-CARE pathway, which includes:


 |
|   ∘ \[C\] Comorbidity and risk factor management |
|   ∘ \[A\] Avoid stroke and thromboembolism |
|   ∘ \[R\] Reduce symptoms by rate and rhythm control |
|   ∘ \[E\] Evaluation and dynamic reassessment |
| 

- Lifestyle recommendations


 |
| 

- Psychosocial support


 |
| 

- Education and awareness for patients, family members, and caregivers


 |
| 

- Seamless co-ordination between primary care and specialized AF care


 |
| **How to implement patient-centred AF management:** |
| 

- Shared decision-making


 |
| 

- Multidisciplinary team approach


 |
| 

- Patient education and empowerment, with emphasis on self-care


 |
| 

- Structured educational programmes for healthcare professionals


 |
| 

- Technology support (e-Health, m-Health, telemedicine)<sup><span class="xrefLink" id="jumplink-tblfn112"></span><a href="javascript:;" reveal-id="tblfn112" data-open="tblfn112" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup>


 |

| Components of patient-centred AF management: .  |
| --- |
| 
- Optimal treatment according to the AF-CARE pathway, which includes:


 |
|   ∘ \[C\] Comorbidity and risk factor management |
|   ∘ \[A\] Avoid stroke and thromboembolism |
|   ∘ \[R\] Reduce symptoms by rate and rhythm control |
|   ∘ \[E\] Evaluation and dynamic reassessment |
| 

- Lifestyle recommendations


 |
| 

- Psychosocial support


 |
| 

- Education and awareness for patients, family members, and caregivers


 |
| 

- Seamless co-ordination between primary care and specialized AF care


 |
| **How to implement patient-centred AF management:** |
| 

- Shared decision-making


 |
| 

- Multidisciplinary team approach


 |
| 

- Patient education and empowerment, with emphasis on self-care


 |
| 

- Structured educational programmes for healthcare professionals


 |
| 

- Technology support (e-Health, m-Health, telemedicine)<sup><span class="xrefLink" id="jumplink-tblfn112"></span><a href="javascript:;" reveal-id="tblfn112" data-open="tblfn112" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup>


 |

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment.

<sup>a</sup>e-Health refers to healthcare services provided using electronic methods; m-Health, refers to healthcare services supported by mobile devices; and telemedicine refers to remote diagnosis or treatment supported by telecommunications technology.

© ESC 2024

#### 4.1.2. Education and shared decision-making

Clear advice about the rationale for treatments, the possibility of treatment modification, and shared decision-making can help patients live with AF (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B92"></span><a href="javascript:;" reveal-id="ehae176-B92" data-open="ehae176-B92" class="link link-ref link-reveal xref-bibr">92</a></sup> An open and effective relationship between the patient and the healthcare professional is critical, with shared decision-making found to improve outcomes for OAC and arrhythmia management.<sup><span class="xrefLink" id="jumplink-ehae176-B93"></span><a href="javascript:;" reveal-id="ehae176-B93" data-open="ehae176-B93" class="link link-ref link-reveal xref-bibr">93</a>,<span class="xrefLink" id="jumplink-ehae176-B94"></span><a href="javascript:;" reveal-id="ehae176-B94" data-open="ehae176-B94" class="link link-ref link-reveal xref-bibr">94</a></sup> In using a shared approach, both the clinician and patient are involved in the decision-making process (to the extent that the patient prefers). Information is shared in both directions. Furthermore, both the clinician and the patient express their preferences and discuss the options. Of the potential treatment decisions, no treatment is also a possibility.<sup><span class="xrefLink" id="jumplink-ehae176-B95"></span><a href="javascript:;" reveal-id="ehae176-B95" data-open="ehae176-B95" class="link link-ref link-reveal xref-bibr">95</a></sup> There are several toolkits available to facilitate this, although most are focused on anticoagulation decisions. For example, the Shared Decision-Making Toolkit ([http://afibguide.com](http://afibguide.com), [http://afibguide.com/clinician](http://afibguide.com/clinician)) and the Successful Intravenous Cardioversion for Atrial Fibrillation (SIC-AF) score have been shown to reduce decisional conflict compared with usual care in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B93"></span><a href="javascript:;" reveal-id="ehae176-B93" data-open="ehae176-B93" class="link link-ref link-reveal xref-bibr">93</a>,<span class="xrefLink" id="jumplink-ehae176-B94"></span><a href="javascript:;" reveal-id="ehae176-B94" data-open="ehae176-B94" class="link link-ref link-reveal xref-bibr">94</a></sup> Patient-support organizations can also make an important contribution to providing understandable and actionable knowledge about AF and its treatments (e.g. local support groups and international charities, such as [http://afa-international.org](http://afa-international.org)). As AF is a chronic or recurrent disease in most patients, education is central to empower patients, their families, and caregivers.

#### 4.1.3. Education of healthcare professionals

Gaps in knowledge and skills across all domains of AF care are consistently described among cardiologists, neurologists, internal medicine specialists, emergency physicians, general practitioners, nurses, and allied health practitioners.<sup><span class="xrefLink" id="jumplink-ehae176-B96 ehae176-B97 ehae176-B98"></span><a href="javascript:;" reveal-id="ehae176-B96 ehae176-B97 ehae176-B98" data-open="ehae176-B96 ehae176-B97 ehae176-B98" class="link link-ref link-reveal xref-bibr">96–98</a></sup> Healthcare professionals involved in multidisciplinary AF management should have a knowledge of all available options for diagnosis and treatment.<sup><span class="xrefLink" id="jumplink-ehae176-B99 ehae176-B100 ehae176-B101"></span><a href="javascript:;" reveal-id="ehae176-B99 ehae176-B100 ehae176-B101" data-open="ehae176-B99 ehae176-B100 ehae176-B101" class="link link-ref link-reveal xref-bibr">99–101</a></sup> In the STEEER-AF trial,<sup><span class="xrefLink" id="jumplink-ehae176-B99"></span><a href="javascript:;" reveal-id="ehae176-B99" data-open="ehae176-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> real-world adherence to clinical practice guidelines for AF across six ESC countries was poor. These findings highlight the critical need for appropriate training and education of healthcare professionals.<sup><span class="xrefLink" id="jumplink-ehae176-B102"></span><a href="javascript:;" reveal-id="ehae176-B102" data-open="ehae176-B102" class="link link-ref link-reveal xref-bibr">102</a></sup>

Specifically targeted education for healthcare professionals can increase knowledge and lead to more appropriate use of OAC for prevention of thromboembolism.<sup><span class="xrefLink" id="jumplink-ehae176-B103"></span><a href="javascript:;" reveal-id="ehae176-B103" data-open="ehae176-B103" class="link link-ref link-reveal xref-bibr">103</a></sup> However, educational interventions for healthcare providers are often not enough to sustainably impact behaviour.<sup><span class="xrefLink" id="jumplink-ehae176-B104"></span><a href="javascript:;" reveal-id="ehae176-B104" data-open="ehae176-B104" class="link link-ref link-reveal xref-bibr">104</a></sup> Other tools may be needed, such as active feedback,<sup><span class="xrefLink" id="jumplink-ehae176-B103"></span><a href="javascript:;" reveal-id="ehae176-B103" data-open="ehae176-B103" class="link link-ref link-reveal xref-bibr">103</a></sup> clinical decision support tools,<sup><span class="xrefLink" id="jumplink-ehae176-B105"></span><a href="javascript:;" reveal-id="ehae176-B105" data-open="ehae176-B105" class="link link-ref link-reveal xref-bibr">105</a></sup> expert consultation,<sup><span class="xrefLink" id="jumplink-ehae176-B106"></span><a href="javascript:;" reveal-id="ehae176-B106" data-open="ehae176-B106" class="link link-ref link-reveal xref-bibr">106</a></sup> or e-Health learning.<sup><span class="xrefLink" id="jumplink-ehae176-B107"></span><a href="javascript:;" reveal-id="ehae176-B107" data-open="ehae176-B107" class="link link-ref link-reveal xref-bibr">107</a></sup>

#### 4.1.4. Inclusive management of AF

Evidence is growing on differences in AF incidence, prevalence, risk factors, comorbidities, and outcomes according to gender.<sup><span class="xrefLink" id="jumplink-ehae176-B108"></span><a href="javascript:;" reveal-id="ehae176-B108" data-open="ehae176-B108" class="link link-ref link-reveal xref-bibr">108</a></sup> Women diagnosed with AF are generally older, have more hypertension and heart failure with preserved ejection fraction (HFpEF), and have less diagnosed coronary artery disease (CAD).<sup><span class="xrefLink" id="jumplink-ehae176-B109"></span><a href="javascript:;" reveal-id="ehae176-B109" data-open="ehae176-B109" class="link link-ref link-reveal xref-bibr">109</a></sup> Registry studies have reported differences in outcomes, with higher morbidity and mortality in women, although these may be confounded by age and comorbidity burden.<sup><span class="xrefLink" id="jumplink-ehae176-B110 ehae176-B111 ehae176-B112"></span><a href="javascript:;" reveal-id="ehae176-B110 ehae176-B111 ehae176-B112" data-open="ehae176-B110 ehae176-B111 ehae176-B112" class="link link-ref link-reveal xref-bibr">110–112</a></sup> Women with AF may be more symptomatic, and report a lower quality of life.<sup><span class="xrefLink" id="jumplink-ehae176-B41"></span><a href="javascript:;" reveal-id="ehae176-B41" data-open="ehae176-B41" class="link link-ref link-reveal xref-bibr">41</a>,<span class="xrefLink" id="jumplink-ehae176-B113"></span><a href="javascript:;" reveal-id="ehae176-B113" data-open="ehae176-B113" class="link link-ref link-reveal xref-bibr">113</a></sup> It is unclear whether this is related to delayed medical assessment in women, or whether there are genuine sex differences. Despite a higher symptom load, women are less likely to undergo AF ablation than men, even though antiarrhythmic drug therapy seems to be associated with more proarrhythmic events in women.<sup><span class="xrefLink" id="jumplink-ehae176-B109"></span><a href="javascript:;" reveal-id="ehae176-B109" data-open="ehae176-B109" class="link link-ref link-reveal xref-bibr">109</a></sup> These observations call for more research on gender differences in order to prevent disparities and inequality in care. Other diversity aspects such as age, race, ethnicity, and transgender issues, as well as social determinants (including socioeconomic status, disability, education level, health literacy, and rural/urban location) are important contributors to inequality that should be actively considered to improve patient outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B114"></span><a href="javascript:;" reveal-id="ehae176-B114" data-open="ehae176-B114" class="link link-ref link-reveal xref-bibr">114</a></sup>

### 4.2. Principles of AF-CARE

The _2024 ESC Guidelines for the management of AF_ have compiled and evolved past approaches to create principles of management to aid implementation of these guidelines, and hence improve patient care and outcomes. There is growing evidence that clinical support tools<sup><span class="xrefLink" id="jumplink-ehae176-B115 ehae176-B116 ehae176-B117 ehae176-B118"></span><a href="javascript:;" reveal-id="ehae176-B115 ehae176-B116 ehae176-B117 ehae176-B118" data-open="ehae176-B115 ehae176-B116 ehae176-B117 ehae176-B118" class="link link-ref link-reveal xref-bibr">115–118</a></sup> can aid best-practice management, with the caveat that any tool is a guide only, and that all patients require personalized attention. The AF-CARE approach covers many established principles in the management of AF, but does so in a systematic, time-orientated format with four essential treatment pillars (_[Figure 3](javascript:;)_; central illustration). Joint management with each patient forms the starting point of the AF-CARE approach. Notably, it takes account of the growing evidence base that therapies for AF are most effective when associated health conditions are addressed. A careful search for these comorbidities and risk factors \[C\] is critical and should be applied in all patients with a diagnosis of AF. Avoidance of stroke and thromboembolism \[A\] in patients with risk factors is considered next, focused on appropriate use of anticoagulant therapy. Reducing AF-related symptoms and morbidity by effective use of heart rate and rhythm control \[R\] is then applied, which in selected patients may also reduce hospitalization or improve prognosis. The potential benefit of rhythm control, accompanied by consideration of all risks involved, should be considered in all patients at each contact point with healthcare professionals. As AF, and its related comorbidities, changes over time, different levels of evaluation \[E\] and re-evaluation are required in each patient, and these approaches should be dynamic. Due to the wide variability in response to therapy, and the changing pathophysiology of AF as age and comorbidities advance, reassessment should be built into the standard care pathway to prevent adverse outcomes for patients and improve population health.

![Central illustration. Patient pathway for AF-CARE (see Figures 4, 5, 6, and 7 for the [R] pathways for first-diagnosed, paroxysmal, persistent and permanent AF).](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f3.jpeg?Expires=1728478929&Signature=zJZqFezmkxa0RyS97axu20ABh1114xZryDgGMF2GAuOER-yNjZk2l8-6FdxDt0LK3uaCTsFeqsuvRH-XdEXwigRVCEp~aUPIlHaqMZ4S7Ls59VbbOjiRkytVfdKe7r0jUDd6RUlIiJi15QF8AEngdQxvwAqtD7rgrVMLIuOD1SciWeSFxEwKEOrzyLyJRr2hlNAFl-XhEFEWqGiI0uEc1icXz9OePpkB2z-T9teNdyjYqPm9YsHKAi4n37-pSwjUyC3q-waoaBj01BS5AG1myesSY3CHZdj~KqzS5ZKjlXLzaQ~0sRirENGWy3146~6Qy-gTetrcSwxeBdNplGgeMg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 3

Central illustration. Patient pathway for AF-CARE (see _[Figures 4](javascript:;), [5](javascript:;), [6](javascript:;)_, and _[7](javascript:;)_ for the \[R\] pathways for first-diagnosed, paroxysmal, persistent and permanent AF).

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CCS, chronic coronary syndrome; CHA<sub>2</sub>DS<sub>2</sub>\-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; DOAC, direct oral anticoagulant; ECG, electrocardiogram; HFrEF, heart failure with reduced ejection fraction; INR, international normalized ratio of prothrombin time; OAC, oral anticoagulant; OSA, obstructive sleep apnoea; PVD, peripheral vascular disease; SGLT2, sodium-glucose cotransporter-2; VKA, vitamin K antagonist. <sup>a</sup>As part of a comprehensive management of cardiometabolic risk factors.

[Open in new tab](https://academic.oup.com/view-large/figure/479884180/ehae176f3.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f3.jpeg?Expires=1728478929&Signature=uyIKPAXDcVOqPOiwbdI2~WFOziMtH~Y~aY0HqafD2jcjebI4t8jbO4ylXsjulYV6uIhSJCjWSR-SmK36qSx5bnugUB8Xj9R10slFw24PJkup5EYOxApqmp8y2H99XBh~nnjOesN2f6bb3izP52W4hKC-y4RnY5eOCyOEr2friPC5COKtxqWooUVJu2r50vVM6yfzT9uonbiB7J753RivchCoCuQCvpOqP-uLBhVUig13vf8Fe9Hf~B5wDb4E9oPU-ZR73bCoNGRtXtG-yeoKd~zrXsyfP8Zf1-1xJ-qMRRdY27QKuEj6gfvQJTuqCE6iqb98Sy0ihL4KRVq5ZoGNQA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884180&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

AF-CARE builds upon prior ESC Guidelines, e.g. the five-step outcome-focused integrated approach in the _2016 ESC Guidelines for the management of AF_,<sup><span class="xrefLink" id="jumplink-ehae176-B119"></span><a href="javascript:;" reveal-id="ehae176-B119" data-open="ehae176-B119" class="link link-ref link-reveal xref-bibr">119</a></sup> and the AF Better Care (ABC) pathway in the _2020 ESC Guidelines for the diagnosis and management of AF_.<sup><span class="xrefLink" id="jumplink-ehae176-B120"></span><a href="javascript:;" reveal-id="ehae176-B120" data-open="ehae176-B120" class="link link-ref link-reveal xref-bibr">120</a></sup> The reorganization into AF-CARE was based on the parallel developments in new approaches and technologies (in particular for rhythm control), with new evidence consistently suggesting that all aspects of AF management are more effective when comorbidities and risk factors have been considered. This includes management relating to symptom benefit, improving prognosis, prevention of thromboembolism, and the response to rate and rhythm control strategies. AF-CARE makes explicit the need for individualized evaluation and follow-up in every patient, with an active approach that accounts for how patients, their AF, and associated comorbidities change over time. The AF-CARE principles have been applied to different patient pathways for ease of implementation into routine clinical care. This includes the management of first-diagnosed AF (_[Figure 4](javascript:;)_), paroxysmal AF (_[Figure 5](javascript:;)_), persistent AF (_[Figure 6](javascript:;)_), and permanent AF (_[Figure 7](javascript:;)_).

![[R] Pathway for patients with first-diagnosed AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f4.jpeg?Expires=1728478929&Signature=3eeYtI4x~bRORLoZGpH1y11e4W-7sEp3M6mkuScw2YS-LzFW2XD8Er6umJv1NgxSikibsPL1EOuSGWcjz7pGeuxDhQIK5Wt9wO4v9MZic0R8yDeF4s6tLBqI62cvI29D7LAA0In~KbqxbNmI3cDPJfc5~8A-I-ug3XpRqsxon--rVXrzK199nEEaBPcBOuawxtJ6XrK~yfExqlhpvheiR6hnFPhGrpE94mOvEYJjrNHughTJqwKS08AqlgMPSE2rV~b1-ykXVld81xMTCjgp6h-TTJancS8wCOBgBS7tbELcAu5qKErVX50233nhOBJsniZyw-rZ4RA5bPyRM5UoEg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 4

\[R\] Pathway for patients with first-diagnosed AF.

AF, atrial fibrillation; AF-CARE, Atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; LVEF, left ventricular ejection fraction. After following the pathway for first-diagnosed AF, patients with recurrent AF should enter the AF-CARE \[R\] pathway for paroxysmal, persistent, or permanent AF, depending on the type of their AF.

[Open in new tab](https://academic.oup.com/view-large/figure/479884182/ehae176f4.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f4.jpeg?Expires=1728478929&Signature=tnES761iKAdaFLrLmMuLV04X03H3yjapOrjqv2Smt2l3KQy1Df8kKlPRck1zQLCCrga~84WCRedF4gdsPnZgYi2T8BKMNSR5G4XAxd-wwpVQOcOL7T94F0W8n890Oww-H8NOm5dVXQoVvPt7iMBsYtgvRRGvasjpASostyNY0znAuPUYWFJpthb~YaCOeVKNcmef0piIITibVMQOKvg5MdxH6PZzBEeZC-zMbdh~R2rkahvw5Wi0PKf9uy~w9G8uc793u-ID8RbIIsigcz6mwANkKBbilf8vbXqq175rcH59WZrWR5BE2XSfWyAersvjIdABEO5L5zutrMILt6bbCg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884182&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![[R] Pathway for patients with paroxysmal AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f5.jpeg?Expires=1728478929&Signature=gleLWqjFGA3c7PhbngMUuwRWimUtZX1zpF8RMIVndC2M8xBx18gnK9W8n7Kj-RrjaTBi5ZK4H50cGVOxGkQHZ48ntCFlz5zrn2TGshQ2LK2DDEl1Q0pSQO4hcHDbZtchKP1qMq9I9mzqkSMwXhuxolEsMA~0uORNdXx~jtk5zfs0VvFca~aIlhIBYo4WD-2GIQNVaTkNHgh5zKzPTUp5cYtWmBcEeWl4BIj86v8NJ9PAU7pXgk3ioTFQhdof0k5bNh2vsKWP2pkrpGZk7Ih0t7wcHUqDTJoU-WwhJ0nP6LlKjn5AzyxZtN~gXuQP0PxBaY4VgrLWHRIjE1LyHZroWA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 5

\[R\] Pathway for patients with paroxysmal AF.

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; b.p.m., beats per minute; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, Heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. <sup>a</sup>In patients with HFrEF: Class I if high probability of tachycardia-induced cardiomyopathy; and Class IIa in selected patients to improve prognosis.

[Open in new tab](https://academic.oup.com/view-large/figure/479884183/ehae176f5.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f5.jpeg?Expires=1728478929&Signature=RP3cfAVmClvel6VQ-dJnFyNmQ7nyibSBpi1m5oXSm7thcrv-RiaRx-ambvfev6h0bGOAqsPTR~s4defX3vsMtkCXQK~jQSobCm8YaCPSQOQX0USZDXlKgaybKL3qrs6nIhGKAaS52o69HyuZJ2TE8-TZMAfCvvmd0Wd0komJqtbuSTGBle-iGLfPzTy5SySdd7kciu8OCKbtGkUwbpODffi3kT7VjUKQdFIKzWnHdXBYGVbu1~nyQ1xHzYDzdTXajDncWQZT1eFBNBo4K85AjjaH0PoGo3nEnB2dC6glDSGFK969DnyzY4CQo0XTiCzdGZt2wpE0qr3080tMD~z8hw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884183&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![[R] Pathway for patients with persistent AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f6.jpeg?Expires=1728478929&Signature=YIyg~Ot8A9KbqGmdWVWPkw7EXqdC6Pdcqj7cwdmmOHMMytU5zLdOZGel54IR7diH2Exe3PvnRC5MQWwNpf-NRvat3zlDNaSuYNeONohJyZ~-svgmleTvw~vO5~esEh42v-cCfILGktZxwO~FLpyaYtUkXUQHqHwYCKwMxt92exkBr6BL6RlupjcUuWrxP0xXcKYrkglyRvwCi~GVSOGD92pOO-yKFRzBxHap4ttjFoVI7B4ec7nJ4bZXACdeeKACO4XKaDTYCIu6vj1C5sZ3k90kAFb1MbaMqvaS6Dgt7rowgrjDzFpRuREWNLD1Hio3V36zRZ56TR8r3vdGzBSi9Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 6

\[R\] Pathway for patients with persistent AF.

AF, atrial fibrillation; AF-CARE, Atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; b.p.m., beats per minute; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. <sup>a</sup>In patients with HFrEF: Class I if high probability of tachycardia-induced cardiomyopathy; and Class IIa in selected patients to improve prognosis.

[Open in new tab](https://academic.oup.com/view-large/figure/479884184/ehae176f6.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f6.jpeg?Expires=1728478929&Signature=Q9tPdW~RQvfAE8sBEFwxIdrf4Aw-64pUhodor3C6p3i7T41kMbv0SUBlOS4MJxqu-~8CfBmTsBFnuWT4qDgYCsez4TM1AyYGpZg8D7o-JOcvWTuaQnA6ZgmMQSJbUIJnIVG3co~8Mw1nwF-RrSE8ymJNVCOeIS-6gmaFn24YOcObzao8ORbPdIywrJRsRwNmyRcXqD2AOEM5Gca3zZMaI94mu5OlrY2C-UpkSr83wkZ~sZCngishsno43uhj3Okpk7eJ2YprhiI7OHr--MLbNXLIDKqMFv7RuzsSW-~qThtQGQzwj3uBwQzgy3nZX7CjO~eGVh9iiYBx207jwk8vVA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884184&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![[R] Pathway for patients with permanent AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f7.jpeg?Expires=1728478929&Signature=1vjTRkfX4u4sbtou~hl8dK6C0074clM2-fLVGDDSnp~gKa3gTNaon~SMncvaxhS8M6p9iUBMEd1junPwsEnYMBo8k7nMKcZUbQ2zojwSjZm5zLJt1BhYdyEoN65sEwh6mX~mqtf8y1KtaZ4KVlfyyhp8I3PsrAxqcCc05s7RZ57lU-A6UlIfQxA8QsS7zk0POnwIYg9lZXAZFpKC2Bg~nYgo8x0RWd8bYaM0ybGZI3plFcjJEK88vgkOn9lYKRwvZnAZBrBy2Iyeu8XYszrC-bow3Lhzg4rXwoZ3HGHgBIwVq4RoP5KewyMwaGngRlr0i-PAbOqFTknE4J3rP0Y1lA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 7

\[R\] Pathway for patients with permanent AF.

AF, atrial fibrillation; AF-CARE, Atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; b.p.m., beats per minute; CRT, cardiac resynchronization therapy; HF, heart failure; LVEF, left ventricular ejection fraction. Permanent AF is a shared decision made between the patient and physician that no further attempts at restoration of sinus rhythm are planned. <sup>a</sup>Note that the combination of beta-blockers with diltiazem or verapamil should only be used under specialist advice, and monitored with an ambulatory ECG to check for bradycardia.

[Open in new tab](https://academic.oup.com/view-large/figure/479884185/ehae176f7.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f7.jpeg?Expires=1728478929&Signature=pGgZylpuPfcRtjqoYirlF01Cdap6wIRSt2lOaWH7Q~4U9uhD-1RHuoNJ5g5dNSd9~SR1UthWWmkjWvSLypeeresfnPqRwHxoNp9Tz8z2YtfPq089tqeXkS6vthFNAxso~r0eLYO3iMRHTb~ORgWtb2xxuTgifaiOCVXQZHyaomUpA0CPLCdl2n9iINvZzbhItX9Lt4ZQ-lVF9WbyxvZTX6a~eAdjFRSf8kjFNVCxRurT~y~ZVGcYCCJvNGGpPaIpUutSzk3oXtKMxz6bgTHZERP-VtfuCUuK93r57JD-EDJsjU2kQHVGy6uuKdClwtnngVzdGF36GWbxjjZuTqcFjQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884185&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884186)

Recommendations for patient-centred care and education (see also Evidence Table 4)

![Recommendations for patient-centred care and education (see also Evidence Table 4)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt4.jpeg?Expires=1728478929&Signature=dSGKHnbd109Sez--XkdmCGDvnfsgwDNmEE-cOBfrFFC2iM-pA20rHiOlzSCVmGgUX3WJEEvJQxPNKcFnl0TpP~PcbPUPWfDpw6Y7Yeorh2wxRmUZNgKw5I70dMODTA-FZA-JceRHTQTzAMMF6Q90mWpp3pJiAtqZwD0kI7CkwN7PH971Q2fCpARE1VXALo4TSaFBMKb8B2~LWHzILMOQgpvzWq9hNgI2zcv~8QfVDrUn3WA69R8Z~YDkEbiHJnUIpsSeGno~40L~-y6rF6SBe3l3Elzk6jJ0V0sAl-EjV6mdY-vTnnb1r8fzxQ0EvRgJi1-aOyvNmxl4SMHjAxboxg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884186)

Recommendations for patient-centred care and education (see also Evidence Table 4)

![Recommendations for patient-centred care and education (see also Evidence Table 4)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt4.jpeg?Expires=1728478929&Signature=dSGKHnbd109Sez--XkdmCGDvnfsgwDNmEE-cOBfrFFC2iM-pA20rHiOlzSCVmGgUX3WJEEvJQxPNKcFnl0TpP~PcbPUPWfDpw6Y7Yeorh2wxRmUZNgKw5I70dMODTA-FZA-JceRHTQTzAMMF6Q90mWpp3pJiAtqZwD0kI7CkwN7PH971Q2fCpARE1VXALo4TSaFBMKb8B2~LWHzILMOQgpvzWq9hNgI2zcv~8QfVDrUn3WA69R8Z~YDkEbiHJnUIpsSeGno~40L~-y6rF6SBe3l3Elzk6jJ0V0sAl-EjV6mdY-vTnnb1r8fzxQ0EvRgJi1-aOyvNmxl4SMHjAxboxg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 5\. \[C\] Comorbidity and risk factor management

A broad array of comorbidities are associated with the recurrence and progression of AF. Managing comorbidities is also central to the success of other aspects of care for patients with AF, with evidence available for hypertension, heart failure, diabetes mellitus, obesity, and sleep apnoea, along with lifestyle changes that improve physical activity and reduce alcohol intake (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Identification and treatment of these comorbidities and clusters of risk factors form an important part of effective AF-CARE (_[Figure 8](javascript:;)_), with the evidence outlined in the rest of this section highlighting where management can improve patient outcomes or prevent AF recurrence. Many of these factors (and more) are also associated with incident AF (see _Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s9)_).

![Management of key comorbidities to reduce AF recurrence.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f8.jpeg?Expires=1728478929&Signature=zJzeMf7YU-Q~iIEpwnzjjXJtqScDDj9Ib7xXSM5jphv4PAcx5RVcA8Km~dOfjNuWjLTmTfXLeSTe6TGXyjzKwWP1wXJobui9GVcxzVXWF~Whzgq7tw-Q2hagtqA5zbCO79u-Mf0ZyqCnGLjWnCWRA911MxG7zt0hPtMkVrllGY53Y4TL89ts~~~m7efl~pEhhAZ2IjsyB3dXn1y8rDt-OkqbKclej3hYQ4TBW~TyZguZnCZWzCWuoJ-qmsY7g~mbrr4BeZmasVM0PG-ufZQmJq17afZzjgoBs6NNJGOkkyIXWaoWg-jgLrMT-AYkc7pwMrOizeRE7idCoBN6WMsNpQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 8

Management of key comorbidities to reduce AF recurrence.

LVEF, left ventricular ejection fraction; SGLT2, sodium-glucose cotransporter-2.

[Open in new tab](https://academic.oup.com/view-large/figure/479884189/ehae176f8.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f8.jpeg?Expires=1728478929&Signature=OfmvrmKFbZDjuqTS5k2TX8HzOyxEVMo9QlDBp9ZmzfazcBCaLZKCVyPvZ~yVP4kyLD9jYHxaNeV8i3xkiOqeH8w0tcFLCzvyJWbq7aDhJ5CPn2MArZqRqj76HEApzTq-EfbZJDBHVe59sQZh064fzhUVGuGIHLYZfFX6RFEUOLubT~0oI9beY74UiKYpODML4gdwt~ERn7JZtYkA~QN34bIpkAgLpvjl-dRS49Qp7nlp3fgzhhr7kHUnWgkE5trfcEq1lcJ-oUzaI579AQu8LNnPFldlu~jh~850T8IXRJ0CobciwqDJ8LsWRpdMzRrcjAJIahAPhDGbrS68GV3hmw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884189&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884190)

Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5)

![Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt5.jpeg?Expires=1728478929&Signature=kd~DZdmPmV2hb6dBThEfHxr41Pia3Fw0abQlzzPL2Yo4oWcCFqs-AKK1sQimGomdDQatS6t6IdKST3-FBQK1f0jMiROW87ZLbWz1uVZKPjCA2T8URX8~YFAEGUs4DvrSCZbj8guwM52EgcW4pQ3iAIHwLr5y73C6kWFSlAfFuraEqBgmWAERnYc-TUpPCbAq4PgqICs8LFSkFVMiNvt9WqnVmFfdwCewxTwdpwnKlcnGqyiHUxQDeqIlpq4ydly7pwTe4pjVZNgBkxkZqY6OLE7-R~Zj5qRJcW1caxypC9FLSrWN5v9SsvpMcqQrg7giiZjzHshLEmOAiQe9i4cnBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884190)

Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5)

![Recommendations for comorbidity and risk factor management in AF (see also Evidence Table 5)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt5.jpeg?Expires=1728478929&Signature=kd~DZdmPmV2hb6dBThEfHxr41Pia3Fw0abQlzzPL2Yo4oWcCFqs-AKK1sQimGomdDQatS6t6IdKST3-FBQK1f0jMiROW87ZLbWz1uVZKPjCA2T8URX8~YFAEGUs4DvrSCZbj8guwM52EgcW4pQ3iAIHwLr5y73C6kWFSlAfFuraEqBgmWAERnYc-TUpPCbAq4PgqICs8LFSkFVMiNvt9WqnVmFfdwCewxTwdpwnKlcnGqyiHUxQDeqIlpq4ydly7pwTe4pjVZNgBkxkZqY6OLE7-R~Zj5qRJcW1caxypC9FLSrWN5v9SsvpMcqQrg7giiZjzHshLEmOAiQe9i4cnBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 5.1. Hypertension

Hypertension in patients with AF is associated with an increased risk of stroke, heart failure, major bleeding, and cardiovascular mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B158 ehae176-B159 ehae176-B160 ehae176-B161"></span><a href="javascript:;" reveal-id="ehae176-B158 ehae176-B159 ehae176-B160 ehae176-B161" data-open="ehae176-B158 ehae176-B159 ehae176-B160 ehae176-B161" class="link link-ref link-reveal xref-bibr">158–161</a></sup> The target for treated systolic blood pressure (BP) in most adults is 120–129 mmHg. Where BP-lowering treatment is poorly tolerated, clinically significant frailty exists or the patient's age is 85 years or older, a more lenient target of <140 mmHg is acceptable or ‘as low as reasonably achievable’. On-treatment diastolic BP should ideally be 70–79 mmHg.<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a></sup> In an individual participant data meta-analysis of 22 randomized trials reporting baseline AF, a 5 mmHg reduction in systolic BP reduced the risk of major cardiovascular events by 9% (HR, 0.91; 95% CI, 0.83–1.00), with identical effect in patients with AF or sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B129"></span><a href="javascript:;" reveal-id="ehae176-B129" data-open="ehae176-B129" class="link link-ref link-reveal xref-bibr">129</a></sup>

In individuals with AF, hypertension often coexists with other modifiable and non-modifiable risk factors that all contribute to recurrence of AF, readmission to hospital, and ongoing symptoms after rhythm control.<sup><span class="xrefLink" id="jumplink-ehae176-B163 ehae176-B164 ehae176-B165 ehae176-B166 ehae176-B167 ehae176-B168 ehae176-B169 ehae176-B170 ehae176-B171"></span><a href="javascript:;" reveal-id="ehae176-B163 ehae176-B164 ehae176-B165 ehae176-B166 ehae176-B167 ehae176-B168 ehae176-B169 ehae176-B170 ehae176-B171" data-open="ehae176-B163 ehae176-B164 ehae176-B165 ehae176-B166 ehae176-B167 ehae176-B168 ehae176-B169 ehae176-B170 ehae176-B171" class="link link-ref link-reveal xref-bibr">163–171</a></sup> Optimal control of blood pressure should be considered an essential component of treating AF and undertaken within a strategy of comprehensive risk factor management.<sup><span class="xrefLink" id="jumplink-ehae176-B126 ehae176-B127 ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B126 ehae176-B127 ehae176-B128" data-open="ehae176-B126 ehae176-B127 ehae176-B128" class="link link-ref link-reveal xref-bibr">126–128</a></sup> Although the majority of research has focused on clinical outcomes, limited comparative data on hypertension medication suggests that use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) may be superior for prevention of recurrent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B172 ehae176-B173 ehae176-B174 ehae176-B175"></span><a href="javascript:;" reveal-id="ehae176-B172 ehae176-B173 ehae176-B174 ehae176-B175" data-open="ehae176-B172 ehae176-B173 ehae176-B174 ehae176-B175" class="link link-ref link-reveal xref-bibr">172–175</a></sup>

### 5.2. Heart failure

Heart failure is a key determinant of prognosis in patients with AF, as well as an important factor associated with recurrence and progression of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B176"></span><a href="javascript:;" reveal-id="ehae176-B176" data-open="ehae176-B176" class="link link-ref link-reveal xref-bibr">176</a>,<span class="xrefLink" id="jumplink-ehae176-B177"></span><a href="javascript:;" reveal-id="ehae176-B177" data-open="ehae176-B177" class="link link-ref link-reveal xref-bibr">177</a></sup> During 30 years of follow-up in the Framingham cohort, 57% of those with new heart failure had concomitant AF, and 37% of those with new AF had heart failure.<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a></sup> Numerous cardiovascular and non-cardiovascular conditions impact the development of both AF and heart failure, leading to the common pathway of atrial cardiomyopathy.<sup><span class="xrefLink" id="jumplink-ehae176-B18"></span><a href="javascript:;" reveal-id="ehae176-B18" data-open="ehae176-B18" class="link link-ref link-reveal xref-bibr">18</a></sup> In patients with acute heart failure attending the emergency department, AF is one of the most prevalent triggering factors of the episode.<sup><span class="xrefLink" id="jumplink-ehae176-B179"></span><a href="javascript:;" reveal-id="ehae176-B179" data-open="ehae176-B179" class="link link-ref link-reveal xref-bibr">179</a></sup> The development of heart failure in patients with AF is associated with a two-fold increase in stroke and thromboembolism,<sup><span class="xrefLink" id="jumplink-ehae176-B180"></span><a href="javascript:;" reveal-id="ehae176-B180" data-open="ehae176-B180" class="link link-ref link-reveal xref-bibr">180</a></sup> even after anticoagulation,<sup><span class="xrefLink" id="jumplink-ehae176-B181"></span><a href="javascript:;" reveal-id="ehae176-B181" data-open="ehae176-B181" class="link link-ref link-reveal xref-bibr">181</a></sup> and 25% higher all-cause mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a></sup> Prognosis may be affected by left ventricular ejection fraction (LVEF), with the rate of death highest with the combination of AF and heart failure with reduced ejection fraction (HFrEF) (LVEF ≤ 40%), as compared with AF and HFpEF (LVEF ≥ 50%). However, rates of stroke and incident heart failure hospitalization are similar regardless of LVEF.<sup><span class="xrefLink" id="jumplink-ehae176-B182"></span><a href="javascript:;" reveal-id="ehae176-B182" data-open="ehae176-B182" class="link link-ref link-reveal xref-bibr">182</a></sup> Due to how common concomitant AF and heart failure are in clinical practice, strategies to improve outcomes in these patients are detailed within each component of the AF-CARE pathway. However, it is also critical that heart failure itself is managed appropriately in patients with AF to prevent avoidable adverse events.

Optimization of heart failure management should follow current ESC Guidelines: 2023 Focused Update<sup><span class="xrefLink" id="jumplink-ehae176-B183"></span><a href="javascript:;" reveal-id="ehae176-B183" data-open="ehae176-B183" class="link link-ref link-reveal xref-bibr">183</a></sup> of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.<sup><span class="xrefLink" id="jumplink-ehae176-B137"></span><a href="javascript:;" reveal-id="ehae176-B137" data-open="ehae176-B137" class="link link-ref link-reveal xref-bibr">137</a></sup> Achieving euvolaemia with diuretics is an important first step that not only manages the heart failure component, but can also facilitate better control of heart rate in AF. For HFrEF, it should be highlighted that many older guideline-recommended therapies lack specific evidence for benefit in patients with coexisting AF. No trial data are available in this context for ACE inhibitors, there are conflicting data on ARBs,<sup><span class="xrefLink" id="jumplink-ehae176-B132"></span><a href="javascript:;" reveal-id="ehae176-B132" data-open="ehae176-B132" class="link link-ref link-reveal xref-bibr">132</a>,<span class="xrefLink" id="jumplink-ehae176-B184"></span><a href="javascript:;" reveal-id="ehae176-B184" data-open="ehae176-B184" class="link link-ref link-reveal xref-bibr">184</a></sup> and an individual patient-level analysis of RCTs found no difference between beta-blockers and placebo for all-cause mortality in HFrEF with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B133"></span><a href="javascript:;" reveal-id="ehae176-B133" data-open="ehae176-B133" class="link link-ref link-reveal xref-bibr">133</a></sup> However, these drugs have clear proof of safety and there may be other indications for these therapies beyond prognosis, including comorbidity management and symptom improvement. These and other therapies may also have dual functions, for example, beta-blockers or digoxin for rate control of AF, in addition to improving heart failure metrics and reducing hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B48" data-open="ehae176-B48" class="link link-ref link-reveal xref-bibr">48</a>,<span class="xrefLink" id="jumplink-ehae176-B185"></span><a href="javascript:;" reveal-id="ehae176-B185" data-open="ehae176-B185" class="link link-ref link-reveal xref-bibr">185</a>,<span class="xrefLink" id="jumplink-ehae176-B186"></span><a href="javascript:;" reveal-id="ehae176-B186" data-open="ehae176-B186" class="link link-ref link-reveal xref-bibr">186</a></sup> More recent additions to HFrEF management, such as eplerenone, sacubitril-valsartan, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, had substantial numbers of patients with AF enrolled in RCTs, with no evidence that AF status affected their ability to reduce cardiovascular mortality/heart failure hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B134 ehae176-B135 ehae176-B136"></span><a href="javascript:;" reveal-id="ehae176-B134 ehae176-B135 ehae176-B136" data-open="ehae176-B134 ehae176-B135 ehae176-B136" class="link link-ref link-reveal xref-bibr">134–136</a></sup> Cardiac resynchronization therapy (CRT) in the context of HFrEF and AF is discussed in detail in the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy, with an important focus on ensuring effective biventricular pacing (with a low threshold for considering atrioventricular node ablation).<sup><span class="xrefLink" id="jumplink-ehae176-B187"></span><a href="javascript:;" reveal-id="ehae176-B187" data-open="ehae176-B187" class="link link-ref link-reveal xref-bibr">187</a></sup> Patients who have heart failure with mildly reduced ejection fraction (HFmrEF) (LVEF 41%–49%) and AF should generally be treated according to guidance for HFrEF,<sup><span class="xrefLink" id="jumplink-ehae176-B137"></span><a href="javascript:;" reveal-id="ehae176-B137" data-open="ehae176-B137" class="link link-ref link-reveal xref-bibr">137</a></sup> albeit with limited evidence to date in AF.<sup><span class="xrefLink" id="jumplink-ehae176-B188 ehae176-B189 ehae176-B190"></span><a href="javascript:;" reveal-id="ehae176-B188 ehae176-B189 ehae176-B190" data-open="ehae176-B188 ehae176-B189 ehae176-B190" class="link link-ref link-reveal xref-bibr">188–190</a></sup> For treatment of HFpEF and AF,<sup><span class="xrefLink" id="jumplink-ehae176-B191"></span><a href="javascript:;" reveal-id="ehae176-B191" data-open="ehae176-B191" class="link link-ref link-reveal xref-bibr">191</a></sup> pre-specified subgroup data on AF from multiple large trials show that the SGLT2 inhibitors dapagliflozin, empaglifozin, and sotagliflozin are effective in improving prognosis.<sup><span class="xrefLink" id="jumplink-ehae176-B138 ehae176-B139 ehae176-B140"></span><a href="javascript:;" reveal-id="ehae176-B138 ehae176-B139 ehae176-B140" data-open="ehae176-B138 ehae176-B139 ehae176-B140" class="link link-ref link-reveal xref-bibr">138–140</a></sup>

Appropriate management of heart failure has the potential to reduce recurrence of AF, e.g. by reducing adverse atrial and ventricular myocardial remodelling, but there are limited data for specific therapies. In the Routine versus Aggressive upstream rhythm Control for prevention of Early AF in heart failure (RACE 3) trial, combined management of mild-to-moderate heart failure with ACE inhibitors/ARBs, mineralocorticoid receptor antagonists, statins, and cardiac rehabilitation increased the maintenance of sinus rhythm on ambulatory monitoring at 12 months.<sup><span class="xrefLink" id="jumplink-ehae176-B39"></span><a href="javascript:;" reveal-id="ehae176-B39" data-open="ehae176-B39" class="link link-ref link-reveal xref-bibr">39</a></sup> This benefit was not preserved at the 5 year follow-up, although this may have been confounded by the lack of ongoing intervention beyond the initial 12 months.<sup><span class="xrefLink" id="jumplink-ehae176-B192"></span><a href="javascript:;" reveal-id="ehae176-B192" data-open="ehae176-B192" class="link link-ref link-reveal xref-bibr">192</a></sup>

### 5.3. Type 2 diabetes mellitus

Diabetes mellitus is present in around 25% of patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B193 ehae176-B194 ehae176-B195"></span><a href="javascript:;" reveal-id="ehae176-B193 ehae176-B194 ehae176-B195" data-open="ehae176-B193 ehae176-B194 ehae176-B195" class="link link-ref link-reveal xref-bibr">193–195</a></sup> Patients with both diabetes and AF have a worse prognosis,<sup><span class="xrefLink" id="jumplink-ehae176-B196"></span><a href="javascript:;" reveal-id="ehae176-B196" data-open="ehae176-B196" class="link link-ref link-reveal xref-bibr">196</a></sup> with increased healthcare utilization and excess mortality and cardiovascular events. The prevalence and incidence of AF and type 2 diabetes are widely increasing, thus making the association of these two conditions a public health challenge.<sup><span class="xrefLink" id="jumplink-ehae176-B195"></span><a href="javascript:;" reveal-id="ehae176-B195" data-open="ehae176-B195" class="link link-ref link-reveal xref-bibr">195</a>,<span class="xrefLink" id="jumplink-ehae176-B197"></span><a href="javascript:;" reveal-id="ehae176-B197" data-open="ehae176-B197" class="link link-ref link-reveal xref-bibr">197</a></sup> Moreover, diabetes is a major factor influencing thromboembolic risk.<sup><span class="xrefLink" id="jumplink-ehae176-B198"></span><a href="javascript:;" reveal-id="ehae176-B198" data-open="ehae176-B198" class="link link-ref link-reveal xref-bibr">198</a>,<span class="xrefLink" id="jumplink-ehae176-B199"></span><a href="javascript:;" reveal-id="ehae176-B199" data-open="ehae176-B199" class="link link-ref link-reveal xref-bibr">199</a></sup> Following catheter ablation of AF, diabetes and higher HbA1c are associated with increased length of stay and a greater recurrence of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B200 ehae176-B201 ehae176-B202 ehae176-B203"></span><a href="javascript:;" reveal-id="ehae176-B200 ehae176-B201 ehae176-B202 ehae176-B203" data-open="ehae176-B200 ehae176-B201 ehae176-B202 ehae176-B203" class="link link-ref link-reveal xref-bibr">200–203</a></sup>

In cohort studies, the management of diabetes mellitus as part of comprehensive risk factor management has been associated with reduced AF symptoms, burden, reversal of the type of AF (from persistent to paroxysmal or no AF), and improved maintenance of sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B126 ehae176-B127 ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B126 ehae176-B127 ehae176-B128" data-open="ehae176-B126 ehae176-B127 ehae176-B128" class="link link-ref link-reveal xref-bibr">126–128</a></sup> However, robust evidence is limited, and individual glucose-lowering medications have had variable effects on AF.<sup><span class="xrefLink" id="jumplink-ehae176-B204 ehae176-B205 ehae176-B206"></span><a href="javascript:;" reveal-id="ehae176-B204 ehae176-B205 ehae176-B206" data-open="ehae176-B204 ehae176-B205 ehae176-B206" class="link link-ref link-reveal xref-bibr">204–206</a></sup> There are emerging data of the use of SGLT2 and glucagon-like peptide-1 antagonists in patients with diabetes and AF that may impact on treatment choice in the near future. Importantly, diabetes frequently coexists with multiple risk factors in patients with AF, and a comprehensive approach to management is required. Further details are provided in the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.<sup><span class="xrefLink" id="jumplink-ehae176-B207"></span><a href="javascript:;" reveal-id="ehae176-B207" data-open="ehae176-B207" class="link link-ref link-reveal xref-bibr">207</a></sup>

### 5.4. Obesity

Obesity frequently coexists with other risk factors that have been independently associated with the development of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B208"></span><a href="javascript:;" reveal-id="ehae176-B208" data-open="ehae176-B208" class="link link-ref link-reveal xref-bibr">208</a>,<span class="xrefLink" id="jumplink-ehae176-B209"></span><a href="javascript:;" reveal-id="ehae176-B209" data-open="ehae176-B209" class="link link-ref link-reveal xref-bibr">209</a></sup> Obesity (body mass index \[BMI\] ≥30 kg/m<sup>2</sup>) and being overweight (BMI >25 kg/m<sup>2</sup>) are associated with a greater risk of recurrent atrial arrhythmias after AF ablation (13% increase for every 5 kg/m<sup>2</sup> higher BMI).<sup><span class="xrefLink" id="jumplink-ehae176-B210 ehae176-B211 ehae176-B212"></span><a href="javascript:;" reveal-id="ehae176-B210 ehae176-B211 ehae176-B212" data-open="ehae176-B210 ehae176-B211 ehae176-B212" class="link link-ref link-reveal xref-bibr">210–212</a></sup> In the setting of comprehensive risk factor management, weight loss of ≥10% in overweight and obese individuals with AF has been associated with reduced AF symptoms and AF burden in an RCT (aiming for BMI <27 kg/m<sup>2</sup>).<sup><span class="xrefLink" id="jumplink-ehae176-B125"></span><a href="javascript:;" reveal-id="ehae176-B125" data-open="ehae176-B125" class="link link-ref link-reveal xref-bibr">125</a></sup> Cohort studies have also shown a graded response to maintenance of sinus rhythm,<sup><span class="xrefLink" id="jumplink-ehae176-B126"></span><a href="javascript:;" reveal-id="ehae176-B126" data-open="ehae176-B126" class="link link-ref link-reveal xref-bibr">126</a></sup> improved ablation outcomes,<sup><span class="xrefLink" id="jumplink-ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B128" data-open="ehae176-B128" class="link link-ref link-reveal xref-bibr">128</a></sup> and reversal of the type of AF<sup><span class="xrefLink" id="jumplink-ehae176-B127"></span><a href="javascript:;" reveal-id="ehae176-B127" data-open="ehae176-B127" class="link link-ref link-reveal xref-bibr">127</a></sup> commensurate with the degree of weight loss and risk factor management. However, in the Supervised Obesity Reduction Trial for AF Ablation Patients (SORT-AF) randomized trial in AF ablation patients, a sole weight loss intervention that achieved 4% loss in weight over 12 months did not impact ablation outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B213"></span><a href="javascript:;" reveal-id="ehae176-B213" data-open="ehae176-B213" class="link link-ref link-reveal xref-bibr">213</a></sup> This is consistent with the findings in LEGACY (Long-Term Effect of Goal directed weight management on Atrial Fibrillation Cohort: a 5 Year follow-up study) that showed that weight loss of ≤3% had no impact on AF recurrence.<sup><span class="xrefLink" id="jumplink-ehae176-B126"></span><a href="javascript:;" reveal-id="ehae176-B126" data-open="ehae176-B126" class="link link-ref link-reveal xref-bibr">126</a></sup> Observational studies have raised the possibility of a point of no return in terms of the benefit of weight loss,<sup><span class="xrefLink" id="jumplink-ehae176-B214"></span><a href="javascript:;" reveal-id="ehae176-B214" data-open="ehae176-B214" class="link link-ref link-reveal xref-bibr">214</a></sup> but also the possibility that bariatric surgery can improve symptoms and reduce AF recurrence.<sup><span class="xrefLink" id="jumplink-ehae176-B215 ehae176-B216 ehae176-B217"></span><a href="javascript:;" reveal-id="ehae176-B215 ehae176-B216 ehae176-B217" data-open="ehae176-B215 ehae176-B216 ehae176-B217" class="link link-ref link-reveal xref-bibr">215–217</a></sup>

### 5.5. Obstructive sleep apnoea

Obstructive sleep apnoea (OSA) is a highly prevalent condition, particularly in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B157"></span><a href="javascript:;" reveal-id="ehae176-B157" data-open="ehae176-B157" class="link link-ref link-reveal xref-bibr">157</a>,<span class="xrefLink" id="jumplink-ehae176-B218"></span><a href="javascript:;" reveal-id="ehae176-B218" data-open="ehae176-B218" class="link link-ref link-reveal xref-bibr">218</a></sup> Optimal screening tools in the AF population are still under evaluation, although it may be reasonable to screen for OSA in patients where a rhythm control strategy is being pursued. Polysomnography or home sleep apnoea testing are suggested in preference to screening questionnaires.<sup><span class="xrefLink" id="jumplink-ehae176-B155 ehae176-B156 ehae176-B157"></span><a href="javascript:;" reveal-id="ehae176-B155 ehae176-B156 ehae176-B157" data-open="ehae176-B155 ehae176-B156 ehae176-B157" class="link link-ref link-reveal xref-bibr">155–157</a>,<span class="xrefLink" id="jumplink-ehae176-B219"></span><a href="javascript:;" reveal-id="ehae176-B219" data-open="ehae176-B219" class="link link-ref link-reveal xref-bibr">219</a></sup> Questionnaires assessing daytime sleepiness are poor predictors of moderate-to-severe OSA.<sup><span class="xrefLink" id="jumplink-ehae176-B155"></span><a href="javascript:;" reveal-id="ehae176-B155" data-open="ehae176-B155" class="link link-ref link-reveal xref-bibr">155</a></sup> Which parameter should be used to focus on risk of AF in patients with OSA, and to guide OSA treatment in patients with AF, is still unclear.<sup><span class="xrefLink" id="jumplink-ehae176-B220"></span><a href="javascript:;" reveal-id="ehae176-B220" data-open="ehae176-B220" class="link link-ref link-reveal xref-bibr">220</a>,<span class="xrefLink" id="jumplink-ehae176-B221"></span><a href="javascript:;" reveal-id="ehae176-B221" data-open="ehae176-B221" class="link link-ref link-reveal xref-bibr">221</a></sup>

Observational studies have suggested that individuals with OSA not treated with continuous positive airway pressure (CPAP) respond poorly to treatments for AF, with an increased risk of recurrence after cardioversion or ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B222"></span><a href="javascript:;" reveal-id="ehae176-B222" data-open="ehae176-B222" class="link link-ref link-reveal xref-bibr">222</a></sup> Conversely, OSA patients treated with CPAP seem to mitigate their propensity toward developing AF.<sup><span class="xrefLink" id="jumplink-ehae176-B148 ehae176-B149 ehae176-B150 ehae176-B151 ehae176-B152 ehae176-B153"></span><a href="javascript:;" reveal-id="ehae176-B148 ehae176-B149 ehae176-B150 ehae176-B151 ehae176-B152 ehae176-B153" data-open="ehae176-B148 ehae176-B149 ehae176-B150 ehae176-B151 ehae176-B152 ehae176-B153" class="link link-ref link-reveal xref-bibr">148–153</a>,<span class="xrefLink" id="jumplink-ehae176-B222 ehae176-B223 ehae176-B224"></span><a href="javascript:;" reveal-id="ehae176-B222 ehae176-B223 ehae176-B224" data-open="ehae176-B222 ehae176-B223 ehae176-B224" class="link link-ref link-reveal xref-bibr">222–224</a></sup> A small randomized trial of CPAP vs. no therapy demonstrated reversal of atrial remodelling in individuals with moderate OSA.<sup><span class="xrefLink" id="jumplink-ehae176-B154"></span><a href="javascript:;" reveal-id="ehae176-B154" data-open="ehae176-B154" class="link link-ref link-reveal xref-bibr">154</a></sup> However, other small RCTs have failed to show a benefit of CPAP therapy on ablation outcomes<sup><span class="xrefLink" id="jumplink-ehae176-B225"></span><a href="javascript:;" reveal-id="ehae176-B225" data-open="ehae176-B225" class="link link-ref link-reveal xref-bibr">225</a></sup> or post-cardioversion.<sup><span class="xrefLink" id="jumplink-ehae176-B226"></span><a href="javascript:;" reveal-id="ehae176-B226" data-open="ehae176-B226" class="link link-ref link-reveal xref-bibr">226</a></sup> Data on the cardiovascular mortality benefit of CPAP therapy in OSA are inconclusive.<sup><span class="xrefLink" id="jumplink-ehae176-B227 ehae176-B228 ehae176-B229 ehae176-B230"></span><a href="javascript:;" reveal-id="ehae176-B227 ehae176-B228 ehae176-B229 ehae176-B230" data-open="ehae176-B227 ehae176-B228 ehae176-B229 ehae176-B230" class="link link-ref link-reveal xref-bibr">227–230</a></sup>

### 5.6. Physical inactivity

Reduced cardiorespiratory fitness frequently coexists with other modifiable risk factors and has been associated with a greater recurrence of AF after catheter ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B141"></span><a href="javascript:;" reveal-id="ehae176-B141" data-open="ehae176-B141" class="link link-ref link-reveal xref-bibr">141</a></sup> Better cardiorespiratory fitness has a demonstrated inverse relationship to AF burden in both middle-aged and elderly people.<sup><span class="xrefLink" id="jumplink-ehae176-B141"></span><a href="javascript:;" reveal-id="ehae176-B141" data-open="ehae176-B141" class="link link-ref link-reveal xref-bibr">141</a></sup> Small RCTs, meta-analyses, and observational cohorts have shown that regular aerobic exercise may also improve AF-related symptoms, quality of life, and exercise capacity.<sup><span class="xrefLink" id="jumplink-ehae176-B142"></span><a href="javascript:;" reveal-id="ehae176-B142" data-open="ehae176-B142" class="link link-ref link-reveal xref-bibr">142</a>,<span class="xrefLink" id="jumplink-ehae176-B143"></span><a href="javascript:;" reveal-id="ehae176-B143" data-open="ehae176-B143" class="link link-ref link-reveal xref-bibr">143</a></sup> Better cardiorespiratory fitness and a gain in cardiorespiratory fitness over time are associated with a greater reduction in AF burden and improved maintenance of sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B141 ehae176-B142 ehae176-B143 ehae176-B144 ehae176-B145"></span><a href="javascript:;" reveal-id="ehae176-B141 ehae176-B142 ehae176-B143 ehae176-B144 ehae176-B145" data-open="ehae176-B141 ehae176-B142 ehae176-B143 ehae176-B144 ehae176-B145" class="link link-ref link-reveal xref-bibr">141–145</a></sup>

### 5.7. Alcohol excess

Alcohol consumption can increase the risk of adverse events in patients with AF, such as thromboembolism, death, or AF-related hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B231"></span><a href="javascript:;" reveal-id="ehae176-B231" data-open="ehae176-B231" class="link link-ref link-reveal xref-bibr">231</a>,<span class="xrefLink" id="jumplink-ehae176-B232"></span><a href="javascript:;" reveal-id="ehae176-B232" data-open="ehae176-B232" class="link link-ref link-reveal xref-bibr">232</a></sup> Alcohol is associated with an increased risk of ischaemic stroke in patients with newly diagnosed AF, and alcohol abstinence after AF diagnosis can reduce the risk of ischaemic stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B233"></span><a href="javascript:;" reveal-id="ehae176-B233" data-open="ehae176-B233" class="link link-ref link-reveal xref-bibr">233</a></sup> In patients receiving OAC, alcohol excess is associated with a greater risk of bleeding,<sup><span class="xrefLink" id="jumplink-ehae176-B234"></span><a href="javascript:;" reveal-id="ehae176-B234" data-open="ehae176-B234" class="link link-ref link-reveal xref-bibr">234</a></sup> mediated by poor adherence, alcohol–drug interactions, liver disease, and variceal bleeding.

Alcohol consumption is associated with a dose-dependent increase in the recurrence of AF after catheter ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B147"></span><a href="javascript:;" reveal-id="ehae176-B147" data-open="ehae176-B147" class="link link-ref link-reveal xref-bibr">147</a>,<span class="xrefLink" id="jumplink-ehae176-B235"></span><a href="javascript:;" reveal-id="ehae176-B235" data-open="ehae176-B235" class="link link-ref link-reveal xref-bibr">235</a></sup> In an RCT among regular non-binge drinkers with AF, the goal of abstinence led to a significant reduction in AF recurrence and burden; alcohol intake was reduced from 16.8 to 2.1 standard drinks per week (≤30 grams or 3 standard drinks of alcohol) in the intervention arm, with 61% attaining abstinence.<sup><span class="xrefLink" id="jumplink-ehae176-B147"></span><a href="javascript:;" reveal-id="ehae176-B147" data-open="ehae176-B147" class="link link-ref link-reveal xref-bibr">147</a></sup> In observational data of patients undergoing catheter ablation, reduction of consumption to ≤7 standard drinks (≤70 grams of alcohol) per week was associated with improved maintenance of sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B128" data-open="ehae176-B128" class="link link-ref link-reveal xref-bibr">128</a>,<span class="xrefLink" id="jumplink-ehae176-B235"></span><a href="javascript:;" reveal-id="ehae176-B235" data-open="ehae176-B235" class="link link-ref link-reveal xref-bibr">235</a></sup>

## 6\. \[A\] Avoid stroke and thromboembolism

### 6.1. Initiating oral anticoagulation

Atrial fibrillation is a major risk factor for thromboembolism, irrespective of whether it is paroxysmal, persistent, or permanent.<sup><span class="xrefLink" id="jumplink-ehae176-B236"></span><a href="javascript:;" reveal-id="ehae176-B236" data-open="ehae176-B236" class="link link-ref link-reveal xref-bibr">236</a>,<span class="xrefLink" id="jumplink-ehae176-B237"></span><a href="javascript:;" reveal-id="ehae176-B237" data-open="ehae176-B237" class="link link-ref link-reveal xref-bibr">237</a></sup> Left untreated, and dependent on other patient-specific factors, the risk of ischaemic stroke in AF is increased five-fold, and one in every five strokes is associated with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B238"></span><a href="javascript:;" reveal-id="ehae176-B238" data-open="ehae176-B238" class="link link-ref link-reveal xref-bibr">238</a></sup> The default approach should therefore be to provide OAC to all eligible patients, except those at low risk of incident stroke or thromboembolism. The effectiveness of OAC to prevent ischaemic stroke in patients with AF is well established.<sup><span class="xrefLink" id="jumplink-ehae176-B239"></span><a href="javascript:;" reveal-id="ehae176-B239" data-open="ehae176-B239" class="link link-ref link-reveal xref-bibr">239</a>,<span class="xrefLink" id="jumplink-ehae176-B240"></span><a href="javascript:;" reveal-id="ehae176-B240" data-open="ehae176-B240" class="link link-ref link-reveal xref-bibr">240</a></sup> Antiplatelet drugs alone (aspirin, or aspirin in combination with clopidogrel) are not recommended for stroke prevention in AF.<sup><span class="xrefLink" id="jumplink-ehae176-B241"></span><a href="javascript:;" reveal-id="ehae176-B241" data-open="ehae176-B241" class="link link-ref link-reveal xref-bibr">241</a>,<span class="xrefLink" id="jumplink-ehae176-B242"></span><a href="javascript:;" reveal-id="ehae176-B242" data-open="ehae176-B242" class="link link-ref link-reveal xref-bibr">242</a></sup>

#### 6.1.1. Decision support for anticoagulation in AF

Tools have been developed to enable easier implementation of OAC in patients with clinical AF. The majority of OAC clinical trials have used variations of the CHADS<sub>2</sub> score to indicate those at risk (with points for chronic heart failure, hypertension, age, diabetes, and 2 points for prior stroke/transient ischaemic attack \[TIA\]). Although most available stroke risk scores are simple and practical, the predictive value of scores is generally modest (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S3](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B243 ehae176-B244 ehae176-B245"></span><a href="javascript:;" reveal-id="ehae176-B243 ehae176-B244 ehae176-B245" data-open="ehae176-B243 ehae176-B244 ehae176-B245" class="link link-ref link-reveal xref-bibr">243–245</a></sup> Classification and discrimination of adverse events is relatively poor for all scores and hence the benefit of using them to select patients for OAC is unclear. There is also considerable variation in the definition of risk factors across countries,<sup><span class="xrefLink" id="jumplink-ehae176-B246"></span><a href="javascript:;" reveal-id="ehae176-B246" data-open="ehae176-B246" class="link link-ref link-reveal xref-bibr">246</a></sup> and a lack of evidence from clinical trials on the ability of stroke risk scoring to enhance clinical practice.<sup><span class="xrefLink" id="jumplink-ehae176-B243"></span><a href="javascript:;" reveal-id="ehae176-B243" data-open="ehae176-B243" class="link link-ref link-reveal xref-bibr">243</a></sup> This guideline continues to provide a Class IA recommendation for the use of OAC in patients at risk of thromboembolism. However, in the absence of strong evidence for how to apply risk scores in real-world patients, this has been separated from the use of any particular risk score. This is also in line with regulatory approvals for direct oral anticoagulants (DOACs), which do not stipulate risk scores or numerical thresholds.<sup><span class="xrefLink" id="jumplink-ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28"></span><a href="javascript:;" reveal-id="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" data-open="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" class="link link-ref link-reveal xref-bibr">25–28</a>,<span class="xrefLink" id="jumplink-ehae176-B245"></span><a href="javascript:;" reveal-id="ehae176-B245" data-open="ehae176-B245" class="link link-ref link-reveal xref-bibr">245</a></sup>

Substantive changes have occurred in the decades since these risk scores were developed in regards to population-level risk factor profiles, therapies, and targets.<sup><span class="xrefLink" id="jumplink-ehae176-B198"></span><a href="javascript:;" reveal-id="ehae176-B198" data-open="ehae176-B198" class="link link-ref link-reveal xref-bibr">198</a></sup> Historical scores do not take into account parameters that have been associated with thromboembolism in contemporary cohorts, such as cancer, chronic kidney disease (CKD), ethnicity, and a range of circulating biomarkers (including troponin and B-type natriuretic peptide \[BNP\]). As an example, for CKD there is a correlation between decreasing glomerular filtration rate and proteinuria with stroke risk,<sup><span class="xrefLink" id="jumplink-ehae176-B247 ehae176-B248 ehae176-B249 ehae176-B250"></span><a href="javascript:;" reveal-id="ehae176-B247 ehae176-B248 ehae176-B249 ehae176-B250" data-open="ehae176-B247 ehae176-B248 ehae176-B249 ehae176-B250" class="link link-ref link-reveal xref-bibr">247–250</a></sup> and cohort data suggest a two-fold increased risk of ischaemic stroke and mortality in AF patients with CKD vs. without.<sup><span class="xrefLink" id="jumplink-ehae176-B251"></span><a href="javascript:;" reveal-id="ehae176-B251" data-open="ehae176-B251" class="link link-ref link-reveal xref-bibr">251</a></sup> Other factors, such as atrial enlargement, hyperlipidaemia, smoking, and obesity, have been identified in specific cohort studies as additional risk factors for ischaemic stroke in AF.<sup><span class="xrefLink" id="jumplink-ehae176-B70"></span><a href="javascript:;" reveal-id="ehae176-B70" data-open="ehae176-B70" class="link link-ref link-reveal xref-bibr">70</a>,<span class="xrefLink" id="jumplink-ehae176-B252"></span><a href="javascript:;" reveal-id="ehae176-B252" data-open="ehae176-B252" class="link link-ref link-reveal xref-bibr">252</a>,<span class="xrefLink" id="jumplink-ehae176-B253"></span><a href="javascript:;" reveal-id="ehae176-B253" data-open="ehae176-B253" class="link link-ref link-reveal xref-bibr">253</a></sup> Biomarkers, such as troponin, natriuretic peptides, growth differentiation factor-15, cystatin C, and interleukin-6, can also indicate residual stroke risk among anticoagulated AF patients.<sup><span class="xrefLink" id="jumplink-ehae176-B254"></span><a href="javascript:;" reveal-id="ehae176-B254" data-open="ehae176-B254" class="link link-ref link-reveal xref-bibr">254</a>,<span class="xrefLink" id="jumplink-ehae176-B255"></span><a href="javascript:;" reveal-id="ehae176-B255" data-open="ehae176-B255" class="link link-ref link-reveal xref-bibr">255</a></sup> Biomarker-guided stroke prevention is currently being evaluated in an ongoing RCT (NCT03753490). Until further validation within RCTs is available, this task force continues to support using simple clinical classification for implementation of OAC. Clinicians should use tools that have been validated in their local population and take an individualized approach to thromboembolic risk stratification that considers the full range of each patient's specific risk factors. The absolute risk level at which to start OAC in individual patients cannot be estimated from population-level studies. It will vary depending on how those factors interact with other medical issues, and the degree of risk acceptable or tolerated by that person. In general, most of the available risk scores have a threshold of 0.6%–1.0% per annum of thromboembolic events for clinical AF to warrant OAC prescription.

Across Europe, the most popular risk score is CHA<sub>2</sub>DS<sub>2</sub>–VASc, giving points for congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/TIA/thromboembolism (2 points), vascular disease, age 65–74 years and female sex. However, implementation has varied in terms of gender. Female sex is an age-dependent stroke risk modifier rather than a risk factor per se.<sup><span class="xrefLink" id="jumplink-ehae176-B112"></span><a href="javascript:;" reveal-id="ehae176-B112" data-open="ehae176-B112" class="link link-ref link-reveal xref-bibr">112</a>,<span class="xrefLink" id="jumplink-ehae176-B256"></span><a href="javascript:;" reveal-id="ehae176-B256" data-open="ehae176-B256" class="link link-ref link-reveal xref-bibr">256</a>,<span class="xrefLink" id="jumplink-ehae176-B257"></span><a href="javascript:;" reveal-id="ehae176-B257" data-open="ehae176-B257" class="link link-ref link-reveal xref-bibr">257</a></sup> The inclusion of gender complicates clinical practice both for healthcare professionals and patients.<sup><span class="xrefLink" id="jumplink-ehae176-B258"></span><a href="javascript:;" reveal-id="ehae176-B258" data-open="ehae176-B258" class="link link-ref link-reveal xref-bibr">258</a></sup> It also omits individuals who identify as non-binary, transgender, or are undergoing sex hormone therapy. Previous guidelines from the ESC (and globally) have not actually used CHA<sub>2</sub>DS<sub>2</sub>\-VASc; instead providing different score levels for women and men with AF to qualify for OAC. Hence, CHA<sub>2</sub>DS<sub>2</sub>\-VA (excluding gender) has effectively been in place (_[Table 10](javascript:;)_).<sup><span class="xrefLink" id="jumplink-ehae176-B78"></span><a href="javascript:;" reveal-id="ehae176-B78" data-open="ehae176-B78" class="link link-ref link-reveal xref-bibr">78</a></sup> This task force proposes, in the absence of other locally validated alternatives, that clinicians and patients should use the CHA<sub>2</sub>DS<sub>2</sub>\-VA score to assist in decisions on OAC therapy (i.e. without a criterion for birth sex or gender). Pending further trials in lower risk patients (NCT04700826,<sup><span class="xrefLink" id="jumplink-ehae176-B259"></span><a href="javascript:;" reveal-id="ehae176-B259" data-open="ehae176-B259" class="link link-ref link-reveal xref-bibr">259</a></sup> NCT02387229<sup><span class="xrefLink" id="jumplink-ehae176-B260"></span><a href="javascript:;" reveal-id="ehae176-B260" data-open="ehae176-B260" class="link link-ref link-reveal xref-bibr">260</a></sup>), OAC are recommended in those with a CHA<sub>2</sub>DS<sub>2</sub>\-VA score of 2 or more and should be considered in those with a CHA<sub>2</sub>DS<sub>2</sub>\-VA score of 1, following a patient-centred and shared care approach. Healthcare professionals should take care to assess for other thromboembolic risk factors that may also indicate the need for OAC prescription.

Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884218)

Updated definitions for the CHA<sub>2</sub>DS<sub>2</sub>\-VA score

| CHA<sub>2</sub>DS<sub>2</sub>\-VA component .  | Definition and comments .  | Points awarded<sup><span class="xrefLink" id="jumplink-tblfn114"></span><a href="javascript:;" reveal-id="tblfn114" data-open="tblfn114" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  |
| --- | --- | --- |
| C | Chronic heart failure | Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and HFrEF), or the presence of asymptomatic LVEF ≤40%.<sup><span class="xrefLink" id="jumplink-ehae176-B261 ehae176-B262 ehae176-B263"></span><a href="javascript:;" reveal-id="ehae176-B261 ehae176-B262 ehae176-B263" data-open="ehae176-B261 ehae176-B262 ehae176-B263" class="link link-ref link-reveal xref-bibr">261–263</a></sup> | 1 |
| H | Hypertension | Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 120–129/70–79 mmHg (or keep as low as reasonably achievable).<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a>,<span class="xrefLink" id="jumplink-ehae176-B264"></span><a href="javascript:;" reveal-id="ehae176-B264" data-open="ehae176-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> | 1 |
| A | Age 75 years or above | Age is an independent determinant of ischaemic stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B265"></span><a href="javascript:;" reveal-id="ehae176-B265" data-open="ehae176-B265" class="link link-ref link-reveal xref-bibr">265</a></sup> Age-related risk is a continuum, but for reasons of practicality, two points are given for age ≥75 years. | 2 |
| D | Diabetes mellitus | Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,<sup><span class="xrefLink" id="jumplink-ehae176-B266"></span><a href="javascript:;" reveal-id="ehae176-B266" data-open="ehae176-B266" class="link link-ref link-reveal xref-bibr">266</a></sup> or treatment with glucose lowering therapy. | 1 |
| S | Prior stroke, TIA, or arterial thromboembolism | Previous thromboembolism is associated with highly elevated risk of recurrence and therefore weighted 2 points. | 2 |
| V | Vascular disease | Coronary artery disease, including prior myocardial infarction, angina, history of coronary revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac imaging.<sup><span class="xrefLink" id="jumplink-ehae176-B267"></span><a href="javascript:;" reveal-id="ehae176-B267" data-open="ehae176-B267" class="link link-ref link-reveal xref-bibr">267</a></sup>
OR
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).<sup><span class="xrefLink" id="jumplink-ehae176-B268"></span><a href="javascript:;" reveal-id="ehae176-B268" data-open="ehae176-B268" class="link link-ref link-reveal xref-bibr">268</a>,<span class="xrefLink" id="jumplink-ehae176-B269"></span><a href="javascript:;" reveal-id="ehae176-B269" data-open="ehae176-B269" class="link link-ref link-reveal xref-bibr">269</a></sup> | 1 |
| A | Age 65–74 years | 1 point is given for age between 65 and 74 years. | 1 |

| CHA<sub>2</sub>DS<sub>2</sub>\-VA component .  | Definition and comments .  | Points awarded<sup><span class="xrefLink" id="jumplink-tblfn114"></span><a href="javascript:;" reveal-id="tblfn114" data-open="tblfn114" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  |
| --- | --- | --- |
| C | Chronic heart failure | Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and HFrEF), or the presence of asymptomatic LVEF ≤40%.<sup><span class="xrefLink" id="jumplink-ehae176-B261 ehae176-B262 ehae176-B263"></span><a href="javascript:;" reveal-id="ehae176-B261 ehae176-B262 ehae176-B263" data-open="ehae176-B261 ehae176-B262 ehae176-B263" class="link link-ref link-reveal xref-bibr">261–263</a></sup> | 1 |
| H | Hypertension | Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 120–129/70–79 mmHg (or keep as low as reasonably achievable).<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a>,<span class="xrefLink" id="jumplink-ehae176-B264"></span><a href="javascript:;" reveal-id="ehae176-B264" data-open="ehae176-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> | 1 |
| A | Age 75 years or above | Age is an independent determinant of ischaemic stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B265"></span><a href="javascript:;" reveal-id="ehae176-B265" data-open="ehae176-B265" class="link link-ref link-reveal xref-bibr">265</a></sup> Age-related risk is a continuum, but for reasons of practicality, two points are given for age ≥75 years. | 2 |
| D | Diabetes mellitus | Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,<sup><span class="xrefLink" id="jumplink-ehae176-B266"></span><a href="javascript:;" reveal-id="ehae176-B266" data-open="ehae176-B266" class="link link-ref link-reveal xref-bibr">266</a></sup> or treatment with glucose lowering therapy. | 1 |
| S | Prior stroke, TIA, or arterial thromboembolism | Previous thromboembolism is associated with highly elevated risk of recurrence and therefore weighted 2 points. | 2 |
| V | Vascular disease | Coronary artery disease, including prior myocardial infarction, angina, history of coronary revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac imaging.<sup><span class="xrefLink" id="jumplink-ehae176-B267"></span><a href="javascript:;" reveal-id="ehae176-B267" data-open="ehae176-B267" class="link link-ref link-reveal xref-bibr">267</a></sup>
OR
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).<sup><span class="xrefLink" id="jumplink-ehae176-B268"></span><a href="javascript:;" reveal-id="ehae176-B268" data-open="ehae176-B268" class="link link-ref link-reveal xref-bibr">268</a>,<span class="xrefLink" id="jumplink-ehae176-B269"></span><a href="javascript:;" reveal-id="ehae176-B269" data-open="ehae176-B269" class="link link-ref link-reveal xref-bibr">269</a></sup> | 1 |
| A | Age 65–74 years | 1 point is given for age between 65 and 74 years. | 1 |

BP, blood pressure; CAD, coronary artery disease; CHA<sub>2</sub>DS<sub>2</sub>\-VA, chronic heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease.

<sup>a</sup>In addition to these factors, other markers that modify an individual's risk for stroke and thromboembolism should be considered, including cancer, chronic kidney disease, ethnicity (black, Hispanic, Asian), biomarkers (troponin and BNP), and in specific groups, atrial enlargement, hyperlipidaemia, smoking, and obesity.

© ESC 2024

Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884218)

Updated definitions for the CHA<sub>2</sub>DS<sub>2</sub>\-VA score

| CHA<sub>2</sub>DS<sub>2</sub>\-VA component .  | Definition and comments .  | Points awarded<sup><span class="xrefLink" id="jumplink-tblfn114"></span><a href="javascript:;" reveal-id="tblfn114" data-open="tblfn114" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  |
| --- | --- | --- |
| C | Chronic heart failure | Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and HFrEF), or the presence of asymptomatic LVEF ≤40%.<sup><span class="xrefLink" id="jumplink-ehae176-B261 ehae176-B262 ehae176-B263"></span><a href="javascript:;" reveal-id="ehae176-B261 ehae176-B262 ehae176-B263" data-open="ehae176-B261 ehae176-B262 ehae176-B263" class="link link-ref link-reveal xref-bibr">261–263</a></sup> | 1 |
| H | Hypertension | Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 120–129/70–79 mmHg (or keep as low as reasonably achievable).<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a>,<span class="xrefLink" id="jumplink-ehae176-B264"></span><a href="javascript:;" reveal-id="ehae176-B264" data-open="ehae176-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> | 1 |
| A | Age 75 years or above | Age is an independent determinant of ischaemic stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B265"></span><a href="javascript:;" reveal-id="ehae176-B265" data-open="ehae176-B265" class="link link-ref link-reveal xref-bibr">265</a></sup> Age-related risk is a continuum, but for reasons of practicality, two points are given for age ≥75 years. | 2 |
| D | Diabetes mellitus | Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,<sup><span class="xrefLink" id="jumplink-ehae176-B266"></span><a href="javascript:;" reveal-id="ehae176-B266" data-open="ehae176-B266" class="link link-ref link-reveal xref-bibr">266</a></sup> or treatment with glucose lowering therapy. | 1 |
| S | Prior stroke, TIA, or arterial thromboembolism | Previous thromboembolism is associated with highly elevated risk of recurrence and therefore weighted 2 points. | 2 |
| V | Vascular disease | Coronary artery disease, including prior myocardial infarction, angina, history of coronary revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac imaging.<sup><span class="xrefLink" id="jumplink-ehae176-B267"></span><a href="javascript:;" reveal-id="ehae176-B267" data-open="ehae176-B267" class="link link-ref link-reveal xref-bibr">267</a></sup>
OR
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).<sup><span class="xrefLink" id="jumplink-ehae176-B268"></span><a href="javascript:;" reveal-id="ehae176-B268" data-open="ehae176-B268" class="link link-ref link-reveal xref-bibr">268</a>,<span class="xrefLink" id="jumplink-ehae176-B269"></span><a href="javascript:;" reveal-id="ehae176-B269" data-open="ehae176-B269" class="link link-ref link-reveal xref-bibr">269</a></sup> | 1 |
| A | Age 65–74 years | 1 point is given for age between 65 and 74 years. | 1 |

| CHA<sub>2</sub>DS<sub>2</sub>\-VA component .  | Definition and comments .  | Points awarded<sup><span class="xrefLink" id="jumplink-tblfn114"></span><a href="javascript:;" reveal-id="tblfn114" data-open="tblfn114" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  |
| --- | --- | --- |
| C | Chronic heart failure | Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and HFrEF), or the presence of asymptomatic LVEF ≤40%.<sup><span class="xrefLink" id="jumplink-ehae176-B261 ehae176-B262 ehae176-B263"></span><a href="javascript:;" reveal-id="ehae176-B261 ehae176-B262 ehae176-B263" data-open="ehae176-B261 ehae176-B262 ehae176-B263" class="link link-ref link-reveal xref-bibr">261–263</a></sup> | 1 |
| H | Hypertension | Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 120–129/70–79 mmHg (or keep as low as reasonably achievable).<sup><span class="xrefLink" id="jumplink-ehae176-B162"></span><a href="javascript:;" reveal-id="ehae176-B162" data-open="ehae176-B162" class="link link-ref link-reveal xref-bibr">162</a>,<span class="xrefLink" id="jumplink-ehae176-B264"></span><a href="javascript:;" reveal-id="ehae176-B264" data-open="ehae176-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> | 1 |
| A | Age 75 years or above | Age is an independent determinant of ischaemic stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B265"></span><a href="javascript:;" reveal-id="ehae176-B265" data-open="ehae176-B265" class="link link-ref link-reveal xref-bibr">265</a></sup> Age-related risk is a continuum, but for reasons of practicality, two points are given for age ≥75 years. | 2 |
| D | Diabetes mellitus | Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,<sup><span class="xrefLink" id="jumplink-ehae176-B266"></span><a href="javascript:;" reveal-id="ehae176-B266" data-open="ehae176-B266" class="link link-ref link-reveal xref-bibr">266</a></sup> or treatment with glucose lowering therapy. | 1 |
| S | Prior stroke, TIA, or arterial thromboembolism | Previous thromboembolism is associated with highly elevated risk of recurrence and therefore weighted 2 points. | 2 |
| V | Vascular disease | Coronary artery disease, including prior myocardial infarction, angina, history of coronary revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac imaging.<sup><span class="xrefLink" id="jumplink-ehae176-B267"></span><a href="javascript:;" reveal-id="ehae176-B267" data-open="ehae176-B267" class="link link-ref link-reveal xref-bibr">267</a></sup>
OR
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).<sup><span class="xrefLink" id="jumplink-ehae176-B268"></span><a href="javascript:;" reveal-id="ehae176-B268" data-open="ehae176-B268" class="link link-ref link-reveal xref-bibr">268</a>,<span class="xrefLink" id="jumplink-ehae176-B269"></span><a href="javascript:;" reveal-id="ehae176-B269" data-open="ehae176-B269" class="link link-ref link-reveal xref-bibr">269</a></sup> | 1 |
| A | Age 65–74 years | 1 point is given for age between 65 and 74 years. | 1 |

BP, blood pressure; CAD, coronary artery disease; CHA<sub>2</sub>DS<sub>2</sub>\-VA, chronic heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease.

<sup>a</sup>In addition to these factors, other markers that modify an individual's risk for stroke and thromboembolism should be considered, including cancer, chronic kidney disease, ethnicity (black, Hispanic, Asian), biomarkers (troponin and BNP), and in specific groups, atrial enlargement, hyperlipidaemia, smoking, and obesity.

© ESC 2024

Recommendation Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884219)

Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6)

![Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt6.jpeg?Expires=1728478929&Signature=FUNXJbhkRpHPHd5xIlQEC7KwxhcRIrgSX68r0co-8mPBuyTsKE8ZSoA7lYqYPSOCXzYg2zIv4WiGUcS-yqX0wc4g2yPN3f803Vl2q1VwLRW1SwsVvjL98SnCRNAY8TyYnr4-kEdlmMuqq-PHmp8qudu4WoRs2Fcpy7w2DS3cYLjE-oTlYk4MJIax4SsgUoyS-LXffEObyTHHEiE1P~GNjz-nliqVKnNvS0OgP0VxMXGEtnMTqyat0209hJVmRVwghui9YgE85VT1DCg23LPnX~3nDlsjw~FNxHcOyrY-OS9uDow3NWo2cZMbtUV5uFcnBY6aVOY-Hr5A8006bud8-g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884219)

Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6)

![Recommendations to assess and manage thromboembolic risk in AF (see also Evidence Table 6)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt6.jpeg?Expires=1728478929&Signature=FUNXJbhkRpHPHd5xIlQEC7KwxhcRIrgSX68r0co-8mPBuyTsKE8ZSoA7lYqYPSOCXzYg2zIv4WiGUcS-yqX0wc4g2yPN3f803Vl2q1VwLRW1SwsVvjL98SnCRNAY8TyYnr4-kEdlmMuqq-PHmp8qudu4WoRs2Fcpy7w2DS3cYLjE-oTlYk4MJIax4SsgUoyS-LXffEObyTHHEiE1P~GNjz-nliqVKnNvS0OgP0VxMXGEtnMTqyat0209hJVmRVwghui9YgE85VT1DCg23LPnX~3nDlsjw~FNxHcOyrY-OS9uDow3NWo2cZMbtUV5uFcnBY6aVOY-Hr5A8006bud8-g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.2. Oral anticoagulants

Vitamin K antagonists (VKA), predominantly warfarin but also other coumarin and indandione derivatives, have been the principal drugs to prevent thromboembolic events in the context of AF. As with any anticoagulant, a balance must be reached between preventing thromboembolism and preserving physiological haemostasis, with VKA-associated intracranial and other major haemorrhage the most critical limitation for acceptance of OAC. The global switch to DOACs as first-line therapy has changed this risk–benefit balance, allowing more widespread prescription with no need for routine monitoring (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Tables S5–S7](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). This component of AF management may see substantive changes in the coming years, with a number of factor XI inhibitors in various stages of clinical evaluation. A phase 2 trial of abelacimab in patients with AF has shown lower rates of bleeding compared with rivaroxaban<sup><span class="xrefLink" id="jumplink-ehae176-B286"></span><a href="javascript:;" reveal-id="ehae176-B286" data-open="ehae176-B286" class="link link-ref link-reveal xref-bibr">286</a></sup>; however, a phase 3 trial of asundexian was terminated early due to lack of efficacy against apixaban (NCT05643573), despite favourable phase 2 results.<sup><span class="xrefLink" id="jumplink-ehae176-B287"></span><a href="javascript:;" reveal-id="ehae176-B287" data-open="ehae176-B287" class="link link-ref link-reveal xref-bibr">287</a></sup> Regardless of the type of OAC prescribed, healthcare teams should be aware of the potential for interactions with other drugs, foods, and supplements, and incorporate this information into the education provided to patients and their carers. The list of potential interactions with VKA is broad,<sup><span class="xrefLink" id="jumplink-ehae176-B288"></span><a href="javascript:;" reveal-id="ehae176-B288" data-open="ehae176-B288" class="link link-ref link-reveal xref-bibr">288</a>,<span class="xrefLink" id="jumplink-ehae176-B289"></span><a href="javascript:;" reveal-id="ehae176-B289" data-open="ehae176-B289" class="link link-ref link-reveal xref-bibr">289</a></sup> but there are also some common cardiovascular and non-cardiovascular drugs that interact with DOACs.<sup><span class="xrefLink" id="jumplink-ehae176-B290"></span><a href="javascript:;" reveal-id="ehae176-B290" data-open="ehae176-B290" class="link link-ref link-reveal xref-bibr">290</a>,<span class="xrefLink" id="jumplink-ehae176-B291"></span><a href="javascript:;" reveal-id="ehae176-B291" data-open="ehae176-B291" class="link link-ref link-reveal xref-bibr">291</a></sup>  _[Figure 9](javascript:;)_ highlights common and major interactions to consider for VKAs and DOACs.

![Common drug interactions with oral anticoagulants.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f9.jpeg?Expires=1728478929&Signature=cTGxy9uzRdKS8fxABvRKotvBjap32Qm3ROZ8PwMDzxqh~K1f~58yWxYbfATWQtE3c4id~WpFIA~0FigUVTTh~eH8jqxjjOLnfvSE1MQWWSHOx6BGKInCd47Uy~dypVtPjCQcqyznDPIVi9fJE4KemZxWxz~lWP9uEMf4CkTcUNQlaAZbQO5AMTlHPD-8AHhEQeSeVa461CwyyfKw-0~6LcXOcluaQD7tgXs-AUY14GQcfCFJDLEFHuOPyyNpi~FKkME7YysVjmTjlvmGoM8qfaNYGUcn3XzhMdQ-EPBveQWN3UdT5rR~WogGFjl62CcCm~RP0op8cQLoApooTPXmeg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 9

Common drug interactions with oral anticoagulants.

INR, international normalized ratio of prothrombin time; NSAID, non-steroidal anti-inflammatory drug. This figure depicts only common or major interactions and is not an exhaustive list of all potential interactions. Please see the European Medicines Agency website or your local formulary for more information.

[Open in new tab](https://academic.oup.com/view-large/figure/479884222/ehae176f9.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f9.jpeg?Expires=1728478929&Signature=e9gILpxeCTc6ULYQ~KMTLzlZfDGrTEXd7T2n6yTc1IBqwLGlrAVEC3TNl1pGk0JwU9K44ZTOnsgDdofK-vT8gDpqtXUZqY91f5EiPD-xodh~UQiNQ7SJNcjgYdY1ZdEPpGimpKZAczf4SNgS6KF9ArtF9ht0m4fQv7L~yOtotdhe7E2GScLERK4malrVthL9ykk0NW8GrlzHc~Krf8NckaN~4TxQKuXb0D0bUDaty3ZzRXe8pyeCbIxt4imMOR25vMhUJgIQ~bwI9ZTQZuWXR4bcHMJwy8jo1ObKr~ZFxJZEiJvxvdN7ZJWhVhjxe1NxuRzeeM9KDVzdD~0VWKgWpQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884222&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884223)

Recommendations for oral anticoagulation in AF (see also Evidence Table 7)

![Recommendations for oral anticoagulation in AF (see also Evidence Table 7)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt7.jpeg?Expires=1728478929&Signature=PTxhz4qtsPD07jddtPh2yuR9mqo~mAXYM1IxIwCVCBWXI-Gb9dKIgqiStIjhhCdY4bz4u7NtmOfEvHJvBcusmKvRkZf74sYXM2fWc6P34dX-ozoXexUil7VRxP-M83tSO9HirA8beQ4oKwO-5pDfM6V4iQXH3loq07xnkC~6xGMmZjfiPmDcFJnVi3aZllJh6p6lL9s6WOtOQujHNc9lsfoyFGfsH-DfOON4BYUEXAvqst1DL~GQ1~yOUDo672CeQNJ2VJ9QfIO~FKIpQLq8-a98iMu1CH~mVkLwbrhFXqz6WqovD6czeXZXr0DOziKDXlkr11O~849llI7X755ejw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884223)

Recommendations for oral anticoagulation in AF (see also Evidence Table 7)

![Recommendations for oral anticoagulation in AF (see also Evidence Table 7)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt7.jpeg?Expires=1728478929&Signature=PTxhz4qtsPD07jddtPh2yuR9mqo~mAXYM1IxIwCVCBWXI-Gb9dKIgqiStIjhhCdY4bz4u7NtmOfEvHJvBcusmKvRkZf74sYXM2fWc6P34dX-ozoXexUil7VRxP-M83tSO9HirA8beQ4oKwO-5pDfM6V4iQXH3loq07xnkC~6xGMmZjfiPmDcFJnVi3aZllJh6p6lL9s6WOtOQujHNc9lsfoyFGfsH-DfOON4BYUEXAvqst1DL~GQ1~yOUDo672CeQNJ2VJ9QfIO~FKIpQLq8-a98iMu1CH~mVkLwbrhFXqz6WqovD6czeXZXr0DOziKDXlkr11O~849llI7X755ejw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 6.2.1. Direct oral anticoagulants

The DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) have all demonstrated at least non-inferior efficacy compared with warfarin for the prevention of thromboembolism, but with the added benefit of a 50% reduction in intracranial haemorrhage (ICH).<sup><span class="xrefLink" id="jumplink-ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28"></span><a href="javascript:;" reveal-id="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" data-open="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" class="link link-ref link-reveal xref-bibr">25–28</a></sup> Meta-analyses of individual data from 71 683 RCT patients showed that standard, full-dose DOAC treatment compared with warfarin reduces the risk of stroke or systemic embolism (HR, 0.81; 95% CI, 0.73–0.91), all-cause mortality (HR, 0.90; 95% CI, 0.85–0.95), and intracranial bleeding (HR, 0.48; 95% CI, 0.39–0.59), with no significant difference in other major bleeding (HR, 0.86; 95% CI, 0.73–1.00) and little or no between-trial heterogeneity.<sup><span class="xrefLink" id="jumplink-ehae176-B292"></span><a href="javascript:;" reveal-id="ehae176-B292" data-open="ehae176-B292" class="link link-ref link-reveal xref-bibr">292</a></sup> Post-marketing observational data on the effectiveness and safety of dabigatran,<sup><span class="xrefLink" id="jumplink-ehae176-B313"></span><a href="javascript:;" reveal-id="ehae176-B313" data-open="ehae176-B313" class="link link-ref link-reveal xref-bibr">313</a>,<span class="xrefLink" id="jumplink-ehae176-B314"></span><a href="javascript:;" reveal-id="ehae176-B314" data-open="ehae176-B314" class="link link-ref link-reveal xref-bibr">314</a></sup> rivaroxaban,<sup><span class="xrefLink" id="jumplink-ehae176-B315"></span><a href="javascript:;" reveal-id="ehae176-B315" data-open="ehae176-B315" class="link link-ref link-reveal xref-bibr">315</a>,<span class="xrefLink" id="jumplink-ehae176-B316"></span><a href="javascript:;" reveal-id="ehae176-B316" data-open="ehae176-B316" class="link link-ref link-reveal xref-bibr">316</a></sup> apixaban,<sup><span class="xrefLink" id="jumplink-ehae176-B317"></span><a href="javascript:;" reveal-id="ehae176-B317" data-open="ehae176-B317" class="link link-ref link-reveal xref-bibr">317</a></sup> and edoxaban<sup><span class="xrefLink" id="jumplink-ehae176-B318"></span><a href="javascript:;" reveal-id="ehae176-B318" data-open="ehae176-B318" class="link link-ref link-reveal xref-bibr">318</a></sup> vs. warfarin show general consistency with the respective phase 3 RCTs.

For patients undergoing cardioversion, three underpowered trials showed non-significantly lower rates of cardiovascular events with DOACs compared with warfarin.<sup><span class="xrefLink" id="jumplink-ehae176-B319 ehae176-B320 ehae176-B321"></span><a href="javascript:;" reveal-id="ehae176-B319 ehae176-B320 ehae176-B321" data-open="ehae176-B319 ehae176-B320 ehae176-B321" class="link link-ref link-reveal xref-bibr">319–321</a></sup> In meta-analysis of these 5203 patients predominantly undergoing electrical cardioversion, the composite of stroke, systemic embolism, myocardial infarction (MI), and cardiovascular death was significantly lower at 0.42% in patients randomized to a DOAC vs. 0.98% in those allocated VKA (risk ratio, 0.42; 95% CI, 0.21–0.86; _P_ = .017), with no heterogeneity between trials and no significant difference in major bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B293"></span><a href="javascript:;" reveal-id="ehae176-B293" data-open="ehae176-B293" class="link link-ref link-reveal xref-bibr">293</a></sup>

Specific patient subgroups show consistent benefit with DOACs vs. VKAs. For heart failure, major thromboembolic events were lower in DOAC-treated patients vs. warfarin in subgroup analysis of landmark RCTs,<sup><span class="xrefLink" id="jumplink-ehae176-B322"></span><a href="javascript:;" reveal-id="ehae176-B322" data-open="ehae176-B322" class="link link-ref link-reveal xref-bibr">322</a></sup> confirmed in large-scale real-world data.<sup><span class="xrefLink" id="jumplink-ehae176-B323"></span><a href="javascript:;" reveal-id="ehae176-B323" data-open="ehae176-B323" class="link link-ref link-reveal xref-bibr">323</a></sup> In a retrospective cohort of patients aged over 80 years, DOAC use was associated with a lower risk of ischaemic stroke, dementia, mortality, and major bleeding than warfarin,<sup><span class="xrefLink" id="jumplink-ehae176-B324"></span><a href="javascript:;" reveal-id="ehae176-B324" data-open="ehae176-B324" class="link link-ref link-reveal xref-bibr">324</a></sup> but this may be confounded by prescription bias.

Direct oral anticoagulants retain their efficacy and safety over VKAs in patients with mild-to-moderate CKD (creatinine clearance \[CrCl\] >30 mL/min),<sup><span class="xrefLink" id="jumplink-ehae176-B325"></span><a href="javascript:;" reveal-id="ehae176-B325" data-open="ehae176-B325" class="link link-ref link-reveal xref-bibr">325</a></sup> although specific dosing adjustments apply.<sup><span class="xrefLink" id="jumplink-ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28"></span><a href="javascript:;" reveal-id="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" data-open="ehae176-B25 ehae176-B26 ehae176-B27 ehae176-B28" class="link link-ref link-reveal xref-bibr">25–28</a>,<span class="xrefLink" id="jumplink-ehae176-B326"></span><a href="javascript:;" reveal-id="ehae176-B326" data-open="ehae176-B326" class="link link-ref link-reveal xref-bibr">326</a></sup> In Europe, reduced doses of rivaroxaban, apixaban, and edoxaban are approved in patients with severe CKD (CrCl 15–29 mL/min), although limited numbers of patients were included in the major RCTs against VKA.<sup><span class="xrefLink" id="jumplink-ehae176-B327"></span><a href="javascript:;" reveal-id="ehae176-B327" data-open="ehae176-B327" class="link link-ref link-reveal xref-bibr">327</a></sup> Dabigatran is more dependent on renal elimination and so is contraindicated with an estimated glomerular filtration rate <30 mL/min/1.73 m<sup>2</sup>. Small trials have been performed in patients on haemodialysis, with two finding no difference between apixaban 2.5 mg twice daily and VKA for efficacy or safety outcomes,<sup><span class="xrefLink" id="jumplink-ehae176-B328"></span><a href="javascript:;" reveal-id="ehae176-B328" data-open="ehae176-B328" class="link link-ref link-reveal xref-bibr">328</a>,<span class="xrefLink" id="jumplink-ehae176-B329"></span><a href="javascript:;" reveal-id="ehae176-B329" data-open="ehae176-B329" class="link link-ref link-reveal xref-bibr">329</a></sup> and one trial showing that rivaroxaban 10 mg led to significantly lower rates of cardiovascular events and major bleeding compared with VKA.<sup><span class="xrefLink" id="jumplink-ehae176-B330"></span><a href="javascript:;" reveal-id="ehae176-B330" data-open="ehae176-B330" class="link link-ref link-reveal xref-bibr">330</a></sup> Careful institution and regular follow-up are advised when instituting anticoagulants in any patient with impaired renal function (See [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table 8](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B326"></span><a href="javascript:;" reveal-id="ehae176-B326" data-open="ehae176-B326" class="link link-ref link-reveal xref-bibr">326</a></sup>

Direct oral anticoagulants as a class should be avoided in specific patient groups, such as those with mechanical heart valves or moderate-to-severe mitral stenosis. In patients with mechanical heart valves, an excess of thromboembolic and major bleeding events among patients on dabigatran therapy vs. VKA was observed, with an RCT terminated prematurely.<sup><span class="xrefLink" id="jumplink-ehae176-B331"></span><a href="javascript:;" reveal-id="ehae176-B331" data-open="ehae176-B331" class="link link-ref link-reveal xref-bibr">331</a></sup> A trial of apixaban vs. VKA after implantation of a mechanical aortic valve was also stopped due to excess thromboembolic events in the apixaban group.<sup><span class="xrefLink" id="jumplink-ehae176-B332"></span><a href="javascript:;" reveal-id="ehae176-B332" data-open="ehae176-B332" class="link link-ref link-reveal xref-bibr">332</a></sup> The restriction on DOAC use does not apply to bioprosthetic heart valves (including mitral) or after transcatheter aortic valve implantation, where DOACs can be used and trial data show non-inferiority for clinical events compared with VKAs.<sup><span class="xrefLink" id="jumplink-ehae176-B304"></span><a href="javascript:;" reveal-id="ehae176-B304" data-open="ehae176-B304" class="link link-ref link-reveal xref-bibr">304</a>,<span class="xrefLink" id="jumplink-ehae176-B333"></span><a href="javascript:;" reveal-id="ehae176-B333" data-open="ehae176-B333" class="link link-ref link-reveal xref-bibr">333</a>,<span class="xrefLink" id="jumplink-ehae176-B334"></span><a href="javascript:;" reveal-id="ehae176-B334" data-open="ehae176-B334" class="link link-ref link-reveal xref-bibr">334</a></sup> With regards to mitral stenosis, the DOAC vs. VKA trials excluded patients with moderate-to-severe disease. In 4531 randomized patients with rheumatic heart disease and AF, VKAs led to a lower rate of composite cardiovascular events and death than rivaroxaban, without a higher rate of bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B294"></span><a href="javascript:;" reveal-id="ehae176-B294" data-open="ehae176-B294" class="link link-ref link-reveal xref-bibr">294</a></sup> Eighty-two per cent of the patients included had a mitral valve area ≤2 cm, supporting the restriction of DOAC use in patients with moderate-to-severe mitral stenosis. Note that patients with other types of valve disease (mitral regurgitation and others) should preferentially be prescribed a DOAC, and the term ‘valvular’ AF is obsolete and should be avoided.

Inappropriate dose reductions for DOACs are frequent in clinical practice,<sup><span class="xrefLink" id="jumplink-ehae176-B311"></span><a href="javascript:;" reveal-id="ehae176-B311" data-open="ehae176-B311" class="link link-ref link-reveal xref-bibr">311</a></sup> but need to be avoided as they increase the risk of stroke without decreasing bleeding risk.<sup><span class="xrefLink" id="jumplink-ehae176-B310"></span><a href="javascript:;" reveal-id="ehae176-B310" data-open="ehae176-B310" class="link link-ref link-reveal xref-bibr">310</a></sup> Hence, DOAC therapy should be instituted according to the standard full dose as tested in phase 3 RCTs and approved by regulators (_[Table 11](javascript:;)_). The prescribed dosage should consider the individual patient's profile.<sup><span class="xrefLink" id="jumplink-ehae176-B335"></span><a href="javascript:;" reveal-id="ehae176-B335" data-open="ehae176-B335" class="link link-ref link-reveal xref-bibr">335</a></sup> Drug interactions need to be considered in all patients taking or planned for DOACs (see _[Figure 9](javascript:;)_ for common drug interactions).<sup><span class="xrefLink" id="jumplink-ehae176-B336"></span><a href="javascript:;" reveal-id="ehae176-B336" data-open="ehae176-B336" class="link link-ref link-reveal xref-bibr">336</a></sup> There is insufficient evidence currently to advise on routine laboratory testing for DOAC levels. However, in certain situations, measurement of DOAC levels (where available) may be helpful, such as severe bleeding, the need for urgent surgery, or thromboembolic events despite apparent DOAC compliance.<sup><span class="xrefLink" id="jumplink-ehae176-B337"></span><a href="javascript:;" reveal-id="ehae176-B337" data-open="ehae176-B337" class="link link-ref link-reveal xref-bibr">337</a>,<span class="xrefLink" id="jumplink-ehae176-B338"></span><a href="javascript:;" reveal-id="ehae176-B338" data-open="ehae176-B338" class="link link-ref link-reveal xref-bibr">338</a></sup> Patients should always be involved in decision-making on anticoagulation,<sup><span class="xrefLink" id="jumplink-ehae176-B339"></span><a href="javascript:;" reveal-id="ehae176-B339" data-open="ehae176-B339" class="link link-ref link-reveal xref-bibr">339</a></sup> leading to better alignment with personal preferences that can help to increase understanding and adherence.

Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884231)

Recommended doses for direct oral anticoagulant therapy

| DOAC .  | Standard full dose .  | Criteria for dose reduction .  | Reduced dose only if criteria met .  |
| --- | --- | --- | --- |
| Apixaban | 5 mg twice daily | Two out of three needed for dose reduction:
(i) age ≥80 years
(ii) body weight ≤60 kg
(iii) serum creatinine ≥133 mmol/L. | 2.5 mg twice daily |
| Dabigatran | 150 mg twice daily | Dose reduction recommended if any apply:
(i) age ≥80 years
(ii) receiving concomitant verapamil.
Dose reduction considered on an individual basis if any apply:
(i) age 75–80
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min)
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux
(iv) others at increased risk of bleeding. | 110 mg twice daily |
| Edoxaban | 60 mg once daily | Dose reduction if any apply:
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min)
(ii) body weight ≤60 kg
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole. | 30 mg once daily |
| Rivaroxaban | 20 mg once daily | Creatinine clearance 15–49 mL/min. | 15 mg once daily |

| DOAC .  | Standard full dose .  | Criteria for dose reduction .  | Reduced dose only if criteria met .  |
| --- | --- | --- | --- |
| Apixaban | 5 mg twice daily | Two out of three needed for dose reduction:
(i) age ≥80 years
(ii) body weight ≤60 kg
(iii) serum creatinine ≥133 mmol/L. | 2.5 mg twice daily |
| Dabigatran | 150 mg twice daily | Dose reduction recommended if any apply:
(i) age ≥80 years
(ii) receiving concomitant verapamil.
Dose reduction considered on an individual basis if any apply:
(i) age 75–80
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min)
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux
(iv) others at increased risk of bleeding. | 110 mg twice daily |
| Edoxaban | 60 mg once daily | Dose reduction if any apply:
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min)
(ii) body weight ≤60 kg
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole. | 30 mg once daily |
| Rivaroxaban | 20 mg once daily | Creatinine clearance 15–49 mL/min. | 15 mg once daily |

DOAC, direct oral anticoagulant.

Dose and dose adjustments are taken from the European Medicines Association Summary of Product Characteristics for each DOAC. There may be other patient-specific reasons for providing a reduced dose, but, in general, the standard full dose should be used to provide optimal prevention of thromboembolism related to AF. Note that antiplatelet agents should be stopped in most patients when commencing a DOAC (see _Section [6.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.3)_). A number of drug interactions exist with each DOAC and should be taken into consideration (see _[Figure 9](javascript:;)_).

© ESC 2024

Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884231)

Recommended doses for direct oral anticoagulant therapy

| DOAC .  | Standard full dose .  | Criteria for dose reduction .  | Reduced dose only if criteria met .  |
| --- | --- | --- | --- |
| Apixaban | 5 mg twice daily | Two out of three needed for dose reduction:
(i) age ≥80 years
(ii) body weight ≤60 kg
(iii) serum creatinine ≥133 mmol/L. | 2.5 mg twice daily |
| Dabigatran | 150 mg twice daily | Dose reduction recommended if any apply:
(i) age ≥80 years
(ii) receiving concomitant verapamil.
Dose reduction considered on an individual basis if any apply:
(i) age 75–80
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min)
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux
(iv) others at increased risk of bleeding. | 110 mg twice daily |
| Edoxaban | 60 mg once daily | Dose reduction if any apply:
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min)
(ii) body weight ≤60 kg
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole. | 30 mg once daily |
| Rivaroxaban | 20 mg once daily | Creatinine clearance 15–49 mL/min. | 15 mg once daily |

| DOAC .  | Standard full dose .  | Criteria for dose reduction .  | Reduced dose only if criteria met .  |
| --- | --- | --- | --- |
| Apixaban | 5 mg twice daily | Two out of three needed for dose reduction:
(i) age ≥80 years
(ii) body weight ≤60 kg
(iii) serum creatinine ≥133 mmol/L. | 2.5 mg twice daily |
| Dabigatran | 150 mg twice daily | Dose reduction recommended if any apply:
(i) age ≥80 years
(ii) receiving concomitant verapamil.
Dose reduction considered on an individual basis if any apply:
(i) age 75–80
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min)
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux
(iv) others at increased risk of bleeding. | 110 mg twice daily |
| Edoxaban | 60 mg once daily | Dose reduction if any apply:
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min)
(ii) body weight ≤60 kg
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole. | 30 mg once daily |
| Rivaroxaban | 20 mg once daily | Creatinine clearance 15–49 mL/min. | 15 mg once daily |

DOAC, direct oral anticoagulant.

Dose and dose adjustments are taken from the European Medicines Association Summary of Product Characteristics for each DOAC. There may be other patient-specific reasons for providing a reduced dose, but, in general, the standard full dose should be used to provide optimal prevention of thromboembolism related to AF. Note that antiplatelet agents should be stopped in most patients when commencing a DOAC (see _Section [6.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.3)_). A number of drug interactions exist with each DOAC and should be taken into consideration (see _[Figure 9](javascript:;)_).

© ESC 2024

#### 6.2.2. Vitamin K antagonists

Vitamin K antagonist therapy reduces stroke risk by 64% and mortality by 26% in patients with AF at elevated thromboembolic risk (mostly warfarin in trials, compared with placebo or no treatment).<sup><span class="xrefLink" id="jumplink-ehae176-B239"></span><a href="javascript:;" reveal-id="ehae176-B239" data-open="ehae176-B239" class="link link-ref link-reveal xref-bibr">239</a></sup> Vitamin K antagonists are still used in many patients worldwide, but prescriptions have declined sharply since the introduction of DOACs.<sup><span class="xrefLink" id="jumplink-ehae176-B340"></span><a href="javascript:;" reveal-id="ehae176-B340" data-open="ehae176-B340" class="link link-ref link-reveal xref-bibr">340</a>,<span class="xrefLink" id="jumplink-ehae176-B341"></span><a href="javascript:;" reveal-id="ehae176-B341" data-open="ehae176-B341" class="link link-ref link-reveal xref-bibr">341</a></sup> Vitamin K antagonists are currently the only treatment option in AF patients with mechanical heart valves or moderate-to-severe mitral valve stenosis.<sup><span class="xrefLink" id="jumplink-ehae176-B294"></span><a href="javascript:;" reveal-id="ehae176-B294" data-open="ehae176-B294" class="link link-ref link-reveal xref-bibr">294</a>,<span class="xrefLink" id="jumplink-ehae176-B331"></span><a href="javascript:;" reveal-id="ehae176-B331" data-open="ehae176-B331" class="link link-ref link-reveal xref-bibr">331</a></sup> The use of VKAs is not only limited by numerous drug and food interactions (_[Figure 9](javascript:;)_), but also a narrow therapeutic range. This requires frequent monitoring and dose adjustment according to the prothrombin time expressed as the international normalized ratio (INR).<sup><span class="xrefLink" id="jumplink-ehae176-B342"></span><a href="javascript:;" reveal-id="ehae176-B342" data-open="ehae176-B342" class="link link-ref link-reveal xref-bibr">342</a></sup> If the time in therapeutic range (TTR) is maintained for long periods (e.g. >70% with INR 2.0–3.0), then VKA can be effective for thromboembolic protection with an acceptable safety profile.<sup><span class="xrefLink" id="jumplink-ehae176-B295 ehae176-B296 ehae176-B297"></span><a href="javascript:;" reveal-id="ehae176-B295 ehae176-B296 ehae176-B297" data-open="ehae176-B295 ehae176-B296 ehae176-B297" class="link link-ref link-reveal xref-bibr">295–297</a>,<span class="xrefLink" id="jumplink-ehae176-B343"></span><a href="javascript:;" reveal-id="ehae176-B343" data-open="ehae176-B343" class="link link-ref link-reveal xref-bibr">343</a></sup> However, VKAs are associated with higher rates of intracranial bleeding,<sup><span class="xrefLink" id="jumplink-ehae176-B299"></span><a href="javascript:;" reveal-id="ehae176-B299" data-open="ehae176-B299" class="link link-ref link-reveal xref-bibr">299</a>,<span class="xrefLink" id="jumplink-ehae176-B300"></span><a href="javascript:;" reveal-id="ehae176-B300" data-open="ehae176-B300" class="link link-ref link-reveal xref-bibr">300</a></sup> and also higher rates of other types of bleeding compared with DOACs.<sup><span class="xrefLink" id="jumplink-ehae176-B83"></span><a href="javascript:;" reveal-id="ehae176-B83" data-open="ehae176-B83" class="link link-ref link-reveal xref-bibr">83</a></sup>

In view of the potential safety benefits, switching from VKAs to a DOAC is justified where there are concerns about intracranial bleeding or for patient-choice reasons, and a switch is recommended where patients have failed to maintain an adequate TTR (<70%). This depends on patients fulfilling eligibility criteria for DOACs and should take into account other correctable reasons for poor INR control. There is limited data on switching OAC in older patients (≥75 years) with polypharmacy or other markers of frailty. A recent trial in this patient group prematurely stopped for futility showed that switching from VKAs to DOACs led to a higher primary outcome rate of major or clinically relevant non-major bleeding events compared with continuing with INR-guided VKA (17.8 vs. 10.5 per 100 patient-years, driven by non-major bleeds).<sup><span class="xrefLink" id="jumplink-ehae176-B309"></span><a href="javascript:;" reveal-id="ehae176-B309" data-open="ehae176-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> Hence, in such patients who are clinically stable with good TTR, VKAs may be continued rather than switching to a DOAC after an open discussion with the patient and shared decision-making.

#### 6.2.3. Clinical vs. device-detected subclinical AF

The known benefit of anticoagulation applies to clinical AF. Two RCTs have been published assessing the value of DOAC therapy in device-detected subclinical AF. The ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) was completed with 4012 patients with device-detected subclinical AF and a mean follow-up of 3.5 years.<sup><span class="xrefLink" id="jumplink-ehae176-B282"></span><a href="javascript:;" reveal-id="ehae176-B282" data-open="ehae176-B282" class="link link-ref link-reveal xref-bibr">282</a></sup> The primary efficacy outcome of stroke or systemic embolism was significantly less in those randomized to apixaban compared with aspirin (HR, 0.63; 95% CI, 0.45–0.88; _P_ = .007). In the intention-to-treat analysis, the primary safety outcome of major bleeding was higher with apixaban (HR, 1.36; 95% CI, 1.01–1.82; _P_ = .04). The NOAH trial (Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes) was stopped prematurely due to safety concerns and futility for the efficacy of edoxaban, and hence provides limited information.<sup><span class="xrefLink" id="jumplink-ehae176-B281"></span><a href="javascript:;" reveal-id="ehae176-B281" data-open="ehae176-B281" class="link link-ref link-reveal xref-bibr">281</a></sup> The analysis of 2536 patients with device-detected atrial high-rate episodes and a median follow-up of 21 months identified no difference in a composite of cardiovascular death, stroke, or embolism comparing edoxaban and placebo (HR, 0.81; 95% CI, 0.60–1.08; _P_ = .15). Those randomized to edoxaban had a higher rate of the composite of death or major bleeding than placebo (HR, 1.31; 95% CI, 1.02–1.67; _P_ = .03). Patients had a low burden of device-detected subclinical AF in both trials (median duration 1.5 h and 2.8 h, respectively), with lower rates of thromboembolism (around 1% per patient-year) than would be expected for an equivalent cohort of patients with clinical AF and a CHA<sub>2</sub>DS<sub>2</sub>\-VASc score of 4.

Considering the trade-off between potential benefit and the risk of major bleeding, this task force concludes that DOAC therapy may be considered in subgroups of patients with asymptomatic device-detected subclinical AF who have high estimated stroke risk and an absence of major bleeding risk factors (see _Section [6.7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.7)_). The duration and burden of subclinical AF that could indicate potential benefit from OAC remains uncertain.<sup><span class="xrefLink" id="jumplink-ehae176-B344"></span><a href="javascript:;" reveal-id="ehae176-B344" data-open="ehae176-B344" class="link link-ref link-reveal xref-bibr">344</a></sup> Regardless of the initial decision on OAC, patients with subclinical AF should receive management and follow-up for all aspects of AF-CARE as the risk of developing clinical AF is high (6%–9% per year).

### 6.3. Antiplatelet drugs and combinations with anticoagulants

Antiplatelet drugs, such as aspirin and clopidogrel, are not an alternative to OAC. They should not be used for stroke prevention, and can lead to potential harm (especially among elderly patients with AF).<sup><span class="xrefLink" id="jumplink-ehae176-B345 ehae176-B346 ehae176-B347"></span><a href="javascript:;" reveal-id="ehae176-B345 ehae176-B346 ehae176-B347" data-open="ehae176-B345 ehae176-B346 ehae176-B347" class="link link-ref link-reveal xref-bibr">345–347</a></sup> In ACTIVE W (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events), dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was less effective than warfarin for the prevention of stroke, systemic embolism, MI, or vascular death (annual risk of events 5.6% vs. 3.9%, respectively; _P_ = .0003), with similar rates of major bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B348"></span><a href="javascript:;" reveal-id="ehae176-B348" data-open="ehae176-B348" class="link link-ref link-reveal xref-bibr">348</a></sup> The AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment) trial demonstrated a lower rate of stroke or systemic embolism with apixaban compared with aspirin (HR, 0.45; 95% CI, 0.32–0.62; _P_ < .001), with no significant difference in major bleeding (there were 11 cases of intracranial bleeding with apixaban and 13 with aspirin).<sup><span class="xrefLink" id="jumplink-ehae176-B242"></span><a href="javascript:;" reveal-id="ehae176-B242" data-open="ehae176-B242" class="link link-ref link-reveal xref-bibr">242</a></sup>

The combination of OAC with antiplatelet agents (especially aspirin) without an adequate indication occurs frequently in clinical practice (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S9](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B349"></span><a href="javascript:;" reveal-id="ehae176-B349" data-open="ehae176-B349" class="link link-ref link-reveal xref-bibr">349</a>,<span class="xrefLink" id="jumplink-ehae176-B350"></span><a href="javascript:;" reveal-id="ehae176-B350" data-open="ehae176-B350" class="link link-ref link-reveal xref-bibr">350</a></sup> Bleeding events are more common when antithrombotic agents are combined, and no clear benefit has been observed in terms of prevention of stroke or death.<sup><span class="xrefLink" id="jumplink-ehae176-B349"></span><a href="javascript:;" reveal-id="ehae176-B349" data-open="ehae176-B349" class="link link-ref link-reveal xref-bibr">349</a></sup> In general, combining antiplatelet drugs with anticoagulants (DOACs or VKAs) should only occur in selected patients with acute vascular disease (e.g. acute coronary syndromes; see _Section [9.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.2)_). The combination of low-dose rivaroxaban (2.5 mg) with aspirin reduced the risk of stroke in patients with chronic vascular disease in a subanalysis of the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial,<sup><span class="xrefLink" id="jumplink-ehae176-B351"></span><a href="javascript:;" reveal-id="ehae176-B351" data-open="ehae176-B351" class="link link-ref link-reveal xref-bibr">351</a>,<span class="xrefLink" id="jumplink-ehae176-B352"></span><a href="javascript:;" reveal-id="ehae176-B352" data-open="ehae176-B352" class="link link-ref link-reveal xref-bibr">352</a></sup> but this cannot be generalized to AF patients because those with an indication for full-dose anticoagulants were excluded.

Recommendation Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884241)

Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8)

![Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt8.jpeg?Expires=1728478929&Signature=abLagSKlqN7nmBc7ZC2t5UeAk8at30lFtWZTgdxEf8RQP6E4kx-3~Rqj~J5cNujtI1ybI4-0cOJ-du1UfvkeQlTXW8DbdKofCu2QeytxWS1Iilr9HrDZOHgt3Fu5cb0UdX3kRItypnKUwb0iUGeo6bsS5KCc~~7Ad95wV13QThfXzkPhXdnAo6yweEU8~2qcF03dJRCM~Q5GtHiS8OBA9D86G2qygaHtr9qfVXOrk6fs8xBvES3oPw6dF47dx2DQbhKDqph53P0PfAVXFQIG7PPTgOnWGF9SPYsx7inTr32J9ZXUGZW-y7waQ0XHjDYng6Q034kn5ujCHR6s5gTo6A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884241)

Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8)

![Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention (see also Evidence Table 8)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt8.jpeg?Expires=1728478929&Signature=abLagSKlqN7nmBc7ZC2t5UeAk8at30lFtWZTgdxEf8RQP6E4kx-3~Rqj~J5cNujtI1ybI4-0cOJ-du1UfvkeQlTXW8DbdKofCu2QeytxWS1Iilr9HrDZOHgt3Fu5cb0UdX3kRItypnKUwb0iUGeo6bsS5KCc~~7Ad95wV13QThfXzkPhXdnAo6yweEU8~2qcF03dJRCM~Q5GtHiS8OBA9D86G2qygaHtr9qfVXOrk6fs8xBvES3oPw6dF47dx2DQbhKDqph53P0PfAVXFQIG7PPTgOnWGF9SPYsx7inTr32J9ZXUGZW-y7waQ0XHjDYng6Q034kn5ujCHR6s5gTo6A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.4. Residual ischaemic stroke risk despite anticoagulation

Although OAC significantly reduces the risk of ischaemic stroke in patients with AF, there remains a residual risk.<sup><span class="xrefLink" id="jumplink-ehae176-B252"></span><a href="javascript:;" reveal-id="ehae176-B252" data-open="ehae176-B252" class="link link-ref link-reveal xref-bibr">252</a>,<span class="xrefLink" id="jumplink-ehae176-B354"></span><a href="javascript:;" reveal-id="ehae176-B354" data-open="ehae176-B354" class="link link-ref link-reveal xref-bibr">354</a></sup> One-third of patients with AF presenting with an ischaemic stroke are already on anticoagulation,<sup><span class="xrefLink" id="jumplink-ehae176-B355"></span><a href="javascript:;" reveal-id="ehae176-B355" data-open="ehae176-B355" class="link link-ref link-reveal xref-bibr">355</a></sup> with heterogeneous aetiology.<sup><span class="xrefLink" id="jumplink-ehae176-B356"></span><a href="javascript:;" reveal-id="ehae176-B356" data-open="ehae176-B356" class="link link-ref link-reveal xref-bibr">356</a></sup> This may include non-AF-related competing stroke mechanisms (such as large artery and small vessel diseases), non-adherence to therapy, an inappropriately low dose of anticoagulant, or thromboembolism despite sufficient anticoagulation.<sup><span class="xrefLink" id="jumplink-ehae176-B357"></span><a href="javascript:;" reveal-id="ehae176-B357" data-open="ehae176-B357" class="link link-ref link-reveal xref-bibr">357</a></sup> Laboratory measurement of INR or DOAC levels may contribute to revealing an amenable cause of the stroke. Regardless of anticoagulation status, patients with ischaemic stroke are more likely to have cardiovascular risk factors.<sup><span class="xrefLink" id="jumplink-ehae176-B358"></span><a href="javascript:;" reveal-id="ehae176-B358" data-open="ehae176-B358" class="link link-ref link-reveal xref-bibr">358</a></sup> Many clinicians managing patients with an incident stroke despite taking anticoagulation will be tempted to switch their anticoagulant regimen. While there may be some advantage in switching from VKAs to DOACs for protection against future recurrent ischaemic or haemorrhagic stroke, this task force does not recommend routinely switching from one DOAC to another, or from a DOAC to a VKA, since this has no proven efficacy.<sup><span class="xrefLink" id="jumplink-ehae176-B252"></span><a href="javascript:;" reveal-id="ehae176-B252" data-open="ehae176-B252" class="link link-ref link-reveal xref-bibr">252</a>,<span class="xrefLink" id="jumplink-ehae176-B356"></span><a href="javascript:;" reveal-id="ehae176-B356" data-open="ehae176-B356" class="link link-ref link-reveal xref-bibr">356</a>,<span class="xrefLink" id="jumplink-ehae176-B359"></span><a href="javascript:;" reveal-id="ehae176-B359" data-open="ehae176-B359" class="link link-ref link-reveal xref-bibr">359</a></sup> There may be individual reasons for switching, including potential interactions with new drugs; however, there is no consistent data across countries that adherence or efficacy differs between once- and twice-daily approaches.<sup><span class="xrefLink" id="jumplink-ehae176-B360"></span><a href="javascript:;" reveal-id="ehae176-B360" data-open="ehae176-B360" class="link link-ref link-reveal xref-bibr">360</a>,<span class="xrefLink" id="jumplink-ehae176-B361"></span><a href="javascript:;" reveal-id="ehae176-B361" data-open="ehae176-B361" class="link link-ref link-reveal xref-bibr">361</a></sup> Emerging, but observational evidence suggests that switching provides limited reduction in the risk of recurrent ischaemic stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B252"></span><a href="javascript:;" reveal-id="ehae176-B252" data-open="ehae176-B252" class="link link-ref link-reveal xref-bibr">252</a>,<span class="xrefLink" id="jumplink-ehae176-B356"></span><a href="javascript:;" reveal-id="ehae176-B356" data-open="ehae176-B356" class="link link-ref link-reveal xref-bibr">356</a>,<span class="xrefLink" id="jumplink-ehae176-B359"></span><a href="javascript:;" reveal-id="ehae176-B359" data-open="ehae176-B359" class="link link-ref link-reveal xref-bibr">359</a></sup> The alternative strategy of adding antiplatelet therapy to OAC may lead to an increased risk of bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B356"></span><a href="javascript:;" reveal-id="ehae176-B356" data-open="ehae176-B356" class="link link-ref link-reveal xref-bibr">356</a>,<span class="xrefLink" id="jumplink-ehae176-B359"></span><a href="javascript:;" reveal-id="ehae176-B359" data-open="ehae176-B359" class="link link-ref link-reveal xref-bibr">359</a></sup> Aside from thorough attention to underlying risk factors and comorbidities, the approach to management of patients with a stroke despite OAC remains a distinct challenge.

Recommendation Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884244)

Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9)

![Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt9.jpeg?Expires=1728478929&Signature=mNNS1jJFgB5riIX0I2HUPoYiP8TI2MFL7irdW-wEQtjl3DSqM-~0GiLFAcwLYqzQJEeCAv~efd6fxQyam2PoMaobaIEyY~kg4rVXpiSHl0k~6N2dzveaxX-UmMeUxvjOEpwilX0x5nvLw88BVUQWVznmRql4aFizjs~2etBVLa-T21IEv2PL2wz6upXPPqNVORO0qiZw3W8uZPEkXOrP1EkPLtN~UfR2NmylRN2YSkoWUdwgxLAoLAb~ZT7Ip3gfY4BS8kfJyMyE2AUNwxI-TPoOSl013fveVSsFEfQAGyHS9dMbrUp3OOnvgIFDt3iMWqyGKv1-KaT~GfTccJ3yww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884244)

Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9)

![Recommendations for thromboembolism despite anticoagulation (see also Evidence Table 9)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt9.jpeg?Expires=1728478929&Signature=mNNS1jJFgB5riIX0I2HUPoYiP8TI2MFL7irdW-wEQtjl3DSqM-~0GiLFAcwLYqzQJEeCAv~efd6fxQyam2PoMaobaIEyY~kg4rVXpiSHl0k~6N2dzveaxX-UmMeUxvjOEpwilX0x5nvLw88BVUQWVznmRql4aFizjs~2etBVLa-T21IEv2PL2wz6upXPPqNVORO0qiZw3W8uZPEkXOrP1EkPLtN~UfR2NmylRN2YSkoWUdwgxLAoLAb~ZT7Ip3gfY4BS8kfJyMyE2AUNwxI-TPoOSl013fveVSsFEfQAGyHS9dMbrUp3OOnvgIFDt3iMWqyGKv1-KaT~GfTccJ3yww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.5. Percutaneous left atrial appendage occlusion

Percutaneous left atrial appendage occlusion (LAAO) is a device-based therapy that aims to prevent ischaemic stroke in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B362"></span><a href="javascript:;" reveal-id="ehae176-B362" data-open="ehae176-B362" class="link link-ref link-reveal xref-bibr">362</a>,<span class="xrefLink" id="jumplink-ehae176-B363"></span><a href="javascript:;" reveal-id="ehae176-B363" data-open="ehae176-B363" class="link link-ref link-reveal xref-bibr">363</a></sup> In the VKA era, two RCTs compared warfarin with LAAO using the Watchman device. The 5-year pooled outcomes demonstrated a similar rate of the composite endpoint (cardiovascular or unexplained death, systemic embolism, and stroke) between the LAAO and warfarin arms. Those randomized to LAAO had significantly lower rates of haemorrhagic stroke and all-cause death, but also a 71% non-significant increase in ischaemic stroke and systemic embolism.<sup><span class="xrefLink" id="jumplink-ehae176-B364"></span><a href="javascript:;" reveal-id="ehae176-B364" data-open="ehae176-B364" class="link link-ref link-reveal xref-bibr">364</a></sup> With DOACs demonstrating similar rates of major bleeding to aspirin,<sup><span class="xrefLink" id="jumplink-ehae176-B242"></span><a href="javascript:;" reveal-id="ehae176-B242" data-open="ehae176-B242" class="link link-ref link-reveal xref-bibr">242</a></sup> warfarin in the control arms in these trials is no longer standard of care and hence the place of LAAO in current practice is unclear. The Amulet occluder is an alternative LAAO device which was non-inferior in an RCT to the Watchman device for safety events (procedure-related complications, death, or major bleeding) and thromboembolism.<sup><span class="xrefLink" id="jumplink-ehae176-B365"></span><a href="javascript:;" reveal-id="ehae176-B365" data-open="ehae176-B365" class="link link-ref link-reveal xref-bibr">365</a></sup> In the PRAGUE-17 trial, 402 AF patients were randomized to DOAC or LAAO (Watchman or Amulet), with non-inferiority reported for a broad composite primary endpoint of stroke, TIA, systemic embolism, cardiovascular death, major or non-major clinically relevant bleeding, and procedure/device-related complications.<sup><span class="xrefLink" id="jumplink-ehae176-B366"></span><a href="javascript:;" reveal-id="ehae176-B366" data-open="ehae176-B366" class="link link-ref link-reveal xref-bibr">366</a>,<span class="xrefLink" id="jumplink-ehae176-B367"></span><a href="javascript:;" reveal-id="ehae176-B367" data-open="ehae176-B367" class="link link-ref link-reveal xref-bibr">367</a></sup> Larger trials<sup><span class="xrefLink" id="jumplink-ehae176-B368"></span><a href="javascript:;" reveal-id="ehae176-B368" data-open="ehae176-B368" class="link link-ref link-reveal xref-bibr">368</a>,<span class="xrefLink" id="jumplink-ehae176-B369"></span><a href="javascript:;" reveal-id="ehae176-B369" data-open="ehae176-B369" class="link link-ref link-reveal xref-bibr">369</a></sup> are expected to provide more comprehensive data that can add to the current evidence base (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S10](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Pending further RCTs (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_), patients with a contraindication to all of the OAC options (the four DOACs and VKAs) have the most appropriate rationale for LAAO implantation, despite the paradox that the need for post-procedure antithrombotic treatment exposes the patient to a bleeding risk that may be equivalent to that of DOACs. Regulatory approvals based on RCT protocols suggest the need for 45 days of VKA plus aspirin after implantation, followed by 6 months of DAPT in patients with no major peri-device leaks, and then ongoing aspirin (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Figure S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B370 ehae176-B371 ehae176-B372"></span><a href="javascript:;" reveal-id="ehae176-B370 ehae176-B371 ehae176-B372" data-open="ehae176-B370 ehae176-B371 ehae176-B372" class="link link-ref link-reveal xref-bibr">370–372</a></sup> However, real-world practice is markedly different and also varied. Direct oral anticoagulant administration at full or reduced dose has been proposed as a treatment alternative to warfarin.<sup><span class="xrefLink" id="jumplink-ehae176-B373"></span><a href="javascript:;" reveal-id="ehae176-B373" data-open="ehae176-B373" class="link link-ref link-reveal xref-bibr">373</a></sup> Observational studies have also supported the use of antiplatelet therapy without associated increases in device-related thrombosis or stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B374 ehae176-B375 ehae176-B376"></span><a href="javascript:;" reveal-id="ehae176-B374 ehae176-B375 ehae176-B376" data-open="ehae176-B374 ehae176-B375 ehae176-B376" class="link link-ref link-reveal xref-bibr">374–376</a></sup> In a propensity-matched comparison of patients receiving limited early OAC vs. antiplatelet treatment post-Watchman implantation, thromboembolic event rates and bleeding complications were similar.<sup><span class="xrefLink" id="jumplink-ehae176-B377"></span><a href="javascript:;" reveal-id="ehae176-B377" data-open="ehae176-B377" class="link link-ref link-reveal xref-bibr">377</a></sup> While waiting for solid RCT data (NCT03445949, NCT03568890),<sup><span class="xrefLink" id="jumplink-ehae176-B378"></span><a href="javascript:;" reveal-id="ehae176-B378" data-open="ehae176-B378" class="link link-ref link-reveal xref-bibr">378</a></sup> pertinent decisions on antithrombotic treatment are usually made on an individualized basis.<sup><span class="xrefLink" id="jumplink-ehae176-B379 ehae176-B380 ehae176-B381"></span><a href="javascript:;" reveal-id="ehae176-B379 ehae176-B380 ehae176-B381" data-open="ehae176-B379 ehae176-B380 ehae176-B381" class="link link-ref link-reveal xref-bibr">379–381</a></sup> Prevention of recurrent stroke, in addition to OAC, is another potential indication for LAAO. Only limited data are so far available from registries,<sup><span class="xrefLink" id="jumplink-ehae176-B382"></span><a href="javascript:;" reveal-id="ehae176-B382" data-open="ehae176-B382" class="link link-ref link-reveal xref-bibr">382</a></sup> with ongoing trials expected to provide more insight (NCT03642509, NCT05963698).

Left atrial appendage occlusion device implantation is associated with procedural risk including stroke, major bleeding, device-related thrombus, pericardial effusion, vascular complications, and death.<sup><span class="xrefLink" id="jumplink-ehae176-B362"></span><a href="javascript:;" reveal-id="ehae176-B362" data-open="ehae176-B362" class="link link-ref link-reveal xref-bibr">362</a>,<span class="xrefLink" id="jumplink-ehae176-B383 ehae176-B384 ehae176-B385"></span><a href="javascript:;" reveal-id="ehae176-B383 ehae176-B384 ehae176-B385" data-open="ehae176-B383 ehae176-B384 ehae176-B385" class="link link-ref link-reveal xref-bibr">383–385</a></sup> Voluntary registries enrolling patients considered ineligible for OAC have reported low peri-procedural risk,<sup><span class="xrefLink" id="jumplink-ehae176-B372"></span><a href="javascript:;" reveal-id="ehae176-B372" data-open="ehae176-B372" class="link link-ref link-reveal xref-bibr">372</a>,<span class="xrefLink" id="jumplink-ehae176-B376"></span><a href="javascript:;" reveal-id="ehae176-B376" data-open="ehae176-B376" class="link link-ref link-reveal xref-bibr">376</a>,<span class="xrefLink" id="jumplink-ehae176-B386"></span><a href="javascript:;" reveal-id="ehae176-B386" data-open="ehae176-B386" class="link link-ref link-reveal xref-bibr">386</a>,<span class="xrefLink" id="jumplink-ehae176-B387"></span><a href="javascript:;" reveal-id="ehae176-B387" data-open="ehae176-B387" class="link link-ref link-reveal xref-bibr">387</a></sup> although national registries report in-hospital major adverse event rates of 9.5% in centres performing 5–15 LAAO cases per year, and 5.6% performing 32–211 cases per year (_P_ < .001).<sup><span class="xrefLink" id="jumplink-ehae176-B388"></span><a href="javascript:;" reveal-id="ehae176-B388" data-open="ehae176-B388" class="link link-ref link-reveal xref-bibr">388</a></sup> Registries with new-generation devices report a lower complication rate compared with RCT data.<sup><span class="xrefLink" id="jumplink-ehae176-B389"></span><a href="javascript:;" reveal-id="ehae176-B389" data-open="ehae176-B389" class="link link-ref link-reveal xref-bibr">389</a>,<span class="xrefLink" id="jumplink-ehae176-B390"></span><a href="javascript:;" reveal-id="ehae176-B390" data-open="ehae176-B390" class="link link-ref link-reveal xref-bibr">390</a></sup> Device-related thrombi occur with an incidence of 1.7%–7.2% and are associated with a higher risk of ischaemic stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B386"></span><a href="javascript:;" reveal-id="ehae176-B386" data-open="ehae176-B386" class="link link-ref link-reveal xref-bibr">386</a>,<span class="xrefLink" id="jumplink-ehae176-B391 ehae176-B392 ehae176-B393 ehae176-B394 ehae176-B395 ehae176-B396 ehae176-B397"></span><a href="javascript:;" reveal-id="ehae176-B391 ehae176-B392 ehae176-B393 ehae176-B394 ehae176-B395 ehae176-B396 ehae176-B397" data-open="ehae176-B391 ehae176-B392 ehae176-B393 ehae176-B394 ehae176-B395 ehae176-B396 ehae176-B397" class="link link-ref link-reveal xref-bibr">391–397</a></sup> Their detection can be documented as late as 1 year post-implantation in one-fifth of patients, thus mandating a late ‘rule-out’ imaging approach.<sup><span class="xrefLink" id="jumplink-ehae176-B391"></span><a href="javascript:;" reveal-id="ehae176-B391" data-open="ehae176-B391" class="link link-ref link-reveal xref-bibr">391</a></sup> Likewise, follow-up screening for peri-device leaks is relevant, as small leaks (0–5 mm) are present in ∼25% and have been associated with higher thromboembolic and bleeding events during 1 year follow-up in a large observational registry of one particular device.<sup><span class="xrefLink" id="jumplink-ehae176-B398"></span><a href="javascript:;" reveal-id="ehae176-B398" data-open="ehae176-B398" class="link link-ref link-reveal xref-bibr">398</a></sup>

Recommendation Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884249)

Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10)

![Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt10.jpeg?Expires=1728478929&Signature=JJCaruoxDFNyB8WhI6JMxPDNNlzw0Dt6YMhlnz9Pj94aAkiXPOsvRzJISaHD4Tk6EKo2BDBE611DBPZ6zjls3h6ik9sur9lavhI3rwOQNqi9rECGZNyqHpmR5vjgfRlIWzmPIG3ahPRlIo0lmWPF7-0i5Gl4qdKkqvOZVWRVz0VNdtnCOI9Z6UGalHyM3e3B8xApNrKUzVT7YVQnbbWAnk2JcLfOtm9waqkGoyjtEECI2mYK6WpUDTdHtjNBAwpLGCaB6kSi8Q7ZNRDFpGnP2j6c3edHY8ryt1Fi09u78bhEdd4e8LegnPgDrTFkY8b3udehcDEWaGqFhbXzz9rSmA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884249)

Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10)

![Recommendations for percutaneous left atrial appendage occlusion (see also Evidence Table 10)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt10.jpeg?Expires=1728478929&Signature=JJCaruoxDFNyB8WhI6JMxPDNNlzw0Dt6YMhlnz9Pj94aAkiXPOsvRzJISaHD4Tk6EKo2BDBE611DBPZ6zjls3h6ik9sur9lavhI3rwOQNqi9rECGZNyqHpmR5vjgfRlIWzmPIG3ahPRlIo0lmWPF7-0i5Gl4qdKkqvOZVWRVz0VNdtnCOI9Z6UGalHyM3e3B8xApNrKUzVT7YVQnbbWAnk2JcLfOtm9waqkGoyjtEECI2mYK6WpUDTdHtjNBAwpLGCaB6kSi8Q7ZNRDFpGnP2j6c3edHY8ryt1Fi09u78bhEdd4e8LegnPgDrTFkY8b3udehcDEWaGqFhbXzz9rSmA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.6. Surgical left atrial appendage occlusion

Surgical occlusion or exclusion of the left atrial appendage (LAA) can contribute to stroke prevention in patients with AF undergoing cardiac surgery.<sup><span class="xrefLink" id="jumplink-ehae176-B399"></span><a href="javascript:;" reveal-id="ehae176-B399" data-open="ehae176-B399" class="link link-ref link-reveal xref-bibr">399</a>,<span class="xrefLink" id="jumplink-ehae176-B400"></span><a href="javascript:;" reveal-id="ehae176-B400" data-open="ehae176-B400" class="link link-ref link-reveal xref-bibr">400</a></sup> The Left Atrial Appendage Occlusion Study (LAAOS III) randomized 4811 patients with AF to undergo or not undergo LAAO at the time of cardiac surgery for another indication. During a mean of 3.8 years follow-up, ischaemic stroke or systemic embolism occurred in 114 patients (4.8%) in the occlusion group and 168 (7.0%) in the control arm (HR, 0.67; 95% CI, 0.53–0.85; _P_ = .001).<sup><span class="xrefLink" id="jumplink-ehae176-B401"></span><a href="javascript:;" reveal-id="ehae176-B401" data-open="ehae176-B401" class="link link-ref link-reveal xref-bibr">401</a></sup> The LAAOS III trial did not compare appendage occlusion with anticoagulation (77% of participants continued to receive OAC), and therefore, surgical LAA closure should be considered as an adjunct therapy to prevent thromboembolism in addition to anticoagulation in patients with AF.

There are no RCT data showing a beneficial effect on ischaemic stroke or systemic embolism in patients with AF undergoing LAAO during endoscopic or hybrid AF ablation. A meta-analysis of RCT and observational data showed no differences in stroke prevention or all-cause mortality when comparing LAA clipping during thoracoscopic AF ablation with percutaneous LAAO and catheter ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B402"></span><a href="javascript:;" reveal-id="ehae176-B402" data-open="ehae176-B402" class="link link-ref link-reveal xref-bibr">402</a></sup> While the percutaneous LAAO/catheter ablation group showed a higher acute success rate, it was also associated with a higher risk of haemorrhage during the peri-operative period. In an observational study evaluating 222 AF patients undergoing LAA closure using a clipping device as a part of endoscopic or hybrid AF ablation, complete closure was achieved in 95% of patients.<sup><span class="xrefLink" id="jumplink-ehae176-B403"></span><a href="javascript:;" reveal-id="ehae176-B403" data-open="ehae176-B403" class="link link-ref link-reveal xref-bibr">403</a></sup> There were no intra-operative complications, and freedom from a combined endpoint of ischaemic stroke, haemorrhagic stroke, or TIA was 99.1% over 369 patient-years of follow-up. Trials evaluating the beneficial effect of surgical LAA closure in patients undergoing cardiac surgery but without a known history of AF are ongoing (NCT03724318, NCT02701062).<sup><span class="xrefLink" id="jumplink-ehae176-B404"></span><a href="javascript:;" reveal-id="ehae176-B404" data-open="ehae176-B404" class="link link-ref link-reveal xref-bibr">404</a></sup>

There is a potential advantage for stand-alone epicardial over percutaneous LAA closure in patients with a contraindication for OAC, as there is no need for post-procedure anticoagulation after epicardial closure. Observational data show that stand-alone LAA closure using an epicardial clip is feasible and safe.<sup><span class="xrefLink" id="jumplink-ehae176-B405"></span><a href="javascript:;" reveal-id="ehae176-B405" data-open="ehae176-B405" class="link link-ref link-reveal xref-bibr">405</a></sup> A multidisciplinary team approach can facilitate the choice between epicardial or percutaneous LAA closure in such patients.<sup><span class="xrefLink" id="jumplink-ehae176-B406"></span><a href="javascript:;" reveal-id="ehae176-B406" data-open="ehae176-B406" class="link link-ref link-reveal xref-bibr">406</a></sup> The majority of safety data and experience in epicardial LAA closure originate from a single clipping device (AtriClip)<sup><span class="xrefLink" id="jumplink-ehae176-B403"></span><a href="javascript:;" reveal-id="ehae176-B403" data-open="ehae176-B403" class="link link-ref link-reveal xref-bibr">403</a>,<span class="xrefLink" id="jumplink-ehae176-B407"></span><a href="javascript:;" reveal-id="ehae176-B407" data-open="ehae176-B407" class="link link-ref link-reveal xref-bibr">407</a>,<span class="xrefLink" id="jumplink-ehae176-B408"></span><a href="javascript:;" reveal-id="ehae176-B408" data-open="ehae176-B408" class="link link-ref link-reveal xref-bibr">408</a></sup> (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S11](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Recommendation Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884254)

Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11)

![Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt11.jpeg?Expires=1728478929&Signature=xvXaidwzlXbQAuf7DkXpIa69pVeEy68QHLYdVZfa-3y2wOeY4QJGCidDXMkUcKr7yYKyl1-52X70ct6j-9t1ojvJZ3oRUNtiNzOGUjVbOiee6Qbizm2CN5baJcJUufV4rmQZQH8aOwaSfsNvuvpX8SAlzgqsq29wfzuzM2YSTATJ6tQUdnUqO3HScapbk32KRMbAMDdc3j0DutZfl6wo4KTVFJ4G162VL61rSc7iohuWBypfFXyxbggQd1FkPyphw5~Vu9HjaXwwmOtKdFoSACRB6b72EfFAIgON1Ipc9zarJyz2B2SdMZFhiFN1KvbUsOxLz7aR9SCDwuQ-4wHkoA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884254)

Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11)

![Recommendations for surgical left atrial appendage occlusion (see also Evidence Table 11)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt11.jpeg?Expires=1728478929&Signature=xvXaidwzlXbQAuf7DkXpIa69pVeEy68QHLYdVZfa-3y2wOeY4QJGCidDXMkUcKr7yYKyl1-52X70ct6j-9t1ojvJZ3oRUNtiNzOGUjVbOiee6Qbizm2CN5baJcJUufV4rmQZQH8aOwaSfsNvuvpX8SAlzgqsq29wfzuzM2YSTATJ6tQUdnUqO3HScapbk32KRMbAMDdc3j0DutZfl6wo4KTVFJ4G162VL61rSc7iohuWBypfFXyxbggQd1FkPyphw5~Vu9HjaXwwmOtKdFoSACRB6b72EfFAIgON1Ipc9zarJyz2B2SdMZFhiFN1KvbUsOxLz7aR9SCDwuQ-4wHkoA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.7. Bleeding risk

#### 6.7.1. Assessment of bleeding risk

When initiating antithrombotic therapy, modifiable bleeding risk factors should be managed to improve safety (_[Figure 10](javascript:;)_).<sup><span class="xrefLink" id="jumplink-ehae176-B414 ehae176-B415 ehae176-B416 ehae176-B417 ehae176-B418"></span><a href="javascript:;" reveal-id="ehae176-B414 ehae176-B415 ehae176-B416 ehae176-B417 ehae176-B418" data-open="ehae176-B414 ehae176-B415 ehae176-B416 ehae176-B417 ehae176-B418" class="link link-ref link-reveal xref-bibr">414–418</a></sup> This includes strict control of hypertension, advice to reduce excess alcohol intake, avoidance of unnecessary antiplatelet or anti-inflammatory agents, and attention to OAC therapy (adherence, control of TTR if on VKAs, and review of interacting medications). Clinicians should consider the balance between stroke and bleeding risk—as factors for both are dynamic and overlapping, they should be re-assessed at each review depending on the individual patient.<sup><span class="xrefLink" id="jumplink-ehae176-B419 ehae176-B420 ehae176-B421"></span><a href="javascript:;" reveal-id="ehae176-B419 ehae176-B420 ehae176-B421" data-open="ehae176-B419 ehae176-B420 ehae176-B421" class="link link-ref link-reveal xref-bibr">419–421</a></sup> Bleeding risk factors are rarely a reason to withdraw or withhold OAC in eligible patients, as the risk of stroke without anticoagulation often outweighs the risk of major bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B422"></span><a href="javascript:;" reveal-id="ehae176-B422" data-open="ehae176-B422" class="link link-ref link-reveal xref-bibr">422</a>,<span class="xrefLink" id="jumplink-ehae176-B423"></span><a href="javascript:;" reveal-id="ehae176-B423" data-open="ehae176-B423" class="link link-ref link-reveal xref-bibr">423</a></sup> Patients with non-modifiable risk factors should be reviewed more often, and where appropriate, a multidisciplinary team approach should be instituted to guide management.

![Modifying the risk of bleeding associated with OAC.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f10.jpeg?Expires=1728478929&Signature=P1kWyoigG8SwZbmpfWg7k0VvuZKYMkp1Xt7yNPtiEp9ecJmrspImsCPk3W0aJioRSM3bBt7wZI5EJuzI4uKqntwz3qbjqAzkFyRFwzW8I09V1A23wdPCFk-LzNRvX4Y6pzhUTt83DEm3GZKyXNi48gjaVqtRdw9TuibJacLWU8ZG4sPivyerBXP5Blwekt98~WHJgU1aq7P8C0ROA7~fTUGmXQ9D7228xFAiuRxwSlxUUnxqA83GDxHba28W2rX77IbnRzVc2-5ukuwoUZGEFXjM1g2aT0r3f3t9tPZAT42C5SakYrYZfwsFMqWM405L1lJDcTghIGC1e4idGpaLtA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 10

Modifying the risk of bleeding associated with OAC.

DOAC, direct oral anticoagulant; GI, gastrointestinal; INR, international normalized ratio of prothrombin time; NSAID, non-steroidal anti-inflammatory drug; OAC, oral anticoagulant; TTR, time in therapeutic range; VKA, vitamin K antagonist. <sup>a</sup>Absolute contraindications for OAC therapy are rare, and include primary intracranial tumours and intracerebral bleeds related to amyloid angiopathy. In most cases, contraindications may be relative or temporary. Left atrial appendage occlusion can be performed through a percutaneous or endoscopic approach.

[Open in new tab](https://academic.oup.com/view-large/figure/479884258/ehae176f10.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f10.jpeg?Expires=1728478929&Signature=bWB9MVXrv-~7Vn7o5rDvc0sbiCztCELC4OOd4Js8xE78aiTd5DO-a7phXtbsIllsOgjhriFuucIQq2UaKBnHwC4rinXngbr~2d4aktfduMAvxX9pdKzoExDQhR5d2H4a6vhj965md2hqqwozVefQWRdP5V-HeLycpcIqbci0Yw-FEJUPOJ8B3GQbfk1F56kvNFbBv0rDbI1hYHJSKN-W-zOOXmH~N4rXz2alcnNWnwNE5OOLuZpQvTkDsvvRd3xOg5VjrMrCEfHjZa4aPbW0RQ4lnLP0-Z6XxNXOiMv-9wVicjlpFoUrkcDAklKDtKjpBPI0eqBVSQ5v3Z6lwI9X7Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884258&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Several bleeding risk scores have been developed to account for a wide range of clinical factors (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[Additional Evidence Tables S12](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S13](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B424"></span><a href="javascript:;" reveal-id="ehae176-B424" data-open="ehae176-B424" class="link link-ref link-reveal xref-bibr">424</a></sup> Systematic reviews and validation studies in external cohorts have shown contrasting results and only modest predictive ability.<sup><span class="xrefLink" id="jumplink-ehae176-B244"></span><a href="javascript:;" reveal-id="ehae176-B244" data-open="ehae176-B244" class="link link-ref link-reveal xref-bibr">244</a>,<span class="xrefLink" id="jumplink-ehae176-B425 ehae176-B426 ehae176-B427 ehae176-B428 ehae176-B429 ehae176-B430 ehae176-B431 ehae176-B432 ehae176-B433 ehae176-B434"></span><a href="javascript:;" reveal-id="ehae176-B425 ehae176-B426 ehae176-B427 ehae176-B428 ehae176-B429 ehae176-B430 ehae176-B431 ehae176-B432 ehae176-B433 ehae176-B434" data-open="ehae176-B425 ehae176-B426 ehae176-B427 ehae176-B428 ehae176-B429 ehae176-B430 ehae176-B431 ehae176-B432 ehae176-B433 ehae176-B434" class="link link-ref link-reveal xref-bibr">425–434</a></sup> This task force does not recommend a specific bleeding risk score given the uncertainty in accuracy and potential adverse implications of not providing appropriate OAC to those at thromboembolic risk. There are very few absolute contraindications to OAC (especially DOAC therapy). Whereas primary intracranial tumours<sup><span class="xrefLink" id="jumplink-ehae176-B435"></span><a href="javascript:;" reveal-id="ehae176-B435" data-open="ehae176-B435" class="link link-ref link-reveal xref-bibr">435</a></sup> or an intracerebral bleed related to cerebral amyloid angiopathy<sup><span class="xrefLink" id="jumplink-ehae176-B436"></span><a href="javascript:;" reveal-id="ehae176-B436" data-open="ehae176-B436" class="link link-ref link-reveal xref-bibr">436</a></sup> are examples where OAC should be avoided, many other contraindications are relative or temporary. For example, a DOAC can often be safely initiated or re-initiated after acute bleeding has stopped, as long as the source has been fully investigated and managed. Co-prescription of proton pump inhibitors is common in clinical practice for patients receiving OAC that are at high risk of gastrointestinal bleeding. However, the evidence base is limited and not specifically in patients with AF. Whereas observational studies have shown potential benefit from proton pump inhibitors,<sup><span class="xrefLink" id="jumplink-ehae176-B437"></span><a href="javascript:;" reveal-id="ehae176-B437" data-open="ehae176-B437" class="link link-ref link-reveal xref-bibr">437</a></sup> a large RCT in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease found that pantoprazole had no significant impact on upper gastrointestinal bleeding events compared with placebo (HR, 0.88; 95% CI, 0.67–1.15).<sup><span class="xrefLink" id="jumplink-ehae176-B438"></span><a href="javascript:;" reveal-id="ehae176-B438" data-open="ehae176-B438" class="link link-ref link-reveal xref-bibr">438</a></sup> Hence, the use of gastric protection should be individualized for each patient according to the totality of their perceived bleeding risk.

Recommendation Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884260)

Recommendations for assessment of bleeding risk (see also Evidence Table 12)

![Recommendations for assessment of bleeding risk (see also Evidence Table 12)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt12.jpeg?Expires=1728478929&Signature=TRtVXNbK5vRv-YGY8UufXbtMMoNREhABrRVXUu65ekppPLOow~eWKPQ0cZ5XErJyh-O1I4-GOQbc7Dc87EHN1Cs-KZqo-7oDdNcpNasXoTW4rC5F~m12xAit3mvhISeVmElmJjxDg26EwEl~6NNYuzH2qdoDUDzNOZ~MZaA9Q11fF2TLhlbVhhYAQ3Fs4WM-z6Q2J6SgCIISCFvqX3OJZr7T0iKdHshT1SkzxRxShFwUOmN0fb2MacDTMtDZusaMzHMOp2buUtt0yM8unHKAiTY1g~QDNqglDQBpzSYpIgFiTcsj~XB9Dcn07uRXUTpKKXH7YgcSyB1dKcC~3UhSRA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884260)

Recommendations for assessment of bleeding risk (see also Evidence Table 12)

![Recommendations for assessment of bleeding risk (see also Evidence Table 12)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt12.jpeg?Expires=1728478929&Signature=TRtVXNbK5vRv-YGY8UufXbtMMoNREhABrRVXUu65ekppPLOow~eWKPQ0cZ5XErJyh-O1I4-GOQbc7Dc87EHN1Cs-KZqo-7oDdNcpNasXoTW4rC5F~m12xAit3mvhISeVmElmJjxDg26EwEl~6NNYuzH2qdoDUDzNOZ~MZaA9Q11fF2TLhlbVhhYAQ3Fs4WM-z6Q2J6SgCIISCFvqX3OJZr7T0iKdHshT1SkzxRxShFwUOmN0fb2MacDTMtDZusaMzHMOp2buUtt0yM8unHKAiTY1g~QDNqglDQBpzSYpIgFiTcsj~XB9Dcn07uRXUTpKKXH7YgcSyB1dKcC~3UhSRA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 6.7.2. Management of bleeding on anticoagulant therapy

General management of bleeding in patients receiving OAC is outlined in _[Figure 11](javascript:;)_. Cause-specific management is beyond the scope of these guidelines, and will depend on the individual circumstances of the patient and the healthcare environment.<sup><span class="xrefLink" id="jumplink-ehae176-B447"></span><a href="javascript:;" reveal-id="ehae176-B447" data-open="ehae176-B447" class="link link-ref link-reveal xref-bibr">447</a></sup> Assessment of patients with active bleeding should include confirmation of the bleeding site, bleeding severity, type/dose/timepoint of last anticoagulant intake, concomitant use of other antithrombotic agents, and other factors influencing bleeding risk (renal function, platelet count, and medications such as non-steroidal anti-inflammatories). INR testing and information on recent results are invaluable for patients taking VKAs. Specific coagulation tests for DOACs include diluted thrombin time, ecarin clotting time, ecarin chromogenic assay for dabigatran, and chromogenic anti-factor Xa assay for rivaroxaban, apixaban, and edoxaban.<sup><span class="xrefLink" id="jumplink-ehae176-B447 ehae176-B448 ehae176-B449"></span><a href="javascript:;" reveal-id="ehae176-B447 ehae176-B448 ehae176-B449" data-open="ehae176-B447 ehae176-B448 ehae176-B449" class="link link-ref link-reveal xref-bibr">447–449</a></sup> Diagnostic and treatment interventions to identify and manage the cause of bleeding (e.g. gastroscopy) should be performed promptly.

![Management of oral anticoagulant-related bleeding in patients with AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f11.jpeg?Expires=1728478929&Signature=oc~YHaIU0JYcL5HNOvSVwuQCoH0PMsMo84Cy24PPhFQ8s-fuGrlypKt6IHnwJTeZnGJFdWHUcIr3mNFjLhppP6UPgnDnrq3YFgyO-YiFNO~DoYw~wdb-6DkobM889mUnPgaPvtlRwVJSU1optLgg0NIJGU3l~IqRkD0QT2GsFQeNfyVm0bpTdkoLZCwQ057lGjCHWfldQZAe9HSK4KkBWuLih9ACNoxEFQVs0QV2EwSLvQiFLzee~sHM360sjX3JLFbZyw8ki7w-RS~t1dd2Azgt4RB98crFgDMo0crUWbzor-3qkfnwV7CGuYVZDnpWZSJ~R0Ykh2Umoju4v8V6qw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 11

Management of oral anticoagulant-related bleeding in patients with AF.

DOAC, direct oral anticoagulant; FFP, fresh frozen plasma; INR, international normalized ratio of prothrombin time; OAC, oral anticoagulant; PCC, prothrombin complex concentrate; VKA, vitamin K antagonist.

[Open in new tab](https://academic.oup.com/view-large/figure/479884263/ehae176f11.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f11.jpeg?Expires=1728478929&Signature=jIPU1r1hkOmBTVVfxlWXZc9vgWb91jyQh3fzSXwiKv5ralvtOr9M4vC~YZshN94t8db1-PlTjyqNpkhhy9GGXLZRxOmFlvHG0P8KDSYm8UpmNAOzytj0g4Fghy5BrKqj095r5Kwhm~22mdDOulauS8QUOC~PKghszdX3oENQ9uqW2F4d-zLytqX1xj8~ZdxgznsvN15qziIV25bKDlhppux3VFIxKd6jBc7jek23HH7YeY8mMK-4V70aar2ilLNWzcEpk8ow1XMfGlq5~RWG4dwXzZYNxL-aWK4nMXIiTf3yXi~D~Dr1jpwS67lVLxWRYuFbjsDc1aI2Vdtrk0Tbjg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884263&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

In cases of minor bleeding, temporary withdrawal of OAC while the cause is managed is usually sufficient, noting that the reduction in anticoagulant effect is dependent on the INR level for VKAs or the half-life of the particular DOAC.

For major bleeding events in patients taking VKAs, administration of fresh frozen plasma restores coagulation more rapidly than vitamin K, but prothrombin complex concentrates achieve even faster blood coagulation with fewer complications, and so are preferrable to achieve haemostasis.<sup><span class="xrefLink" id="jumplink-ehae176-B450"></span><a href="javascript:;" reveal-id="ehae176-B450" data-open="ehae176-B450" class="link link-ref link-reveal xref-bibr">450</a></sup> In DOAC-treated patients where the last DOAC dose was taken within 2–4 h, charcoal administration and/or gastric lavage may reduce further exposure. If the patient is taking dabigatran, idarucizumab can fully reverse its anticoagulant effect and help to achieve haemostasis within 2–4 h in uncontrolled bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B451"></span><a href="javascript:;" reveal-id="ehae176-B451" data-open="ehae176-B451" class="link link-ref link-reveal xref-bibr">451</a></sup> Dialysis can also be effective in reducing dabigatran concentration. Andexanet alfa rapidly reverses the activity of factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional evidence Table S14](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). An open-label RCT comparing andexanet alfa to usual care in patients presenting with acute ICH within 6 h of symptom onset was stopped early due to improved control of bleeding after 450 patients had been randomized.<sup><span class="xrefLink" id="jumplink-ehae176-B452"></span><a href="javascript:;" reveal-id="ehae176-B452" data-open="ehae176-B452" class="link link-ref link-reveal xref-bibr">452</a></sup> As DOAC-specific antidotes are not yet available in all institutions, prothrombin complex concentrates are often used in cases of serious bleeding on factor Xa inhibitors, with evidence limited to observational studies.<sup><span class="xrefLink" id="jumplink-ehae176-B453"></span><a href="javascript:;" reveal-id="ehae176-B453" data-open="ehae176-B453" class="link link-ref link-reveal xref-bibr">453</a></sup>

Due to the complexities of managing bleeding in patients taking OAC, it is advisable that each institution develop specific policies involving a multidisciplinary team that includes cardiologists, haematologists, emergency physicians/intensive care specialists, surgeons, and others. It is also important to educate patients taking anticoagulants on the signs and symptoms of bleeding events and to alert their healthcare provider when such events occur.<sup><span class="xrefLink" id="jumplink-ehae176-B335"></span><a href="javascript:;" reveal-id="ehae176-B335" data-open="ehae176-B335" class="link link-ref link-reveal xref-bibr">335</a></sup>

The decision to reinstate OAC will be determined by the severity, cause, and subsequent management of bleeding, preferably by a multidisciplinary team and with close monitoring. Failure to reinstitute OAC after a bleed significantly increases the risk of MI, stroke, and death.<sup><span class="xrefLink" id="jumplink-ehae176-B454"></span><a href="javascript:;" reveal-id="ehae176-B454" data-open="ehae176-B454" class="link link-ref link-reveal xref-bibr">454</a></sup> However, if the cause of severe or life-threatening bleeds cannot be treated or reversed, the risk of ongoing bleeding may outweigh the benefit of thromboembolic protection.<sup><span class="xrefLink" id="jumplink-ehae176-B335"></span><a href="javascript:;" reveal-id="ehae176-B335" data-open="ehae176-B335" class="link link-ref link-reveal xref-bibr">335</a></sup>

Recommendation Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884268)

Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13)

![Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt13.jpeg?Expires=1728478929&Signature=GOuxrlh5yTzWTdZc-QdYnEBIu7~bsrcswCZ9I8eLdwWmqHgThwFaVtfwCsVp1Zkn5yafetqM6YmSeHIiKZLAPbv9UZoZMGzvJKHCLUsB6vwoReyGvQWu0waUM3E9Ivp4mrZ-otR6DFjHhsMLl5t4U-psy7jgCp4ndzgyS2e5NSKt6JEJcblTqRJlLWFOB8lpIzDya8uMO-dnO3xu6md2b8RQgnjdvchQzL-~FLHykX10F~xMqCt070fZv82pwAnz1UiYQwzPU5kw457vadW5hjnlWTmRwt2DqwALxr46ttf2p7VMapqMtstMIthM~GanQVDH6n0hhhmFzCdO5cbXCA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884268)

Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13)

![Recommendations for management of bleeding in anticoagulated patients (see also Evidence Table 13)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt13.jpeg?Expires=1728478929&Signature=GOuxrlh5yTzWTdZc-QdYnEBIu7~bsrcswCZ9I8eLdwWmqHgThwFaVtfwCsVp1Zkn5yafetqM6YmSeHIiKZLAPbv9UZoZMGzvJKHCLUsB6vwoReyGvQWu0waUM3E9Ivp4mrZ-otR6DFjHhsMLl5t4U-psy7jgCp4ndzgyS2e5NSKt6JEJcblTqRJlLWFOB8lpIzDya8uMO-dnO3xu6md2b8RQgnjdvchQzL-~FLHykX10F~xMqCt070fZv82pwAnz1UiYQwzPU5kw457vadW5hjnlWTmRwt2DqwALxr46ttf2p7VMapqMtstMIthM~GanQVDH6n0hhhmFzCdO5cbXCA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 7\. \[R\] Reduce symptoms by rate and rhythm control

Most patients diagnosed with AF will need therapies and/or interventions to control heart rate, revert to sinus rhythm, or maintain sinus rhythm to limit symptoms or improve outcomes. While the concept of choosing between rate and rhythm control is often discussed, in reality most patients require a combination approach which should be consciously re-evaluated during follow-up. Within a patient-centred and shared-management approach, rhythm control should be a consideration in all suitable AF patients, with explicit discussion of benefits and risks.

### 7.1. Management of heart rate in patients with AF

Limiting tachycardia is an integral part of AF management and is often sufficient to improve AF-related symptoms. Rate control is indicated as initial therapy in the acute setting, in combination with rhythm control therapies, or as the sole treatment strategy to control heart rate and reduce symptoms. Limited evidence exists to inform the best type and intensity of rate control treatment.<sup><span class="xrefLink" id="jumplink-ehae176-B457"></span><a href="javascript:;" reveal-id="ehae176-B457" data-open="ehae176-B457" class="link link-ref link-reveal xref-bibr">457</a></sup> The approach to heart rate control presented in _[Figure 7](javascript:;)_ can be used for all types of AF, including paroxysmal, persistent, and permanent AF.

Recommendation Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884273)

Recommendations for heart rate control in patients with AF (see also Evidence Table 14)

![Recommendations for heart rate control in patients with AF (see also Evidence Table 14)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt14.jpeg?Expires=1728478929&Signature=U6RIZNLOzuE6hNozMykRpeN0aTe-rzAE9CvadCBdAbBFF553skmWt5BXh8LhevFslMFbGF8YfL~uwRSN4u19sMYkZD5cFmVXNmPwG5XxArh0xHVdQg1zfxYpEZHjnI7r6NMzMX5HNkZRQ11hS26-AW3-UFjKLCWnVHyuu9SvJQeKkGl-EBbuiMxP733LUONh675mJp2w6XBdzWDNKB~NR5I3g7nr6xkMXkCZC6AnB~rdOoZgrvFvoFawSL9At~ZFWnUvaVPQvHf~ULmE1wMD~BJqWYrVC5ZrYxu4aOrmDrs-EuXXcSvttsFJ9JC2tDKJRskmVlrhZLlNnXPm7Jodbw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884273)

Recommendations for heart rate control in patients with AF (see also Evidence Table 14)

![Recommendations for heart rate control in patients with AF (see also Evidence Table 14)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt14.jpeg?Expires=1728478929&Signature=U6RIZNLOzuE6hNozMykRpeN0aTe-rzAE9CvadCBdAbBFF553skmWt5BXh8LhevFslMFbGF8YfL~uwRSN4u19sMYkZD5cFmVXNmPwG5XxArh0xHVdQg1zfxYpEZHjnI7r6NMzMX5HNkZRQ11hS26-AW3-UFjKLCWnVHyuu9SvJQeKkGl-EBbuiMxP733LUONh675mJp2w6XBdzWDNKB~NR5I3g7nr6xkMXkCZC6AnB~rdOoZgrvFvoFawSL9At~ZFWnUvaVPQvHf~ULmE1wMD~BJqWYrVC5ZrYxu4aOrmDrs-EuXXcSvttsFJ9JC2tDKJRskmVlrhZLlNnXPm7Jodbw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.1.1. Indications and target heart rate

The optimal heart rate target in AF patients depends on the setting, symptom burden, presence of heart failure, and whether rate control is combined with a rhythm control strategy. In the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation) RCT of patients with permanent AF, lenient rate control (target heart rate <110  \[beats per minute\] b.p.m.) was non-inferior to a strict approach (<80 b.p.m. at rest; <110 b.p.m. during exercise; Holter for safety) for a composite of clinical events, NYHA class, or hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B186"></span><a href="javascript:;" reveal-id="ehae176-B186" data-open="ehae176-B186" class="link link-ref link-reveal xref-bibr">186</a>,<span class="xrefLink" id="jumplink-ehae176-B459"></span><a href="javascript:;" reveal-id="ehae176-B459" data-open="ehae176-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> Similar results were found in a post-hoc combined analysis from the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) and the RACE (Rate Control versus Electrical cardioversion) studies.<sup><span class="xrefLink" id="jumplink-ehae176-B474"></span><a href="javascript:;" reveal-id="ehae176-B474" data-open="ehae176-B474" class="link link-ref link-reveal xref-bibr">474</a></sup> Therefore, lenient rate control is an acceptable initial approach, unless there are ongoing symptoms or suspicion of tachycardia-induced cardiomyopathy, where stricter targets may be indicated.

#### 7.1.2. Heart rate control in the acute setting

In acute settings, physicians should always evaluate and manage underlying causes for the initiation of AF prior to, or in parallel to, instituting acute rate and/or rhythm control. These include treating sepsis, addressing fluid overload, or managing cardiogenic shock. The choice of drug (_[Table 12](javascript:;)_) will depend on the patient's characteristics, presence of heart failure and LVEF, and haemodynamic profile (_[Figure 7](javascript:;)_). In general for acute rate control, beta-blockers (for all LVEF) and diltiazem/verapamil (for LVEF >40%) are preferred over digoxin because of their more rapid onset of action and dose-dependent effects.<sup><span class="xrefLink" id="jumplink-ehae176-B462"></span><a href="javascript:;" reveal-id="ehae176-B462" data-open="ehae176-B462" class="link link-ref link-reveal xref-bibr">462</a>,<span class="xrefLink" id="jumplink-ehae176-B475"></span><a href="javascript:;" reveal-id="ehae176-B475" data-open="ehae176-B475" class="link link-ref link-reveal xref-bibr">475</a>,<span class="xrefLink" id="jumplink-ehae176-B476"></span><a href="javascript:;" reveal-id="ehae176-B476" data-open="ehae176-B476" class="link link-ref link-reveal xref-bibr">476</a></sup> More selective beta-1 receptor blockers have a better efficacy and safety profile than unselective beta-blockers.<sup><span class="xrefLink" id="jumplink-ehae176-B477"></span><a href="javascript:;" reveal-id="ehae176-B477" data-open="ehae176-B477" class="link link-ref link-reveal xref-bibr">477</a></sup> Combination therapy with digoxin may be required in acute settings (combination of beta-blockers with diltiazem/verapamil should be avoided except in closely monitored situations).<sup><span class="xrefLink" id="jumplink-ehae176-B177"></span><a href="javascript:;" reveal-id="ehae176-B177" data-open="ehae176-B177" class="link link-ref link-reveal xref-bibr">177</a>,<span class="xrefLink" id="jumplink-ehae176-B478"></span><a href="javascript:;" reveal-id="ehae176-B478" data-open="ehae176-B478" class="link link-ref link-reveal xref-bibr">478</a></sup> In selected patients who are haemodynamically unstable or with severely impaired LVEF, intravenous amiodarone, landiolol, or digoxin can be used.<sup><span class="xrefLink" id="jumplink-ehae176-B472"></span><a href="javascript:;" reveal-id="ehae176-B472" data-open="ehae176-B472" class="link link-ref link-reveal xref-bibr">472</a>,<span class="xrefLink" id="jumplink-ehae176-B473"></span><a href="javascript:;" reveal-id="ehae176-B473" data-open="ehae176-B473" class="link link-ref link-reveal xref-bibr">473</a>,<span class="xrefLink" id="jumplink-ehae176-B479"></span><a href="javascript:;" reveal-id="ehae176-B479" data-open="ehae176-B479" class="link link-ref link-reveal xref-bibr">479</a></sup>

#### 7.1.3. Long-term heart rate control

Pharmacological rate control can be achieved with beta-blockers, diltiazem, verapamil, digoxin, or combination therapy (_[Table 12](javascript:;)_) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S15](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B480"></span><a href="javascript:;" reveal-id="ehae176-B480" data-open="ehae176-B480" class="link link-ref link-reveal xref-bibr">480</a></sup>

Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884280)

Drugs for rate control in AF

| Agent<sup><span class="xrefLink" id="jumplink-tblfn118"></span><a href="javascript:;" reveal-id="tblfn118" data-open="tblfn118" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  | Intravenous administration .  | Usual range for oral maintenance dose .  | Contraindicated .  |
| --- | --- | --- | --- |
| **Beta-blockers**<sup><span class="xrefLink" id="jumplink-tblfn119"></span><a href="javascript:;" reveal-id="tblfn119" data-open="tblfn119" class="link link-ref link-reveal xref-fn js-xref-fn">b</a></sup> |
| Metoprolol tartrate | 2.5–5 mg bolus over 2 mins; up to 15 mg maximal cumulative dose | 25–100 mg twice daily | In case of asthma, non-selective beta-blockers should be avoided. Contraindicated in acute HF and history of severe bronchospasm. |
| Metoprolol XL (succinate) | N/A | 50–200 mg once daily |
| Bisoprolol | N/A | 1.25–20 mg once daily |
| Atenolol<sup><span class="xrefLink" id="jumplink-tblfn120"></span><a href="javascript:;" reveal-id="tblfn120" data-open="tblfn120" class="link link-ref link-reveal xref-fn js-xref-fn">c</a></sup> | N/A | 25–100 mg once daily |
| Esmolol | 500 µg/kg i.v. bolus over 1 min; followed by 50–300 µg/kg/min | N/A |
| Landiolol | 100 µg/kg i.v. bolus over 1 min; followed by 10–40 µg/kg/min | N/A |
| Nebivolol | N/A | 2.5–10 mg once daily |
| Carvedilol | N/A | 3.125–50 mg twice daily |
| **Non-dihydropyridine calcium channel antagonists** |
| Verapamil | 2.5–10 mg i.v. bolus over 5 min | 40 mg twice daily to 480 mg (extended release) once daily | Contraindicated if LVEF ≤40%. Adapt doses in hepatic and renal impairment. |
| Diltiazem | 0.25 mg/kg i.v. bolus over 5 min, then 5–15 mg/h | 60 mg three times daily to 360 mg (extended release) once daily |
| **Digitalis glycosides** |
| Digoxin | 0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in divided doses) | 0.0625–0.25 mg once daily | High plasma levels associated with adverse events.
Check renal function before starting digoxin and adapt dose in CKD patients. |
| Digitoxin | 0.4–0.6 mg | 0.05–0.1 mg once daily |
| **Other** |
| Amiodarone<sup><span class="xrefLink" id="jumplink-tblfn121"></span><a href="javascript:;" reveal-id="tblfn121" data-open="tblfn121" class="link link-ref link-reveal xref-fn js-xref-fn">d</a></sup> | 300 mg i.v. diluted in 250 mL 5% dextrose over 30–60 min (preferably via central venous cannula), followed by 900–1200 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula | 200 mg once daily after loading
Loading: 200 mg three times daily for 4 weeks, then 200 mg daily or less as appropriate (reduce other rate control drugs according to heart rate) | Contraindicated in iodine sensitivity.
Serious potential adverse effects (including pulmonary, ophthalmic, hepatic, and thyroid). Consider numerous drug interactions. |

| Agent<sup><span class="xrefLink" id="jumplink-tblfn118"></span><a href="javascript:;" reveal-id="tblfn118" data-open="tblfn118" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  | Intravenous administration .  | Usual range for oral maintenance dose .  | Contraindicated .  |
| --- | --- | --- | --- |
| **Beta-blockers**<sup><span class="xrefLink" id="jumplink-tblfn119"></span><a href="javascript:;" reveal-id="tblfn119" data-open="tblfn119" class="link link-ref link-reveal xref-fn js-xref-fn">b</a></sup> |
| Metoprolol tartrate | 2.5–5 mg bolus over 2 mins; up to 15 mg maximal cumulative dose | 25–100 mg twice daily | In case of asthma, non-selective beta-blockers should be avoided. Contraindicated in acute HF and history of severe bronchospasm. |
| Metoprolol XL (succinate) | N/A | 50–200 mg once daily |
| Bisoprolol | N/A | 1.25–20 mg once daily |
| Atenolol<sup><span class="xrefLink" id="jumplink-tblfn120"></span><a href="javascript:;" reveal-id="tblfn120" data-open="tblfn120" class="link link-ref link-reveal xref-fn js-xref-fn">c</a></sup> | N/A | 25–100 mg once daily |
| Esmolol | 500 µg/kg i.v. bolus over 1 min; followed by 50–300 µg/kg/min | N/A |
| Landiolol | 100 µg/kg i.v. bolus over 1 min; followed by 10–40 µg/kg/min | N/A |
| Nebivolol | N/A | 2.5–10 mg once daily |
| Carvedilol | N/A | 3.125–50 mg twice daily |
| **Non-dihydropyridine calcium channel antagonists** |
| Verapamil | 2.5–10 mg i.v. bolus over 5 min | 40 mg twice daily to 480 mg (extended release) once daily | Contraindicated if LVEF ≤40%. Adapt doses in hepatic and renal impairment. |
| Diltiazem | 0.25 mg/kg i.v. bolus over 5 min, then 5–15 mg/h | 60 mg three times daily to 360 mg (extended release) once daily |
| **Digitalis glycosides** |
| Digoxin | 0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in divided doses) | 0.0625–0.25 mg once daily | High plasma levels associated with adverse events.
Check renal function before starting digoxin and adapt dose in CKD patients. |
| Digitoxin | 0.4–0.6 mg | 0.05–0.1 mg once daily |
| **Other** |
| Amiodarone<sup><span class="xrefLink" id="jumplink-tblfn121"></span><a href="javascript:;" reveal-id="tblfn121" data-open="tblfn121" class="link link-ref link-reveal xref-fn js-xref-fn">d</a></sup> | 300 mg i.v. diluted in 250 mL 5% dextrose over 30–60 min (preferably via central venous cannula), followed by 900–1200 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula | 200 mg once daily after loading
Loading: 200 mg three times daily for 4 weeks, then 200 mg daily or less as appropriate (reduce other rate control drugs according to heart rate) | Contraindicated in iodine sensitivity.
Serious potential adverse effects (including pulmonary, ophthalmic, hepatic, and thyroid). Consider numerous drug interactions. |

AF, atrial fibrillation; CKD, chronic kidney disease; HF, heart failure; i.v., intravenous; min, minutes; N/A, not available or not widely available. Maximum doses have been defined based on the summary of product characteristic of each drug.

<sup>a</sup>All rate control drugs are contraindicated in Wolff–Parkinson–White syndrome; also intravenous amiodarone.

<sup>b</sup>Other beta-blockers are available but not recommended as specific rate control therapy in AF and therefore not mentioned here (e.g. propranolol and labetalol).

<sup>c</sup>No data on atenolol; should not be used in heart failure with reduced ejection fraction or in pregnancy.

<sup>d</sup>Loading regimen may vary; i.v. dosage should be considered when calculating total load.

© ESC 2024

Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884280)

Drugs for rate control in AF

| Agent<sup><span class="xrefLink" id="jumplink-tblfn118"></span><a href="javascript:;" reveal-id="tblfn118" data-open="tblfn118" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  | Intravenous administration .  | Usual range for oral maintenance dose .  | Contraindicated .  |
| --- | --- | --- | --- |
| **Beta-blockers**<sup><span class="xrefLink" id="jumplink-tblfn119"></span><a href="javascript:;" reveal-id="tblfn119" data-open="tblfn119" class="link link-ref link-reveal xref-fn js-xref-fn">b</a></sup> |
| Metoprolol tartrate | 2.5–5 mg bolus over 2 mins; up to 15 mg maximal cumulative dose | 25–100 mg twice daily | In case of asthma, non-selective beta-blockers should be avoided. Contraindicated in acute HF and history of severe bronchospasm. |
| Metoprolol XL (succinate) | N/A | 50–200 mg once daily |
| Bisoprolol | N/A | 1.25–20 mg once daily |
| Atenolol<sup><span class="xrefLink" id="jumplink-tblfn120"></span><a href="javascript:;" reveal-id="tblfn120" data-open="tblfn120" class="link link-ref link-reveal xref-fn js-xref-fn">c</a></sup> | N/A | 25–100 mg once daily |
| Esmolol | 500 µg/kg i.v. bolus over 1 min; followed by 50–300 µg/kg/min | N/A |
| Landiolol | 100 µg/kg i.v. bolus over 1 min; followed by 10–40 µg/kg/min | N/A |
| Nebivolol | N/A | 2.5–10 mg once daily |
| Carvedilol | N/A | 3.125–50 mg twice daily |
| **Non-dihydropyridine calcium channel antagonists** |
| Verapamil | 2.5–10 mg i.v. bolus over 5 min | 40 mg twice daily to 480 mg (extended release) once daily | Contraindicated if LVEF ≤40%. Adapt doses in hepatic and renal impairment. |
| Diltiazem | 0.25 mg/kg i.v. bolus over 5 min, then 5–15 mg/h | 60 mg three times daily to 360 mg (extended release) once daily |
| **Digitalis glycosides** |
| Digoxin | 0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in divided doses) | 0.0625–0.25 mg once daily | High plasma levels associated with adverse events.
Check renal function before starting digoxin and adapt dose in CKD patients. |
| Digitoxin | 0.4–0.6 mg | 0.05–0.1 mg once daily |
| **Other** |
| Amiodarone<sup><span class="xrefLink" id="jumplink-tblfn121"></span><a href="javascript:;" reveal-id="tblfn121" data-open="tblfn121" class="link link-ref link-reveal xref-fn js-xref-fn">d</a></sup> | 300 mg i.v. diluted in 250 mL 5% dextrose over 30–60 min (preferably via central venous cannula), followed by 900–1200 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula | 200 mg once daily after loading
Loading: 200 mg three times daily for 4 weeks, then 200 mg daily or less as appropriate (reduce other rate control drugs according to heart rate) | Contraindicated in iodine sensitivity.
Serious potential adverse effects (including pulmonary, ophthalmic, hepatic, and thyroid). Consider numerous drug interactions. |

| Agent<sup><span class="xrefLink" id="jumplink-tblfn118"></span><a href="javascript:;" reveal-id="tblfn118" data-open="tblfn118" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> .  | Intravenous administration .  | Usual range for oral maintenance dose .  | Contraindicated .  |
| --- | --- | --- | --- |
| **Beta-blockers**<sup><span class="xrefLink" id="jumplink-tblfn119"></span><a href="javascript:;" reveal-id="tblfn119" data-open="tblfn119" class="link link-ref link-reveal xref-fn js-xref-fn">b</a></sup> |
| Metoprolol tartrate | 2.5–5 mg bolus over 2 mins; up to 15 mg maximal cumulative dose | 25–100 mg twice daily | In case of asthma, non-selective beta-blockers should be avoided. Contraindicated in acute HF and history of severe bronchospasm. |
| Metoprolol XL (succinate) | N/A | 50–200 mg once daily |
| Bisoprolol | N/A | 1.25–20 mg once daily |
| Atenolol<sup><span class="xrefLink" id="jumplink-tblfn120"></span><a href="javascript:;" reveal-id="tblfn120" data-open="tblfn120" class="link link-ref link-reveal xref-fn js-xref-fn">c</a></sup> | N/A | 25–100 mg once daily |
| Esmolol | 500 µg/kg i.v. bolus over 1 min; followed by 50–300 µg/kg/min | N/A |
| Landiolol | 100 µg/kg i.v. bolus over 1 min; followed by 10–40 µg/kg/min | N/A |
| Nebivolol | N/A | 2.5–10 mg once daily |
| Carvedilol | N/A | 3.125–50 mg twice daily |
| **Non-dihydropyridine calcium channel antagonists** |
| Verapamil | 2.5–10 mg i.v. bolus over 5 min | 40 mg twice daily to 480 mg (extended release) once daily | Contraindicated if LVEF ≤40%. Adapt doses in hepatic and renal impairment. |
| Diltiazem | 0.25 mg/kg i.v. bolus over 5 min, then 5–15 mg/h | 60 mg three times daily to 360 mg (extended release) once daily |
| **Digitalis glycosides** |
| Digoxin | 0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in divided doses) | 0.0625–0.25 mg once daily | High plasma levels associated with adverse events.
Check renal function before starting digoxin and adapt dose in CKD patients. |
| Digitoxin | 0.4–0.6 mg | 0.05–0.1 mg once daily |
| **Other** |
| Amiodarone<sup><span class="xrefLink" id="jumplink-tblfn121"></span><a href="javascript:;" reveal-id="tblfn121" data-open="tblfn121" class="link link-ref link-reveal xref-fn js-xref-fn">d</a></sup> | 300 mg i.v. diluted in 250 mL 5% dextrose over 30–60 min (preferably via central venous cannula), followed by 900–1200 mg i.v. over 24 h diluted in 500–1000 mL via a central venous cannula | 200 mg once daily after loading
Loading: 200 mg three times daily for 4 weeks, then 200 mg daily or less as appropriate (reduce other rate control drugs according to heart rate) | Contraindicated in iodine sensitivity.
Serious potential adverse effects (including pulmonary, ophthalmic, hepatic, and thyroid). Consider numerous drug interactions. |

AF, atrial fibrillation; CKD, chronic kidney disease; HF, heart failure; i.v., intravenous; min, minutes; N/A, not available or not widely available. Maximum doses have been defined based on the summary of product characteristic of each drug.

<sup>a</sup>All rate control drugs are contraindicated in Wolff–Parkinson–White syndrome; also intravenous amiodarone.

<sup>b</sup>Other beta-blockers are available but not recommended as specific rate control therapy in AF and therefore not mentioned here (e.g. propranolol and labetalol).

<sup>c</sup>No data on atenolol; should not be used in heart failure with reduced ejection fraction or in pregnancy.

<sup>d</sup>Loading regimen may vary; i.v. dosage should be considered when calculating total load.

© ESC 2024

The choice of rate control drugs depends on symptoms, comorbidities, and the potential for side effects and interactions. Combination therapy of different rate-controlling drugs should be considered only when needed to achieve the target heart rate, and careful follow-up to avoid bradycardia is advised. Combining beta-blockers with verapamil or diltiazem should only be performed in secondary care with regular monitoring of heart rate by 24 h ECG to check for bradycardia.<sup><span class="xrefLink" id="jumplink-ehae176-B459"></span><a href="javascript:;" reveal-id="ehae176-B459" data-open="ehae176-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> Some antiarrhythmic drugs (AADs) also have rate-limiting properties (e.g. amiodarone, sotalol), but they should generally be used only for rhythm control. Dronedarone should not be instituted for rate control since it increases rates of heart failure, stroke, and cardiovascular death in permanent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B481"></span><a href="javascript:;" reveal-id="ehae176-B481" data-open="ehae176-B481" class="link link-ref link-reveal xref-bibr">481</a></sup>

**Beta-blockers**, specifically beta-1 selective adrenoreceptor antagonists, are often first-line rate-controlling agents largely based on their acute effect on heart rate and the beneficial effects demonstrated in patients with chronic HFrEF. However, the prognostic benefit of beta-blockers seen in HFrEF patients with sinus rhythm may not be present in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B133"></span><a href="javascript:;" reveal-id="ehae176-B133" data-open="ehae176-B133" class="link link-ref link-reveal xref-bibr">133</a>,<span class="xrefLink" id="jumplink-ehae176-B482"></span><a href="javascript:;" reveal-id="ehae176-B482" data-open="ehae176-B482" class="link link-ref link-reveal xref-bibr">482</a></sup>

**Verapamil** and **diltiazem** are non-dihydropyridine calcium channel blockers. They provide rate control<sup><span class="xrefLink" id="jumplink-ehae176-B461"></span><a href="javascript:;" reveal-id="ehae176-B461" data-open="ehae176-B461" class="link link-ref link-reveal xref-bibr">461</a></sup> and have a different adverse effect profile, making verapamil or diltiazem useful for those experiencing side effects from beta-blockers.<sup><span class="xrefLink" id="jumplink-ehae176-B483"></span><a href="javascript:;" reveal-id="ehae176-B483" data-open="ehae176-B483" class="link link-ref link-reveal xref-bibr">483</a></sup> In a 60 patient crossover RCT, verapamil and diltiazem did not lead to the same reduction in exercise capacity as seen with beta-blockers, and had a beneficial impact on BNP.<sup><span class="xrefLink" id="jumplink-ehae176-B480"></span><a href="javascript:;" reveal-id="ehae176-B480" data-open="ehae176-B480" class="link link-ref link-reveal xref-bibr">480</a></sup>

**Digoxin** and **digitoxin** are cardiac glycosides that inhibit the sodium–potassium adenosine triphosphatase and augment parasympathetic tone. In RCTs, there is no association between the use of digoxin and any increase in all-cause mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B185"></span><a href="javascript:;" reveal-id="ehae176-B185" data-open="ehae176-B185" class="link link-ref link-reveal xref-bibr">185</a>,<span class="xrefLink" id="jumplink-ehae176-B484"></span><a href="javascript:;" reveal-id="ehae176-B484" data-open="ehae176-B484" class="link link-ref link-reveal xref-bibr">484</a></sup> Lower doses of digoxin may be associated with better prognosis.<sup><span class="xrefLink" id="jumplink-ehae176-B185"></span><a href="javascript:;" reveal-id="ehae176-B185" data-open="ehae176-B185" class="link link-ref link-reveal xref-bibr">185</a></sup> Serum digoxin concentrations can be monitored to avoid toxicity,<sup><span class="xrefLink" id="jumplink-ehae176-B485"></span><a href="javascript:;" reveal-id="ehae176-B485" data-open="ehae176-B485" class="link link-ref link-reveal xref-bibr">485</a></sup> especially in patients at higher risk due to older age, renal dysfunction, or use of interacting medications. In RATE-AF (RAte control Therapy Evaluation in permanent Atrial Fibrillation), a trial in patients with symptomatic permanent AF, there was no difference between low-dose digoxin and bisoprolol for patient-reported quality of life outcomes at 6 months. However, those randomized to digoxin demonstrated fewer adverse effects, a greater improvement in mEHRA and NYHA scores, and a reduction in BNP.<sup><span class="xrefLink" id="jumplink-ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B48" data-open="ehae176-B48" class="link link-ref link-reveal xref-bibr">48</a></sup> Two ongoing RCTs are addressing digoxin and digitoxin use in patients with HFrEF with and without AF (EudraCT-2013-005326-38, NCT03783429).<sup><span class="xrefLink" id="jumplink-ehae176-B486"></span><a href="javascript:;" reveal-id="ehae176-B486" data-open="ehae176-B486" class="link link-ref link-reveal xref-bibr">486</a></sup>

Due to its broad extracardiac adverse effect profile, **amiodarone** is reserved as a last option when heart rate cannot be controlled even with maximal tolerated combination therapy, or in patients who do not qualify for atrioventricular node ablation and pacing. Many of the adverse effects from amiodarone have a direct relationship with cumulative dose, restricting the long-term value of amiodarone for rate control.<sup><span class="xrefLink" id="jumplink-ehae176-B487"></span><a href="javascript:;" reveal-id="ehae176-B487" data-open="ehae176-B487" class="link link-ref link-reveal xref-bibr">487</a></sup>

#### 7.1.4. Atrioventricular node ablation and pacemaker implantation

Ablation of the atrioventricular node and pacemaker implantation (‘ablate and pace’) can lower and regularize heart rate in patients with AF (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S16](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). The procedure has a low complication rate and a low long-term mortality risk.<sup><span class="xrefLink" id="jumplink-ehae176-B468"></span><a href="javascript:;" reveal-id="ehae176-B468" data-open="ehae176-B468" class="link link-ref link-reveal xref-bibr">468</a>,<span class="xrefLink" id="jumplink-ehae176-B488"></span><a href="javascript:;" reveal-id="ehae176-B488" data-open="ehae176-B488" class="link link-ref link-reveal xref-bibr">488</a></sup> The pacemaker should be implanted a few weeks before the atrioventricular node ablation, with the initial pacing rate after ablation set at 70–90 b.p.m.<sup><span class="xrefLink" id="jumplink-ehae176-B489"></span><a href="javascript:;" reveal-id="ehae176-B489" data-open="ehae176-B489" class="link link-ref link-reveal xref-bibr">489</a>,<span class="xrefLink" id="jumplink-ehae176-B490"></span><a href="javascript:;" reveal-id="ehae176-B490" data-open="ehae176-B490" class="link link-ref link-reveal xref-bibr">490</a></sup> This strategy does not worsen LV function,<sup><span class="xrefLink" id="jumplink-ehae176-B491"></span><a href="javascript:;" reveal-id="ehae176-B491" data-open="ehae176-B491" class="link link-ref link-reveal xref-bibr">491</a></sup> and may even improve LVEF in selected patients.<sup><span class="xrefLink" id="jumplink-ehae176-B492"></span><a href="javascript:;" reveal-id="ehae176-B492" data-open="ehae176-B492" class="link link-ref link-reveal xref-bibr">492</a>,<span class="xrefLink" id="jumplink-ehae176-B493"></span><a href="javascript:;" reveal-id="ehae176-B493" data-open="ehae176-B493" class="link link-ref link-reveal xref-bibr">493</a></sup> The evidence base has typically included older patients. For younger patients, ablate and pace should only be considered if heart rate remains uncontrolled despite consideration of other pharmacological and non-pharmacological treatment options. The choice of pacing therapy (right ventricular or biventricular pacing) depends on patient characteristics, presence of heart failure, and LVEF.<sup><span class="xrefLink" id="jumplink-ehae176-B187"></span><a href="javascript:;" reveal-id="ehae176-B187" data-open="ehae176-B187" class="link link-ref link-reveal xref-bibr">187</a>,<span class="xrefLink" id="jumplink-ehae176-B494"></span><a href="javascript:;" reveal-id="ehae176-B494" data-open="ehae176-B494" class="link link-ref link-reveal xref-bibr">494</a></sup>

In severely symptomatic patients with permanent AF and at least one hospitalization for heart failure, atrioventricular node ablation combined with CRT should be considered. In the APAF-CRT (Ablate and Pace for Atrial Fibrillation-cardiac resynchronization therapy) trial in a population with narrow QRS complexes, atrioventricular node ablation combined with CRT was superior to rate control drugs for the primary outcomes (all-cause mortality, and death or hospitalization for heart failure), and secondary outcomes (symptom burden and physical limitation).<sup><span class="xrefLink" id="jumplink-ehae176-B470"></span><a href="javascript:;" reveal-id="ehae176-B470" data-open="ehae176-B470" class="link link-ref link-reveal xref-bibr">470</a>,<span class="xrefLink" id="jumplink-ehae176-B471"></span><a href="javascript:;" reveal-id="ehae176-B471" data-open="ehae176-B471" class="link link-ref link-reveal xref-bibr">471</a></sup> Conduction system pacing may become a potentially useful alternate pacing mode when implementing a pace and ablate strategy, once safety and efficacy have been confirmed in larger RCTs.<sup><span class="xrefLink" id="jumplink-ehae176-B495"></span><a href="javascript:;" reveal-id="ehae176-B495" data-open="ehae176-B495" class="link link-ref link-reveal xref-bibr">495</a>,<span class="xrefLink" id="jumplink-ehae176-B496"></span><a href="javascript:;" reveal-id="ehae176-B496" data-open="ehae176-B496" class="link link-ref link-reveal xref-bibr">496</a></sup> In CRT recipients, the presence (or occurrence) of AF is one of the main reasons for suboptimal biventricular pacing.<sup><span class="xrefLink" id="jumplink-ehae176-B187"></span><a href="javascript:;" reveal-id="ehae176-B187" data-open="ehae176-B187" class="link link-ref link-reveal xref-bibr">187</a></sup> Improvement of biventricular pacing is indicated and can be reached by intensification of rate control drug regimens, atrioventricular node ablation, or rhythm control, depending on patient and AF characteristics.<sup><span class="xrefLink" id="jumplink-ehae176-B187"></span><a href="javascript:;" reveal-id="ehae176-B187" data-open="ehae176-B187" class="link link-ref link-reveal xref-bibr">187</a></sup>

### 7.2. Rhythm control strategies in patients with AF

#### 7.2.1. General principles and anticoagulation

Rhythm control refers to therapies dedicated to restoring and maintaining sinus rhythm. These treatments include cardioversion, AADs, percutaneous catheter ablation, endoscopic and hybrid ablation, and open surgical approaches (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S17](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Rhythm control is never a strategy on its own; instead, it should always be part of the AF-CARE approach.

In patients with acute or worsening haemodynamic instability thought to be caused by AF, rapid electrical cardioversion is recommended. For other patients, a wait-and-see approach should be considered as an alternative to immediate cardioversion (_[Figure 12](javascript:;)_). The Rate Control versus Electrical Cardioversion Trial 7–Acute Cardioversion versus Wait and See (RACE 7 ACWAS) trial in patients with recent-onset symptomatic AF without haemodynamic compromise showed a wait-and-see approach for spontaneous conversion until 48 h after the onset of AF symptoms was non-inferior as compared with immediate cardioversion at 4 weeks follow-up.<sup><span class="xrefLink" id="jumplink-ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B10" data-open="ehae176-B10" class="link link-ref link-reveal xref-bibr">10</a></sup>

![Approaches for cardioversion in patients with AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f12.jpeg?Expires=1728478929&Signature=4DaAjFe1~rapm2tK31uVgPhifiAHtjxg8qStK8aVSpyWue~ckl0AlAjcg86uc3-ShjIIdR1nNxypyzFD0Lg27AEGuO2kexgmqT-9r3lEXPJXIAiFJ5YdxDkY6Fj9H6~m7V4aP0PkGVI6be1pa5~Czb7kRYWBOoP~P6J~aSuQqe8GhYOrXs4hDglHvR0FwszmRfRulYLYePU41bDP5xi4iSVqXjzc03mKWcecJvEky4F2P0wHG-xWel~FwMm~v3ZjKGcwy~XTzKFVbbhbyINegOv~4VTwBVdMnqKrbAF215li7D40iVssvV0gmczhVxLX1ZJPzz1HKY0lOV6GFp4sYA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 12

Approaches for cardioversion in patients with AF.

AF, atrial fibrillation; CHA<sub>2</sub>DS<sub>2</sub>\-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; h, hour; LMWH, low molecular weight heparin; DOAC, direct oral anticoagulant; OAC, oral anticoagulant; TOE, transoesophageal echocardiography; UFH, unfractionated heparin; VKA, vitamin K antagonist. Flowchart for decision-making on cardioversion of AF depending on clinical presentation, AF onset, oral anticoagulation intake, and risk factors for stroke. <sup>a</sup>See _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5)_.

[Open in new tab](https://academic.oup.com/view-large/figure/479884293/ehae176f12.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f12.jpeg?Expires=1728478929&Signature=hKJWdIPRA8QdylcbSQzVQAePcSzD0Fe4tXhJJDpSa8vX~~5QCoXY7uavUbN2~x--WRH0RrA2d3le6EuK5G01ThxCl6pop4JFjKO2xjuzRAGVB~XYgfWtaCoCIsPVRVUS0MkwfEq4CRfBKH~vgT~uivAYg3KEqWZ59AYnpxmSu6YGukjQukZfUNOrH5JTAdmcpdeGSSkPjxa6mdmMg8W7-mfSyQts25vUEIjBytAnOsa~8WOk1cRwmAkS7J7Owt3fXChL-ZtYcf93yuqqlMBPU4hlu5Ctmnn0017Qi7BE-CwxclBKfIJnw4z5blMF-PYIpdJCUKqtOCvSf8-44vFzKQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884293&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Since the publication of landmark trials more than 20 years ago, the main reason to consider longer-term rhythm control therapy has been the reduction in symptoms from AF.<sup><span class="xrefLink" id="jumplink-ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500"></span><a href="javascript:;" reveal-id="ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500" data-open="ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500" class="link link-ref link-reveal xref-bibr">497–500</a></sup> Older studies have shown that the institution of a rhythm control strategy using AADs does not reduce mortality and morbidity when compared with a rate control-only strategy,<sup><span class="xrefLink" id="jumplink-ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500"></span><a href="javascript:;" reveal-id="ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500" data-open="ehae176-B497 ehae176-B498 ehae176-B499 ehae176-B500" class="link link-ref link-reveal xref-bibr">497–500</a></sup> and may increase hospitalization.<sup><span class="xrefLink" id="jumplink-ehae176-B457"></span><a href="javascript:;" reveal-id="ehae176-B457" data-open="ehae176-B457" class="link link-ref link-reveal xref-bibr">457</a></sup> In contrast, multiple studies have shown that rhythm control strategies have a positive effect on quality of life once sinus rhythm is maintained.<sup><span class="xrefLink" id="jumplink-ehae176-B501"></span><a href="javascript:;" reveal-id="ehae176-B501" data-open="ehae176-B501" class="link link-ref link-reveal xref-bibr">501</a>,<span class="xrefLink" id="jumplink-ehae176-B502"></span><a href="javascript:;" reveal-id="ehae176-B502" data-open="ehae176-B502" class="link link-ref link-reveal xref-bibr">502</a></sup> Therefore, in the case of uncertainty of the presence of symptoms associated with AF, an attempt to restore sinus rhythm is a rational first step. In patients with symptoms, patient factors that favour an attempt at rhythm control should be considered, including suspected tachycardiomyopathy, a brief AF history, non-dilated left atrium, or patient preference.

Rhythm control strategies have significantly evolved due to an increasing experience in the safe use of antiarrhythmic drugs,<sup><span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a></sup> consistent use of OAC, improvements in ablation technology,<sup><span class="xrefLink" id="jumplink-ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509"></span><a href="javascript:;" reveal-id="ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509" data-open="ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509" class="link link-ref link-reveal xref-bibr">503–509</a></sup> and identification and management of risk factors and comorbidities.<sup><span class="xrefLink" id="jumplink-ehae176-B39"></span><a href="javascript:;" reveal-id="ehae176-B39" data-open="ehae176-B39" class="link link-ref link-reveal xref-bibr">39</a>,<span class="xrefLink" id="jumplink-ehae176-B510"></span><a href="javascript:;" reveal-id="ehae176-B510" data-open="ehae176-B510" class="link link-ref link-reveal xref-bibr">510</a>,<span class="xrefLink" id="jumplink-ehae176-B511"></span><a href="javascript:;" reveal-id="ehae176-B511" data-open="ehae176-B511" class="link link-ref link-reveal xref-bibr">511</a></sup> In the ATHENA trial (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg twice daily for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter), dronedarone significantly reduced the risk of hospitalization due to cardiovascular events or death as compared with placebo in patients with paroxysmal or persistent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B512"></span><a href="javascript:;" reveal-id="ehae176-B512" data-open="ehae176-B512" class="link link-ref link-reveal xref-bibr">512</a></sup> The CASTLE-AF trial (Catheter Ablation versus Standard Conventional Treatment in Patients With Left Ventricle Dysfunction and AF) demonstrated that a rhythm control strategy with catheter ablation can improve mortality and morbidity in selected patients with HFrEF and an implanted cardiac device.<sup><span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a></sup> In end-stage HFrEF, the CASTLE-HTx trial (Catheter Ablation for Atrial Fibrillation in Patients With End-Stage Heart Failure and Eligibility for Heart Transplantation) found, in a single centre, that catheter ablation combined with guideline-directed medical therapy significantly reduced the composite of death from any cause, implantation of left ventricular assist device, or urgent heart transplantation compared with medical treatment.<sup><span class="xrefLink" id="jumplink-ehae176-B513"></span><a href="javascript:;" reveal-id="ehae176-B513" data-open="ehae176-B513" class="link link-ref link-reveal xref-bibr">513</a></sup> At the same time, however, the CABANA trial (Catheter Ablation versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation) could not demonstrate a significant difference in mortality and morbidity between catheter ablation and standard rhythm and/or rate control drugs in symptomatic AF patients older than 64 years, or younger than 65 years with risk factors for stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a></sup> EAST-AFNET 4 (Early treatment of Atrial fibrillation for Stroke prevention Trial) reported that implementation of a rhythm control strategy within 1 year compared with usual care significantly reduced the risk of cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome in patients older than 75 years or with cardiovascular conditions.<sup><span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a></sup> Of note, rhythm control was predominantly pursued with antiarrhythmic drugs (80% of patients in the intervention arm). Usual care consisted of rate control therapy; only when uncontrolled AF-related symptoms occurred was rhythm control considered. Patients in the EAST-AFNET 4 trial all had cardiovascular risk factors but were at an early stage of AF, with more than 50% being in sinus rhythm and 30% being asymptomatic at the start of the study.

Based on all of these studies, this task force concludes that implementation of a rhythm control strategy can be safely instituted and confers amelioration of AF-related symptoms. Beyond control of symptoms, sinus rhythm maintenance should also be pursued to reduce morbidity and mortality in selected groups of patients.<sup><span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a>,<span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a>,<span class="xrefLink" id="jumplink-ehae176-B502"></span><a href="javascript:;" reveal-id="ehae176-B502" data-open="ehae176-B502" class="link link-ref link-reveal xref-bibr">502</a>,<span class="xrefLink" id="jumplink-ehae176-B513"></span><a href="javascript:;" reveal-id="ehae176-B513" data-open="ehae176-B513" class="link link-ref link-reveal xref-bibr">513</a>,<span class="xrefLink" id="jumplink-ehae176-B514"></span><a href="javascript:;" reveal-id="ehae176-B514" data-open="ehae176-B514" class="link link-ref link-reveal xref-bibr">514</a></sup>

Any rhythm control procedure has an inherent risk of thromboembolism. Patients undergoing cardioversion require at least 3 weeks of therapeutic anticoagulation (adherence to DOACs or INR >2 if VKA) prior to the electrical or pharmacological procedure. In acute settings or when early cardioversion is needed, transoesophageal echocardiography (TOE) can be performed to exclude cardiac thrombus prior to cardioversion. These approaches have been tested in multiple RCTs.<sup><span class="xrefLink" id="jumplink-ehae176-B319 ehae176-B320 ehae176-B321"></span><a href="javascript:;" reveal-id="ehae176-B319 ehae176-B320 ehae176-B321" data-open="ehae176-B319 ehae176-B320 ehae176-B321" class="link link-ref link-reveal xref-bibr">319–321</a></sup> In the case of thrombus detection, therapeutic anticoagulation should be instituted for a minimum of 4 weeks followed by repeat TOE to ensure thrombus resolution. When the definite duration of AF is less than 48 hours, cardioversion has typically been considered without the need for pre-procedure OAC or TOE for thrombus exclusion. However, the ‘definite’ onset of AF is often not known, and observational data suggest that stroke/thromboembolism risk is lowest within a much shorter time period.<sup><span class="xrefLink" id="jumplink-ehae176-B515 ehae176-B516 ehae176-B517 ehae176-B518 ehae176-B519"></span><a href="javascript:;" reveal-id="ehae176-B515 ehae176-B516 ehae176-B517 ehae176-B518 ehae176-B519" data-open="ehae176-B515 ehae176-B516 ehae176-B517 ehae176-B518 ehae176-B519" class="link link-ref link-reveal xref-bibr">515–519</a></sup> This task force reached consensus that safety should come first. Cardioversion is not recommended if AF duration is longer than 24 hours, unless the patient has already received at least 3 weeks of therapeutic anticoagulation or a TOE is performed to exclude intracardiac thrombus. Most patients should continue OAC for at least 4 weeks post-cardioversion. Only for those without thromboembolic risk factors and sinus rhythm restoration within 24 h of AF onset is post-cardioversion OAC optional. In the presence of any thromboembolic risk factors, long-term OAC should be instituted irrespective of the rhythm outcome.

Recommendation Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884298)

Recommendations for general concepts in rhythm control (see also Evidence Table 15)

![Recommendations for general concepts in rhythm control (see also Evidence Table 15)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt15.jpeg?Expires=1728478929&Signature=XwWRNIH1SwXJEPoI98WSrhux7KhesauETjuyKoAH0A806qPiqNbVgMX23VBFItFXaBb9RyMomhFNeDtPMFRFrUOoQ6O14mHSmvihEZ3yVAOM73PWeKXVbqOGpIjNiPSfPEENdRH4uEsl500By08eTq0UclyFF1rmUxykbTWbr5RBun0SaPYWiuhravTz0ar62-579NouJi6PdG5~PvQdk9IrF-HqTs0vbfrzTHnJHfW3YOJKRor8-LUZB6Yej2KrSl9nuBmEu3ywwk4ju7xOOXsBeJ~gm2oW5Lx0~NWWaWy6YhsHIRkZVooB4H6uxYLhHiwzLTk7F1oqrk6T3ShyzA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884298)

Recommendations for general concepts in rhythm control (see also Evidence Table 15)

![Recommendations for general concepts in rhythm control (see also Evidence Table 15)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt15.jpeg?Expires=1728478929&Signature=XwWRNIH1SwXJEPoI98WSrhux7KhesauETjuyKoAH0A806qPiqNbVgMX23VBFItFXaBb9RyMomhFNeDtPMFRFrUOoQ6O14mHSmvihEZ3yVAOM73PWeKXVbqOGpIjNiPSfPEENdRH4uEsl500By08eTq0UclyFF1rmUxykbTWbr5RBun0SaPYWiuhravTz0ar62-579NouJi6PdG5~PvQdk9IrF-HqTs0vbfrzTHnJHfW3YOJKRor8-LUZB6Yej2KrSl9nuBmEu3ywwk4ju7xOOXsBeJ~gm2oW5Lx0~NWWaWy6YhsHIRkZVooB4H6uxYLhHiwzLTk7F1oqrk6T3ShyzA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.2. Electrical cardioversion

Electrical cardioversion (ECV) can be safely applied in the elective and acute setting (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S18](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_) with sedation by intravenous midazolam, propofol, or etomidate.<sup><span class="xrefLink" id="jumplink-ehae176-B530"></span><a href="javascript:;" reveal-id="ehae176-B530" data-open="ehae176-B530" class="link link-ref link-reveal xref-bibr">530</a></sup> Structured and integrated care for patients with acute-onset AF at the emergency department is associated with better outcomes without compromising safety.<sup><span class="xrefLink" id="jumplink-ehae176-B531"></span><a href="javascript:;" reveal-id="ehae176-B531" data-open="ehae176-B531" class="link link-ref link-reveal xref-bibr">531</a></sup> Rates of major adverse clinical events after cardioversion are significantly lower with DOACs compared with warfarin.<sup><span class="xrefLink" id="jumplink-ehae176-B293"></span><a href="javascript:;" reveal-id="ehae176-B293" data-open="ehae176-B293" class="link link-ref link-reveal xref-bibr">293</a></sup>

Blood pressure monitoring and oximetry should be used routinely. Intravenous atropine or isoproterenol, or temporary transcutaneous pacing, should be available in case of post-cardioversion bradycardia. Biphasic defibrillators are standard because of their superior efficacy compared with monophasic defibrillators.<sup><span class="xrefLink" id="jumplink-ehae176-B532 ehae176-B533 ehae176-B534"></span><a href="javascript:;" reveal-id="ehae176-B532 ehae176-B533 ehae176-B534" data-open="ehae176-B532 ehae176-B533 ehae176-B534" class="link link-ref link-reveal xref-bibr">532–534</a></sup> There is no single optimal position for electrodes, with a meta-analysis of 10 RCTs showing no difference in sinus rhythm restoration comparing anterior-posterior with antero-lateral electrode positioning.<sup><span class="xrefLink" id="jumplink-ehae176-B535"></span><a href="javascript:;" reveal-id="ehae176-B535" data-open="ehae176-B535" class="link link-ref link-reveal xref-bibr">535</a></sup> Applying active compression to the defibrillation pads is associated with lower defibrillation thresholds, lower total energy delivery, fewer shocks for successful ECV, and higher success rates.<sup><span class="xrefLink" id="jumplink-ehae176-B536"></span><a href="javascript:;" reveal-id="ehae176-B536" data-open="ehae176-B536" class="link link-ref link-reveal xref-bibr">536</a></sup> A randomized trial showed that maximum fixed-energy shocks were more effective than low-escalating energy for ECV.<sup><span class="xrefLink" id="jumplink-ehae176-B537"></span><a href="javascript:;" reveal-id="ehae176-B537" data-open="ehae176-B537" class="link link-ref link-reveal xref-bibr">537</a></sup>

Immediate administration of vernakalant,<sup><span class="xrefLink" id="jumplink-ehae176-B538"></span><a href="javascript:;" reveal-id="ehae176-B538" data-open="ehae176-B538" class="link link-ref link-reveal xref-bibr">538</a></sup> or pre-treatment for 3–4 days with flecainide,<sup><span class="xrefLink" id="jumplink-ehae176-B539"></span><a href="javascript:;" reveal-id="ehae176-B539" data-open="ehae176-B539" class="link link-ref link-reveal xref-bibr">539</a>,<span class="xrefLink" id="jumplink-ehae176-B540"></span><a href="javascript:;" reveal-id="ehae176-B540" data-open="ehae176-B540" class="link link-ref link-reveal xref-bibr">540</a></sup> ibutilide,<sup><span class="xrefLink" id="jumplink-ehae176-B541"></span><a href="javascript:;" reveal-id="ehae176-B541" data-open="ehae176-B541" class="link link-ref link-reveal xref-bibr">541</a>,<span class="xrefLink" id="jumplink-ehae176-B542"></span><a href="javascript:;" reveal-id="ehae176-B542" data-open="ehae176-B542" class="link link-ref link-reveal xref-bibr">542</a></sup> propafenone,<sup><span class="xrefLink" id="jumplink-ehae176-B543"></span><a href="javascript:;" reveal-id="ehae176-B543" data-open="ehae176-B543" class="link link-ref link-reveal xref-bibr">543</a></sup> or amiodarone<sup><span class="xrefLink" id="jumplink-ehae176-B544 ehae176-B545 ehae176-B546"></span><a href="javascript:;" reveal-id="ehae176-B544 ehae176-B545 ehae176-B546" data-open="ehae176-B544 ehae176-B545 ehae176-B546" class="link link-ref link-reveal xref-bibr">544–546</a></sup> improves the rate of successful ECV and can facilitate long-term maintenance of sinus rhythm by preventing early recurrent AF.<sup><span class="xrefLink" id="jumplink-ehae176-B547"></span><a href="javascript:;" reveal-id="ehae176-B547" data-open="ehae176-B547" class="link link-ref link-reveal xref-bibr">547</a></sup> A meta-analysis demonstrated that pre-treatment with amiodarone (200–800 mg/day for 1–6 weeks pre-cardioversion) and post-treatment (200 mg/day) significantly improved the restoration and maintenance of sinus rhythm after ECV of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B546"></span><a href="javascript:;" reveal-id="ehae176-B546" data-open="ehae176-B546" class="link link-ref link-reveal xref-bibr">546</a></sup>

In some cases of persistent AF there is no clear relationship between the arrhythmia and symptoms. In these cases, restoring sinus rhythm by ECV might serve to confirm the impact of arrhythmia on symptoms and/or on heart failure symptoms and signs. Such an approach might be useful to identify truly asymptomatic individuals, to assess the impact of AF on LV function in patients with HFrEF, and to distinguish AF-related symptoms from heart failure symptoms.

Recommendation Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884304)

Recommendations for electrical cardioversion of AF (see also Evidence Table 16)

![Recommendations for electrical cardioversion of AF (see also Evidence Table 16)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt16.jpeg?Expires=1728478929&Signature=DSaaO4Mdu67CEMNfNxKOKKNq9my3haJ3GQE5AC5V77XlLaeBC6EnojJF7vpmfHZwNeXJi8j4O1UbkhENp8qy2FJTbvE9R41BEQ3pnFGKmFFIrrJonkgqWxCFiMXjTQ0hj5D82uO9KzTDOHQGzzXNh4EMxerOm4yxc26zj6W4pDuxZzJNRG~LDCdNsXrt7SBAG0T0Weo775aMOW7LTBOf0Fny-QFP1iNpwoBDyTHIqEKZnu5N~3393hE7zwVRK9qDtHUVtDeaFxmvgIT9bYc52e8-uYG53DZWryi1OYvLo9uRRU0-Mmxud4NLttjQ3ohJvorTXSc~VXxul0CAMOgNpg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884304)

Recommendations for electrical cardioversion of AF (see also Evidence Table 16)

![Recommendations for electrical cardioversion of AF (see also Evidence Table 16)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt16.jpeg?Expires=1728478929&Signature=DSaaO4Mdu67CEMNfNxKOKKNq9my3haJ3GQE5AC5V77XlLaeBC6EnojJF7vpmfHZwNeXJi8j4O1UbkhENp8qy2FJTbvE9R41BEQ3pnFGKmFFIrrJonkgqWxCFiMXjTQ0hj5D82uO9KzTDOHQGzzXNh4EMxerOm4yxc26zj6W4pDuxZzJNRG~LDCdNsXrt7SBAG0T0Weo775aMOW7LTBOf0Fny-QFP1iNpwoBDyTHIqEKZnu5N~3393hE7zwVRK9qDtHUVtDeaFxmvgIT9bYc52e8-uYG53DZWryi1OYvLo9uRRU0-Mmxud4NLttjQ3ohJvorTXSc~VXxul0CAMOgNpg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.3. Pharmacological cardioversion

Pharmacological cardioversion to sinus rhythm is an elective procedure in haemodynamically stable patients. It is less effective than electrical cardioversion for restoration of sinus rhythm,<sup><span class="xrefLink" id="jumplink-ehae176-B549"></span><a href="javascript:;" reveal-id="ehae176-B549" data-open="ehae176-B549" class="link link-ref link-reveal xref-bibr">549</a></sup> with timing of cardioversion being a significant determinant of success.<sup><span class="xrefLink" id="jumplink-ehae176-B550"></span><a href="javascript:;" reveal-id="ehae176-B550" data-open="ehae176-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> There are limited contemporary data on the true efficacy of pharmacological cardioversion, which are likely biased by the spontaneous restoration of sinus rhythm in 76%–83% of patients with recent-onset AF (10%–18% within the first 3 h, 55%–66% within 24 h, and 69% within 48 h).<sup><span class="xrefLink" id="jumplink-ehae176-B10"></span><a href="javascript:;" reveal-id="ehae176-B10" data-open="ehae176-B10" class="link link-ref link-reveal xref-bibr">10</a>,<span class="xrefLink" id="jumplink-ehae176-B119"></span><a href="javascript:;" reveal-id="ehae176-B119" data-open="ehae176-B119" class="link link-ref link-reveal xref-bibr">119</a>,<span class="xrefLink" id="jumplink-ehae176-B445"></span><a href="javascript:;" reveal-id="ehae176-B445" data-open="ehae176-B445" class="link link-ref link-reveal xref-bibr">445</a>,<span class="xrefLink" id="jumplink-ehae176-B551 ehae176-B552 ehae176-B553 ehae176-B554 ehae176-B555"></span><a href="javascript:;" reveal-id="ehae176-B551 ehae176-B552 ehae176-B553 ehae176-B554 ehae176-B555" data-open="ehae176-B551 ehae176-B552 ehae176-B553 ehae176-B554 ehae176-B555" class="link link-ref link-reveal xref-bibr">551–555</a></sup>

The choice of a specific drug is based on the type and severity of concomitant heart disease (_[Table 13](javascript:;)_). A meta-analysis demonstrated that intravenous vernakalant and flecainide have the highest conversion rate within 4 h, possibly allowing discharge from the emergency department and reducing hospital admissions. Intravenous and oral formulations of Class IC antiarrhythmics (flecainide more so than propafenone) are superior regarding conversion rates within 12 h, while amiodarone efficacy is exhibited in a delayed fashion (within 24 h).<sup><span class="xrefLink" id="jumplink-ehae176-B556"></span><a href="javascript:;" reveal-id="ehae176-B556" data-open="ehae176-B556" class="link link-ref link-reveal xref-bibr">556</a></sup> Pharmacological cardioversion does not require fasting, sedation, or anaesthesia. Anticoagulation should be started or continued according to a formal (re-)assessment of thromboembolic risk.<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B557 ehae176-B558 ehae176-B559"></span><a href="javascript:;" reveal-id="ehae176-B557 ehae176-B558 ehae176-B559" data-open="ehae176-B557 ehae176-B558 ehae176-B559" class="link link-ref link-reveal xref-bibr">557–559</a></sup>

Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884308)

Antiarrhythmic drugs for sinus rhythm restoration

| Drug .  | Administration route .  | Initial dosing .  | Subsequent dosing \[long-term approach\] .  | Acute success rate and time to sinus rhythm .  | Contraindications and precautions .  |
| --- | --- | --- | --- | --- | --- |
| Flecainide | Oral | 200–300 mg | \[long-term 50−150 mg twice daily\] | 50%–60% at 3 h and 75%–85% at 6–8 h (3–8 h) | 
- Should not be used in patients with severe structural or coronary artery disease, Brugada syndrome, or severe renal failure (CrCl <35 mL/min/1.73 m<sup>2</sup>).

- Prior documentation of safety and efficacy in an inpatient setting is recommended prior to pill-in-the-pocket use.

- An AVN-blocking agent should be administered to avoid 1:1 conduction if transformation to AFL.

- Drug infusion should be discontinued in case of QRS widening >25% or bundle branch block occurrence.

- Caution is needed in patients with sinus node disease and AVN dysfunction.

- Do NOT use for conversion of atrial flutter.


 |
| Intravenous | 1–2 mg/kg over 10 min || 52%–95% (Up to 6 h) |
| Propafenone | Oral | 450–600 mg | \[long-term 150-300 mg three times daily\] | 45%–55% at 3 h, 69%–78% at 8 h (3–8 h) |
| Intravenous | 1.5–2 mg/kg over 10 min || 43%–89% (Up to 6 h) |
| Amiodarone | Intravenous (/oral) | 300 mg intravenous over 30–60 min | 900-1200 mg intravenous over 24 hours (or 200 mg oral three times daily for 4 weeks).\[long-term 200 mg oral daily\] | 44% (8–12 h to several days) | 

- May cause phlebitis (use a large peripheral vein, avoid i.v. administration >24 h and use preferably volumetric pump).

- May cause hypotension, bradycardia/atrioventricular block, QT prolongation.

- Only if no other option in patients with hyperthyroidism (risk of thyrotoxicosis).

- Consider the broad range of drug interactions.


 |
| Ibutilide | Intravenous | 1 mg over 10 min (0.01 mg/kg if body weight <60 kg) | 1 mg over 10 min
(10–20 min after the initial dose) | 31%–51% (30–90 min) in AF
60–75% in AFL (60 min) | 

- Should be used in the setting of a cardiac care unit as it may cause QT prolongation and torsades de pointes.

- ECG monitoring for at least 4 h after administration to detect any proarrhythmic effects.

- Should not be used in patients with prolonged QT, severe LVH, or low LVEF.


 |
| Vernakalant | Intravenous | 3 mg/kg over 10 min (maximum 339 mg) | 2 mg/kg over 10 min
(10–15 min after the initial dose) (maximum 226 mg) | 50% within 10 min | 

- Should not be used in patients with arterial hypotension (SBP <100 mmHg), recent ACS (within 1 month), NYHA III or IV HF, QT prolongation or severe aortic stenosis.

- May cause arterial hypotension, QT prolongation, QRS widening, or non-sustained ventricular tachycardia.


 |

| Drug .  | Administration route .  | Initial dosing .  | Subsequent dosing \[long-term approach\] .  | Acute success rate and time to sinus rhythm .  | Contraindications and precautions .  |
| --- | --- | --- | --- | --- | --- |
| Flecainide | Oral | 200–300 mg | \[long-term 50−150 mg twice daily\] | 50%–60% at 3 h and 75%–85% at 6–8 h (3–8 h) | 
- Should not be used in patients with severe structural or coronary artery disease, Brugada syndrome, or severe renal failure (CrCl <35 mL/min/1.73 m<sup>2</sup>).

- Prior documentation of safety and efficacy in an inpatient setting is recommended prior to pill-in-the-pocket use.

- An AVN-blocking agent should be administered to avoid 1:1 conduction if transformation to AFL.

- Drug infusion should be discontinued in case of QRS widening >25% or bundle branch block occurrence.

- Caution is needed in patients with sinus node disease and AVN dysfunction.

- Do NOT use for conversion of atrial flutter.


 |
| Intravenous | 1–2 mg/kg over 10 min || 52%–95% (Up to 6 h) |
| Propafenone | Oral | 450–600 mg | \[long-term 150-300 mg three times daily\] | 45%–55% at 3 h, 69%–78% at 8 h (3–8 h) |
| Intravenous | 1.5–2 mg/kg over 10 min || 43%–89% (Up to 6 h) |
| Amiodarone | Intravenous (/oral) | 300 mg intravenous over 30–60 min | 900-1200 mg intravenous over 24 hours (or 200 mg oral three times daily for 4 weeks).\[long-term 200 mg oral daily\] | 44% (8–12 h to several days) | 

- May cause phlebitis (use a large peripheral vein, avoid i.v. administration >24 h and use preferably volumetric pump).

- May cause hypotension, bradycardia/atrioventricular block, QT prolongation.

- Only if no other option in patients with hyperthyroidism (risk of thyrotoxicosis).

- Consider the broad range of drug interactions.


 |
| Ibutilide | Intravenous | 1 mg over 10 min (0.01 mg/kg if body weight <60 kg) | 1 mg over 10 min
(10–20 min after the initial dose) | 31%–51% (30–90 min) in AF
60–75% in AFL (60 min) | 

- Should be used in the setting of a cardiac care unit as it may cause QT prolongation and torsades de pointes.

- ECG monitoring for at least 4 h after administration to detect any proarrhythmic effects.

- Should not be used in patients with prolonged QT, severe LVH, or low LVEF.


 |
| Vernakalant | Intravenous | 3 mg/kg over 10 min (maximum 339 mg) | 2 mg/kg over 10 min
(10–15 min after the initial dose) (maximum 226 mg) | 50% within 10 min | 

- Should not be used in patients with arterial hypotension (SBP <100 mmHg), recent ACS (within 1 month), NYHA III or IV HF, QT prolongation or severe aortic stenosis.

- May cause arterial hypotension, QT prolongation, QRS widening, or non-sustained ventricular tachycardia.


 |

ACS, acute coronary syndromes; AF, atrial fibrillation; AFL, atrial flutter; AVN, atrioventricular node; CrCl, creatinine clearance; ECG, electrocardiogram; HF, heart failure; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; QT, QT interval; SBP, systolic blood pressure. Long-term dosage for maintenance of sinus rhythm is indicated in \[square brackets\]. Long-term oral dosing for dronedarone is 400 mg twice daily, and for sotalol 80-160 mg twice daily.

© ESC 2024

Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884308)

Antiarrhythmic drugs for sinus rhythm restoration

| Drug .  | Administration route .  | Initial dosing .  | Subsequent dosing \[long-term approach\] .  | Acute success rate and time to sinus rhythm .  | Contraindications and precautions .  |
| --- | --- | --- | --- | --- | --- |
| Flecainide | Oral | 200–300 mg | \[long-term 50−150 mg twice daily\] | 50%–60% at 3 h and 75%–85% at 6–8 h (3–8 h) | 
- Should not be used in patients with severe structural or coronary artery disease, Brugada syndrome, or severe renal failure (CrCl <35 mL/min/1.73 m<sup>2</sup>).

- Prior documentation of safety and efficacy in an inpatient setting is recommended prior to pill-in-the-pocket use.

- An AVN-blocking agent should be administered to avoid 1:1 conduction if transformation to AFL.

- Drug infusion should be discontinued in case of QRS widening >25% or bundle branch block occurrence.

- Caution is needed in patients with sinus node disease and AVN dysfunction.

- Do NOT use for conversion of atrial flutter.


 |
| Intravenous | 1–2 mg/kg over 10 min || 52%–95% (Up to 6 h) |
| Propafenone | Oral | 450–600 mg | \[long-term 150-300 mg three times daily\] | 45%–55% at 3 h, 69%–78% at 8 h (3–8 h) |
| Intravenous | 1.5–2 mg/kg over 10 min || 43%–89% (Up to 6 h) |
| Amiodarone | Intravenous (/oral) | 300 mg intravenous over 30–60 min | 900-1200 mg intravenous over 24 hours (or 200 mg oral three times daily for 4 weeks).\[long-term 200 mg oral daily\] | 44% (8–12 h to several days) | 

- May cause phlebitis (use a large peripheral vein, avoid i.v. administration >24 h and use preferably volumetric pump).

- May cause hypotension, bradycardia/atrioventricular block, QT prolongation.

- Only if no other option in patients with hyperthyroidism (risk of thyrotoxicosis).

- Consider the broad range of drug interactions.


 |
| Ibutilide | Intravenous | 1 mg over 10 min (0.01 mg/kg if body weight <60 kg) | 1 mg over 10 min
(10–20 min after the initial dose) | 31%–51% (30–90 min) in AF
60–75% in AFL (60 min) | 

- Should be used in the setting of a cardiac care unit as it may cause QT prolongation and torsades de pointes.

- ECG monitoring for at least 4 h after administration to detect any proarrhythmic effects.

- Should not be used in patients with prolonged QT, severe LVH, or low LVEF.


 |
| Vernakalant | Intravenous | 3 mg/kg over 10 min (maximum 339 mg) | 2 mg/kg over 10 min
(10–15 min after the initial dose) (maximum 226 mg) | 50% within 10 min | 

- Should not be used in patients with arterial hypotension (SBP <100 mmHg), recent ACS (within 1 month), NYHA III or IV HF, QT prolongation or severe aortic stenosis.

- May cause arterial hypotension, QT prolongation, QRS widening, or non-sustained ventricular tachycardia.


 |

| Drug .  | Administration route .  | Initial dosing .  | Subsequent dosing \[long-term approach\] .  | Acute success rate and time to sinus rhythm .  | Contraindications and precautions .  |
| --- | --- | --- | --- | --- | --- |
| Flecainide | Oral | 200–300 mg | \[long-term 50−150 mg twice daily\] | 50%–60% at 3 h and 75%–85% at 6–8 h (3–8 h) | 
- Should not be used in patients with severe structural or coronary artery disease, Brugada syndrome, or severe renal failure (CrCl <35 mL/min/1.73 m<sup>2</sup>).

- Prior documentation of safety and efficacy in an inpatient setting is recommended prior to pill-in-the-pocket use.

- An AVN-blocking agent should be administered to avoid 1:1 conduction if transformation to AFL.

- Drug infusion should be discontinued in case of QRS widening >25% or bundle branch block occurrence.

- Caution is needed in patients with sinus node disease and AVN dysfunction.

- Do NOT use for conversion of atrial flutter.


 |
| Intravenous | 1–2 mg/kg over 10 min || 52%–95% (Up to 6 h) |
| Propafenone | Oral | 450–600 mg | \[long-term 150-300 mg three times daily\] | 45%–55% at 3 h, 69%–78% at 8 h (3–8 h) |
| Intravenous | 1.5–2 mg/kg over 10 min || 43%–89% (Up to 6 h) |
| Amiodarone | Intravenous (/oral) | 300 mg intravenous over 30–60 min | 900-1200 mg intravenous over 24 hours (or 200 mg oral three times daily for 4 weeks).\[long-term 200 mg oral daily\] | 44% (8–12 h to several days) | 

- May cause phlebitis (use a large peripheral vein, avoid i.v. administration >24 h and use preferably volumetric pump).

- May cause hypotension, bradycardia/atrioventricular block, QT prolongation.

- Only if no other option in patients with hyperthyroidism (risk of thyrotoxicosis).

- Consider the broad range of drug interactions.


 |
| Ibutilide | Intravenous | 1 mg over 10 min (0.01 mg/kg if body weight <60 kg) | 1 mg over 10 min
(10–20 min after the initial dose) | 31%–51% (30–90 min) in AF
60–75% in AFL (60 min) | 

- Should be used in the setting of a cardiac care unit as it may cause QT prolongation and torsades de pointes.

- ECG monitoring for at least 4 h after administration to detect any proarrhythmic effects.

- Should not be used in patients with prolonged QT, severe LVH, or low LVEF.


 |
| Vernakalant | Intravenous | 3 mg/kg over 10 min (maximum 339 mg) | 2 mg/kg over 10 min
(10–15 min after the initial dose) (maximum 226 mg) | 50% within 10 min | 

- Should not be used in patients with arterial hypotension (SBP <100 mmHg), recent ACS (within 1 month), NYHA III or IV HF, QT prolongation or severe aortic stenosis.

- May cause arterial hypotension, QT prolongation, QRS widening, or non-sustained ventricular tachycardia.


 |

ACS, acute coronary syndromes; AF, atrial fibrillation; AFL, atrial flutter; AVN, atrioventricular node; CrCl, creatinine clearance; ECG, electrocardiogram; HF, heart failure; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; QT, QT interval; SBP, systolic blood pressure. Long-term dosage for maintenance of sinus rhythm is indicated in \[square brackets\]. Long-term oral dosing for dronedarone is 400 mg twice daily, and for sotalol 80-160 mg twice daily.

© ESC 2024

A single self-administered oral dose of flecainide or propafenone (pill-in-the-pocket) is effective in symptomatic patients with infrequent and recent-onset paroxysmal AF. Safe implementation of this strategy requires patient screening to exclude sinus node dysfunction, atrioventricular conduction defects, or Brugada syndrome, as well as prior in-hospital validation of its efficacy and safety.<sup><span class="xrefLink" id="jumplink-ehae176-B560"></span><a href="javascript:;" reveal-id="ehae176-B560" data-open="ehae176-B560" class="link link-ref link-reveal xref-bibr">560</a></sup> An atrioventricular node-blocking drug should be instituted in patients treated with Class IC AADs to avoid 1:1 conduction if the rhythm transforms to AFL.<sup><span class="xrefLink" id="jumplink-ehae176-B561"></span><a href="javascript:;" reveal-id="ehae176-B561" data-open="ehae176-B561" class="link link-ref link-reveal xref-bibr">561</a></sup>

Recommendation Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884310)

Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17)

![Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt17.jpeg?Expires=1728478929&Signature=dxyUlR7R1pMqSjh17L6J1KGLikcdkURLLL~FpzfMeL4k5CRpVeagskQ7e7XtRSV0LfXreBFDT3n5ly0gMGK9R-UDtjTfr9uztU62ZzvvWwoKc646a~WSIkaBweSOfXGBaUyJtnuGgGFCNnOdgyD7MiotTC5JuthHQh6HMGEcer76mLtAjbQRtxIEFbGf0PnRRoANqsB9mXzeWBhUD1zQSgyndCLCv9bG3xY3XUAZpO9tan~RMVkn7bRfrhGDz5I0p955vpv5cWJrnftqu7q1ng8WYdbx9-gD-GHQ9XfUbrWnLO~npc4~-oDcw2J~hi4QcpSDdgc92UTxl91m5Tp6hw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884310)

Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17)

![Recommendations for pharmacological cardioversion of AF (see also Evidence Table 17)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt17.jpeg?Expires=1728478929&Signature=dxyUlR7R1pMqSjh17L6J1KGLikcdkURLLL~FpzfMeL4k5CRpVeagskQ7e7XtRSV0LfXreBFDT3n5ly0gMGK9R-UDtjTfr9uztU62ZzvvWwoKc646a~WSIkaBweSOfXGBaUyJtnuGgGFCNnOdgyD7MiotTC5JuthHQh6HMGEcer76mLtAjbQRtxIEFbGf0PnRRoANqsB9mXzeWBhUD1zQSgyndCLCv9bG3xY3XUAZpO9tan~RMVkn7bRfrhGDz5I0p955vpv5cWJrnftqu7q1ng8WYdbx9-gD-GHQ9XfUbrWnLO~npc4~-oDcw2J~hi4QcpSDdgc92UTxl91m5Tp6hw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.4. Antiarrhythmic drugs

The aims of long-term rhythm control are to maintain sinus rhythm, improve quality of life, slow the progression of AF, and potentially reduce morbidity related to AF episodes (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S19](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a>,<span class="xrefLink" id="jumplink-ehae176-B445"></span><a href="javascript:;" reveal-id="ehae176-B445" data-open="ehae176-B445" class="link link-ref link-reveal xref-bibr">445</a>,<span class="xrefLink" id="jumplink-ehae176-B574"></span><a href="javascript:;" reveal-id="ehae176-B574" data-open="ehae176-B574" class="link link-ref link-reveal xref-bibr">574</a>,<span class="xrefLink" id="jumplink-ehae176-B575"></span><a href="javascript:;" reveal-id="ehae176-B575" data-open="ehae176-B575" class="link link-ref link-reveal xref-bibr">575</a></sup> Antiarrhythmic drugs do not eliminate recurrences of AF, but in patients with paroxysmal or persistent AF, a recurrence is not equivalent to treatment failure if episodes are less frequent, briefer, or less symptomatic. Antiarrhythmic drugs also have a role for long-term rhythm control in AF patients that are considered ineligible or unwilling to undergo catheter or surgical ablation.

Before starting AAD treatment, reversible triggers should be identified and underlying comorbidities treated to reduce the arrhythmogenic substrate, prevent progression of AF, and facilitate maintenance of sinus rhythm.<sup><span class="xrefLink" id="jumplink-ehae176-B39"></span><a href="javascript:;" reveal-id="ehae176-B39" data-open="ehae176-B39" class="link link-ref link-reveal xref-bibr">39</a>,<span class="xrefLink" id="jumplink-ehae176-B128"></span><a href="javascript:;" reveal-id="ehae176-B128" data-open="ehae176-B128" class="link link-ref link-reveal xref-bibr">128</a></sup> The RACE 3 trial, including patients with early persistent AF and mild-to-moderate heart failure (predominantly HFpEF and HFmrEF), showed that targeted therapy of underlying conditions improved sinus rhythm maintenance at 1 year (75% vs. 63% as compared with standard care).<sup><span class="xrefLink" id="jumplink-ehae176-B39"></span><a href="javascript:;" reveal-id="ehae176-B39" data-open="ehae176-B39" class="link link-ref link-reveal xref-bibr">39</a></sup> The selection of an AAD for long-term rhythm control requires careful evaluation that takes into account AF type, patient parameters, and safety profile.<sup><span class="xrefLink" id="jumplink-ehae176-B445"></span><a href="javascript:;" reveal-id="ehae176-B445" data-open="ehae176-B445" class="link link-ref link-reveal xref-bibr">445</a></sup> It also includes shared decision-making, balancing the benefit/risk ratio of AADs in comparison with other strategies. Notably, recent evidence has shown that careful institution of AADs can be performed safely.<sup><span class="xrefLink" id="jumplink-ehae176-B17"></span><a href="javascript:;" reveal-id="ehae176-B17" data-open="ehae176-B17" class="link link-ref link-reveal xref-bibr">17</a></sup>

The long-term effectiveness of AADs is limited. In a meta-analysis of 59 RCTs, AADs reduced AF recurrences by 20%–50% compared with no treatment, placebo, or drugs for rate control.<sup><span class="xrefLink" id="jumplink-ehae176-B576"></span><a href="javascript:;" reveal-id="ehae176-B576" data-open="ehae176-B576" class="link link-ref link-reveal xref-bibr">576</a>,<span class="xrefLink" id="jumplink-ehae176-B577"></span><a href="javascript:;" reveal-id="ehae176-B577" data-open="ehae176-B577" class="link link-ref link-reveal xref-bibr">577</a></sup> When one AAD fails to reduce AF recurrences, a clinically acceptable response may be achieved with another drug, particularly if from a different class.<sup><span class="xrefLink" id="jumplink-ehae176-B578"></span><a href="javascript:;" reveal-id="ehae176-B578" data-open="ehae176-B578" class="link link-ref link-reveal xref-bibr">578</a></sup> Combinations of AADs are not recommended. The data available suggest that AADs do not produce an appreciable effect on mortality or other cardiovascular complications with the exception of increased mortality signals for sotalol<sup><span class="xrefLink" id="jumplink-ehae176-B574"></span><a href="javascript:;" reveal-id="ehae176-B574" data-open="ehae176-B574" class="link link-ref link-reveal xref-bibr">574</a>,<span class="xrefLink" id="jumplink-ehae176-B579"></span><a href="javascript:;" reveal-id="ehae176-B579" data-open="ehae176-B579" class="link link-ref link-reveal xref-bibr">579</a>,<span class="xrefLink" id="jumplink-ehae176-B580"></span><a href="javascript:;" reveal-id="ehae176-B580" data-open="ehae176-B580" class="link link-ref link-reveal xref-bibr">580</a></sup> and amiodarone.<sup><span class="xrefLink" id="jumplink-ehae176-B581"></span><a href="javascript:;" reveal-id="ehae176-B581" data-open="ehae176-B581" class="link link-ref link-reveal xref-bibr">581</a></sup> In contrast, use of AADs within a rhythm control strategy can be associated with reduction of morbidity and mortality in selected patients.<sup><span class="xrefLink" id="jumplink-ehae176-B582"></span><a href="javascript:;" reveal-id="ehae176-B582" data-open="ehae176-B582" class="link link-ref link-reveal xref-bibr">582</a></sup>

All AADs may produce serious cardiac (proarrhythmia, negative inotropism, hypotension) and extracardiac adverse effects (organ toxicity, predominantly amiodarone). Drug safety, rather than efficacy, should determine the choice of drug. The risk of proarrhythmia increases in patients with structural heart disease. Suggested doses for long-term oral AAD are presented in _[Table 13](javascript:;)_.<sup><span class="xrefLink" id="jumplink-ehae176-B577"></span><a href="javascript:;" reveal-id="ehae176-B577" data-open="ehae176-B577" class="link link-ref link-reveal xref-bibr">577</a>,<span class="xrefLink" id="jumplink-ehae176-B583"></span><a href="javascript:;" reveal-id="ehae176-B583" data-open="ehae176-B583" class="link link-ref link-reveal xref-bibr">583</a>,<span class="xrefLink" id="jumplink-ehae176-B584"></span><a href="javascript:;" reveal-id="ehae176-B584" data-open="ehae176-B584" class="link link-ref link-reveal xref-bibr">584</a></sup>

Recommendation Table 18

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884316)

Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18)

![Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt18.jpeg?Expires=1728478929&Signature=o-dNSa11BQdncRdoxDHBqh2DadckAxgfvNW~7mhxEC07eeYopPjT9MxqeSKc1teTBaro95ulhF5qVu6cFRTKvfYRIhwSkzPpE6j0Qe5nmlTR2FyE5-Q20kTFTD1Ku4MDBqWjhdUN-Zr9M0Ku5NrqZFw-xKQXM3VOGv9mQtCr88xV4RutU9z0kwYZk8Yxk4yEn8XUMo5vwUD1pzod5rzuvjzC61sRdYw38cv1zoX7-BHCg2uAd5wPcGSaPooAJwqrq8UV7~-Dh~KdpMnMuhnctGRbm7S4nXF2LMdLJKHj820WvpWQrzSRJvHuhC4h8kq7j5HnF-BKRRafecLQ9FCcwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 18

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884316)

Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18)

![Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm (see also Evidence Table 18)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt18.jpeg?Expires=1728478929&Signature=o-dNSa11BQdncRdoxDHBqh2DadckAxgfvNW~7mhxEC07eeYopPjT9MxqeSKc1teTBaro95ulhF5qVu6cFRTKvfYRIhwSkzPpE6j0Qe5nmlTR2FyE5-Q20kTFTD1Ku4MDBqWjhdUN-Zr9M0Ku5NrqZFw-xKQXM3VOGv9mQtCr88xV4RutU9z0kwYZk8Yxk4yEn8XUMo5vwUD1pzod5rzuvjzC61sRdYw38cv1zoX7-BHCg2uAd5wPcGSaPooAJwqrq8UV7~-Dh~KdpMnMuhnctGRbm7S4nXF2LMdLJKHj820WvpWQrzSRJvHuhC4h8kq7j5HnF-BKRRafecLQ9FCcwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.5. Catheter ablation

Catheter ablation prevents AF recurrences, reduces AF burden, and improves quality of life in symptomatic paroxysmal or persistent AF where the patient is intolerant or does not respond to AAD.<sup><span class="xrefLink" id="jumplink-ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509"></span><a href="javascript:;" reveal-id="ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509" data-open="ehae176-B503 ehae176-B504 ehae176-B505 ehae176-B506 ehae176-B507 ehae176-B508 ehae176-B509" class="link link-ref link-reveal xref-bibr">503–509</a></sup> Multiple RCTs have provided evidence in favour of catheter ablation as a first-line approach for rhythm control in patients with paroxysmal AF, with a similar risk of adverse events as compared with initial AAD treatment (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S20](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B15"></span><a href="javascript:;" reveal-id="ehae176-B15" data-open="ehae176-B15" class="link link-ref link-reveal xref-bibr">15</a>,<span class="xrefLink" id="jumplink-ehae176-B16"></span><a href="javascript:;" reveal-id="ehae176-B16" data-open="ehae176-B16" class="link link-ref link-reveal xref-bibr">16</a>,<span class="xrefLink" id="jumplink-ehae176-B591 ehae176-B592 ehae176-B593 ehae176-B594"></span><a href="javascript:;" reveal-id="ehae176-B591 ehae176-B592 ehae176-B593 ehae176-B594" data-open="ehae176-B591 ehae176-B592 ehae176-B593 ehae176-B594" class="link link-ref link-reveal xref-bibr">591–594</a></sup> In contrast, it is not clear whether first-line ablation is superior to drug therapy in persistent AF. Catheter ablation may also have a role in patients with symptoms due to prolonged pauses upon AF termination, where non-randomized data have shown improved symptoms, and avoidance of pacemaker implantation.<sup><span class="xrefLink" id="jumplink-ehae176-B595 ehae176-B596 ehae176-B597 ehae176-B598"></span><a href="javascript:;" reveal-id="ehae176-B595 ehae176-B596 ehae176-B597 ehae176-B598" data-open="ehae176-B595 ehae176-B596 ehae176-B597 ehae176-B598" class="link link-ref link-reveal xref-bibr">595–598</a></sup>

Pulmonary vein isolation (PVI) remains the cornerstone of AF catheter ablation,<sup><span class="xrefLink" id="jumplink-ehae176-B503"></span><a href="javascript:;" reveal-id="ehae176-B503" data-open="ehae176-B503" class="link link-ref link-reveal xref-bibr">503</a>,<span class="xrefLink" id="jumplink-ehae176-B508"></span><a href="javascript:;" reveal-id="ehae176-B508" data-open="ehae176-B508" class="link link-ref link-reveal xref-bibr">508</a>,<span class="xrefLink" id="jumplink-ehae176-B593"></span><a href="javascript:;" reveal-id="ehae176-B593" data-open="ehae176-B593" class="link link-ref link-reveal xref-bibr">593</a>,<span class="xrefLink" id="jumplink-ehae176-B599"></span><a href="javascript:;" reveal-id="ehae176-B599" data-open="ehae176-B599" class="link link-ref link-reveal xref-bibr">599</a></sup> but the optimal ablation strategy has not been clarified in the non-paroxysmal AF population.<sup><span class="xrefLink" id="jumplink-ehae176-B600"></span><a href="javascript:;" reveal-id="ehae176-B600" data-open="ehae176-B600" class="link link-ref link-reveal xref-bibr">600</a></sup> New technologies are emerging, such as pulsed field ablation, in which high-amplitude electrical pulses are used to ablate the myocardium by electroporation with high tissue specificity. In a single-blind RCT of 607 patients, pulsed field ablation was non-inferior for efficacy and safety endpoints compared with conventional radiofrequency or cryoballoon ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B601"></span><a href="javascript:;" reveal-id="ehae176-B601" data-open="ehae176-B601" class="link link-ref link-reveal xref-bibr">601</a></sup> Regarding timing of ablation, a small RCT found that delaying catheter ablation in patients with paroxysmal or persistent AF by 12 months (while on optimized medical therapy) did not impact on arrhythmia-free survival compared with ablation within 1 month.<sup><span class="xrefLink" id="jumplink-ehae176-B602"></span><a href="javascript:;" reveal-id="ehae176-B602" data-open="ehae176-B602" class="link link-ref link-reveal xref-bibr">602</a></sup>

As with any type of rhythm control, many patients in clinical practice will not be suitable for catheter ablation due to factors that reduce the likelihood of a positive response, such as left atrial dilatation. Definitive evidence that supports the prognostic benefit of catheter ablation is needed before this invasive treatment can be considered for truly asymptomatic patients. As previously noted, the CABANA trial did not confirm a benefit of catheter ablation compared with medical therapy, although high crossover rates and low event rates may have diluted the treatment effect.<sup><span class="xrefLink" id="jumplink-ehae176-B3"></span><a href="javascript:;" reveal-id="ehae176-B3" data-open="ehae176-B3" class="link link-ref link-reveal xref-bibr">3</a></sup> Therefore, only highly selected asymptomatic patients could be candidates for catheter ablation, and only after detailed discussion of associated risks and potential benefit of delaying AF progression.<sup><span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a>,<span class="xrefLink" id="jumplink-ehae176-B603"></span><a href="javascript:;" reveal-id="ehae176-B603" data-open="ehae176-B603" class="link link-ref link-reveal xref-bibr">603</a></sup> Randomized trials have shown that AF catheter ablation in patients with HFrEF significantly reduces arrhythmia recurrence and increases ejection fraction, with improvement in clinical outcomes and mortality also observed in selected patients.<sup><span class="xrefLink" id="jumplink-ehae176-B4"></span><a href="javascript:;" reveal-id="ehae176-B4" data-open="ehae176-B4" class="link link-ref link-reveal xref-bibr">4</a>,<span class="xrefLink" id="jumplink-ehae176-B513"></span><a href="javascript:;" reveal-id="ehae176-B513" data-open="ehae176-B513" class="link link-ref link-reveal xref-bibr">513</a>,<span class="xrefLink" id="jumplink-ehae176-B514"></span><a href="javascript:;" reveal-id="ehae176-B514" data-open="ehae176-B514" class="link link-ref link-reveal xref-bibr">514</a>,<span class="xrefLink" id="jumplink-ehae176-B604 ehae176-B605 ehae176-B606 ehae176-B607 ehae176-B608 ehae176-B609 ehae176-B610 ehae176-B611 ehae176-B612"></span><a href="javascript:;" reveal-id="ehae176-B604 ehae176-B605 ehae176-B606 ehae176-B607 ehae176-B608 ehae176-B609 ehae176-B610 ehae176-B611 ehae176-B612" data-open="ehae176-B604 ehae176-B605 ehae176-B606 ehae176-B607 ehae176-B608 ehae176-B609 ehae176-B610 ehae176-B611 ehae176-B612" class="link link-ref link-reveal xref-bibr">604–612</a></sup> Several characteristics, including but not limited to AF type, left atrial dilatation, and the presence of atrial and/or ventricular fibrosis, could refine patient selection to maximize outcome benefit from AF catheter ablation in patients with HFrEF.<sup><span class="xrefLink" id="jumplink-ehae176-B604"></span><a href="javascript:;" reveal-id="ehae176-B604" data-open="ehae176-B604" class="link link-ref link-reveal xref-bibr">604</a>,<span class="xrefLink" id="jumplink-ehae176-B608"></span><a href="javascript:;" reveal-id="ehae176-B608" data-open="ehae176-B608" class="link link-ref link-reveal xref-bibr">608</a>,<span class="xrefLink" id="jumplink-ehae176-B613 ehae176-B614 ehae176-B615 ehae176-B616 ehae176-B617"></span><a href="javascript:;" reveal-id="ehae176-B613 ehae176-B614 ehae176-B615 ehae176-B616 ehae176-B617" data-open="ehae176-B613 ehae176-B614 ehae176-B615 ehae176-B616 ehae176-B617" class="link link-ref link-reveal xref-bibr">613–617</a></sup> The prognostic value of catheter ablation in patients with HFpEF is less well established than for HFrEF.<sup><span class="xrefLink" id="jumplink-ehae176-B617 ehae176-B618 ehae176-B619 ehae176-B620 ehae176-B621 ehae176-B622 ehae176-B623 ehae176-B624 ehae176-B625 ehae176-B626"></span><a href="javascript:;" reveal-id="ehae176-B617 ehae176-B618 ehae176-B619 ehae176-B620 ehae176-B621 ehae176-B622 ehae176-B623 ehae176-B624 ehae176-B625 ehae176-B626" data-open="ehae176-B617 ehae176-B618 ehae176-B619 ehae176-B620 ehae176-B621 ehae176-B622 ehae176-B623 ehae176-B624 ehae176-B625 ehae176-B626" class="link link-ref link-reveal xref-bibr">617–626</a></sup>

Recent registries and trials report varying rates of peri-procedural serious adverse events associated with catheter ablation (2.9%–7.2%) with a very low 30 day mortality rate (<0.1%). Operator experience and procedural volume at the ablation centre are critical, since they are associated with complication rates and 30 day mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B627 ehae176-B628 ehae176-B629 ehae176-B630 ehae176-B631"></span><a href="javascript:;" reveal-id="ehae176-B627 ehae176-B628 ehae176-B629 ehae176-B630 ehae176-B631" data-open="ehae176-B627 ehae176-B628 ehae176-B629 ehae176-B630 ehae176-B631" class="link link-ref link-reveal xref-bibr">627–631</a></sup>

Intermittent rhythm monitoring has typically been used to detect AF relapses following catheter ablation. Recent technology developments such as smartwatch or smartphone photoplethysmography and wearable patches may have an emerging role in post-ablation monitoring.<sup><span class="xrefLink" id="jumplink-ehae176-B632"></span><a href="javascript:;" reveal-id="ehae176-B632" data-open="ehae176-B632" class="link link-ref link-reveal xref-bibr">632</a>,<span class="xrefLink" id="jumplink-ehae176-B633"></span><a href="javascript:;" reveal-id="ehae176-B633" data-open="ehae176-B633" class="link link-ref link-reveal xref-bibr">633</a></sup> In addition, implantable loop recorders have been used to quantify AF burden before and after ablation as an additional endpoint beyond binary AF elimination.<sup><span class="xrefLink" id="jumplink-ehae176-B634"></span><a href="javascript:;" reveal-id="ehae176-B634" data-open="ehae176-B634" class="link link-ref link-reveal xref-bibr">634</a></sup> Management of arrhythmia recurrence post-ablation is an informed, shared decision-making process driven by available options for symptom control. In the post-AF ablation context, there is data supporting a role for AAD continuation or re-initiation, even for previously ineffective drugs.<sup><span class="xrefLink" id="jumplink-ehae176-B635"></span><a href="javascript:;" reveal-id="ehae176-B635" data-open="ehae176-B635" class="link link-ref link-reveal xref-bibr">635</a></sup> A short-term AAD treatment (2–3 months) following ablation reduces early recurrences of AF,<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B635 ehae176-B636 ehae176-B637 ehae176-B638 ehae176-B639"></span><a href="javascript:;" reveal-id="ehae176-B635 ehae176-B636 ehae176-B637 ehae176-B638 ehae176-B639" data-open="ehae176-B635 ehae176-B636 ehae176-B637 ehae176-B638 ehae176-B639" class="link link-ref link-reveal xref-bibr">635–639</a></sup> but does not affect late recurrences<sup><span class="xrefLink" id="jumplink-ehae176-B636"></span><a href="javascript:;" reveal-id="ehae176-B636" data-open="ehae176-B636" class="link link-ref link-reveal xref-bibr">636</a>,<span class="xrefLink" id="jumplink-ehae176-B637"></span><a href="javascript:;" reveal-id="ehae176-B637" data-open="ehae176-B637" class="link link-ref link-reveal xref-bibr">637</a>,<span class="xrefLink" id="jumplink-ehae176-B640 ehae176-B641 ehae176-B642"></span><a href="javascript:;" reveal-id="ehae176-B640 ehae176-B641 ehae176-B642" data-open="ehae176-B640 ehae176-B641 ehae176-B642" class="link link-ref link-reveal xref-bibr">640–642</a></sup> or 1 year clinical outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B642"></span><a href="javascript:;" reveal-id="ehae176-B642" data-open="ehae176-B642" class="link link-ref link-reveal xref-bibr">642</a></sup> Repeat PVI should be offered in patients with AF recurrence if symptom improvement was demonstrated after the first ablation, with shared decision-making and clear goals of treatment.<sup><span class="xrefLink" id="jumplink-ehae176-B643 ehae176-B644 ehae176-B645"></span><a href="javascript:;" reveal-id="ehae176-B643 ehae176-B644 ehae176-B645" data-open="ehae176-B643 ehae176-B644 ehae176-B645" class="link link-ref link-reveal xref-bibr">643–645</a></sup>

Recommendation Table 19

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884323)

Recommendations for catheter ablation of AF (see also Evidence Table 19)

![Recommendations for catheter ablation of AF (see also Evidence Table 19)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt19.jpeg?Expires=1728478929&Signature=l5a4SPCgi9wF7s1DGLVqfYewBV22PEaBjLM6XxZAlwHcYzpHgnc-1L1wzwVR8IINQM-7E5b-Cw4HRNGXZuiE7mSlnATJbEO--SZdyMZzp3Y-MAtmYPJ9X8HL0cYfEOs4BXkV4hQiLcA6OkcDhRF0uRSq~hZjLj7Qne43qhcaWVLGAojY5KIQR2pve2vebmTLYUXK-UFu7cxiJmUy2JnbQN~doHIADCUNQR0pdfQsfvMKgcBppzpyDXBLi4uhrv1fEXyzw9q81wI97UsYhh4nj1c3VcdVXN6mEO3kFXP6Kexu5aUmBtIC8vCUqeVj4Vf7YEAX9HFAU0oi6vWwS1NjSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 19

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884323)

Recommendations for catheter ablation of AF (see also Evidence Table 19)

![Recommendations for catheter ablation of AF (see also Evidence Table 19)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt19.jpeg?Expires=1728478929&Signature=l5a4SPCgi9wF7s1DGLVqfYewBV22PEaBjLM6XxZAlwHcYzpHgnc-1L1wzwVR8IINQM-7E5b-Cw4HRNGXZuiE7mSlnATJbEO--SZdyMZzp3Y-MAtmYPJ9X8HL0cYfEOs4BXkV4hQiLcA6OkcDhRF0uRSq~hZjLj7Qne43qhcaWVLGAojY5KIQR2pve2vebmTLYUXK-UFu7cxiJmUy2JnbQN~doHIADCUNQR0pdfQsfvMKgcBppzpyDXBLi4uhrv1fEXyzw9q81wI97UsYhh4nj1c3VcdVXN6mEO3kFXP6Kexu5aUmBtIC8vCUqeVj4Vf7YEAX9HFAU0oi6vWwS1NjSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.6. Anticoagulation in patients undergoing catheter ablation

The presence of left atrial thrombus is a contraindication to catheter-based AF ablation due to the risk of thrombus dislodgement leading to ischaemic stroke. Patients planned for catheter ablation of AF with an increased risk of thromboembolism should be on OAC for at least 3 full weeks prior to the procedure.<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B647"></span><a href="javascript:;" reveal-id="ehae176-B647" data-open="ehae176-B647" class="link link-ref link-reveal xref-bibr">647</a></sup>

There is a wide range in practice for visualization of intra-atrial thrombi prior to catheter ablation, including TOE, intracardiac echocardiography, or delayed phase cardiac computed tomography (CT).<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B648"></span><a href="javascript:;" reveal-id="ehae176-B648" data-open="ehae176-B648" class="link link-ref link-reveal xref-bibr">648</a></sup> The prevalence of left atrial thrombus was 1.3% and 2.7% in two meta-analyses of observational studies in patients planned for catheter ablation of AF on adequate OAC.<sup><span class="xrefLink" id="jumplink-ehae176-B649"></span><a href="javascript:;" reveal-id="ehae176-B649" data-open="ehae176-B649" class="link link-ref link-reveal xref-bibr">649</a>,<span class="xrefLink" id="jumplink-ehae176-B650"></span><a href="javascript:;" reveal-id="ehae176-B650" data-open="ehae176-B650" class="link link-ref link-reveal xref-bibr">650</a></sup> The prevalence of left atrial thrombus was higher in patients with elevated stroke risk scores, and in patients with non-paroxysmal compared with paroxysmal AF.<sup><span class="xrefLink" id="jumplink-ehae176-B650"></span><a href="javascript:;" reveal-id="ehae176-B650" data-open="ehae176-B650" class="link link-ref link-reveal xref-bibr">650</a></sup> In addition, several patient subgroups with AF have increased risk of ischaemic stroke and intracardiac thrombus even if treated with adequate anticoagulation, including those with cardiac amyloidosis, rheumatic heart disease, and hypertrophic cardiomyopathy (HCM). Cardiac imaging before catheter ablation should be considered in these high-risk patient groups regardless of preceding effective OAC. Observational studies suggest that patients with a low thromboembolic risk profile may be managed without visualization of the LAA,<sup><span class="xrefLink" id="jumplink-ehae176-B651 ehae176-B652 ehae176-B653"></span><a href="javascript:;" reveal-id="ehae176-B651 ehae176-B652 ehae176-B653" data-open="ehae176-B651 ehae176-B652 ehae176-B653" class="link link-ref link-reveal xref-bibr">651–653</a></sup> but no RCTs have been performed (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S21](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

For patients who have been anticoagulated prior to the ablation procedure it is recommended to avoid interruption of OAC (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S22](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B654 ehae176-B655 ehae176-B656"></span><a href="javascript:;" reveal-id="ehae176-B654 ehae176-B655 ehae176-B656" data-open="ehae176-B654 ehae176-B655 ehae176-B656" class="link link-ref link-reveal xref-bibr">654–656</a></sup> Patients with interrupted OAC showed an increase in silent stroke detected by brain magnetic resonance imaging (MRI) as compared with those with uninterrupted OAC.<sup><span class="xrefLink" id="jumplink-ehae176-B657 ehae176-B658 ehae176-B659"></span><a href="javascript:;" reveal-id="ehae176-B657 ehae176-B658 ehae176-B659" data-open="ehae176-B657 ehae176-B658 ehae176-B659" class="link link-ref link-reveal xref-bibr">657–659</a></sup> In a true uninterrupted DOAC strategy for once-daily dosing, a pre-procedural shift to evening intake might be considered to mitigate bleeding risk. Randomized trials show comparable safety and efficacy with minimally interrupted OAC (withholding the morning DOAC dose on the day of the procedure) and a totally uninterrupted peri-ablation OAC strategy.<sup><span class="xrefLink" id="jumplink-ehae176-B655"></span><a href="javascript:;" reveal-id="ehae176-B655" data-open="ehae176-B655" class="link link-ref link-reveal xref-bibr">655</a></sup>

Anticoagulation with heparin during AF ablation is common practice.<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a></sup> Post-ablation DOACs should be continued as per the dosing regimen when haemostasis has been achieved.<sup><span class="xrefLink" id="jumplink-ehae176-B335"></span><a href="javascript:;" reveal-id="ehae176-B335" data-open="ehae176-B335" class="link link-ref link-reveal xref-bibr">335</a>,<span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a>,<span class="xrefLink" id="jumplink-ehae176-B647"></span><a href="javascript:;" reveal-id="ehae176-B647" data-open="ehae176-B647" class="link link-ref link-reveal xref-bibr">647</a></sup> All patients should be kept on an OAC for at least 2 months after an AF ablation procedure irrespective of estimated thromboembolic risk (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S23](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B647"></span><a href="javascript:;" reveal-id="ehae176-B647" data-open="ehae176-B647" class="link link-ref link-reveal xref-bibr">647</a></sup> Meta-analyses of observational studies have tried to assess the safety of stopping OAC treatment after catheter ablation for AF, but the results have been heterogenous.<sup><span class="xrefLink" id="jumplink-ehae176-B660 ehae176-B661 ehae176-B662 ehae176-B663"></span><a href="javascript:;" reveal-id="ehae176-B660 ehae176-B661 ehae176-B662 ehae176-B663" data-open="ehae176-B660 ehae176-B661 ehae176-B662 ehae176-B663" class="link link-ref link-reveal xref-bibr">660–663</a></sup> Until the completion of relevant RCTs (e.g. NCT02168829), it is recommended to continue OAC therapy post-AF ablation according to the patient's CHA<sub>2</sub>DS<sub>2</sub>\-VA score and not the perceived success of the ablation procedure.<sup><span class="xrefLink" id="jumplink-ehae176-B554"></span><a href="javascript:;" reveal-id="ehae176-B554" data-open="ehae176-B554" class="link link-ref link-reveal xref-bibr">554</a></sup>

Recommendation Table 20

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884329)

Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20)

![Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt20.jpeg?Expires=1728478929&Signature=IxAwZumdINE4wvbOHuDdXWx-qc~4IzEW9M~MSG375NyEUgQTcyPPFcW7fOLw0b7Hq2b3cIrO50WaitRpFJEk1Cl-hoka6y2BG7OVVuK3kclsy-RE16XxBSudo~ylWABoTDQ7msXQIkWBg6jpNQM40cFe9qTO24shs~7cIvmRAi218ec8~1b9h9vTrid73xSGovkxVtSPTsMUkvxf1qGIvgMaF7k5Tkk2RXBGjJVGH7oPWiOct~LqI6L6GpTa3wJ8WcZraHPV8N8F9UaWG0sOFn6LAZWo~RMzHU3FUxhw2tzH5EhDb6nWgbcReiRQdVK0XqzmTjRKOLK1iSTPf07QUg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 20

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884329)

Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20)

![Recommendations for anticoagulation in patients undergoing catheter ablation (see also Evidence Table 20)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt20.jpeg?Expires=1728478929&Signature=IxAwZumdINE4wvbOHuDdXWx-qc~4IzEW9M~MSG375NyEUgQTcyPPFcW7fOLw0b7Hq2b3cIrO50WaitRpFJEk1Cl-hoka6y2BG7OVVuK3kclsy-RE16XxBSudo~ylWABoTDQ7msXQIkWBg6jpNQM40cFe9qTO24shs~7cIvmRAi218ec8~1b9h9vTrid73xSGovkxVtSPTsMUkvxf1qGIvgMaF7k5Tkk2RXBGjJVGH7oPWiOct~LqI6L6GpTa3wJ8WcZraHPV8N8F9UaWG0sOFn6LAZWo~RMzHU3FUxhw2tzH5EhDb6nWgbcReiRQdVK0XqzmTjRKOLK1iSTPf07QUg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.7. Endoscopic and hybrid AF ablation

Minimally invasive surgical AF ablation can be performed via a thoracoscopic approach or a subxiphoid approach. The term endoscopic covers both strategies. Hybrid ablation approaches have been developed where endoscopic epicardial ablation on the beating heart is performed in combination with endocardial catheter ablation, either in a simultaneous or sequential procedure. The rationale for combining an endocardial with an epicardial approach is that a more effective transmural ablation strategy can be pursued.<sup><span class="xrefLink" id="jumplink-ehae176-B666"></span><a href="javascript:;" reveal-id="ehae176-B666" data-open="ehae176-B666" class="link link-ref link-reveal xref-bibr">666</a>,<span class="xrefLink" id="jumplink-ehae176-B667"></span><a href="javascript:;" reveal-id="ehae176-B667" data-open="ehae176-B667" class="link link-ref link-reveal xref-bibr">667</a></sup>

For paroxysmal AF, an endoscopic or hybrid ablation approach may be considered after a failed percutaneous catheter ablation strategy.<sup><span class="xrefLink" id="jumplink-ehae176-B668 ehae176-B669 ehae176-B670"></span><a href="javascript:;" reveal-id="ehae176-B668 ehae176-B669 ehae176-B670" data-open="ehae176-B668 ehae176-B669 ehae176-B670" class="link link-ref link-reveal xref-bibr">668–670</a></sup> Long-term follow-up of the FAST RCT (mean of 7.0 years), which included patients with paroxysmal and persistent AF, found arrhythmia recurrence was common but substantially lower with thoracoscopic ablation than catheter ablation: 34/61 patients (56%) compared with 55/63 patients (87%), with _P_ < .001 for the comparison.<sup><span class="xrefLink" id="jumplink-ehae176-B669"></span><a href="javascript:;" reveal-id="ehae176-B669" data-open="ehae176-B669" class="link link-ref link-reveal xref-bibr">669</a></sup> For persistent AF, endoscopic or hybrid ablation approaches are suitable as a first procedure to maintain long-term sinus rhythm in selected patients.<sup><span class="xrefLink" id="jumplink-ehae176-B667 ehae176-B668 ehae176-B669 ehae176-B670 ehae176-B671 ehae176-B672"></span><a href="javascript:;" reveal-id="ehae176-B667 ehae176-B668 ehae176-B669 ehae176-B670 ehae176-B671 ehae176-B672" data-open="ehae176-B667 ehae176-B668 ehae176-B669 ehae176-B670 ehae176-B671 ehae176-B672" class="link link-ref link-reveal xref-bibr">667–672</a></sup> A meta-analysis of three RCTs confirmed a lower rate of atrial arrhythmia recurrence after thoracoscopic vs. catheter ablation (incidence rate ratio, 0.55; 95% CI, 0.38–0.78; with no heterogeneity between trials).<sup><span class="xrefLink" id="jumplink-ehae176-B669"></span><a href="javascript:;" reveal-id="ehae176-B669" data-open="ehae176-B669" class="link link-ref link-reveal xref-bibr">669</a></sup> An RCT with 12 month follow-up published after the meta-analysis in patients with long-standing persistent AF found no difference in arrhythmia freedom comparing thoracoscopic with catheter ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B673"></span><a href="javascript:;" reveal-id="ehae176-B673" data-open="ehae176-B673" class="link link-ref link-reveal xref-bibr">673</a></sup> Although overall morbidity and mortality of both techniques is low, endoscopic and hybrid ablation have higher complication rates than catheter ablation, but similar long-term rates of the composite of mortality, MI, or stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B667"></span><a href="javascript:;" reveal-id="ehae176-B667" data-open="ehae176-B667" class="link link-ref link-reveal xref-bibr">667</a>,<span class="xrefLink" id="jumplink-ehae176-B669"></span><a href="javascript:;" reveal-id="ehae176-B669" data-open="ehae176-B669" class="link link-ref link-reveal xref-bibr">669</a></sup>

More recent trials have assessed the efficacy and safety of the hybrid epicardial-plus-endocardial approach in persistent AF refractory to AAD therapy, including a single-centre RCT<sup><span class="xrefLink" id="jumplink-ehae176-B670"></span><a href="javascript:;" reveal-id="ehae176-B670" data-open="ehae176-B670" class="link link-ref link-reveal xref-bibr">670</a></sup> and two multicentre RCTs.<sup><span class="xrefLink" id="jumplink-ehae176-B671"></span><a href="javascript:;" reveal-id="ehae176-B671" data-open="ehae176-B671" class="link link-ref link-reveal xref-bibr">671</a>,<span class="xrefLink" id="jumplink-ehae176-B674"></span><a href="javascript:;" reveal-id="ehae176-B674" data-open="ehae176-B674" class="link link-ref link-reveal xref-bibr">674</a></sup> Across these trials, hybrid ablation was consistently superior to catheter ablation alone for maintaining long-term sinus rhythm, without significant differences in major adverse events. Notably, these studies were typically performed in highly experienced centres (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S24](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Similar to other rhythm control approaches, this task force recommends that OAC are continued in all patients who have a risk of thromboembolism, irrespective of rhythm outcome, and regardless of LAA exclusion performed as part of the surgical procedure.

Recommendation Table 21

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884335)

Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21)

![Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt21.jpeg?Expires=1728478929&Signature=LI6nN6fiZWTYP~Iws9nRpiw6kmYRZDHIw2jm1QglWBdeaRSuYxEkOr~t-e5xMN45uQB92aKYU6c~6cfoB7Tm-4Igp3JiZ~5B85uD~v9zhnOJNUejqzOJm1Rg13zyoZn9Recv~GAbYOScCnrPXRQH-ncMbT7F13e3bfMByA~CBDvtPuVZ5bt8pHdkmjZOX7FBFLz1sOXttngoRVumRmmgtpBR2tA5MYyVgkktpe7Pl9Tm~An84jra1ggslplKDo1R6IVp6TD4hVs6Yt0LW~0LBhFXBsMAYpdV2gfThjgGGafz5BED5A275QEnpWCCSQnoDZLHaCUOpCK8JJs0tjIn~g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 21

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884335)

Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21)

![Recommendations for endoscopic and hybrid AF ablation (see also Evidence Table 21)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt21.jpeg?Expires=1728478929&Signature=LI6nN6fiZWTYP~Iws9nRpiw6kmYRZDHIw2jm1QglWBdeaRSuYxEkOr~t-e5xMN45uQB92aKYU6c~6cfoB7Tm-4Igp3JiZ~5B85uD~v9zhnOJNUejqzOJm1Rg13zyoZn9Recv~GAbYOScCnrPXRQH-ncMbT7F13e3bfMByA~CBDvtPuVZ5bt8pHdkmjZOX7FBFLz1sOXttngoRVumRmmgtpBR2tA5MYyVgkktpe7Pl9Tm~An84jra1ggslplKDo1R6IVp6TD4hVs6Yt0LW~0LBhFXBsMAYpdV2gfThjgGGafz5BED5A275QEnpWCCSQnoDZLHaCUOpCK8JJs0tjIn~g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.8. AF ablation during cardiac surgery

Atrial fibrillation is a significant risk factor for early mortality, late mortality, and stroke in patients referred for cardiac surgery.<sup><span class="xrefLink" id="jumplink-ehae176-B675 ehae176-B676 ehae176-B677"></span><a href="javascript:;" reveal-id="ehae176-B675 ehae176-B676 ehae176-B677" data-open="ehae176-B675 ehae176-B676 ehae176-B677" class="link link-ref link-reveal xref-bibr">675–677</a></sup> The best validated method of surgical ablation is the Maze procedure, consisting of a pattern of transmural lesions including PVI, with subsequent modifications using bipolar radiofrequency and/or cryothermy ablation with LAA amputation (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S25](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B678 ehae176-B679 ehae176-B680 ehae176-B681"></span><a href="javascript:;" reveal-id="ehae176-B678 ehae176-B679 ehae176-B680 ehae176-B681" data-open="ehae176-B678 ehae176-B679 ehae176-B680 ehae176-B681" class="link link-ref link-reveal xref-bibr">678–681</a></sup> Education and training, close co-operation within a multidisciplinary team, and shared decision-making can improve the quality and outcomes of surgical ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B682"></span><a href="javascript:;" reveal-id="ehae176-B682" data-open="ehae176-B682" class="link link-ref link-reveal xref-bibr">682</a></sup>

A number of RCTs have shown that surgical AF ablation during cardiac surgery increases freedom from arrhythmia recurrence.<sup><span class="xrefLink" id="jumplink-ehae176-B683 ehae176-B684 ehae176-B685 ehae176-B686 ehae176-B687 ehae176-B688"></span><a href="javascript:;" reveal-id="ehae176-B683 ehae176-B684 ehae176-B685 ehae176-B686 ehae176-B687 ehae176-B688" data-open="ehae176-B683 ehae176-B684 ehae176-B685 ehae176-B686 ehae176-B687 ehae176-B688" class="link link-ref link-reveal xref-bibr">683–688</a></sup> Performing surgical AF ablation, mainly targeting those patients needing mitral valve surgery, is not associated with increased morbidity or mortality.<sup><span class="xrefLink" id="jumplink-ehae176-B678"></span><a href="javascript:;" reveal-id="ehae176-B678" data-open="ehae176-B678" class="link link-ref link-reveal xref-bibr">678</a>,<span class="xrefLink" id="jumplink-ehae176-B683 ehae176-B684 ehae176-B685"></span><a href="javascript:;" reveal-id="ehae176-B683 ehae176-B684 ehae176-B685" data-open="ehae176-B683 ehae176-B684 ehae176-B685" class="link link-ref link-reveal xref-bibr">683–685</a></sup> Observational data, including large registries, have supported the potential value of surgical AF ablation,<sup><span class="xrefLink" id="jumplink-ehae176-B689 ehae176-B690 ehae176-B691 ehae176-B692 ehae176-B693 ehae176-B694 ehae176-B695 ehae176-B696 ehae176-B697 ehae176-B698 ehae176-B699 ehae176-B700"></span><a href="javascript:;" reveal-id="ehae176-B689 ehae176-B690 ehae176-B691 ehae176-B692 ehae176-B693 ehae176-B694 ehae176-B695 ehae176-B696 ehae176-B697 ehae176-B698 ehae176-B699 ehae176-B700" data-open="ehae176-B689 ehae176-B690 ehae176-B691 ehae176-B692 ehae176-B693 ehae176-B694 ehae176-B695 ehae176-B696 ehae176-B697 ehae176-B698 ehae176-B699 ehae176-B700" class="link link-ref link-reveal xref-bibr">689–700</a></sup> but further RCTs are needed to evaluate which patients should be selected, and whether this approach contributes to the prevention of stroke, thromboembolism, and death.

Data on pacemaker implantation rates after surgical AF ablation are variable and are likely influenced by centre experience and the patients treated (e.g. underlying sinus node disease). In a systematic review of 22 RCTs (1726 patients), permanent pacemaker implantation rates were higher with surgical AF ablation than without concomitant AF surgery (6.0% vs. 4.1%; RR, 1.69; 95% CI, 1.12–2.54).<sup><span class="xrefLink" id="jumplink-ehae176-B701"></span><a href="javascript:;" reveal-id="ehae176-B701" data-open="ehae176-B701" class="link link-ref link-reveal xref-bibr">701</a></sup> Observational registry data from contemporary cohorts (2011–2020) suggest an overall pacemaker rate post-operatively of 2.1% in patients selected for surgical AF ablation, with no discernible impact of surgical ablation on the need for a pacemaker, but higher rates in those needing multivalve surgery.<sup><span class="xrefLink" id="jumplink-ehae176-B702"></span><a href="javascript:;" reveal-id="ehae176-B702" data-open="ehae176-B702" class="link link-ref link-reveal xref-bibr">702</a></sup> With a safety-first approach in mind, imaging is advised during surgical AF ablation to exclude thrombus and help to plan the surgical approach (e.g. with TOE), regardless of effective pre-procedural anticoagulant use.

Recommendation Table 22

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884340)

Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22)

![Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt22.jpeg?Expires=1728478929&Signature=PKiJQhFz6wATUb9ELYU3WPE4YqPur~DAXKbEHtTdeXk2P9ZXd2~UT2JSYUyFLcvWN1i83uKq6lM~w5q0h9NhJl6wDHf42N96E3KpfR0zd72YeAOBPF6E0Hxi6WaD1HHDjs7H3yi-eBusgUR93GhxA2HtpVErSZEt4M1NSG2bN5BaNaFEnGpgnQAd~wyD4m5YHoJQTXvbYtugrmF3xTX7p9UdtcJviF4BCV6Bt4~oEMam49OHFJT52pmc2eGCLeR4LbYTr4o2rala9rIfNkL4ighaJjyKTmvN-LmXbAg1FSvpeUh5LMms7sQOaiMKzEIxSqvggr78cG5FUEjPhLfvMw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 22

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884340)

Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22)

![Recommendations for AF ablation during cardiac surgery (see also Evidence Table 22)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt22.jpeg?Expires=1728478929&Signature=PKiJQhFz6wATUb9ELYU3WPE4YqPur~DAXKbEHtTdeXk2P9ZXd2~UT2JSYUyFLcvWN1i83uKq6lM~w5q0h9NhJl6wDHf42N96E3KpfR0zd72YeAOBPF6E0Hxi6WaD1HHDjs7H3yi-eBusgUR93GhxA2HtpVErSZEt4M1NSG2bN5BaNaFEnGpgnQAd~wyD4m5YHoJQTXvbYtugrmF3xTX7p9UdtcJviF4BCV6Bt4~oEMam49OHFJT52pmc2eGCLeR4LbYTr4o2rala9rIfNkL4ighaJjyKTmvN-LmXbAg1FSvpeUh5LMms7sQOaiMKzEIxSqvggr78cG5FUEjPhLfvMw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.2.9. Atrial tachycardia after pulmonary vein isolation

After any ablation for AF, recurrent arrhythmias may manifest as AF, but also as atrial tachycardia (AT). Although AT may be perceived as a step in the right direction by the treating physician, this view is often not shared by the patient because AT can be equally or more symptomatic than the original AF. Conventionally, an early arrhythmia recurrence post-PVI (whether AT, AF, or flutter) is considered potentially transitory.<sup><span class="xrefLink" id="jumplink-ehae176-B708"></span><a href="javascript:;" reveal-id="ehae176-B708" data-open="ehae176-B708" class="link link-ref link-reveal xref-bibr">708</a></sup> Recent trials using continuous implantable loop recorders for peri-procedural monitoring have provided insight into the incidence and significance of early arrhythmia recurrences, and have confirmed a link between early and later recurrence.<sup><span class="xrefLink" id="jumplink-ehae176-B709"></span><a href="javascript:;" reveal-id="ehae176-B709" data-open="ehae176-B709" class="link link-ref link-reveal xref-bibr">709</a></sup> Discussion of management options for AT post-ablation should ideally involve a multidisciplinary team with experience in interventional management of complex arrhythmias, considering technical challenges, procedural efficacy, and safety, in the context of patient preferences.

## 8\. \[E\] Evaluation and dynamic reassessment

The development and progression of AF results from continuous interactions between underlying mechanisms (electrical, cellular, neurohormonal, and haemodynamic), coupled with a broad range of clinical factors and associated comorbidities. Each individual factor has considerable variability over time, affecting its contribution to the AF-promoting substrate. The risk profile of each patient is also far from static, and requires a dynamic mode of care to ensure optimal AF management.<sup><span class="xrefLink" id="jumplink-ehae176-B710"></span><a href="javascript:;" reveal-id="ehae176-B710" data-open="ehae176-B710" class="link link-ref link-reveal xref-bibr">710</a>,<span class="xrefLink" id="jumplink-ehae176-B711"></span><a href="javascript:;" reveal-id="ehae176-B711" data-open="ehae176-B711" class="link link-ref link-reveal xref-bibr">711</a></sup> Patients with AF require periodic reassessment of therapy based on this changing risk status if we are to improve the overall quality of care. Timely attention to modifiable factors and underpinning comorbidities has the potential to slow or reverse the progression of AF, increase quality of life, and prevent adverse outcomes such as heart failure, thromboembolism, and major bleeding.

The \[E\] in AF-CARE encompasses the range of activity needed by healthcare professionals and patients to: (i) thoroughly evaluate associated comorbidities and risk factors that can guide treatment; and (ii) provide the dynamic assessment needed to ensure that treatment plans remain suited to that particular patient. This task force recommends an adaptive strategy that not only reacts to changes notified by a patient, but also proactively seeks out issues where altering management could impact on patient wellbeing. Avoidance of unnecessary and costly follow-up is also inherent in this framework, with educated and empowered patients contributing to identifying the need for access to specialist care or an escalation of management. The patient-centred, shared decision philosophy is embedded to improve efficiency in models of care and to address the needs of patients with AF.

Medical history and the results of any tests should be regularly re-evaluated to address the dynamic nature of comorbidities and risk factors.<sup><span class="xrefLink" id="jumplink-ehae176-B712"></span><a href="javascript:;" reveal-id="ehae176-B712" data-open="ehae176-B712" class="link link-ref link-reveal xref-bibr">712</a></sup> This may have impact on therapeutic decisions; e.g. resumption of full-dose DOAC therapy after improvement in the patient's renal function. The timing of review of the AF-CARE pathway is patient specific and should respond to changes in clinical status. In most cases, this task force advises re-evaluation 6 months after initial presentation, and then at least annually by a healthcare professional in primary or secondary care (see _[Figure 3](javascript:;)_).

### 8.1. Implementation of dynamic care

A multidisciplinary-based approach is advocated to improve implementation of dynamic AF-CARE (see _[Figure 2](javascript:;)_); although potentially resource intensive, this is preferred to more simplistic or opportunistic methods. For example, in a pragmatic trial of 47 333 AF patients identified through health insurance claims, there was no difference in OAC initiation at 1 year in those randomized to a single mailout of patient and clinician education, compared with those in the usual care group.<sup><span class="xrefLink" id="jumplink-ehae176-B713"></span><a href="javascript:;" reveal-id="ehae176-B713" data-open="ehae176-B713" class="link link-ref link-reveal xref-bibr">713</a></sup> For co-ordination of care there is a core role for cardiologists, general practitioners, specialized nurses, and pharmacists.<sup><span class="xrefLink" id="jumplink-ehae176-B714"></span><a href="javascript:;" reveal-id="ehae176-B714" data-open="ehae176-B714" class="link link-ref link-reveal xref-bibr">714</a></sup> If needed, and depending on local resources, others may also be involved (cardiac surgeons, physiotherapists, neurologists, psychologists, and other allied health professionals). It is strongly advocated that one core team member co-ordinates care, and that additional team members become involved according to the needs of the individual patient throughout their AF trajectory.

Several organizational models of integrated care for AF have been evaluated, but which components are most useful remains unclear. Some models include a multidisciplinary team,<sup><span class="xrefLink" id="jumplink-ehae176-B715"></span><a href="javascript:;" reveal-id="ehae176-B715" data-open="ehae176-B715" class="link link-ref link-reveal xref-bibr">715</a>,<span class="xrefLink" id="jumplink-ehae176-B716"></span><a href="javascript:;" reveal-id="ehae176-B716" data-open="ehae176-B716" class="link link-ref link-reveal xref-bibr">716</a></sup> while others are nurse-led<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a>,<span class="xrefLink" id="jumplink-ehae176-B122"></span><a href="javascript:;" reveal-id="ehae176-B122" data-open="ehae176-B122" class="link link-ref link-reveal xref-bibr">122</a>,<span class="xrefLink" id="jumplink-ehae176-B124"></span><a href="javascript:;" reveal-id="ehae176-B124" data-open="ehae176-B124" class="link link-ref link-reveal xref-bibr">124</a>,<span class="xrefLink" id="jumplink-ehae176-B717"></span><a href="javascript:;" reveal-id="ehae176-B717" data-open="ehae176-B717" class="link link-ref link-reveal xref-bibr">717</a></sup> or cardiologist-led.<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a>,<span class="xrefLink" id="jumplink-ehae176-B122"></span><a href="javascript:;" reveal-id="ehae176-B122" data-open="ehae176-B122" class="link link-ref link-reveal xref-bibr">122</a>,<span class="xrefLink" id="jumplink-ehae176-B124"></span><a href="javascript:;" reveal-id="ehae176-B124" data-open="ehae176-B124" class="link link-ref link-reveal xref-bibr">124</a>,<span class="xrefLink" id="jumplink-ehae176-B717"></span><a href="javascript:;" reveal-id="ehae176-B717" data-open="ehae176-B717" class="link link-ref link-reveal xref-bibr">717</a></sup> Several published models used computerized decision support systems or electronic health applications.<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a>,<span class="xrefLink" id="jumplink-ehae176-B122"></span><a href="javascript:;" reveal-id="ehae176-B122" data-open="ehae176-B122" class="link link-ref link-reveal xref-bibr">122</a>,<span class="xrefLink" id="jumplink-ehae176-B715"></span><a href="javascript:;" reveal-id="ehae176-B715" data-open="ehae176-B715" class="link link-ref link-reveal xref-bibr">715</a>,<span class="xrefLink" id="jumplink-ehae176-B718"></span><a href="javascript:;" reveal-id="ehae176-B718" data-open="ehae176-B718" class="link link-ref link-reveal xref-bibr">718</a></sup> Evaluation within RCTs has demonstrated mixed results due to the variety of methods tested and differences in regional care. Several studies report significant improvements with respect to adherence to anticoagulation, cardiovascular mortality, and hospitalization relative to standard of care.<sup><span class="xrefLink" id="jumplink-ehae176-B121 ehae176-B122 ehae176-B123"></span><a href="javascript:;" reveal-id="ehae176-B121 ehae176-B122 ehae176-B123" data-open="ehae176-B121 ehae176-B122 ehae176-B123" class="link link-ref link-reveal xref-bibr">121–123</a></sup> However, the RACE 4 (IntegRAted Chronic Care Program at Specialized AF Clinic Versus Usual CarE in Patients with Atrial Fibrillation) trial, which included 1375 patients, failed to demonstrate superiority of nurse-led over usual care.<sup><span class="xrefLink" id="jumplink-ehae176-B79"></span><a href="javascript:;" reveal-id="ehae176-B79" data-open="ehae176-B79" class="link link-ref link-reveal xref-bibr">79</a></sup> New studies of the components and optimal models for delivery for integrated care approaches in routine practice are ongoing (ACTRN12616001109493, NCT03924739).

### 8.2. Improving treatment adherence

Advances in the care of patients with AF can only be effective if appropriate tools are available to support the implementation of the treatment regimen.<sup><span class="xrefLink" id="jumplink-ehae176-B719"></span><a href="javascript:;" reveal-id="ehae176-B719" data-open="ehae176-B719" class="link link-ref link-reveal xref-bibr">719</a></sup> A number of factors are related to the optimal implementation of care at the level of: (i) the individual patient (culture, cognitive impairment, and psychological status); (ii) the treatment (complexity, side effects, polypharmacy, impact on daily life, and cost); (iii) the healthcare system (access to treatment and multidisciplinary approach); and (iv) the healthcare professional (knowledge, awareness of guidelines, expertise, and communication skills). A collaborative approach to patient care, based upon shared decision-making and goals tailored to individual patient needs, is crucial in promoting ongoing patient adherence to the agreed treatment regimen.<sup><span class="xrefLink" id="jumplink-ehae176-B720"></span><a href="javascript:;" reveal-id="ehae176-B720" data-open="ehae176-B720" class="link link-ref link-reveal xref-bibr">720</a></sup> Even when treatment seems feasible for the individual, patients often lack access to reliable and up-to-date information about risks and benefits of various treatment options, and consequently are not empowered to engage in their own management. A sense of ownership that promotes the achievement of joint goals can be encouraged through the use of educational programmes, websites (such as [https://afibmatters.org](https://afibmatters.org)), app-based tools, and individually tailored treatment protocols which take into account gender, ethnic, socioeconomic, environmental, and work factors. In addition, practical tools (e.g. schedules, apps, brochures, reminders, pillboxes) can help to implement treatment in daily life.<sup><span class="xrefLink" id="jumplink-ehae176-B721"></span><a href="javascript:;" reveal-id="ehae176-B721" data-open="ehae176-B721" class="link link-ref link-reveal xref-bibr">721</a>,<span class="xrefLink" id="jumplink-ehae176-B722"></span><a href="javascript:;" reveal-id="ehae176-B722" data-open="ehae176-B722" class="link link-ref link-reveal xref-bibr">722</a></sup> Regular review by members of the multidisciplinary team enables the evolution of a flexible and responsive management regimen that the patient will find easier to follow.

### 8.3. Cardiac imaging

A TTE is a valuable asset across all four AF-CARE domains when there are changes in the clinical status of an individual patient (_[Figure 13](javascript:;)_).<sup><span class="xrefLink" id="jumplink-ehae176-B723 ehae176-B724 ehae176-B725"></span><a href="javascript:;" reveal-id="ehae176-B723 ehae176-B724 ehae176-B725" data-open="ehae176-B723 ehae176-B724 ehae176-B725" class="link link-ref link-reveal xref-bibr">723–725</a></sup> The key findings to consider from an echocardiogram are any structural heart disease (e.g. valvular disease or left ventricular hypertrophy), impairment of left ventricular function (systolic and/or diastolic to classify heart failure subtype), left atrial dilatation, and right heart dysfunction.<sup><span class="xrefLink" id="jumplink-ehae176-B59"></span><a href="javascript:;" reveal-id="ehae176-B59" data-open="ehae176-B59" class="link link-ref link-reveal xref-bibr">59</a>,<span class="xrefLink" id="jumplink-ehae176-B67"></span><a href="javascript:;" reveal-id="ehae176-B67" data-open="ehae176-B67" class="link link-ref link-reveal xref-bibr">67</a>,<span class="xrefLink" id="jumplink-ehae176-B726"></span><a href="javascript:;" reveal-id="ehae176-B726" data-open="ehae176-B726" class="link link-ref link-reveal xref-bibr">726</a></sup> To counter irregularity when in AF, obtaining measurements in cardiac cycles that follow two similar RR intervals can improve the value of parameters compared with sequential averaging of cardiac cycles.<sup><span class="xrefLink" id="jumplink-ehae176-B723"></span><a href="javascript:;" reveal-id="ehae176-B723" data-open="ehae176-B723" class="link link-ref link-reveal xref-bibr">723</a>,<span class="xrefLink" id="jumplink-ehae176-B727"></span><a href="javascript:;" reveal-id="ehae176-B727" data-open="ehae176-B727" class="link link-ref link-reveal xref-bibr">727</a></sup> Contrast TTE or alternative imaging modalities may be required where image quality is poor, and quantification of left ventricular systolic function is needed for decisions on rate or rhythm control. Other cardiac imaging techniques, such as cardiac magnetic resonance (CMR), CT, TOE, and nuclear imaging can be valuable when: (i) TTE quality is suboptimal for diagnostic purposes; (ii) additional information is needed on structure, substrate, or function; and (iii) to support decisions on interventional procedures (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Figure S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B59"></span><a href="javascript:;" reveal-id="ehae176-B59" data-open="ehae176-B59" class="link link-ref link-reveal xref-bibr">59</a>,<span class="xrefLink" id="jumplink-ehae176-B724"></span><a href="javascript:;" reveal-id="ehae176-B724" data-open="ehae176-B724" class="link link-ref link-reveal xref-bibr">724</a>,<span class="xrefLink" id="jumplink-ehae176-B725"></span><a href="javascript:;" reveal-id="ehae176-B725" data-open="ehae176-B725" class="link link-ref link-reveal xref-bibr">725</a>,<span class="xrefLink" id="jumplink-ehae176-B728"></span><a href="javascript:;" reveal-id="ehae176-B728" data-open="ehae176-B728" class="link link-ref link-reveal xref-bibr">728</a></sup> As with TTE, other types of cardiac imaging can be challenging in the context of AF irregularity or with rapid heart rate, requiring technique-specific modifications when acquiring ECG-gated sequences.<sup><span class="xrefLink" id="jumplink-ehae176-B729 ehae176-B730 ehae176-B731"></span><a href="javascript:;" reveal-id="ehae176-B729 ehae176-B730 ehae176-B731" data-open="ehae176-B729 ehae176-B730 ehae176-B731" class="link link-ref link-reveal xref-bibr">729–731</a></sup>

![Relevance of echocardiography in the AF-CARE pathway.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f13.jpeg?Expires=1728478929&Signature=K3Bs-JM-j7uQmY1GDAwZKDCJxHDHj5piZOL5nZ4nQes~LRiM1XmAZbYeyiVMLrGRf6pH2FruV9Rq85pXs7lAh61IY-tbPMFHrlqlINO8FcIA5qxKNdQUdT4IX4RdkGFouRk2C0ZHf9wYYRwkIUYlGUPEvGfkbrAj8DqZdvPAgEhJ6rhUwYUmYj90Om-WUXRcCUcLxL-6o-d8fk3Xh-u8moMujKRXjwnIq3Ll2yKiLUdv2sKR0bxY3yJYfwRpdNOMqZwqizLzeXKYFIChhsjg6BQHXtF3LxYJx5CSkwz7UmPDUx7T53qccIrQdeqfJYsiIgU5YSTuPrjHvNx24eDMvg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 13

Relevance of echocardiography in the AF-CARE pathway.

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CHA<sub>2</sub>DS<sub>2</sub>\-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; LAA, left atrial appendage; LV, left ventricle.

[Open in new tab](https://academic.oup.com/view-large/figure/479884354/ehae176f13.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f13.jpeg?Expires=1728478929&Signature=ew1Fin9XtTJSV-XUhJivNuCYRSp3NMCdPnssgQLpgzh0Ti-poCbA7GW5DtWAURMxMC18XpdfBED~YdUY8k2FJxSTcA51xzsMJUum6-VgoLR-U2dCkQWbu8swE-6pqT7IuycC3CNrW3iqRWIS3owKvIaNWMy~hImiKBjmH6bbmSN8klqrNFy6oe4L7nlpZHSBOeWXk5Xrhl2pGRZCsFAu2OawcizO82iX7-DOo9kZlZpLYtbilIW-jbRfMoBiZJiPb6keCrVM429B6cyDjCowt7Cc0E~zV6QC1WQEP51dFfkUZQuRKRfagDjph9b93vFYt7Gq4FYLYnmLvbMiIRBxcQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884354&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

### 8.4. Patient-reported outcome measures

Patients with AF have a lower quality of life compared with the general population.<sup><span class="xrefLink" id="jumplink-ehae176-B732"></span><a href="javascript:;" reveal-id="ehae176-B732" data-open="ehae176-B732" class="link link-ref link-reveal xref-bibr">732</a></sup> Improvement in quality of life and functional status should play a key role in assessing and reassessing treatment decisions (see [Supplementary data online, Additional Evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  _[Table S26](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B36"></span><a href="javascript:;" reveal-id="ehae176-B36" data-open="ehae176-B36" class="link link-ref link-reveal xref-bibr">36</a></sup> Patient-reported outcome measures are valuable to measure quality of life, functional status, symptoms, and treatment burden for patients with AF over time.<sup><span class="xrefLink" id="jumplink-ehae176-B55"></span><a href="javascript:;" reveal-id="ehae176-B55" data-open="ehae176-B55" class="link link-ref link-reveal xref-bibr">55</a>,<span class="xrefLink" id="jumplink-ehae176-B733 ehae176-B734 ehae176-B735"></span><a href="javascript:;" reveal-id="ehae176-B733 ehae176-B734 ehae176-B735" data-open="ehae176-B733 ehae176-B734 ehae176-B735" class="link link-ref link-reveal xref-bibr">733–735</a></sup> Patient-reported outcome measures are playing an increasing role in clinical trials to assess the success of treatment; however, they remain under-utilized.<sup><span class="xrefLink" id="jumplink-ehae176-B736"></span><a href="javascript:;" reveal-id="ehae176-B736" data-open="ehae176-B736" class="link link-ref link-reveal xref-bibr">736</a>,<span class="xrefLink" id="jumplink-ehae176-B737"></span><a href="javascript:;" reveal-id="ehae176-B737" data-open="ehae176-B737" class="link link-ref link-reveal xref-bibr">737</a></sup> They can be divided into generic or disease-specific tools, with the latter helping to provide insight into AF-related impacts.<sup><span class="xrefLink" id="jumplink-ehae176-B738"></span><a href="javascript:;" reveal-id="ehae176-B738" data-open="ehae176-B738" class="link link-ref link-reveal xref-bibr">738</a></sup> However, multimorbidity can still confound the sensitivity of all PROMs, impacting on association with other established metrics of treatment performance such as mEHRA symptom class and natriuretic peptides.<sup><span class="xrefLink" id="jumplink-ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B48" data-open="ehae176-B48" class="link link-ref link-reveal xref-bibr">48</a></sup> Intervention studies have demonstrated an association between improvement in PROM scores and reduction in AF burden and symptoms.<sup><span class="xrefLink" id="jumplink-ehae176-B48"></span><a href="javascript:;" reveal-id="ehae176-B48" data-open="ehae176-B48" class="link link-ref link-reveal xref-bibr">48</a>,<span class="xrefLink" id="jumplink-ehae176-B738"></span><a href="javascript:;" reveal-id="ehae176-B738" data-open="ehae176-B738" class="link link-ref link-reveal xref-bibr">738</a></sup>

Atrial fibrillation-specific questionnaires include the AF 6 (AF6),<sup><span class="xrefLink" id="jumplink-ehae176-B739"></span><a href="javascript:;" reveal-id="ehae176-B739" data-open="ehae176-B739" class="link link-ref link-reveal xref-bibr">739</a></sup> Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT),<sup><span class="xrefLink" id="jumplink-ehae176-B740"></span><a href="javascript:;" reveal-id="ehae176-B740" data-open="ehae176-B740" class="link link-ref link-reveal xref-bibr">740</a></sup> the Atrial Fibrillation Quality of Life Questionnaire (AFQLQ),<sup><span class="xrefLink" id="jumplink-ehae176-B741"></span><a href="javascript:;" reveal-id="ehae176-B741" data-open="ehae176-B741" class="link link-ref link-reveal xref-bibr">741</a></sup> the Atrial Fibrillation Quality of Life (AF-QoL),<sup><span class="xrefLink" id="jumplink-ehae176-B742"></span><a href="javascript:;" reveal-id="ehae176-B742" data-open="ehae176-B742" class="link link-ref link-reveal xref-bibr">742</a></sup> and the Quality of Life in Atrial Fibrillation (QLAF).<sup><span class="xrefLink" id="jumplink-ehae176-B743"></span><a href="javascript:;" reveal-id="ehae176-B743" data-open="ehae176-B743" class="link link-ref link-reveal xref-bibr">743</a></sup> The measurement properties of most of these tools lack sufficient validation.<sup><span class="xrefLink" id="jumplink-ehae176-B49"></span><a href="javascript:;" reveal-id="ehae176-B49" data-open="ehae176-B49" class="link link-ref link-reveal xref-bibr">49</a></sup> The International Consortium for Health Outcomes Measurement (ICHOM) working group recommends the use of the AFEQT PROM or a symptom questionnaire called the Atrial Fibrillation Severity Scale (AFSS) for measuring exercise tolerance and the impact of symptoms in AF.<sup><span class="xrefLink" id="jumplink-ehae176-B744"></span><a href="javascript:;" reveal-id="ehae176-B744" data-open="ehae176-B744" class="link link-ref link-reveal xref-bibr">744</a></sup> Through wider use of patient experience measures, there is an opportunity at the institutional level to improve the quality of care delivered to patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B49 ehae176-B50 ehae176-B51 ehae176-B52 ehae176-B53 ehae176-B54 ehae176-B55"></span><a href="javascript:;" reveal-id="ehae176-B49 ehae176-B50 ehae176-B51 ehae176-B52 ehae176-B53 ehae176-B54 ehae176-B55" data-open="ehae176-B49 ehae176-B50 ehae176-B51 ehae176-B52 ehae176-B53 ehae176-B54 ehae176-B55" class="link link-ref link-reveal xref-bibr">49–55</a></sup>

Recommendation Table 23

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884358)

Recommendations to improve patient experience (see also Evidence Table 23)

![Recommendations to improve patient experience (see also Evidence Table 23)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt23.jpeg?Expires=1728478929&Signature=3RBXaWsps45dcMNtehck62CTBKam9~RoChyQqZoxmWija-sc1KdJMGNyekDn-tMFsbaTDkumTdkoHNGBzeQVcfvgcTA--DeYexOYNOF7JwGRLvd3kZKnrsZeR0Zfq2iYyzvBPIj0ZWLJ7R66L4-6mMX67r-Yvbkzo9Pgtwp8~M~S3fHsDTfDzO6JtAoq4VLS1kaEawlr8IMvpDbrr9-QsPpK8DKQh~-M8qRapEhbMKcoP9RJUAd8OR4PMlAZjCQodQMSpgTI42yuKo3DBhXs9ezEVaWKwbqZMCYIqii7Ceky07psFnDbot9jbnZyNs5wwqAnXvSKNjcua7GAT2TZJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 23

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884358)

Recommendations to improve patient experience (see also Evidence Table 23)

![Recommendations to improve patient experience (see also Evidence Table 23)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt23.jpeg?Expires=1728478929&Signature=3RBXaWsps45dcMNtehck62CTBKam9~RoChyQqZoxmWija-sc1KdJMGNyekDn-tMFsbaTDkumTdkoHNGBzeQVcfvgcTA--DeYexOYNOF7JwGRLvd3kZKnrsZeR0Zfq2iYyzvBPIj0ZWLJ7R66L4-6mMX67r-Yvbkzo9Pgtwp8~M~S3fHsDTfDzO6JtAoq4VLS1kaEawlr8IMvpDbrr9-QsPpK8DKQh~-M8qRapEhbMKcoP9RJUAd8OR4PMlAZjCQodQMSpgTI42yuKo3DBhXs9ezEVaWKwbqZMCYIqii7Ceky07psFnDbot9jbnZyNs5wwqAnXvSKNjcua7GAT2TZJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 9\. The AF-CARE pathway in specific clinical settings

The following sections detail specific clinical settings where approaches to AF-CARE may vary. Unless specially discussed, measures for \[C\] comorbidity and risk factor management, \[A\] avoidance of stroke and thromboembolism, \[R\] rate and rhythm control, and \[E\] evaluation and dynamic reassessment should follow the standard pathways introduced in _Section [4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s3)_.

### 9.1. AF-CARE in unstable patients

Unstable patients with AF include those with haemodynamic instability caused by the arrhythmia or acute cardiac conditions, and severely ill patients who develop AF (sepsis, trauma, surgery, and particularly cancer-related surgery). Conditions such as sepsis, adrenergic overstimulation, and electrolyte disturbances contribute to onset and recurrence of AF in these patients. Spontaneous restoration of sinus rhythm has been reported in up to 83% during the first 48 h after appropriate treatment of the underlying cause.<sup><span class="xrefLink" id="jumplink-ehae176-B551"></span><a href="javascript:;" reveal-id="ehae176-B551" data-open="ehae176-B551" class="link link-ref link-reveal xref-bibr">551</a>,<span class="xrefLink" id="jumplink-ehae176-B745"></span><a href="javascript:;" reveal-id="ehae176-B745" data-open="ehae176-B745" class="link link-ref link-reveal xref-bibr">745</a></sup>

Emergency electrical cardioversion is still considered the first-choice treatment if sinus rhythm is thought to be beneficial, despite the limitation of having a high rate of immediate relapse.<sup><span class="xrefLink" id="jumplink-ehae176-B746"></span><a href="javascript:;" reveal-id="ehae176-B746" data-open="ehae176-B746" class="link link-ref link-reveal xref-bibr">746</a></sup> Amiodarone is a second-line option because of its delayed activity; however, it may be an appropriate alternative in the acute setting.<sup><span class="xrefLink" id="jumplink-ehae176-B747"></span><a href="javascript:;" reveal-id="ehae176-B747" data-open="ehae176-B747" class="link link-ref link-reveal xref-bibr">747</a>,<span class="xrefLink" id="jumplink-ehae176-B748"></span><a href="javascript:;" reveal-id="ehae176-B748" data-open="ehae176-B748" class="link link-ref link-reveal xref-bibr">748</a></sup> In a multicentre cohort study carried out in the United Kingdom and the United States of America, amiodarone and beta-blockers were similarly effective for rate control in intensive care patients, and superior to digoxin and calcium channel blockers.<sup><span class="xrefLink" id="jumplink-ehae176-B749"></span><a href="javascript:;" reveal-id="ehae176-B749" data-open="ehae176-B749" class="link link-ref link-reveal xref-bibr">749</a></sup> The ultra-short acting and highly selective beta-blocker landiolol can safely control rapid AF in patients with low ejection fraction and acutely decompensated heart failure, with a limited impact on myocardial contractility or blood pressure.<sup><span class="xrefLink" id="jumplink-ehae176-B477"></span><a href="javascript:;" reveal-id="ehae176-B477" data-open="ehae176-B477" class="link link-ref link-reveal xref-bibr">477</a>,<span class="xrefLink" id="jumplink-ehae176-B750"></span><a href="javascript:;" reveal-id="ehae176-B750" data-open="ehae176-B750" class="link link-ref link-reveal xref-bibr">750</a>,<span class="xrefLink" id="jumplink-ehae176-B751"></span><a href="javascript:;" reveal-id="ehae176-B751" data-open="ehae176-B751" class="link link-ref link-reveal xref-bibr">751</a></sup>

### 9.2. AF-CARE in acute and chronic coronary syndromes

The incidence of AF in acute coronary syndromes (ACS) ranges from 2% to 23%.<sup><span class="xrefLink" id="jumplink-ehae176-B752"></span><a href="javascript:;" reveal-id="ehae176-B752" data-open="ehae176-B752" class="link link-ref link-reveal xref-bibr">752</a></sup> The risk of new-onset AF is increased by 60%–77% in patients suffering an MI,<sup><span class="xrefLink" id="jumplink-ehae176-B753"></span><a href="javascript:;" reveal-id="ehae176-B753" data-open="ehae176-B753" class="link link-ref link-reveal xref-bibr">753</a></sup> and AF may be associated with an increased risk of ST-segment elevation myocardial infarction (STEMI) or non-STEMI ACS.<sup><span class="xrefLink" id="jumplink-ehae176-B754"></span><a href="javascript:;" reveal-id="ehae176-B754" data-open="ehae176-B754" class="link link-ref link-reveal xref-bibr">754</a></sup> Overall, 10%–15% of AF patients undergo percutaneous intervention (PCI) for CAD.<sup><span class="xrefLink" id="jumplink-ehae176-B755"></span><a href="javascript:;" reveal-id="ehae176-B755" data-open="ehae176-B755" class="link link-ref link-reveal xref-bibr">755</a></sup> In addition, AF is a common precipitant for type 2 MI.<sup><span class="xrefLink" id="jumplink-ehae176-B756"></span><a href="javascript:;" reveal-id="ehae176-B756" data-open="ehae176-B756" class="link link-ref link-reveal xref-bibr">756</a></sup> Observational studies show that patients with both ACS and AF are less likely to receive appropriate antithrombotic therapy<sup><span class="xrefLink" id="jumplink-ehae176-B757"></span><a href="javascript:;" reveal-id="ehae176-B757" data-open="ehae176-B757" class="link link-ref link-reveal xref-bibr">757</a></sup> and more likely to experience adverse outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B758"></span><a href="javascript:;" reveal-id="ehae176-B758" data-open="ehae176-B758" class="link link-ref link-reveal xref-bibr">758</a></sup> Peri-procedural management of patients with ACS or chronic coronary syndromes (CCS) are detailed in the _2023 ESC Guidelines for the management of acute coronary syndromes_ and _2024 ESC Guidelines for the management of chronic coronary syndromes_.<sup><span class="xrefLink" id="jumplink-ehae176-B759"></span><a href="javascript:;" reveal-id="ehae176-B759" data-open="ehae176-B759" class="link link-ref link-reveal xref-bibr">759</a>,<span class="xrefLink" id="jumplink-ehae176-B760"></span><a href="javascript:;" reveal-id="ehae176-B760" data-open="ehae176-B760" class="link link-ref link-reveal xref-bibr">760</a></sup>

The combination of AF with ACS is the area where use of multiple antithrombotic drugs is most frequently indicated, consisting of antiplatelet agents plus OAC (_[Figure 14](javascript:;)_) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S27](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). There is a general trend to decrease the duration of DAPT to reduce bleeding; however, this may increase ischaemic events and stent thrombosis.<sup><span class="xrefLink" id="jumplink-ehae176-B761"></span><a href="javascript:;" reveal-id="ehae176-B761" data-open="ehae176-B761" class="link link-ref link-reveal xref-bibr">761</a>,<span class="xrefLink" id="jumplink-ehae176-B762"></span><a href="javascript:;" reveal-id="ehae176-B762" data-open="ehae176-B762" class="link link-ref link-reveal xref-bibr">762</a></sup> In ACS there is a high risk of predominantly platelet-driven atherothrombosis and thus of coronary ischaemic events. Acute coronary syndromes treated by PCI require DAPT for improved short- and long-term prognosis. Therefore, a peri-procedural triple antithrombotic regimen including an OAC, aspirin, and a P2Y<sub>12</sub> inhibitor should be the default strategy for most patients. Major thrombotic events vs. major bleeding risk need to be balanced when prescribing antiplatelet therapy and OAC after the acute phase and/or after PCI. The combination of OAC (preferably a DOAC) and a P2Y<sub>12</sub> inhibitor results in less major bleeding than triple therapy that includes aspirin. Clopidogrel is the preferred P2Y<sub>12</sub> inhibitor, as the evidence for ticagrelor and prasugrel is less clear with higher bleeding risk.<sup><span class="xrefLink" id="jumplink-ehae176-B763 ehae176-B764 ehae176-B765 ehae176-B766 ehae176-B767 ehae176-B768 ehae176-B769"></span><a href="javascript:;" reveal-id="ehae176-B763 ehae176-B764 ehae176-B765 ehae176-B766 ehae176-B767 ehae176-B768 ehae176-B769" data-open="ehae176-B763 ehae176-B764 ehae176-B765 ehae176-B766 ehae176-B767 ehae176-B768 ehae176-B769" class="link link-ref link-reveal xref-bibr">763–769</a></sup> Ongoing trials will add to our knowledge about safely combining DOACs with antiplatelet agents (NCT04981041, NCT04436978). When using VKAs with antiplatelet agents, there is consensus opinion to use an INR range of 2.0–2.5 to mitigate excess bleeding risk.

![Antithrombotic therapy in patients with AF and acute or chronic coronary syndromes.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f14.jpeg?Expires=1728478929&Signature=Yzw2~hkelfsBJmq9jcJyDWci73lZ5nv0-T8PVSvhlStgygpOtdOPHg98QbPVnEe24-rGtTgQHMEHLxrvaHSUSzcLHdmNniHJTSHo-PII62GP90zjK-hpyKm4mmei3QhDZcQjWIIV7ibAYwWgIJCYzmsZ4WYEMfljmh6xdwAPP2PkNI1XECMkQ9-dT4hGtNWIY4aGje4Botv7cF76BsKjQtPMuzvMa6TbJwl9fU4VX5mmSrpb86EWbELGAS5mmvK5nccWGv3ghYm4eL3RAXhT0JuWwIa8nOo-ibOXLKPuCiXcwdAwoO3~1R3Kxyx6Skv8y-JBsMr~TTr4rfqCFS6mvA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 14

Antithrombotic therapy in patients with AF and acute or chronic coronary syndromes.

ACS, acute coronary syndromes; CCS, chronic coronary syndrome; DOAC, direct oral anticoagulant; INR, international normalized ratio of prothrombin time; OAC, oral anticoagulant; P2Y<sub>12</sub>i, P2Y<sub>12</sub>\-receptor inhibitor antiplatelet agents (clopidogrel, prasugrel, ticagrelor); PCI, percutaneous intervention; TTR, time in therapeutic range; VKA, vitamin K antagonist. The flowchart applies to those patients with an indication for oral anticoagulant therapy. <sup>a</sup>The full standard dose of DOACs should be used unless the patient fulfils dose-reduction criteria (_[Table 11](javascript:;)_). When rivaroxaban or dabigatran are used as the DOAC and concerns about bleeding risk prevail over stent thrombosis or ischaemic stroke, the reduced dose should be considered (15 mg and 110 mg respectively; Class IIa). <sup>b</sup>In patients with diabetes mellitus undergoing coronary stent implantation, prolonging triple antithrombotic therapy for up to 3 months may be of value if thrombotic risk outweighs the bleeding risk.

[Open in new tab](https://academic.oup.com/view-large/figure/479884367/ehae176f14.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f14.jpeg?Expires=1728478929&Signature=nb34nQSLhXdOKX0rjtD3WbHmiDO9FE-ZkpoloJqQvbmKHU3Z04ILDWdqZf5iw-6HEfL1in9lbAlqp~p8KU2yu8U~Pvw0CtR5~AqNBe7IiNF~LTRLN6zwbPB-LRFiHPiy9OxOwFgKPiysWuMg-jCMsMRqDm34Z2jSAtgDw5lMvjdp7TBK0~GOUawCGBbDaxOf3SWL63IbiJZpHPHrzSingcOFyv98uDifaUG9rHk~X3mMSGRajaEnGPnT-40WnKtpBFldSrg40PAzfcYMDhrlmHFmhOUcz7-JgvXQsGeIjv6EmhZGyJKYoypJ6AwJYz3m9Ip9CwmI3bt1eeI4QYlzLw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884367&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Short–term triple therapy (≤1 week) is recommended for all patients without diabetes after ACS or PCI. In pooled analyses of RCTs, omitting aspirin in patients with ACS undergoing PCI has the potential for higher rates of ischaemic/stent thrombosis, without impact on incident stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B761"></span><a href="javascript:;" reveal-id="ehae176-B761" data-open="ehae176-B761" class="link link-ref link-reveal xref-bibr">761</a>,<span class="xrefLink" id="jumplink-ehae176-B762"></span><a href="javascript:;" reveal-id="ehae176-B762" data-open="ehae176-B762" class="link link-ref link-reveal xref-bibr">762</a>,<span class="xrefLink" id="jumplink-ehae176-B770 ehae176-B771 ehae176-B772"></span><a href="javascript:;" reveal-id="ehae176-B770 ehae176-B771 ehae176-B772" data-open="ehae176-B770 ehae176-B771 ehae176-B772" class="link link-ref link-reveal xref-bibr">770–772</a></sup> None of the trials were powered for ischaemic events. All patients in AUGUSTUS (an open–label, 2 × 2 factorial, randomized controlled clinical trial to evaluate the safety of apixaban vs. vitamin k antagonist and aspirin vs. aspirin placebo in patients with AF and ACS or PCI) received aspirin plus a P2Y<sub>12</sub> inhibitor for a median time of 6 days.<sup><span class="xrefLink" id="jumplink-ehae176-B773"></span><a href="javascript:;" reveal-id="ehae176-B773" data-open="ehae176-B773" class="link link-ref link-reveal xref-bibr">773</a></sup> At the end of the trial, apixaban and a P2Y<sub>12</sub> inhibitor without aspirin was the optimal treatment regimen for most patients with AF and ACS and/or PCI, irrespective of the patient's baseline bleeding and stroke risk.<sup><span class="xrefLink" id="jumplink-ehae176-B774"></span><a href="javascript:;" reveal-id="ehae176-B774" data-open="ehae176-B774" class="link link-ref link-reveal xref-bibr">774</a>,<span class="xrefLink" id="jumplink-ehae176-B775"></span><a href="javascript:;" reveal-id="ehae176-B775" data-open="ehae176-B775" class="link link-ref link-reveal xref-bibr">775</a></sup>

Prolonged triple therapy up to 1 month after ACS/PCI should be considered in patients at high ischaemic risk, e.g. STEMI, prior stent thrombosis, complex coronary procedures, and prolonged cardiac instability, even though these patients were not adequately represented in the RCTs so far available.<sup><span class="xrefLink" id="jumplink-ehae176-B776"></span><a href="javascript:;" reveal-id="ehae176-B776" data-open="ehae176-B776" class="link link-ref link-reveal xref-bibr">776</a></sup> In AF patients with ACS or CCS and diabetes mellitus undergoing coronary stent implantation, prolonging triple therapy with low-dose aspirin, clopidogrel, and an OAC up to 3 months may be of benefit if thrombotic risk outweighs bleeding risk in the individual patient.<sup><span class="xrefLink" id="jumplink-ehae176-B207"></span><a href="javascript:;" reveal-id="ehae176-B207" data-open="ehae176-B207" class="link link-ref link-reveal xref-bibr">207</a></sup>

The evidence for ACS treated without revascularization is limited. Six to 12 months of a single antiplatelet agent in addition to a long-term DOAC is usually sufficient and can minimize bleeding risk.<sup><span class="xrefLink" id="jumplink-ehae176-B760"></span><a href="javascript:;" reveal-id="ehae176-B760" data-open="ehae176-B760" class="link link-ref link-reveal xref-bibr">760</a>,<span class="xrefLink" id="jumplink-ehae176-B764"></span><a href="javascript:;" reveal-id="ehae176-B764" data-open="ehae176-B764" class="link link-ref link-reveal xref-bibr">764</a>,<span class="xrefLink" id="jumplink-ehae176-B774"></span><a href="javascript:;" reveal-id="ehae176-B774" data-open="ehae176-B774" class="link link-ref link-reveal xref-bibr">774</a></sup> Although there are no head-to-head comparisons between aspirin and clopidogrel, studies have typically used clopidogrel. In patients with stable CCS for more than 12 months, sole therapy with a DOAC is sufficient and no additional antiplatelet therapy is required.<sup><span class="xrefLink" id="jumplink-ehae176-B353"></span><a href="javascript:;" reveal-id="ehae176-B353" data-open="ehae176-B353" class="link link-ref link-reveal xref-bibr">353</a></sup> In patients at potential risk of gastrointestinal bleeding, use of proton pump inhibitors is reasonable during combined antithrombotic therapy, although evidence in AF patients is limited.<sup><span class="xrefLink" id="jumplink-ehae176-B437"></span><a href="javascript:;" reveal-id="ehae176-B437" data-open="ehae176-B437" class="link link-ref link-reveal xref-bibr">437</a>,<span class="xrefLink" id="jumplink-ehae176-B777 ehae176-B778 ehae176-B779"></span><a href="javascript:;" reveal-id="ehae176-B777 ehae176-B778 ehae176-B779" data-open="ehae176-B777 ehae176-B778 ehae176-B779" class="link link-ref link-reveal xref-bibr">777–779</a></sup> Multimorbid patients with ACS or CCS need careful assessment of ischaemic risk and management of modifiable bleeding risk factors, with a comprehensive work-up to individually adapt antithrombotic therapy.

Recommendation Table 24

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884371)

Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24)

![Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt24.jpeg?Expires=1728478929&Signature=1KqML8y4Mpfbey6F5nbv87qyqKf3m8j~lctuTurpN-KpfdEkRArHC8xPXwJJscKItyhK7nOj-1ozv-VDqTjAflCVffi0bJHJzmyUdxqnW8veNT7gMXUtmPoSkB633xcUeIj~GUz9opm7IiLWuhLiRJdDqkeOiE6Sk9~MDsrUYanbjUOcGLoisWdUYB-Lu7GkMeOCLN7XdFv1ykicoFAmfHyZBPZAVgE8PuZpAfGURpLW0dlVGOR0Q4r9Ij1iWmr2WC5dzLU2nX54acLDcJOcl3H5yZitCsH06U8tpobo0O0LG3SAy7-F2pcBAsc8HVvfu2o5EEZ9Yyacg2H3-ZYI5Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 24

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884371)

Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24)

![Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention (see also Evidence Table 24)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt24.jpeg?Expires=1728478929&Signature=1KqML8y4Mpfbey6F5nbv87qyqKf3m8j~lctuTurpN-KpfdEkRArHC8xPXwJJscKItyhK7nOj-1ozv-VDqTjAflCVffi0bJHJzmyUdxqnW8veNT7gMXUtmPoSkB633xcUeIj~GUz9opm7IiLWuhLiRJdDqkeOiE6Sk9~MDsrUYanbjUOcGLoisWdUYB-Lu7GkMeOCLN7XdFv1ykicoFAmfHyZBPZAVgE8PuZpAfGURpLW0dlVGOR0Q4r9Ij1iWmr2WC5dzLU2nX54acLDcJOcl3H5yZitCsH06U8tpobo0O0LG3SAy7-F2pcBAsc8HVvfu2o5EEZ9Yyacg2H3-ZYI5Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.3. AF-CARE in vascular disease

Peripheral arterial disease (PAD) is common in patients with AF, ranging from 6.7% to 14% of patients.<sup><span class="xrefLink" id="jumplink-ehae176-B783"></span><a href="javascript:;" reveal-id="ehae176-B783" data-open="ehae176-B783" class="link link-ref link-reveal xref-bibr">783</a>,<span class="xrefLink" id="jumplink-ehae176-B784"></span><a href="javascript:;" reveal-id="ehae176-B784" data-open="ehae176-B784" class="link link-ref link-reveal xref-bibr">784</a></sup> Manifest PAD is associated with incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup> PAD predicts a higher mortality in patients with AF and is an independent predictor of stroke in those not on OAC.<sup><span class="xrefLink" id="jumplink-ehae176-B783"></span><a href="javascript:;" reveal-id="ehae176-B783" data-open="ehae176-B783" class="link link-ref link-reveal xref-bibr">783</a>,<span class="xrefLink" id="jumplink-ehae176-B786"></span><a href="javascript:;" reveal-id="ehae176-B786" data-open="ehae176-B786" class="link link-ref link-reveal xref-bibr">786</a></sup> Patients with lower extremity artery disease and AF also have a higher overall mortality and risk of major cardiac events.<sup><span class="xrefLink" id="jumplink-ehae176-B784"></span><a href="javascript:;" reveal-id="ehae176-B784" data-open="ehae176-B784" class="link link-ref link-reveal xref-bibr">784</a>,<span class="xrefLink" id="jumplink-ehae176-B787"></span><a href="javascript:;" reveal-id="ehae176-B787" data-open="ehae176-B787" class="link link-ref link-reveal xref-bibr">787</a>,<span class="xrefLink" id="jumplink-ehae176-B788"></span><a href="javascript:;" reveal-id="ehae176-B788" data-open="ehae176-B788" class="link link-ref link-reveal xref-bibr">788</a></sup> A public health database of >40 000 patients hospitalized for PAD or critical limb ischaemia showed AF to be an independent predictor for mortality (HR, 1.46; 95% CI, 1.39–1.52) and ischaemic stroke (HR, 1.63; 95% CI, 1.44–1.85) as compared with propensity-matched controls.<sup><span class="xrefLink" id="jumplink-ehae176-B784"></span><a href="javascript:;" reveal-id="ehae176-B784" data-open="ehae176-B784" class="link link-ref link-reveal xref-bibr">784</a></sup> Similarly, in patients undergoing carotid endarterectomy or stenting, the presence of AF is associated with higher mortality (OR, 1.59; 95% CI, 1.11–2.26).<sup><span class="xrefLink" id="jumplink-ehae176-B789"></span><a href="javascript:;" reveal-id="ehae176-B789" data-open="ehae176-B789" class="link link-ref link-reveal xref-bibr">789</a></sup>

Anticoagulation alone is usually sufficient in the chronic disease phase, with DOACs being the preferred agents despite one RCT subanalysis showing a higher risk of bleeding as compared with warfarin.<sup><span class="xrefLink" id="jumplink-ehae176-B790"></span><a href="javascript:;" reveal-id="ehae176-B790" data-open="ehae176-B790" class="link link-ref link-reveal xref-bibr">790</a></sup> In the case of recent endovascular revascularization, a period of combination with single antiplatelet therapy should be considered, weighing bleeding and thrombotic risks and keeping the period of combination antithrombotic therapy as brief as possible (ranging between 1 month for peripheral<sup><span class="xrefLink" id="jumplink-ehae176-B791"></span><a href="javascript:;" reveal-id="ehae176-B791" data-open="ehae176-B791" class="link link-ref link-reveal xref-bibr">791</a></sup> and 90 days for neuro-interventional procedures).<sup><span class="xrefLink" id="jumplink-ehae176-B792"></span><a href="javascript:;" reveal-id="ehae176-B792" data-open="ehae176-B792" class="link link-ref link-reveal xref-bibr">792</a></sup>

### 9.4. AF-CARE in acute stroke or intracranial haemorrhage

#### 9.4.1. Management of acute ischaemic stroke

Management of acute stroke in patients with AF is beyond the scope of these guidelines. In AF patients presenting with acute ischaemic stroke while taking OAC, acute therapy depends on the treatment regimen and intensity of OAC. Management should be co-ordinated by a specialist neurologist team according to relevant guidelines.<sup><span class="xrefLink" id="jumplink-ehae176-B793"></span><a href="javascript:;" reveal-id="ehae176-B793" data-open="ehae176-B793" class="link link-ref link-reveal xref-bibr">793</a></sup>

#### 9.4.2. Introduction or re-introduction of anticoagulation after ischaemic stroke

The optimal time for administering OAC in patients with acute cardioembolic stroke and AF remains unclear. Randomized control trials have been unable to provide any evidence to support the administration of anticoagulants or heparin in patients with acute ischaemic stroke within 48 h from stroke onset. This suggests that low-dose aspirin should be administered to all patients during this timeframe.<sup><span class="xrefLink" id="jumplink-ehae176-B794"></span><a href="javascript:;" reveal-id="ehae176-B794" data-open="ehae176-B794" class="link link-ref link-reveal xref-bibr">794</a></sup>

Two trials have examined the use of DOAC therapy early after stroke, with no difference in clinical outcomes compared with delayed DOAC prescription. The ELAN (Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN) trial randomized 2013 patients with acute ischaemic stroke and AF to open-label early use of DOACs (<48 h after minor/moderate stroke; day 6–7 after major stroke) vs. later DOAC prescription (day 3–4 after minor stroke; day 6–7 after moderate stroke; day 12–14 after major stroke). There was no significant difference in the composite thromboembolic, bleeding, and vascular death outcome at 30 days (risk difference early vs. late, −1.18%; 95% CI, −2.84 to 0.47).<sup><span class="xrefLink" id="jumplink-ehae176-B795"></span><a href="javascript:;" reveal-id="ehae176-B795" data-open="ehae176-B795" class="link link-ref link-reveal xref-bibr">795</a></sup> The TIMING (Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation) trial, a registry-based, non-inferiority, open-label, blinded endpoint trial randomized 888 patients within 72 h of ischaemic stroke onset to early (≤4 days) or delayed (5–10 days) DOAC initiation. Early DOAC use was non-inferior to the delayed strategy for the composite of thromboembolism, bleeding and all-cause mortality at 90 days (risk difference, −1.79%; 95% CI, −5.31% to 1.74%).<sup><span class="xrefLink" id="jumplink-ehae176-B796"></span><a href="javascript:;" reveal-id="ehae176-B796" data-open="ehae176-B796" class="link link-ref link-reveal xref-bibr">796</a></sup> Two ongoing trials will provide further guidance on the most appropriate timing of DOAC therapy after ischaemic stroke (NCT03759938, NCT03021928).

#### 9.4.3. Introduction or re-introduction of anticoagulation after haemorrhagic stroke

There is insufficient evidence currently to recommend whether OAC should be started or re-started after ICH to protect against the high risk of ischaemic stroke in these patients (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S28](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Data from two pilot trials are available. The APACHE-AF (Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation) trial was a prospective, randomized, open-label trial with masked endpoint assessment; 101 patients who survived 7–90 days after anticoagulation-associated ICH were randomized to apixaban or no OAC. During a median of 1.9 years follow-up (222 person-years), there was no difference in non-fatal stroke or vascular death, with an annual event rate of 12.6% with apixaban and 11.9% with no OAC (adjusted HR, 1.05; 95% CI, 0.48–2.31; _P_ = .90).<sup><span class="xrefLink" id="jumplink-ehae176-B797"></span><a href="javascript:;" reveal-id="ehae176-B797" data-open="ehae176-B797" class="link link-ref link-reveal xref-bibr">797</a></sup> SoSTART (Start or STop Anticoagulants Randomised Trial) was an open-label RCT in 203 patients with AF after symptomatic spontaneous ICH. Starting OAC was not non-inferior to avoiding long-term (≥1 year) OAC, with ICH recurrence in 8/101 (8%) vs. 4/102 (4%) patients (adjusted HR, 2.42; 95% CI, 0.72–8.09). Mortality occurred in 22/101 (22%) patients in the OAC group vs. 11/102 (11%) patients where OAC were avoided.<sup><span class="xrefLink" id="jumplink-ehae176-B798"></span><a href="javascript:;" reveal-id="ehae176-B798" data-open="ehae176-B798" class="link link-ref link-reveal xref-bibr">798</a></sup>

Until additional trials report on the clinical challenge of post-ICH anticoagulation (NCT03950076, NCT03996772), an individualized multidisciplinary approach is advised led by an expert neurology team.

### 9.5. AF-CARE for trigger-induced AF

Trigger-induced AF is defined as new AF in the immediate association of a precipitating and potentially reversible factor. Also known as ‘secondary’ AF, this task force prefer the term trigger-induced as there are almost always underlying factors in individual patients that can benefit from full consideration of the AF-CARE pathway. The most common precipitant unmasking a tendency to AF is acute sepsis, where AF prevalence is between 9% and 20% and has been associated with a worse prognosis.<sup><span class="xrefLink" id="jumplink-ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14"></span><a href="javascript:;" reveal-id="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" data-open="ehae176-B11 ehae176-B12 ehae176-B13 ehae176-B14" class="link link-ref link-reveal xref-bibr">11–14</a></sup> The degree of inflammation correlates with the incidence of AF,<sup><span class="xrefLink" id="jumplink-ehae176-B799"></span><a href="javascript:;" reveal-id="ehae176-B799" data-open="ehae176-B799" class="link link-ref link-reveal xref-bibr">799</a></sup> which may partly explain the wide variability across studies in prevalence, as well as recurrence of AF. Longer-term data suggest that AF triggered by sepsis recurs after discharge in between a third to a half of patients.<sup><span class="xrefLink" id="jumplink-ehae176-B12"></span><a href="javascript:;" reveal-id="ehae176-B12" data-open="ehae176-B12" class="link link-ref link-reveal xref-bibr">12</a>,<span class="xrefLink" id="jumplink-ehae176-B800 ehae176-B801 ehae176-B802 ehae176-B803 ehae176-B804 ehae176-B805 ehae176-B806 ehae176-B807"></span><a href="javascript:;" reveal-id="ehae176-B800 ehae176-B801 ehae176-B802 ehae176-B803 ehae176-B804 ehae176-B805 ehae176-B806 ehae176-B807" data-open="ehae176-B800 ehae176-B801 ehae176-B802 ehae176-B803 ehae176-B804 ehae176-B805 ehae176-B806 ehae176-B807" class="link link-ref link-reveal xref-bibr">800–807</a></sup> In addition to other acute triggers which may be causal (such as alcohol<sup><span class="xrefLink" id="jumplink-ehae176-B808"></span><a href="javascript:;" reveal-id="ehae176-B808" data-open="ehae176-B808" class="link link-ref link-reveal xref-bibr">808</a>,<span class="xrefLink" id="jumplink-ehae176-B809"></span><a href="javascript:;" reveal-id="ehae176-B809" data-open="ehae176-B809" class="link link-ref link-reveal xref-bibr">809</a></sup> and illicit drug use<sup><span class="xrefLink" id="jumplink-ehae176-B810"></span><a href="javascript:;" reveal-id="ehae176-B810" data-open="ehae176-B810" class="link link-ref link-reveal xref-bibr">810</a></sup>), numerous conditions are also associated with chronic inflammation leading to subacute stimuli for AF (_[Table 14](javascript:;)_). The specific trigger of an operative procedure is discussed in _Section [9.6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.6)_.

Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884386)

Non-cardiac conditions associated with trigger-induced AF

| Acute conditions .  |
| --- |
| Infections (bacterial and viral) |
| Pericarditis, myocarditis |
| Emergency conditions (burn injury, severe trauma, shock) |
| Binge alcohol consumption |
| Drug use, including methamphetamines, cocaine, opiates, and cannabis |
| Acute interventions, procedures, and surgery |
| Endocrine disorders (thyroid, adrenal, pituitary, others) |

| Acute conditions .  |
| --- |
| Infections (bacterial and viral) |
| Pericarditis, myocarditis |
| Emergency conditions (burn injury, severe trauma, shock) |
| Binge alcohol consumption |
| Drug use, including methamphetamines, cocaine, opiates, and cannabis |
| Acute interventions, procedures, and surgery |
| Endocrine disorders (thyroid, adrenal, pituitary, others) |

| Chronic conditions with inflammation and enhanced AF substrate .  |
| --- |
| Immune-mediated diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, others) |
| Obesity |
| Chronic obstructive airways disease |
| Obstructive sleep apnoea |
| Cancer |
| Fatty liver disease |
| Stress |
| Endocrine disorders (see _Section [9.10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.10)_) |

| Chronic conditions with inflammation and enhanced AF substrate .  |
| --- |
| Immune-mediated diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, others) |
| Obesity |
| Chronic obstructive airways disease |
| Obstructive sleep apnoea |
| Cancer |
| Fatty liver disease |
| Stress |
| Endocrine disorders (see _Section [9.10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.10)_) |

Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884386)

Non-cardiac conditions associated with trigger-induced AF

| Acute conditions .  |
| --- |
| Infections (bacterial and viral) |
| Pericarditis, myocarditis |
| Emergency conditions (burn injury, severe trauma, shock) |
| Binge alcohol consumption |
| Drug use, including methamphetamines, cocaine, opiates, and cannabis |
| Acute interventions, procedures, and surgery |
| Endocrine disorders (thyroid, adrenal, pituitary, others) |

| Acute conditions .  |
| --- |
| Infections (bacterial and viral) |
| Pericarditis, myocarditis |
| Emergency conditions (burn injury, severe trauma, shock) |
| Binge alcohol consumption |
| Drug use, including methamphetamines, cocaine, opiates, and cannabis |
| Acute interventions, procedures, and surgery |
| Endocrine disorders (thyroid, adrenal, pituitary, others) |

| Chronic conditions with inflammation and enhanced AF substrate .  |
| --- |
| Immune-mediated diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, others) |
| Obesity |
| Chronic obstructive airways disease |
| Obstructive sleep apnoea |
| Cancer |
| Fatty liver disease |
| Stress |
| Endocrine disorders (see _Section [9.10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.10)_) |

| Chronic conditions with inflammation and enhanced AF substrate .  |
| --- |
| Immune-mediated diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, others) |
| Obesity |
| Chronic obstructive airways disease |
| Obstructive sleep apnoea |
| Cancer |
| Fatty liver disease |
| Stress |
| Endocrine disorders (see _Section [9.10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s8.10)_) |

After meeting the diagnostic criteria for AF (see _Section [3.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s2.2)_), the management of trigger-induced AF is recommended to follow the AF-CARE principles, with critical consideration of underlying risk factors and comorbidities. Based on retrospective and observational data, patients with AF and trigger-induced AF seem to carry the same thromboembolic risk as patients with primary AF.<sup><span class="xrefLink" id="jumplink-ehae176-B811"></span><a href="javascript:;" reveal-id="ehae176-B811" data-open="ehae176-B811" class="link link-ref link-reveal xref-bibr">811</a>,<span class="xrefLink" id="jumplink-ehae176-B812"></span><a href="javascript:;" reveal-id="ehae176-B812" data-open="ehae176-B812" class="link link-ref link-reveal xref-bibr">812</a></sup> In the acute phase of sepsis, patients show an unclear risk–benefit profile with anticoagulation therapy.<sup><span class="xrefLink" id="jumplink-ehae176-B813"></span><a href="javascript:;" reveal-id="ehae176-B813" data-open="ehae176-B813" class="link link-ref link-reveal xref-bibr">813</a>,<span class="xrefLink" id="jumplink-ehae176-B814"></span><a href="javascript:;" reveal-id="ehae176-B814" data-open="ehae176-B814" class="link link-ref link-reveal xref-bibr">814</a></sup> Prospective studies on anticoagulation in patients with triggered AF episodes are lacking.<sup><span class="xrefLink" id="jumplink-ehae176-B802"></span><a href="javascript:;" reveal-id="ehae176-B802" data-open="ehae176-B802" class="link link-ref link-reveal xref-bibr">802</a>,<span class="xrefLink" id="jumplink-ehae176-B812"></span><a href="javascript:;" reveal-id="ehae176-B812" data-open="ehae176-B812" class="link link-ref link-reveal xref-bibr">812</a>,<span class="xrefLink" id="jumplink-ehae176-B815"></span><a href="javascript:;" reveal-id="ehae176-B815" data-open="ehae176-B815" class="link link-ref link-reveal xref-bibr">815</a></sup> Acknowledging that there are no RCTs specifically available in this population to assess trigger-induced AF, long-term OAC therapy should be considered in suitable patients with trigger-induced AF who are at elevated risk of thromboembolism, starting OAC after the acute trigger has been corrected and considering the anticipated net clinical benefit and informed patient preferences. As with any decision on OAC, not all patients will be suitable for OAC, depending on relative and absolute contraindications and the risk of major bleeding. The approach to rate and rhythm control will depend on subsequent recurrence of AF or any associated symptoms, and re-evaluation should be individualized to take account of the often high AF recurrence rate.

Recommendation Table 25

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884388)

Recommendations for trigger-induced AF (see also Evidence Table 25)

![Recommendations for trigger-induced AF (see also Evidence Table 25)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt25.jpeg?Expires=1728478929&Signature=onbEC~BN009T4GOHmJp6gpk3-VslP7~qJPRW18Lb4RmEQ7AUXbWDgd2a8It8QZGjAil6-DOUy64o~N1NWmel~wutOdYWUhC5yogII2DXUiZ3ANRBPq3yUFY9ZgiJo3RbO-ngZh04wE-dalXMe98xzMOhiaeFuVC64UurfVczAacqMwAQykCnvwcveXeayIuq4oXrqMQuMMsTbU2Mt1XNV2YtlXDCV8i8pDJKgEvK5YrTEIpjpNwF7kZt7kOpBMNZPEMkIdzG0AbWydyYNR7AbEUNbHVsTG1hT65PP82kqAKabrGYDrNrIKDWtPimx8jb3cKpbgMJugFjDIV3DcMWEA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 25

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884388)

Recommendations for trigger-induced AF (see also Evidence Table 25)

![Recommendations for trigger-induced AF (see also Evidence Table 25)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt25.jpeg?Expires=1728478929&Signature=onbEC~BN009T4GOHmJp6gpk3-VslP7~qJPRW18Lb4RmEQ7AUXbWDgd2a8It8QZGjAil6-DOUy64o~N1NWmel~wutOdYWUhC5yogII2DXUiZ3ANRBPq3yUFY9ZgiJo3RbO-ngZh04wE-dalXMe98xzMOhiaeFuVC64UurfVczAacqMwAQykCnvwcveXeayIuq4oXrqMQuMMsTbU2Mt1XNV2YtlXDCV8i8pDJKgEvK5YrTEIpjpNwF7kZt7kOpBMNZPEMkIdzG0AbWydyYNR7AbEUNbHVsTG1hT65PP82kqAKabrGYDrNrIKDWtPimx8jb3cKpbgMJugFjDIV3DcMWEA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.6. AF-CARE in post-operative patients

Peri-operative AF describes the onset of the arrhythmia during an ongoing intervention. Post-operative AF (POAF), defined as new-onset AF in the immediate post-operative period, is a common complication with clinical impact that occurs in 30%–50% of patients undergoing cardiac surgery,<sup><span class="xrefLink" id="jumplink-ehae176-B816 ehae176-B817 ehae176-B818"></span><a href="javascript:;" reveal-id="ehae176-B816 ehae176-B817 ehae176-B818" data-open="ehae176-B816 ehae176-B817 ehae176-B818" class="link link-ref link-reveal xref-bibr">816–818</a></sup> and in 5%–30% of patients undergoing non-cardiac surgery. Intra- and post-operative changes and specific AF triggers (including peri-operative complications) and pre-existing AF-related risk factors and comorbidities increase the susceptibility to POAF.<sup><span class="xrefLink" id="jumplink-ehae176-B819"></span><a href="javascript:;" reveal-id="ehae176-B819" data-open="ehae176-B819" class="link link-ref link-reveal xref-bibr">819</a></sup> Although POAF episodes may be self-terminating, POAF is associated with 4–5 times increase in recurrent AF during the next 5 years,<sup><span class="xrefLink" id="jumplink-ehae176-B820"></span><a href="javascript:;" reveal-id="ehae176-B820" data-open="ehae176-B820" class="link link-ref link-reveal xref-bibr">820</a>,<span class="xrefLink" id="jumplink-ehae176-B821"></span><a href="javascript:;" reveal-id="ehae176-B821" data-open="ehae176-B821" class="link link-ref link-reveal xref-bibr">821</a></sup> and is a risk factor for stroke, MI, heart failure, and death.<sup><span class="xrefLink" id="jumplink-ehae176-B822 ehae176-B823 ehae176-B824 ehae176-B825 ehae176-B826 ehae176-B827"></span><a href="javascript:;" reveal-id="ehae176-B822 ehae176-B823 ehae176-B824 ehae176-B825 ehae176-B826 ehae176-B827" data-open="ehae176-B822 ehae176-B823 ehae176-B824 ehae176-B825 ehae176-B826 ehae176-B827" class="link link-ref link-reveal xref-bibr">822–827</a></sup> Other adverse events associated with POAF include haemodynamic instability, prolonged hospital stay, infections, renal complications, bleeding, increased in-hospital death, and greater healthcare cost.<sup><span class="xrefLink" id="jumplink-ehae176-B828 ehae176-B829 ehae176-B830"></span><a href="javascript:;" reveal-id="ehae176-B828 ehae176-B829 ehae176-B830" data-open="ehae176-B828 ehae176-B829 ehae176-B830" class="link link-ref link-reveal xref-bibr">828–830</a></sup>

While multiple strategies to prevent POAF with pre-treatment or acute drug treatment have been described, there is a lack of evidence from large RCTs. Pre-operative use of propranolol or carvedilol plus _N_\-acetyl cysteine in cardiac and non-cardiac surgery is associated with a reduced incidence of POAF,<sup><span class="xrefLink" id="jumplink-ehae176-B831 ehae176-B832 ehae176-B833 ehae176-B834"></span><a href="javascript:;" reveal-id="ehae176-B831 ehae176-B832 ehae176-B833 ehae176-B834" data-open="ehae176-B831 ehae176-B832 ehae176-B833 ehae176-B834" class="link link-ref link-reveal xref-bibr">831–834</a></sup> but not major adverse events.<sup><span class="xrefLink" id="jumplink-ehae176-B835"></span><a href="javascript:;" reveal-id="ehae176-B835" data-open="ehae176-B835" class="link link-ref link-reveal xref-bibr">835</a></sup> An umbrella review of 89 RCTs from 23 meta-analyses (19 211 patients, but not necessarily in AF) showed no benefit from beta-blockers in cardiac surgery for mortality, MI, or stroke. In non-cardiac surgery, beta-blockers were associated with reduced rates of MI after surgery (RR range, 0.08–0.92), but higher mortality (RR range, 1.03–1.31), and increased risk of stroke (RR range, 1.33–7.72).<sup><span class="xrefLink" id="jumplink-ehae176-B836"></span><a href="javascript:;" reveal-id="ehae176-B836" data-open="ehae176-B836" class="link link-ref link-reveal xref-bibr">836</a></sup> Prevention of peri-operative AF can also be achieved with amiodarone. In a meta-analyses, amiodarone (oral or intravenous \[i.v.\]) and beta-blockers were equally effective in reducing post-operative AF,<sup><span class="xrefLink" id="jumplink-ehae176-B837"></span><a href="javascript:;" reveal-id="ehae176-B837" data-open="ehae176-B837" class="link link-ref link-reveal xref-bibr">837</a></sup> but their combination was better than beta-blockers alone.<sup><span class="xrefLink" id="jumplink-ehae176-B838"></span><a href="javascript:;" reveal-id="ehae176-B838" data-open="ehae176-B838" class="link link-ref link-reveal xref-bibr">838</a></sup> Lower cumulative doses of amiodarone (<3000 mg during the loading phase) could be effective, with fewer adverse events.<sup><span class="xrefLink" id="jumplink-ehae176-B837"></span><a href="javascript:;" reveal-id="ehae176-B837" data-open="ehae176-B837" class="link link-ref link-reveal xref-bibr">837</a>,<span class="xrefLink" id="jumplink-ehae176-B839"></span><a href="javascript:;" reveal-id="ehae176-B839" data-open="ehae176-B839" class="link link-ref link-reveal xref-bibr">839</a>,<span class="xrefLink" id="jumplink-ehae176-B840"></span><a href="javascript:;" reveal-id="ehae176-B840" data-open="ehae176-B840" class="link link-ref link-reveal xref-bibr">840</a></sup> Withdrawal of beta-blockers should be avoided due to increased risk of POAF.<sup><span class="xrefLink" id="jumplink-ehae176-B841"></span><a href="javascript:;" reveal-id="ehae176-B841" data-open="ehae176-B841" class="link link-ref link-reveal xref-bibr">841</a></sup> Other treatment strategies (steroids, magnesium, sotalol, (bi)atrial pacing, and botulium injection into the epicardial fat pad) lack scientific evidence for the prevention of peri-operative AF.<sup><span class="xrefLink" id="jumplink-ehae176-B842"></span><a href="javascript:;" reveal-id="ehae176-B842" data-open="ehae176-B842" class="link link-ref link-reveal xref-bibr">842</a>,<span class="xrefLink" id="jumplink-ehae176-B843"></span><a href="javascript:;" reveal-id="ehae176-B843" data-open="ehae176-B843" class="link link-ref link-reveal xref-bibr">843</a></sup> Peri-operative posterior pericardiotomy, due to the reduction of post-operative pericardial effusion, showed a significant decrease in POAF in patients undergoing cardiac surgery (OR, 0.44; 95% CI, 0.27–0.70; _P_ = .0005).<sup><span class="xrefLink" id="jumplink-ehae176-B844 ehae176-B845 ehae176-B846"></span><a href="javascript:;" reveal-id="ehae176-B844 ehae176-B845 ehae176-B846" data-open="ehae176-B844 ehae176-B845 ehae176-B846" class="link link-ref link-reveal xref-bibr">844–846</a></sup> In 3209 patients undergoing non-cardiac thoracic surgery, colchicine did not lead to any significant reduction in AF compared with placebo (HR, 0.85; 95% CI, 0.65–1.10; _P_ = .22).<sup><span class="xrefLink" id="jumplink-ehae176-B847"></span><a href="javascript:;" reveal-id="ehae176-B847" data-open="ehae176-B847" class="link link-ref link-reveal xref-bibr">847</a></sup>

The evidence for prevention of ischaemic stroke in POAF by OAC is limited.<sup><span class="xrefLink" id="jumplink-ehae176-B822"></span><a href="javascript:;" reveal-id="ehae176-B822" data-open="ehae176-B822" class="link link-ref link-reveal xref-bibr">822</a>,<span class="xrefLink" id="jumplink-ehae176-B827"></span><a href="javascript:;" reveal-id="ehae176-B827" data-open="ehae176-B827" class="link link-ref link-reveal xref-bibr">827</a></sup> Oral anticoagulant therapy is associated with a high bleeding risk soon after cardiac surgery or major non-cardiac interventions.<sup><span class="xrefLink" id="jumplink-ehae176-B827"></span><a href="javascript:;" reveal-id="ehae176-B827" data-open="ehae176-B827" class="link link-ref link-reveal xref-bibr">827</a></sup> Conversely, meta-analyses of observational cohort studies suggest a possible protective impact of OAC in POAF for all-cause mortality<sup><span class="xrefLink" id="jumplink-ehae176-B848"></span><a href="javascript:;" reveal-id="ehae176-B848" data-open="ehae176-B848" class="link link-ref link-reveal xref-bibr">848</a></sup> and a lower risk of thromboembolic events following cardiac surgery, accompanied by higher rates of bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B849"></span><a href="javascript:;" reveal-id="ehae176-B849" data-open="ehae176-B849" class="link link-ref link-reveal xref-bibr">849</a></sup> This task force recommends to treat post-operative AF according to the AF-CARE pathway as discussed for trigger-induced AF (with the \[R\] pathway the same as for first-diagnosed AF). Ongoing RCTs in cardiac surgery (NCT04045665) and non-cardiac surgery (NCT03968393) will inform optimal long-term OAC use among patients with POAF. While awaiting the results of these trials, this task force recommends that after acute bleeding risk has settled, long-term OAC should be considered in patients with POAF according to their thromboembolic risk factors.

Recommendation Table 26

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884393)

Recommendations for management of post-operative AF (see also Evidence Table 26)

![Recommendations for management of post-operative AF (see also Evidence Table 26)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt26.jpeg?Expires=1728478929&Signature=Kbv2oXbQL0MWDTdDaS00RFTSr30WqRx3D3Gph6PBD~zDgTrNvLTP6cGbm-05yEJJmceSjo4PQavjGHLbUl3aYIvuJMRiafCNbxUpE1ZcIMZ8aZcSTzgCb2Q~0UdKRu7QSUK-mbyaNoZRAnb~vM2nI08Sh1kajtABwUx7vLdwcuzmo~scj116h9rd-R4-OiYXm7jA3tcS4-Sjz2W8LLb0ysw41fMFd4aMOkgO9ycYNTy~RHbm5j65l-to-CVWyrhQDL~GmXycAsABOMshP3e1wqKZCZts4Io9yxC2l3yQXNkUNpfeVdom60o5-AgLjJA9gMcW9PyZ1EV9u~5yNcG4Lg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 26

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884393)

Recommendations for management of post-operative AF (see also Evidence Table 26)

![Recommendations for management of post-operative AF (see also Evidence Table 26)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt26.jpeg?Expires=1728478929&Signature=Kbv2oXbQL0MWDTdDaS00RFTSr30WqRx3D3Gph6PBD~zDgTrNvLTP6cGbm-05yEJJmceSjo4PQavjGHLbUl3aYIvuJMRiafCNbxUpE1ZcIMZ8aZcSTzgCb2Q~0UdKRu7QSUK-mbyaNoZRAnb~vM2nI08Sh1kajtABwUx7vLdwcuzmo~scj116h9rd-R4-OiYXm7jA3tcS4-Sjz2W8LLb0ysw41fMFd4aMOkgO9ycYNTy~RHbm5j65l-to-CVWyrhQDL~GmXycAsABOMshP3e1wqKZCZts4Io9yxC2l3yQXNkUNpfeVdom60o5-AgLjJA9gMcW9PyZ1EV9u~5yNcG4Lg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.7. AF-CARE in embolic stroke of unknown source

The term ‘embolic stroke of undetermined source’ (ESUS) was introduced to identify non-lacunar strokes whose mechanism is likely to be embolic, but the source remains unidentified.<sup><span class="xrefLink" id="jumplink-ehae176-B856"></span><a href="javascript:;" reveal-id="ehae176-B856" data-open="ehae176-B856" class="link link-ref link-reveal xref-bibr">856</a></sup> Of note, these patients have a recurrent risk of stroke of 4%–5% per year.<sup><span class="xrefLink" id="jumplink-ehae176-B856"></span><a href="javascript:;" reveal-id="ehae176-B856" data-open="ehae176-B856" class="link link-ref link-reveal xref-bibr">856</a></sup> The main embolic sources associated with ESUS are concealed AF, atrial cardiomyopathy, left ventricular disease, atherosclerotic plaques, patent foramen ovale (PFO), valvular diseases, and cancer. Atrial cardiomyopathy and left ventricular disease are the most prevalent causes.<sup><span class="xrefLink" id="jumplink-ehae176-B856"></span><a href="javascript:;" reveal-id="ehae176-B856" data-open="ehae176-B856" class="link link-ref link-reveal xref-bibr">856</a></sup> AF is reported to be the underlying mechanism in 30% of ESUS patients.<sup><span class="xrefLink" id="jumplink-ehae176-B857 ehae176-B858 ehae176-B859"></span><a href="javascript:;" reveal-id="ehae176-B857 ehae176-B858 ehae176-B859" data-open="ehae176-B857 ehae176-B858 ehae176-B859" class="link link-ref link-reveal xref-bibr">857–859</a></sup> The detection of AF among ESUS patients increases the longer cardiac monitoring is provided (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S29](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B857"></span><a href="javascript:;" reveal-id="ehae176-B857" data-open="ehae176-B857" class="link link-ref link-reveal xref-bibr">857</a>,<span class="xrefLink" id="jumplink-ehae176-B860 ehae176-B861 ehae176-B862 ehae176-B863 ehae176-B864"></span><a href="javascript:;" reveal-id="ehae176-B860 ehae176-B861 ehae176-B862 ehae176-B863 ehae176-B864" data-open="ehae176-B860 ehae176-B861 ehae176-B862 ehae176-B863 ehae176-B864" class="link link-ref link-reveal xref-bibr">860–864</a></sup> This also holds for the duration of implantable cardiac monitoring, with probability of AF detection ranging from 2% with 1 week to over 20% by 3 years.<sup><span class="xrefLink" id="jumplink-ehae176-B865"></span><a href="javascript:;" reveal-id="ehae176-B865" data-open="ehae176-B865" class="link link-ref link-reveal xref-bibr">865</a></sup> In patients with ESUS, factors associated with an increased detection of AF are increasing age,<sup><span class="xrefLink" id="jumplink-ehae176-B866"></span><a href="javascript:;" reveal-id="ehae176-B866" data-open="ehae176-B866" class="link link-ref link-reveal xref-bibr">866</a>,<span class="xrefLink" id="jumplink-ehae176-B867"></span><a href="javascript:;" reveal-id="ehae176-B867" data-open="ehae176-B867" class="link link-ref link-reveal xref-bibr">867</a></sup> left atrial enlargement,<sup><span class="xrefLink" id="jumplink-ehae176-B866"></span><a href="javascript:;" reveal-id="ehae176-B866" data-open="ehae176-B866" class="link link-ref link-reveal xref-bibr">866</a></sup> cortical location of stroke,<sup><span class="xrefLink" id="jumplink-ehae176-B868"></span><a href="javascript:;" reveal-id="ehae176-B868" data-open="ehae176-B868" class="link link-ref link-reveal xref-bibr">868</a></sup> large or small vessel disease,<sup><span class="xrefLink" id="jumplink-ehae176-B863"></span><a href="javascript:;" reveal-id="ehae176-B863" data-open="ehae176-B863" class="link link-ref link-reveal xref-bibr">863</a></sup> an increased number of atrial premature beats per 24 h,<sup><span class="xrefLink" id="jumplink-ehae176-B868"></span><a href="javascript:;" reveal-id="ehae176-B868" data-open="ehae176-B868" class="link link-ref link-reveal xref-bibr">868</a></sup> rhythm irregularity,<sup><span class="xrefLink" id="jumplink-ehae176-B859"></span><a href="javascript:;" reveal-id="ehae176-B859" data-open="ehae176-B859" class="link link-ref link-reveal xref-bibr">859</a></sup> and risk stratification scores (such as CHA<sub>2</sub>DS<sub>2-</sub>VASc,<sup><span class="xrefLink" id="jumplink-ehae176-B869"></span><a href="javascript:;" reveal-id="ehae176-B869" data-open="ehae176-B869" class="link link-ref link-reveal xref-bibr">869</a></sup> Brown ESUS-AF,<sup><span class="xrefLink" id="jumplink-ehae176-B870"></span><a href="javascript:;" reveal-id="ehae176-B870" data-open="ehae176-B870" class="link link-ref link-reveal xref-bibr">870</a></sup> HAVOC,<sup><span class="xrefLink" id="jumplink-ehae176-B871"></span><a href="javascript:;" reveal-id="ehae176-B871" data-open="ehae176-B871" class="link link-ref link-reveal xref-bibr">871</a></sup> and C<sub>2</sub>HEST<sup><span class="xrefLink" id="jumplink-ehae176-B872"></span><a href="javascript:;" reveal-id="ehae176-B872" data-open="ehae176-B872" class="link link-ref link-reveal xref-bibr">872</a></sup>). This task force recommends prolonged monitoring depending on the presence of the above-mentioned risk markers.<sup><span class="xrefLink" id="jumplink-ehae176-B865"></span><a href="javascript:;" reveal-id="ehae176-B865" data-open="ehae176-B865" class="link link-ref link-reveal xref-bibr">865</a>,<span class="xrefLink" id="jumplink-ehae176-B873"></span><a href="javascript:;" reveal-id="ehae176-B873" data-open="ehae176-B873" class="link link-ref link-reveal xref-bibr">873</a>,<span class="xrefLink" id="jumplink-ehae176-B874"></span><a href="javascript:;" reveal-id="ehae176-B874" data-open="ehae176-B874" class="link link-ref link-reveal xref-bibr">874</a></sup>

Currently available evidence, including two completed RCTs and one stopped for futility, do not support the use of DOACs compared with aspirin in patients with acute ESUS without documented AF.<sup><span class="xrefLink" id="jumplink-ehae176-B875 ehae176-B876 ehae176-B877"></span><a href="javascript:;" reveal-id="ehae176-B875 ehae176-B876 ehae176-B877" data-open="ehae176-B875 ehae176-B876 ehae176-B877" class="link link-ref link-reveal xref-bibr">875–877</a></sup> Ongoing trials will provide further guidance (NCT05134454, NCT05293080, NCT04371055).

Recommendation Table 27

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884397)

Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27)

![Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt27.jpeg?Expires=1728478929&Signature=jvl2RulOn-nPv0e0rbFPdDY21Ri~sc~J4UULYhaY-vmXo~iVuJJ0uB66a0RnbF2UQqRhobhnvR-cLzoBxC4tGoX8Akw7gvMxJV0A1YhbTbbr5RnOAZA-5E8DXog6fJYtbhVASXaHLAK6dGKoO~6hDu4QF73QutZ~JbxXeov-bF0xzJgflv9LdGBWze3PDPy8exeHnHus8h1Q66iF0duqoEjKcztVLAqEshQERsTrwKuFMlmUsqCKC3vU5ch4pgvPHav6sV4m0k1IvepypejYdVq8TAZuBPNnqa9S0ixiUmyBcrAfVfSTVKmm26Fh4SJYnF2TVm7~JO2Irwz1rO797g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 27

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884397)

Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27)

![Recommendations for patients with embolic stroke of unknown source (see also Evidence Table 27)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt27.jpeg?Expires=1728478929&Signature=jvl2RulOn-nPv0e0rbFPdDY21Ri~sc~J4UULYhaY-vmXo~iVuJJ0uB66a0RnbF2UQqRhobhnvR-cLzoBxC4tGoX8Akw7gvMxJV0A1YhbTbbr5RnOAZA-5E8DXog6fJYtbhVASXaHLAK6dGKoO~6hDu4QF73QutZ~JbxXeov-bF0xzJgflv9LdGBWze3PDPy8exeHnHus8h1Q66iF0duqoEjKcztVLAqEshQERsTrwKuFMlmUsqCKC3vU5ch4pgvPHav6sV4m0k1IvepypejYdVq8TAZuBPNnqa9S0ixiUmyBcrAfVfSTVKmm26Fh4SJYnF2TVm7~JO2Irwz1rO797g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.8. AF-CARE during pregnancy

Atrial fibrillation is one of the most common arrhythmias during pregnancy, with prevalence increasing due to higher maternal age and changes in lifestyle, and because more women with congenital heart disease survive to childbearing age.<sup><span class="xrefLink" id="jumplink-ehae176-B878 ehae176-B879 ehae176-B880 ehae176-B881"></span><a href="javascript:;" reveal-id="ehae176-B878 ehae176-B879 ehae176-B880 ehae176-B881" data-open="ehae176-B878 ehae176-B879 ehae176-B880 ehae176-B881" class="link link-ref link-reveal xref-bibr">878–881</a></sup> Rapid atrioventricular conduction of AF may have serious haemodynamic consequences for mother and foetus. AF during pregnancy is associated with an increased risk of death.<sup><span class="xrefLink" id="jumplink-ehae176-B882"></span><a href="javascript:;" reveal-id="ehae176-B882" data-open="ehae176-B882" class="link link-ref link-reveal xref-bibr">882</a></sup> A multidisciplinary approach is essential to prevent maternal and foetal complications, bringing together gynaecologists, neonatologists, anaesthesiologists, and cardiologists experienced in maternal medicine.<sup><span class="xrefLink" id="jumplink-ehae176-B883"></span><a href="javascript:;" reveal-id="ehae176-B883" data-open="ehae176-B883" class="link link-ref link-reveal xref-bibr">883</a></sup>

Pregnancy is associated with a hypercoagulable state and increased thromboembolic risk.<sup><span class="xrefLink" id="jumplink-ehae176-B884"></span><a href="javascript:;" reveal-id="ehae176-B884" data-open="ehae176-B884" class="link link-ref link-reveal xref-bibr">884</a></sup> The same rules for risk assessment of thromboembolism should be used as in non-pregnant women, as detailed in the _2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy_.<sup><span class="xrefLink" id="jumplink-ehae176-B885"></span><a href="javascript:;" reveal-id="ehae176-B885" data-open="ehae176-B885" class="link link-ref link-reveal xref-bibr">885</a></sup> The preferred agents for anticoagulation of AF during pregnancy are unfractionated or low molecular weight heparins (LMWHs), which do not cross the placenta. Vitamin K antagonists should be avoided in the first trimester (risk of miscarriage, teratogenicity) and from week 36 onwards (risk of foetal intracranial bleeding if early unexpected delivery). Direct oral anticoagulants are not recommended during pregnancy due to concerns about safety.<sup><span class="xrefLink" id="jumplink-ehae176-B886"></span><a href="javascript:;" reveal-id="ehae176-B886" data-open="ehae176-B886" class="link link-ref link-reveal xref-bibr">886</a></sup> However, an accidental exposure during pregnancy should not lead to a recommendation for termination of the pregnancy.<sup><span class="xrefLink" id="jumplink-ehae176-B887"></span><a href="javascript:;" reveal-id="ehae176-B887" data-open="ehae176-B887" class="link link-ref link-reveal xref-bibr">887</a></sup> Vaginal delivery should be advised for most women, but is contraindicated during VKA treatment because of the risk of foetal intracranial bleeding.<sup><span class="xrefLink" id="jumplink-ehae176-B885"></span><a href="javascript:;" reveal-id="ehae176-B885" data-open="ehae176-B885" class="link link-ref link-reveal xref-bibr">885</a></sup>

Intravenous selective beta-1 receptor blockers are recommended as first choice for acute heart rate control of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B888"></span><a href="javascript:;" reveal-id="ehae176-B888" data-open="ehae176-B888" class="link link-ref link-reveal xref-bibr">888</a></sup> This does not include atenolol, which can lead to intrauterine growth retardation.<sup><span class="xrefLink" id="jumplink-ehae176-B889"></span><a href="javascript:;" reveal-id="ehae176-B889" data-open="ehae176-B889" class="link link-ref link-reveal xref-bibr">889</a></sup> If beta-blockers fail, digoxin and verapamil can be considered for rate control (verapamil should be avoided in the first trimester). Rhythm control is the preferred strategy during pregnancy. Electrical cardioversion is recommended if there is haemodynamic instability, considerable risk to mother or foetus, or with concomitant HCM. Electrical cardioversion can be performed safely without compromising foetal blood flow, and the consequent risk for foetal arrhythmias or pre-term labour is low. The foetal heart rate should be closely monitored throughout and after cardioversion, which should generally be preceded by anticoagulation.<sup><span class="xrefLink" id="jumplink-ehae176-B885"></span><a href="javascript:;" reveal-id="ehae176-B885" data-open="ehae176-B885" class="link link-ref link-reveal xref-bibr">885</a></sup> In haemodynamically stable women without structural heart disease, intravenous ibutilide or flecainide may be considered for termination of AF, but experience is limited.<sup><span class="xrefLink" id="jumplink-ehae176-B890"></span><a href="javascript:;" reveal-id="ehae176-B890" data-open="ehae176-B890" class="link link-ref link-reveal xref-bibr">890</a></sup> Catheter ablation is normally avoided during pregnancy,<sup><span class="xrefLink" id="jumplink-ehae176-B883"></span><a href="javascript:;" reveal-id="ehae176-B883" data-open="ehae176-B883" class="link link-ref link-reveal xref-bibr">883</a></sup> but is technically feasible without radiation in refractory symptomatic cases with a minimal/zero fluoroscopy approach.<sup><span class="xrefLink" id="jumplink-ehae176-B883"></span><a href="javascript:;" reveal-id="ehae176-B883" data-open="ehae176-B883" class="link link-ref link-reveal xref-bibr">883</a></sup>

Counselling is important in women of childbearing potential prior to pregnancy, highlighting the potential risks of anticoagulation and rate or rhythm control drugs (including teratogenic risk, where relevant). Contraception and timely switch to safe drugs should be proactively discussed.

Recommendation Table 28

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884403)

Recommendations for patients with AF during pregnancy (see also Evidence Table 28)

![Recommendations for patients with AF during pregnancy (see also Evidence Table 28)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt28.jpeg?Expires=1728478929&Signature=d-e9bkaTk8NW45OcwVlkvqDJhKkwj-QgYx1ulj8mA6JvBrJk6CByVsDPmo1jUnUEkx7kbm2MvLiB8nVd1zQM48LsiaJsjw4dUsXp~DcWgBC9vJmJec75e0ZzShnhy~fijMZzVpPFvh17YlSKgxUpvnLJA6y25uZsWa2N0WZitJwn7mHH-fubJJe0J9sz~TqhM9812czkViXgzw5JQ-ck~xSqVOluLVxEoUt1RvWai1qhgaRbmzOTigDMEwIB1JcXZafpWzxPmg4Zj28gk4fjKfZSBpc6sy8muR7WiLmc6Wrag5LeSTWGE0WM9WzSf32AWdoJhd28PkCjuKVbo7srsw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 28

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884403)

Recommendations for patients with AF during pregnancy (see also Evidence Table 28)

![Recommendations for patients with AF during pregnancy (see also Evidence Table 28)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt28.jpeg?Expires=1728478929&Signature=d-e9bkaTk8NW45OcwVlkvqDJhKkwj-QgYx1ulj8mA6JvBrJk6CByVsDPmo1jUnUEkx7kbm2MvLiB8nVd1zQM48LsiaJsjw4dUsXp~DcWgBC9vJmJec75e0ZzShnhy~fijMZzVpPFvh17YlSKgxUpvnLJA6y25uZsWa2N0WZitJwn7mHH-fubJJe0J9sz~TqhM9812czkViXgzw5JQ-ck~xSqVOluLVxEoUt1RvWai1qhgaRbmzOTigDMEwIB1JcXZafpWzxPmg4Zj28gk4fjKfZSBpc6sy8muR7WiLmc6Wrag5LeSTWGE0WM9WzSf32AWdoJhd28PkCjuKVbo7srsw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.9. AF-CARE in congenital heart disease

Survival of patients with congenital heart disease has increased over time, but robust data on the management of AF are missing and available evidence is derived mainly from observational studies. Oral anticoagulants are recommended for all patients with AF and intracardiac repair, cyanotic congenital heart disease, Fontan palliation, or systemic right ventricle irrespective of the individuals' thromboembolic risk factors.<sup><span class="xrefLink" id="jumplink-ehae176-B897"></span><a href="javascript:;" reveal-id="ehae176-B897" data-open="ehae176-B897" class="link link-ref link-reveal xref-bibr">897</a></sup> Patients with AF and other congenital heart diseases should follow the general risk stratification for OAC use in AF (i.e. depending on the thromboembolic risk or CHA<sub>2</sub>DS<sub>2</sub>\-VA score). Direct oral anticoagulants are contraindicated in patients with mechanical heart valves,<sup><span class="xrefLink" id="jumplink-ehae176-B331"></span><a href="javascript:;" reveal-id="ehae176-B331" data-open="ehae176-B331" class="link link-ref link-reveal xref-bibr">331</a></sup> but appear safe in patients with congenital heart disease,<sup><span class="xrefLink" id="jumplink-ehae176-B898"></span><a href="javascript:;" reveal-id="ehae176-B898" data-open="ehae176-B898" class="link link-ref link-reveal xref-bibr">898</a>,<span class="xrefLink" id="jumplink-ehae176-B899"></span><a href="javascript:;" reveal-id="ehae176-B899" data-open="ehae176-B899" class="link link-ref link-reveal xref-bibr">899</a></sup> or those with a valvular bioprosthesis.<sup><span class="xrefLink" id="jumplink-ehae176-B900"></span><a href="javascript:;" reveal-id="ehae176-B900" data-open="ehae176-B900" class="link link-ref link-reveal xref-bibr">900</a>,<span class="xrefLink" id="jumplink-ehae176-B901"></span><a href="javascript:;" reveal-id="ehae176-B901" data-open="ehae176-B901" class="link link-ref link-reveal xref-bibr">901</a></sup>

Rate control drugs such as selective beta-1 receptor blockers, verapamil, diltiazem, and digoxin can be used with caution, with monitoring for bradycardia and hypotension. Rhythm control strategies such as amiodarone may be effective, but warrant monitoring for bradycardia. When cardioversion is planned, both 3 weeks of OAC and TOE should be considered because thrombi are common in patients with congenital heart disease and atrial arrhythmias.<sup><span class="xrefLink" id="jumplink-ehae176-B902"></span><a href="javascript:;" reveal-id="ehae176-B902" data-open="ehae176-B902" class="link link-ref link-reveal xref-bibr">902</a>,<span class="xrefLink" id="jumplink-ehae176-B903"></span><a href="javascript:;" reveal-id="ehae176-B903" data-open="ehae176-B903" class="link link-ref link-reveal xref-bibr">903</a></sup> Ablation approaches can be successful in patients with congenital heart disease, but AF recurrence rates may be high (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S30](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

In patients with atrial septal defect, closure may be performed before the fourth decade of life to decrease the risk of AF or AFL.<sup><span class="xrefLink" id="jumplink-ehae176-B904"></span><a href="javascript:;" reveal-id="ehae176-B904" data-open="ehae176-B904" class="link link-ref link-reveal xref-bibr">904</a></sup> Patients with stroke who underwent closure of their PFO may have an increased risk of AF,<sup><span class="xrefLink" id="jumplink-ehae176-B905"></span><a href="javascript:;" reveal-id="ehae176-B905" data-open="ehae176-B905" class="link link-ref link-reveal xref-bibr">905</a></sup> but in patients with PFO and AF, PFO closure is not recommended for stroke prevention. AF surgery or catheter ablation can be considered at the time of closure of the atrial septal defect within a multidisciplinary team.<sup><span class="xrefLink" id="jumplink-ehae176-B906 ehae176-B907 ehae176-B908"></span><a href="javascript:;" reveal-id="ehae176-B906 ehae176-B907 ehae176-B908" data-open="ehae176-B906 ehae176-B907 ehae176-B908" class="link link-ref link-reveal xref-bibr">906–908</a></sup> AF catheter ablation of late atrial arrhythmias is likely to be effective after surgical atrial septal closure.<sup><span class="xrefLink" id="jumplink-ehae176-B909"></span><a href="javascript:;" reveal-id="ehae176-B909" data-open="ehae176-B909" class="link link-ref link-reveal xref-bibr">909</a></sup>

Recommendation Table 29

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884408)

Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29)

![Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt29.jpeg?Expires=1728478929&Signature=hNCpWZg8C033PHHzeSK2Y-tWpfbA62RsFLc5cgWvoqcjIqy~ErwDlz8Ta9FLQMfSP3KmmmSrsqSVDdfeYXsq37iNo9~1f7y844jkDHmjT8UvLNGN7sSPNs4b2TVzTnJzKZk9XmtxWduZGWxp9-vYQbw7EHC4fXeUJFrPZcU2bwznO7XaZ47X7AOvtu9NV1pYr2APenbtcdNalmBvzP1k59YbClsS1b5gVJdRudtqIIg1ZAeaSHtRH~N4yAvwDBgFQMk8LsIh3haBRIbkcIRxiWutDnSSGIMYh~n-~cSrepwrGxDJcLdP65~gwJuRJYzSGARuITZnm4Yu9rIo5OHYpA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 29

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884408)

Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29)

![Recommendations for patients with AF and congenital heart disease (see also Evidence Table 29)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt29.jpeg?Expires=1728478929&Signature=hNCpWZg8C033PHHzeSK2Y-tWpfbA62RsFLc5cgWvoqcjIqy~ErwDlz8Ta9FLQMfSP3KmmmSrsqSVDdfeYXsq37iNo9~1f7y844jkDHmjT8UvLNGN7sSPNs4b2TVzTnJzKZk9XmtxWduZGWxp9-vYQbw7EHC4fXeUJFrPZcU2bwznO7XaZ47X7AOvtu9NV1pYr2APenbtcdNalmBvzP1k59YbClsS1b5gVJdRudtqIIg1ZAeaSHtRH~N4yAvwDBgFQMk8LsIh3haBRIbkcIRxiWutDnSSGIMYh~n-~cSrepwrGxDJcLdP65~gwJuRJYzSGARuITZnm4Yu9rIo5OHYpA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.10. AF-CARE in endocrine disorders

Endocrine dysfunction is closely related to AF, both as the direct action of endocrine hormones and as a consequence of treatments for endocrine disease. Optimal management of endocrine disorders is therefore part of the AF-CARE pathway.<sup><span class="xrefLink" id="jumplink-ehae176-B910"></span><a href="javascript:;" reveal-id="ehae176-B910" data-open="ehae176-B910" class="link link-ref link-reveal xref-bibr">910</a>,<span class="xrefLink" id="jumplink-ehae176-B911"></span><a href="javascript:;" reveal-id="ehae176-B911" data-open="ehae176-B911" class="link link-ref link-reveal xref-bibr">911</a></sup>

Clinical and subclinical hyperthyroidism, as well as subclinical hypothyroidism, are associated with an increased risk of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B913"></span><a href="javascript:;" reveal-id="ehae176-B913" data-open="ehae176-B913" class="link link-ref link-reveal xref-bibr">913</a></sup> Patients presenting with new-onset or recurrent AF should be tested for thyroid-stimulating hormone (TSH) levels. The risk of AF is enhanced in vulnerable patients, including the elderly and those with structural atrial diseases,<sup><span class="xrefLink" id="jumplink-ehae176-B914"></span><a href="javascript:;" reveal-id="ehae176-B914" data-open="ehae176-B914" class="link link-ref link-reveal xref-bibr">914</a>,<span class="xrefLink" id="jumplink-ehae176-B915"></span><a href="javascript:;" reveal-id="ehae176-B915" data-open="ehae176-B915" class="link link-ref link-reveal xref-bibr">915</a></sup> as well as cancer patients on immune checkpoint inhibitors.<sup><span class="xrefLink" id="jumplink-ehae176-B916"></span><a href="javascript:;" reveal-id="ehae176-B916" data-open="ehae176-B916" class="link link-ref link-reveal xref-bibr">916</a>,<span class="xrefLink" id="jumplink-ehae176-B917"></span><a href="javascript:;" reveal-id="ehae176-B917" data-open="ehae176-B917" class="link link-ref link-reveal xref-bibr">917</a></sup> In hyperthyroidism, and even in the euthyroid range, the risk of AF increases according to the reduction in TSH and elevated levels of thyroxine.<sup><span class="xrefLink" id="jumplink-ehae176-B918"></span><a href="javascript:;" reveal-id="ehae176-B918" data-open="ehae176-B918" class="link link-ref link-reveal xref-bibr">918</a>,<span class="xrefLink" id="jumplink-ehae176-B919"></span><a href="javascript:;" reveal-id="ehae176-B919" data-open="ehae176-B919" class="link link-ref link-reveal xref-bibr">919</a></sup> Moreover, the risk of stroke is higher in patients with hyperthyroidism, which can be mitigated by treating the thyroid disorder.<sup><span class="xrefLink" id="jumplink-ehae176-B920"></span><a href="javascript:;" reveal-id="ehae176-B920" data-open="ehae176-B920" class="link link-ref link-reveal xref-bibr">920</a>,<span class="xrefLink" id="jumplink-ehae176-B921"></span><a href="javascript:;" reveal-id="ehae176-B921" data-open="ehae176-B921" class="link link-ref link-reveal xref-bibr">921</a></sup> Amiodarone induces thyroid dysfunction in 15%–20% of treated patients, leading to both hypo- and hyperthyroidism,<sup><span class="xrefLink" id="jumplink-ehae176-B922"></span><a href="javascript:;" reveal-id="ehae176-B922" data-open="ehae176-B922" class="link link-ref link-reveal xref-bibr">922</a>,<span class="xrefLink" id="jumplink-ehae176-B923"></span><a href="javascript:;" reveal-id="ehae176-B923" data-open="ehae176-B923" class="link link-ref link-reveal xref-bibr">923</a></sup> which warrants referral to an endocrinologist (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) for further details).

Hypercalcaemia may also induce arrhythmias, but the role of primary hyperparathyroidism in incident AF is poorly studied. Surgical parathyroidectomy has been found to reduce both supraventricular and ventricular premature beats.<sup><span class="xrefLink" id="jumplink-ehae176-B924 ehae176-B925 ehae176-B926"></span><a href="javascript:;" reveal-id="ehae176-B924 ehae176-B925 ehae176-B926" data-open="ehae176-B924 ehae176-B925 ehae176-B926" class="link link-ref link-reveal xref-bibr">924–926</a></sup> Primary aldosteronism is related to an increased risk of AF through direct actions and vascular effects,<sup><span class="xrefLink" id="jumplink-ehae176-B927"></span><a href="javascript:;" reveal-id="ehae176-B927" data-open="ehae176-B927" class="link link-ref link-reveal xref-bibr">927</a>,<span class="xrefLink" id="jumplink-ehae176-B928"></span><a href="javascript:;" reveal-id="ehae176-B928" data-open="ehae176-B928" class="link link-ref link-reveal xref-bibr">928</a></sup> with a three-fold higher rate of incident AF compared with patients with essential hypertension.<sup><span class="xrefLink" id="jumplink-ehae176-B929"></span><a href="javascript:;" reveal-id="ehae176-B929" data-open="ehae176-B929" class="link link-ref link-reveal xref-bibr">929</a></sup> Increases in genetically predicted plasma cortisol are associated with greater risk of AF, and patients with adrenal incidentalomas with subclinical cortisol secretion have a higher prevalence of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B930"></span><a href="javascript:;" reveal-id="ehae176-B930" data-open="ehae176-B930" class="link link-ref link-reveal xref-bibr">930</a>,<span class="xrefLink" id="jumplink-ehae176-B931"></span><a href="javascript:;" reveal-id="ehae176-B931" data-open="ehae176-B931" class="link link-ref link-reveal xref-bibr">931</a></sup> Acromegaly may predispose to an increased substrate for AF, with incident AF rates significantly higher than controls in long-term follow-up, even after adjusting for AF risk factors.<sup><span class="xrefLink" id="jumplink-ehae176-B932"></span><a href="javascript:;" reveal-id="ehae176-B932" data-open="ehae176-B932" class="link link-ref link-reveal xref-bibr">932</a></sup>

The association between type 2 diabetes and AF is discussed in _Sections [5.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s4.3)_ (AF recurrence) and _Section [10.5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s9.5)_ (incident AF). In addition to insulin-resistance mechanisms typical of type 2 diabetes, the loss of insulin signalling has recently been associated with electrical changes that can lead to AF. Type 1 diabetes is associated with an increased risk of several cardiovascular diseases including AF.<sup><span class="xrefLink" id="jumplink-ehae176-B933 ehae176-B934 ehae176-B935 ehae176-B936 ehae176-B937"></span><a href="javascript:;" reveal-id="ehae176-B933 ehae176-B934 ehae176-B935 ehae176-B936 ehae176-B937" data-open="ehae176-B933 ehae176-B934 ehae176-B935 ehae176-B936 ehae176-B937" class="link link-ref link-reveal xref-bibr">933–937</a></sup>

### 9.11. AF-CARE in inherited cardiomyopathies and primary arrhythmia syndromes

A higher incidence and prevalence of AF have been described in patients with inherited cardiomyopathies and primary arrhythmia syndromes.<sup><span class="xrefLink" id="jumplink-ehae176-B271"></span><a href="javascript:;" reveal-id="ehae176-B271" data-open="ehae176-B271" class="link link-ref link-reveal xref-bibr">271</a>,<span class="xrefLink" id="jumplink-ehae176-B938 ehae176-B939 ehae176-B940 ehae176-B941 ehae176-B942 ehae176-B943 ehae176-B944 ehae176-B945 ehae176-B946 ehae176-B947 ehae176-B948 ehae176-B949 ehae176-B950 ehae176-B951 ehae176-B952 ehae176-B953 ehae176-B954 ehae176-B955 ehae176-B956 ehae176-B957 ehae176-B958 ehae176-B959 ehae176-B960 ehae176-B961 ehae176-B962 ehae176-B963 ehae176-B964 ehae176-B965 ehae176-B966 ehae176-B967 ehae176-B968 ehae176-B969 ehae176-B970"></span><a href="javascript:;" reveal-id="ehae176-B938 ehae176-B939 ehae176-B940 ehae176-B941 ehae176-B942 ehae176-B943 ehae176-B944 ehae176-B945 ehae176-B946 ehae176-B947 ehae176-B948 ehae176-B949 ehae176-B950 ehae176-B951 ehae176-B952 ehae176-B953 ehae176-B954 ehae176-B955 ehae176-B956 ehae176-B957 ehae176-B958 ehae176-B959 ehae176-B960 ehae176-B961 ehae176-B962 ehae176-B963 ehae176-B964 ehae176-B965 ehae176-B966 ehae176-B967 ehae176-B968 ehae176-B969 ehae176-B970" data-open="ehae176-B938 ehae176-B939 ehae176-B940 ehae176-B941 ehae176-B942 ehae176-B943 ehae176-B944 ehae176-B945 ehae176-B946 ehae176-B947 ehae176-B948 ehae176-B949 ehae176-B950 ehae176-B951 ehae176-B952 ehae176-B953 ehae176-B954 ehae176-B955 ehae176-B956 ehae176-B957 ehae176-B958 ehae176-B959 ehae176-B960 ehae176-B961 ehae176-B962 ehae176-B963 ehae176-B964 ehae176-B965 ehae176-B966 ehae176-B967 ehae176-B968 ehae176-B969 ehae176-B970" class="link link-ref link-reveal xref-bibr">938–970</a></sup> AF can be the presenting or only clinically overt feature.<sup><span class="xrefLink" id="jumplink-ehae176-B969"></span><a href="javascript:;" reveal-id="ehae176-B969" data-open="ehae176-B969" class="link link-ref link-reveal xref-bibr">969</a>,<span class="xrefLink" id="jumplink-ehae176-B971 ehae176-B972 ehae176-B973 ehae176-B974 ehae176-B975"></span><a href="javascript:;" reveal-id="ehae176-B971 ehae176-B972 ehae176-B973 ehae176-B974 ehae176-B975" data-open="ehae176-B971 ehae176-B972 ehae176-B973 ehae176-B974 ehae176-B975" class="link link-ref link-reveal xref-bibr">971–975</a></sup> AF in these patients is associated with adverse clinical outcomes,<sup><span class="xrefLink" id="jumplink-ehae176-B947"></span><a href="javascript:;" reveal-id="ehae176-B947" data-open="ehae176-B947" class="link link-ref link-reveal xref-bibr">947</a>,<span class="xrefLink" id="jumplink-ehae176-B954"></span><a href="javascript:;" reveal-id="ehae176-B954" data-open="ehae176-B954" class="link link-ref link-reveal xref-bibr">954</a>,<span class="xrefLink" id="jumplink-ehae176-B959"></span><a href="javascript:;" reveal-id="ehae176-B959" data-open="ehae176-B959" class="link link-ref link-reveal xref-bibr">959</a>,<span class="xrefLink" id="jumplink-ehae176-B963"></span><a href="javascript:;" reveal-id="ehae176-B963" data-open="ehae176-B963" class="link link-ref link-reveal xref-bibr">963</a>,<span class="xrefLink" id="jumplink-ehae176-B965"></span><a href="javascript:;" reveal-id="ehae176-B965" data-open="ehae176-B965" class="link link-ref link-reveal xref-bibr">965</a>,<span class="xrefLink" id="jumplink-ehae176-B976 ehae176-B977 ehae176-B978"></span><a href="javascript:;" reveal-id="ehae176-B976 ehae176-B977 ehae176-B978" data-open="ehae176-B976 ehae176-B977 ehae176-B978" class="link link-ref link-reveal xref-bibr">976–978</a></sup> and has important implications on management (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S31](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). When AF presents at a young age, there should be a careful interrogation about family history and a search for underlying disease.<sup><span class="xrefLink" id="jumplink-ehae176-B979"></span><a href="javascript:;" reveal-id="ehae176-B979" data-open="ehae176-B979" class="link link-ref link-reveal xref-bibr">979</a></sup>

Rhythm control approaches may be challenging in patients with inherited cardiomyopathies and primary arrhythmia syndromes. For example, many drugs have a higher risk of adverse events or may be contraindicated (e.g. amiodarone and sotalol in congenital long QT syndrome, and Class IC AADs in Brugada syndrome) (see [Supplementary Data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S6](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Owing to long-term adverse effects, chronic use of amiodarone is problematic in these typically young individuals. In patients with an implantable cardioverter defibrillator, AF is a common cause of inappropriate shocks.<sup><span class="xrefLink" id="jumplink-ehae176-B959"></span><a href="javascript:;" reveal-id="ehae176-B959" data-open="ehae176-B959" class="link link-ref link-reveal xref-bibr">959</a>,<span class="xrefLink" id="jumplink-ehae176-B966"></span><a href="javascript:;" reveal-id="ehae176-B966" data-open="ehae176-B966" class="link link-ref link-reveal xref-bibr">966</a>,<span class="xrefLink" id="jumplink-ehae176-B980"></span><a href="javascript:;" reveal-id="ehae176-B980" data-open="ehae176-B980" class="link link-ref link-reveal xref-bibr">980</a>,<span class="xrefLink" id="jumplink-ehae176-B981"></span><a href="javascript:;" reveal-id="ehae176-B981" data-open="ehae176-B981" class="link link-ref link-reveal xref-bibr">981</a></sup> Programming a single high-rate ventricular fibrillation zone ≥210–220 b.p.m. with long detection time is safe,<sup><span class="xrefLink" id="jumplink-ehae176-B950"></span><a href="javascript:;" reveal-id="ehae176-B950" data-open="ehae176-B950" class="link link-ref link-reveal xref-bibr">950</a>,<span class="xrefLink" id="jumplink-ehae176-B953"></span><a href="javascript:;" reveal-id="ehae176-B953" data-open="ehae176-B953" class="link link-ref link-reveal xref-bibr">953</a>,<span class="xrefLink" id="jumplink-ehae176-B982"></span><a href="javascript:;" reveal-id="ehae176-B982" data-open="ehae176-B982" class="link link-ref link-reveal xref-bibr">982</a></sup> and is suggested in patients without documented slow monomorphic ventricular tachycardia. Implantation of an atrial lead may be considered in the case of significant bradycardia with beta-blocker treatment.

Patients with Wolff–Parkinson–White syndrome and AF are at risk of fast ventricular rates from rapid conduction of atrial electrical activity to the ventricles via the accessory pathway, potentially leading to ventricular fibrillation and sudden death.<sup><span class="xrefLink" id="jumplink-ehae176-B983"></span><a href="javascript:;" reveal-id="ehae176-B983" data-open="ehae176-B983" class="link link-ref link-reveal xref-bibr">983</a>,<span class="xrefLink" id="jumplink-ehae176-B984"></span><a href="javascript:;" reveal-id="ehae176-B984" data-open="ehae176-B984" class="link link-ref link-reveal xref-bibr">984</a></sup> Immediate electrical cardioversion is needed for haemodynamically compromised patients with pre-excited AF, and atrioventricular node-modulating drugs should be avoided.<sup><span class="xrefLink" id="jumplink-ehae176-B985"></span><a href="javascript:;" reveal-id="ehae176-B985" data-open="ehae176-B985" class="link link-ref link-reveal xref-bibr">985</a>,<span class="xrefLink" id="jumplink-ehae176-B986"></span><a href="javascript:;" reveal-id="ehae176-B986" data-open="ehae176-B986" class="link link-ref link-reveal xref-bibr">986</a></sup> Pharmacological cardioversion can be attempted using ibutilide<sup><span class="xrefLink" id="jumplink-ehae176-B987"></span><a href="javascript:;" reveal-id="ehae176-B987" data-open="ehae176-B987" class="link link-ref link-reveal xref-bibr">987</a></sup> or flecainide, while propafenone should be used with caution due to effects on the atrioventricular node.<sup><span class="xrefLink" id="jumplink-ehae176-B988"></span><a href="javascript:;" reveal-id="ehae176-B988" data-open="ehae176-B988" class="link link-ref link-reveal xref-bibr">988</a>,<span class="xrefLink" id="jumplink-ehae176-B989"></span><a href="javascript:;" reveal-id="ehae176-B989" data-open="ehae176-B989" class="link link-ref link-reveal xref-bibr">989</a></sup> Amiodarone should be avoided in pre-excited AF due to its delayed action. Further details on inherited cardiomyopathies can be found in the _2023 ESC Guidelines for the management of cardiomyopathies_.<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a></sup>

### 9.12. AF-CARE in cancer

All types of cancer show an increased risk of AF, with prevalence varying from 2% to 28%.<sup><span class="xrefLink" id="jumplink-ehae176-B991 ehae176-B992 ehae176-B993 ehae176-B994 ehae176-B995"></span><a href="javascript:;" reveal-id="ehae176-B991 ehae176-B992 ehae176-B993 ehae176-B994 ehae176-B995" data-open="ehae176-B991 ehae176-B992 ehae176-B993 ehae176-B994 ehae176-B995" class="link link-ref link-reveal xref-bibr">991–995</a></sup> The occurrence of AF may often be related to a pre-existing atrial substrate with vulnerability to AF. AF may be an indicator of an occult cancer, but also can appear in the context of concomitant surgery, chemotherapy, or radiotherapy.<sup><span class="xrefLink" id="jumplink-ehae176-B916"></span><a href="javascript:;" reveal-id="ehae176-B916" data-open="ehae176-B916" class="link link-ref link-reveal xref-bibr">916</a>,<span class="xrefLink" id="jumplink-ehae176-B994"></span><a href="javascript:;" reveal-id="ehae176-B994" data-open="ehae176-B994" class="link link-ref link-reveal xref-bibr">994</a>,<span class="xrefLink" id="jumplink-ehae176-B996"></span><a href="javascript:;" reveal-id="ehae176-B996" data-open="ehae176-B996" class="link link-ref link-reveal xref-bibr">996</a></sup> Risk of AF is dependent on, among other factors, the cancer type and stage,<sup><span class="xrefLink" id="jumplink-ehae176-B997"></span><a href="javascript:;" reveal-id="ehae176-B997" data-open="ehae176-B997" class="link link-ref link-reveal xref-bibr">997</a></sup> and is greater in older patients with pre-existing cardiovascular disease.<sup><span class="xrefLink" id="jumplink-ehae176-B991"></span><a href="javascript:;" reveal-id="ehae176-B991" data-open="ehae176-B991" class="link link-ref link-reveal xref-bibr">991</a>,<span class="xrefLink" id="jumplink-ehae176-B993"></span><a href="javascript:;" reveal-id="ehae176-B993" data-open="ehae176-B993" class="link link-ref link-reveal xref-bibr">993</a>,<span class="xrefLink" id="jumplink-ehae176-B994"></span><a href="javascript:;" reveal-id="ehae176-B994" data-open="ehae176-B994" class="link link-ref link-reveal xref-bibr">994</a></sup> Some procedures are associated with higher incidence of AF, including lung surgery (from 6% to 32%) and non-thoracic surgery such as a colectomy (4%–5%).<sup><span class="xrefLink" id="jumplink-ehae176-B994"></span><a href="javascript:;" reveal-id="ehae176-B994" data-open="ehae176-B994" class="link link-ref link-reveal xref-bibr">994</a></sup>

Atrial fibrillation in the context of cancer is associated with a two-fold higher risk of systemic thromboembolism and stroke, and six-fold increased risk of heart failure.<sup><span class="xrefLink" id="jumplink-ehae176-B991"></span><a href="javascript:;" reveal-id="ehae176-B991" data-open="ehae176-B991" class="link link-ref link-reveal xref-bibr">991</a>,<span class="xrefLink" id="jumplink-ehae176-B994"></span><a href="javascript:;" reveal-id="ehae176-B994" data-open="ehae176-B994" class="link link-ref link-reveal xref-bibr">994</a></sup> On the other hand, the coexistence of cancer increases the risk of all-cause mortality and major bleeding in patients with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B998"></span><a href="javascript:;" reveal-id="ehae176-B998" data-open="ehae176-B998" class="link link-ref link-reveal xref-bibr">998</a></sup> Bleeding in those receiving OAC can also unmask the presence of cancer.<sup><span class="xrefLink" id="jumplink-ehae176-B999"></span><a href="javascript:;" reveal-id="ehae176-B999" data-open="ehae176-B999" class="link link-ref link-reveal xref-bibr">999</a></sup>

Stroke risk scores may underestimate thromboembolic risk in cancer patients.<sup><span class="xrefLink" id="jumplink-ehae176-B1000"></span><a href="javascript:;" reveal-id="ehae176-B1000" data-open="ehae176-B1000" class="link link-ref link-reveal xref-bibr">1000</a></sup> The association between cancer, AF, and ischaemic stroke also differs between cancer types. In some types of cancer, the risk of bleeding seems to exceed the risk of thromboembolism.<sup><span class="xrefLink" id="jumplink-ehae176-B998"></span><a href="javascript:;" reveal-id="ehae176-B998" data-open="ehae176-B998" class="link link-ref link-reveal xref-bibr">998</a></sup> Risk stratification is therefore complex in this population, and should be performed on an individual basis considering cancer type, stage, prognosis, bleeding risk, and other risk factors. These aspects can change within a short period of time, requiring dynamic assessment and management.

As with non-cancer patients, DOACs in those with cancer have similar efficacy and better safety compared with VKAs.<sup><span class="xrefLink" id="jumplink-ehae176-B1001 ehae176-B1002 ehae176-B1003 ehae176-B1004 ehae176-B1005 ehae176-B1006 ehae176-B1007 ehae176-B1008 ehae176-B1009 ehae176-B1010"></span><a href="javascript:;" reveal-id="ehae176-B1001 ehae176-B1002 ehae176-B1003 ehae176-B1004 ehae176-B1005 ehae176-B1006 ehae176-B1007 ehae176-B1008 ehae176-B1009 ehae176-B1010" data-open="ehae176-B1001 ehae176-B1002 ehae176-B1003 ehae176-B1004 ehae176-B1005 ehae176-B1006 ehae176-B1007 ehae176-B1008 ehae176-B1009 ehae176-B1010" class="link link-ref link-reveal xref-bibr">1001–1010</a></sup> Low molecular weight heparin is a short-term anticoagulation option, mostly during some cancer treatments, recent active bleeding, or thrombocytopaenia.<sup><span class="xrefLink" id="jumplink-ehae176-B1011"></span><a href="javascript:;" reveal-id="ehae176-B1011" data-open="ehae176-B1011" class="link link-ref link-reveal xref-bibr">1011</a></sup> Decision-making on AF management, including on rhythm control, is best performed within a cardio-oncology multidisciplinary team.<sup><span class="xrefLink" id="jumplink-ehae176-B916"></span><a href="javascript:;" reveal-id="ehae176-B916" data-open="ehae176-B916" class="link link-ref link-reveal xref-bibr">916</a>,<span class="xrefLink" id="jumplink-ehae176-B1012"></span><a href="javascript:;" reveal-id="ehae176-B1012" data-open="ehae176-B1012" class="link link-ref link-reveal xref-bibr">1012</a></sup> Attention is required on interactions with cancer treatments, in particular QT-interval prolongation with AADs.

### 9.13. AF-CARE in older, multimorbid, or frail patients

Atrial fibrillation increases with age, and older patients more frequently have multimorbidity and frailty which are associated with worse clinical outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B1013 ehae176-B1014 ehae176-B1015 ehae176-B1016"></span><a href="javascript:;" reveal-id="ehae176-B1013 ehae176-B1014 ehae176-B1015 ehae176-B1016" data-open="ehae176-B1013 ehae176-B1014 ehae176-B1015 ehae176-B1016" class="link link-ref link-reveal xref-bibr">1013–1016</a></sup> Multimorbidity is the coexistence of two or more medically diagnosed diseases in the same individual. Frailty is defined as a person more vulnerable and less able to respond to a stressor or acute event, increasing the risk of adverse outcomes.<sup><span class="xrefLink" id="jumplink-ehae176-B1016"></span><a href="javascript:;" reveal-id="ehae176-B1016" data-open="ehae176-B1016" class="link link-ref link-reveal xref-bibr">1016</a>,<span class="xrefLink" id="jumplink-ehae176-B1017"></span><a href="javascript:;" reveal-id="ehae176-B1017" data-open="ehae176-B1017" class="link link-ref link-reveal xref-bibr">1017</a></sup> The prevalence of frailty in AF varies due to different methods of assessment from 4.4% to 75.4%, and AF prevalence in the frail population ranges from 48.2% to 75.4%.<sup><span class="xrefLink" id="jumplink-ehae176-B1018"></span><a href="javascript:;" reveal-id="ehae176-B1018" data-open="ehae176-B1018" class="link link-ref link-reveal xref-bibr">1018</a></sup> Frailty status is a strong independent risk factor for new-onset AF among older adults with hypertension.<sup><span class="xrefLink" id="jumplink-ehae176-B1019"></span><a href="javascript:;" reveal-id="ehae176-B1019" data-open="ehae176-B1019" class="link link-ref link-reveal xref-bibr">1019</a></sup>

Atrial fibrillation in frail patients is associated with less use of OAC and lower rates of management with a rhythm control strategy.<sup><span class="xrefLink" id="jumplink-ehae176-B1015"></span><a href="javascript:;" reveal-id="ehae176-B1015" data-open="ehae176-B1015" class="link link-ref link-reveal xref-bibr">1015</a>,<span class="xrefLink" id="jumplink-ehae176-B1018"></span><a href="javascript:;" reveal-id="ehae176-B1018" data-open="ehae176-B1018" class="link link-ref link-reveal xref-bibr">1018</a>,<span class="xrefLink" id="jumplink-ehae176-B1020"></span><a href="javascript:;" reveal-id="ehae176-B1020" data-open="ehae176-B1020" class="link link-ref link-reveal xref-bibr">1020</a></sup> Oral anticoagulation initiation in older, frail multimorbid AF patients has improved since the introduction of DOACs, but is still lower in AF patients at older age (OR, 0.98 per year; 95% CI, 0.98–0.98), with dementia (OR, 0.57; 95% CI, 0.55–0.58), or frailty (OR, 0.74; 95% CI, 0.72–0.76).<sup><span class="xrefLink" id="jumplink-ehae176-B1021"></span><a href="javascript:;" reveal-id="ehae176-B1021" data-open="ehae176-B1021" class="link link-ref link-reveal xref-bibr">1021</a></sup> The value of observational data which show potential benefit from OAC (in particular, DOACs) is limited due to prescription biases.<sup><span class="xrefLink" id="jumplink-ehae176-B1022 ehae176-B1023 ehae176-B1024 ehae176-B1025 ehae176-B1026 ehae176-B1027"></span><a href="javascript:;" reveal-id="ehae176-B1022 ehae176-B1023 ehae176-B1024 ehae176-B1025 ehae176-B1026 ehae176-B1027" data-open="ehae176-B1022 ehae176-B1023 ehae176-B1024 ehae176-B1025 ehae176-B1026 ehae176-B1027" class="link link-ref link-reveal xref-bibr">1022–1027</a></sup> Frail patients aged ≥75 years with polypharmacy and stable on a VKA may remain on the VKA rather than switching to a DOAC (_Section [6.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.2)_).<sup><span class="xrefLink" id="jumplink-ehae176-B309"></span><a href="javascript:;" reveal-id="ehae176-B309" data-open="ehae176-B309" class="link link-ref link-reveal xref-bibr">309</a></sup>

### 9.14. AF-CARE in atrial flutter

Due to the association between AFL and thromboembolic outcomes, and the frequent development of AF in patients with AFL, the management of comorbidities and risk factors in AFL should mirror that for AF (see _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s4)_). Similarly, the approach to prevent thromboembolism in AFL includes peri-procedural and long-term OAC (see _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5)_). Rate control can be difficult to achieve in AFL, despite combination therapy. Rhythm control is often the first-line approach,<sup><span class="xrefLink" id="jumplink-ehae176-B983"></span><a href="javascript:;" reveal-id="ehae176-B983" data-open="ehae176-B983" class="link link-ref link-reveal xref-bibr">983</a></sup> with small randomized trials showing that cavo-tricuspid isthmus (CTI) ablation is superior to AADs.<sup><span class="xrefLink" id="jumplink-ehae176-B1028"></span><a href="javascript:;" reveal-id="ehae176-B1028" data-open="ehae176-B1028" class="link link-ref link-reveal xref-bibr">1028</a>,<span class="xrefLink" id="jumplink-ehae176-B1029"></span><a href="javascript:;" reveal-id="ehae176-B1029" data-open="ehae176-B1029" class="link link-ref link-reveal xref-bibr">1029</a></sup> Recurrence of AFL is uncommon after achieving and confirming bidirectional block in typical CTI-dependent AFL. However, the majority of patients (50%–70%) have manifested AF during long-term follow-up in observational studies after AFL ablation.<sup><span class="xrefLink" id="jumplink-ehae176-B1030"></span><a href="javascript:;" reveal-id="ehae176-B1030" data-open="ehae176-B1030" class="link link-ref link-reveal xref-bibr">1030</a>,<span class="xrefLink" id="jumplink-ehae176-B1031"></span><a href="javascript:;" reveal-id="ehae176-B1031" data-open="ehae176-B1031" class="link link-ref link-reveal xref-bibr">1031</a></sup> Hence the necessity for long-term dynamic re-evaluation in all patients with AFL in keeping with the AF-CARE approach. More detail on the management of AFL and other atrial arrhythmias is described in the _2019 ESC Guidelines for the management of patients with supraventricular tachycardia_.<sup><span class="xrefLink" id="jumplink-ehae176-B983"></span><a href="javascript:;" reveal-id="ehae176-B983" data-open="ehae176-B983" class="link link-ref link-reveal xref-bibr">983</a></sup>

Recommendation Table 30

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884428)

Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30)

![Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt30.jpeg?Expires=1728478929&Signature=jVBeb-LOPeKiXfC6kizs1qyXo05jZ8TxEOzDDFrsUFiaBk-6WCfnDJt1GlFVNTz6rLyzJGRtsYFxF9w1YqIvw2DD7zu-lrAAY5Q177OVgM8GXnfz5aZCtitooyUdyRniJbWLuwSzfDZJDxMDp-fstu-442BX5nc8ePwp2~NruI97Oy3q6C3wJqDPf8WPihasA20qgY~FtfnpeuC11o1ZOTSWbHFUkLBDkLHVV7Im0nI~nCoNspNnMzrkFkYDpA7r-GVlsOMYxMzNU6pe3yYTD5EAxD9PVZc8PrGrfxObFR0XmSq8PT83odIByxjkU7HJ4nlz7sm~BgjkIykf4GYOxQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 30

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884428)

Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30)

![Recommendations for prevention of thromboembolism in atrial flutter (see also Evidence Table 30)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt30.jpeg?Expires=1728478929&Signature=jVBeb-LOPeKiXfC6kizs1qyXo05jZ8TxEOzDDFrsUFiaBk-6WCfnDJt1GlFVNTz6rLyzJGRtsYFxF9w1YqIvw2DD7zu-lrAAY5Q177OVgM8GXnfz5aZCtitooyUdyRniJbWLuwSzfDZJDxMDp-fstu-442BX5nc8ePwp2~NruI97Oy3q6C3wJqDPf8WPihasA20qgY~FtfnpeuC11o1ZOTSWbHFUkLBDkLHVV7Im0nI~nCoNspNnMzrkFkYDpA7r-GVlsOMYxMzNU6pe3yYTD5EAxD9PVZc8PrGrfxObFR0XmSq8PT83odIByxjkU7HJ4nlz7sm~BgjkIykf4GYOxQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 10\. Screening and prevention of AF

### 10.1. Epidemiology of AF

Atrial fibrillation is the most common sustained arrhythmia worldwide, with an estimated global prevalence in 2019 of 59.7 million persons with AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1033"></span><a href="javascript:;" reveal-id="ehae176-B1033" data-open="ehae176-B1033" class="link link-ref link-reveal xref-bibr">1033</a></sup> Incident cases of AF are doubling every few decades.<sup><span class="xrefLink" id="jumplink-ehae176-B1034"></span><a href="javascript:;" reveal-id="ehae176-B1034" data-open="ehae176-B1034" class="link link-ref link-reveal xref-bibr">1034</a></sup> Future increases are anticipated, in particular in middle-income countries.<sup><span class="xrefLink" id="jumplink-ehae176-B1034"></span><a href="javascript:;" reveal-id="ehae176-B1034" data-open="ehae176-B1034" class="link link-ref link-reveal xref-bibr">1034</a></sup> In community-based individuals, the prevalence of AF in a United States of America cohort was up to 5.9%.<sup><span class="xrefLink" id="jumplink-ehae176-B1035"></span><a href="javascript:;" reveal-id="ehae176-B1035" data-open="ehae176-B1035" class="link link-ref link-reveal xref-bibr">1035</a></sup> The age-standardized prevalence and incidence rates have remained constant over time.<sup><span class="xrefLink" id="jumplink-ehae176-B1033"></span><a href="javascript:;" reveal-id="ehae176-B1033" data-open="ehae176-B1033" class="link link-ref link-reveal xref-bibr">1033</a>,<span class="xrefLink" id="jumplink-ehae176-B1036"></span><a href="javascript:;" reveal-id="ehae176-B1036" data-open="ehae176-B1036" class="link link-ref link-reveal xref-bibr">1036</a></sup> The increase in overall prevalence is largely attributable to population growth, ageing, and survival from other cardiac conditions. In parallel, increases in risk factor burden, better awareness, and improved detection of AF have been observed.<sup><span class="xrefLink" id="jumplink-ehae176-B1037"></span><a href="javascript:;" reveal-id="ehae176-B1037" data-open="ehae176-B1037" class="link link-ref link-reveal xref-bibr">1037</a></sup> The lifetime risk of AF has been estimated to be as high as 1 in 3 for older individuals,<sup><span class="xrefLink" id="jumplink-ehae176-B1038"></span><a href="javascript:;" reveal-id="ehae176-B1038" data-open="ehae176-B1038" class="link link-ref link-reveal xref-bibr">1038</a></sup> with age-standardized incidence rates higher for men than women. Populations of European ancestry are typically found to have higher AF prevalence, individuals of African ancestry have worse outcomes, and other groups may have less access to interventions.<sup><span class="xrefLink" id="jumplink-ehae176-B1039 ehae176-B1040 ehae176-B1041"></span><a href="javascript:;" reveal-id="ehae176-B1039 ehae176-B1040 ehae176-B1041" data-open="ehae176-B1039 ehae176-B1040 ehae176-B1041" class="link link-ref link-reveal xref-bibr">1039–1041</a></sup> Socioeconomic and other factors likely play a role in racial and ethnic differences in AF, but studies are also limited due to differences in how groups access healthcare. Greater deprivation in socioeconomic and living status is associated with higher AF incidence.<sup><span class="xrefLink" id="jumplink-ehae176-B1042"></span><a href="javascript:;" reveal-id="ehae176-B1042" data-open="ehae176-B1042" class="link link-ref link-reveal xref-bibr">1042</a></sup>

### 10.2. Screening tools for AF

In recent years, an abundance of novel devices that can monitor heart rhythm have come to the market, including fitness bands and smartwatches. Although the evidence for clinical effectiveness of digital devices is limited, they may be useful in detecting AF, and their clinical, economic, legal, and policy implications merit further investigation.<sup><span class="xrefLink" id="jumplink-ehae176-B1043"></span><a href="javascript:;" reveal-id="ehae176-B1043" data-open="ehae176-B1043" class="link link-ref link-reveal xref-bibr">1043</a>,<span class="xrefLink" id="jumplink-ehae176-B1044"></span><a href="javascript:;" reveal-id="ehae176-B1044" data-open="ehae176-B1044" class="link link-ref link-reveal xref-bibr">1044</a></sup> Devices for AF detection can broadly be divided into those that provide an ECG, and those with non-ECG approaches such as photoplethysmography (_[Figure 15](javascript:;)_ and _[Table 15](javascript:;)_).

![Non-invasive diagnostic methods for AF screening.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f15.jpeg?Expires=1728478929&Signature=H4UiMQDvUAPgxEzgpikJQygpuUJFjVeRcSvbPjBcLEy6o27o5vRF3shQIAyI2Ixh7GBXj8fr6xsCjMO7A5SixLiATRprMARfGEHXGy6MDBhnqNrs7Af-yo2jkKJa9CH6-LUTEVKi6Lq3HFvhFLEJr7G2Xz4UqE-dToNNxyiJbTPEcxQWmj79kcjPh-ZsKDRdXptF4auFh2G4PM8c9Wuj9dn~Nj7fn142HEqQ2hoyNKTtYCMRVYz0X2PIh-KYdZxOAZcZL~CP0e7Fve19kTiv8MniJ3sXgOBu3SdI37Qt5sdKiguev9nk5yT2JC-cJQicXiyTi6XALMh66XUtoRIPHg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 15

Non-invasive diagnostic methods for AF screening.

AF, atrial fibrillation; BP, blood pressure; ECG, electrocardiogram; PPG, photoplethysmography.

[Open in new tab](https://academic.oup.com/view-large/figure/479884434/ehae176f15.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f15.jpeg?Expires=1728478929&Signature=BLyBQRhJNs06nNBJRsbrlmbnGHbUeeopAdHAYZBkWb~rDl7DQFMXY~Udvav2NE6GCd9iLxv7wgBtrt8S7PEHkiEsAUhDdtoVOkRt3kcHtId5jTenJyDmmfVf6YwiJVT79AYQ9g~s7-BcQjGLl3CA77StCA2Zoor2lH3ioyYLTLxeVIn3sFmfkKhPPWCc8J3vO69~7PPY-9KEsW5SL44r2MxzibP3noERE33Ww~utNjA3ilE3HEVfJa8a-Ln6H4Zwo-lo5Ds7zvypuXAE43-ywhyR343V~laj~k22qLiiTuyZXrQBr2PW-FT5~8~G3EEJG8i3k0G5omcVdaqh84ZOyw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884434&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884435)

Tools for AF screening

| Tools for AF screening .  |
| --- |
| 
- (i) Pulse palpation<sup><span class="xrefLink" id="jumplink-ehae176-B1045"></span><a href="javascript:;" reveal-id="ehae176-B1045" data-open="ehae176-B1045" class="link link-ref link-reveal xref-bibr">1045</a></sup>

- (ii) Use of artificial intelligence algorithms to identify patients at risk<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup>

- (iii) ECG-based devices

- (a) Conventional ECG devices

- (1) Classic 12-lead ECG <sup><span class="xrefLink" id="jumplink-ehae176-B1047"></span><a href="javascript:;" reveal-id="ehae176-B1047" data-open="ehae176-B1047" class="link link-ref link-reveal xref-bibr">1047</a></sup>

- (2) Holter monitoring (from 24 h to a week or more)<sup><span class="xrefLink" id="jumplink-ehae176-B1048"></span><a href="javascript:;" reveal-id="ehae176-B1048" data-open="ehae176-B1048" class="link link-ref link-reveal xref-bibr">1048</a></sup>

- (3) Mobile cardiac telemetry (during hospitalization)<sup><span class="xrefLink" id="jumplink-ehae176-B1049"></span><a href="javascript:;" reveal-id="ehae176-B1049" data-open="ehae176-B1049" class="link link-ref link-reveal xref-bibr">1049</a></sup>

- (4) Handheld devices<sup><span class="xrefLink" id="jumplink-ehae176-B1050 ehae176-B1051 ehae176-B1052"></span><a href="javascript:;" reveal-id="ehae176-B1050 ehae176-B1051 ehae176-B1052" data-open="ehae176-B1050 ehae176-B1051 ehae176-B1052" class="link link-ref link-reveal xref-bibr">1050–1052</a></sup>

- (5) Wearable patches (up to 14 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067"></span><a href="javascript:;" reveal-id="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" data-open="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" class="link link-ref link-reveal xref-bibr">1053–1067</a></sup>

- (6) Biotextiles (up to 30 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072"></span><a href="javascript:;" reveal-id="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" data-open="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" class="link link-ref link-reveal xref-bibr">1068–1072</a></sup>

- (7) Smart devices (30 s)<sup><span class="xrefLink" id="jumplink-ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" data-open="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" class="link link-ref link-reveal xref-bibr">1073–1091</a></sup>

- (b) Implantable loop recorders (3–5 years)<sup><span class="xrefLink" id="jumplink-ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099"></span><a href="javascript:;" reveal-id="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" data-open="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" class="link link-ref link-reveal xref-bibr">1092–1099</a></sup>

- (iv) Non-ECG-based devices

- (a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)<sup><span class="xrefLink" id="jumplink-ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106"></span><a href="javascript:;" reveal-id="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" data-open="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" class="link link-ref link-reveal xref-bibr">1100–1106</a></sup>

- (b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)<sup><span class="xrefLink" id="jumplink-ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110"></span><a href="javascript:;" reveal-id="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" data-open="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" class="link link-ref link-reveal xref-bibr">1107–1110</a></sup>

- (c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)<sup><span class="xrefLink" id="jumplink-ehae176-B1111"></span><a href="javascript:;" reveal-id="ehae176-B1111" data-open="ehae176-B1111" class="link link-ref link-reveal xref-bibr">1111</a></sup>

- (d) Contactless video plethysmography (through video monitoring)<sup><span class="xrefLink" id="jumplink-ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115"></span><a href="javascript:;" reveal-id="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" data-open="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" class="link link-ref link-reveal xref-bibr">1112–1115</a></sup>

- (e) Smart speakers (through the identification of abnormal heart rate patterns)<sup><span class="xrefLink" id="jumplink-ehae176-B1116"></span><a href="javascript:;" reveal-id="ehae176-B1116" data-open="ehae176-B1116" class="link link-ref link-reveal xref-bibr">1116</a></sup>


 |

| Tools for AF screening .  |
| --- |
| 
- (i) Pulse palpation<sup><span class="xrefLink" id="jumplink-ehae176-B1045"></span><a href="javascript:;" reveal-id="ehae176-B1045" data-open="ehae176-B1045" class="link link-ref link-reveal xref-bibr">1045</a></sup>

- (ii) Use of artificial intelligence algorithms to identify patients at risk<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup>

- (iii) ECG-based devices

- (a) Conventional ECG devices

- (1) Classic 12-lead ECG <sup><span class="xrefLink" id="jumplink-ehae176-B1047"></span><a href="javascript:;" reveal-id="ehae176-B1047" data-open="ehae176-B1047" class="link link-ref link-reveal xref-bibr">1047</a></sup>

- (2) Holter monitoring (from 24 h to a week or more)<sup><span class="xrefLink" id="jumplink-ehae176-B1048"></span><a href="javascript:;" reveal-id="ehae176-B1048" data-open="ehae176-B1048" class="link link-ref link-reveal xref-bibr">1048</a></sup>

- (3) Mobile cardiac telemetry (during hospitalization)<sup><span class="xrefLink" id="jumplink-ehae176-B1049"></span><a href="javascript:;" reveal-id="ehae176-B1049" data-open="ehae176-B1049" class="link link-ref link-reveal xref-bibr">1049</a></sup>

- (4) Handheld devices<sup><span class="xrefLink" id="jumplink-ehae176-B1050 ehae176-B1051 ehae176-B1052"></span><a href="javascript:;" reveal-id="ehae176-B1050 ehae176-B1051 ehae176-B1052" data-open="ehae176-B1050 ehae176-B1051 ehae176-B1052" class="link link-ref link-reveal xref-bibr">1050–1052</a></sup>

- (5) Wearable patches (up to 14 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067"></span><a href="javascript:;" reveal-id="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" data-open="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" class="link link-ref link-reveal xref-bibr">1053–1067</a></sup>

- (6) Biotextiles (up to 30 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072"></span><a href="javascript:;" reveal-id="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" data-open="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" class="link link-ref link-reveal xref-bibr">1068–1072</a></sup>

- (7) Smart devices (30 s)<sup><span class="xrefLink" id="jumplink-ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" data-open="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" class="link link-ref link-reveal xref-bibr">1073–1091</a></sup>

- (b) Implantable loop recorders (3–5 years)<sup><span class="xrefLink" id="jumplink-ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099"></span><a href="javascript:;" reveal-id="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" data-open="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" class="link link-ref link-reveal xref-bibr">1092–1099</a></sup>

- (iv) Non-ECG-based devices

- (a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)<sup><span class="xrefLink" id="jumplink-ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106"></span><a href="javascript:;" reveal-id="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" data-open="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" class="link link-ref link-reveal xref-bibr">1100–1106</a></sup>

- (b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)<sup><span class="xrefLink" id="jumplink-ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110"></span><a href="javascript:;" reveal-id="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" data-open="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" class="link link-ref link-reveal xref-bibr">1107–1110</a></sup>

- (c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)<sup><span class="xrefLink" id="jumplink-ehae176-B1111"></span><a href="javascript:;" reveal-id="ehae176-B1111" data-open="ehae176-B1111" class="link link-ref link-reveal xref-bibr">1111</a></sup>

- (d) Contactless video plethysmography (through video monitoring)<sup><span class="xrefLink" id="jumplink-ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115"></span><a href="javascript:;" reveal-id="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" data-open="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" class="link link-ref link-reveal xref-bibr">1112–1115</a></sup>

- (e) Smart speakers (through the identification of abnormal heart rate patterns)<sup><span class="xrefLink" id="jumplink-ehae176-B1116"></span><a href="javascript:;" reveal-id="ehae176-B1116" data-open="ehae176-B1116" class="link link-ref link-reveal xref-bibr">1116</a></sup>


 |

ECG, electrocardiogram.

© ESC 2024

Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884435)

Tools for AF screening

| Tools for AF screening .  |
| --- |
| 
- (i) Pulse palpation<sup><span class="xrefLink" id="jumplink-ehae176-B1045"></span><a href="javascript:;" reveal-id="ehae176-B1045" data-open="ehae176-B1045" class="link link-ref link-reveal xref-bibr">1045</a></sup>

- (ii) Use of artificial intelligence algorithms to identify patients at risk<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup>

- (iii) ECG-based devices

- (a) Conventional ECG devices

- (1) Classic 12-lead ECG <sup><span class="xrefLink" id="jumplink-ehae176-B1047"></span><a href="javascript:;" reveal-id="ehae176-B1047" data-open="ehae176-B1047" class="link link-ref link-reveal xref-bibr">1047</a></sup>

- (2) Holter monitoring (from 24 h to a week or more)<sup><span class="xrefLink" id="jumplink-ehae176-B1048"></span><a href="javascript:;" reveal-id="ehae176-B1048" data-open="ehae176-B1048" class="link link-ref link-reveal xref-bibr">1048</a></sup>

- (3) Mobile cardiac telemetry (during hospitalization)<sup><span class="xrefLink" id="jumplink-ehae176-B1049"></span><a href="javascript:;" reveal-id="ehae176-B1049" data-open="ehae176-B1049" class="link link-ref link-reveal xref-bibr">1049</a></sup>

- (4) Handheld devices<sup><span class="xrefLink" id="jumplink-ehae176-B1050 ehae176-B1051 ehae176-B1052"></span><a href="javascript:;" reveal-id="ehae176-B1050 ehae176-B1051 ehae176-B1052" data-open="ehae176-B1050 ehae176-B1051 ehae176-B1052" class="link link-ref link-reveal xref-bibr">1050–1052</a></sup>

- (5) Wearable patches (up to 14 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067"></span><a href="javascript:;" reveal-id="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" data-open="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" class="link link-ref link-reveal xref-bibr">1053–1067</a></sup>

- (6) Biotextiles (up to 30 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072"></span><a href="javascript:;" reveal-id="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" data-open="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" class="link link-ref link-reveal xref-bibr">1068–1072</a></sup>

- (7) Smart devices (30 s)<sup><span class="xrefLink" id="jumplink-ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" data-open="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" class="link link-ref link-reveal xref-bibr">1073–1091</a></sup>

- (b) Implantable loop recorders (3–5 years)<sup><span class="xrefLink" id="jumplink-ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099"></span><a href="javascript:;" reveal-id="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" data-open="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" class="link link-ref link-reveal xref-bibr">1092–1099</a></sup>

- (iv) Non-ECG-based devices

- (a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)<sup><span class="xrefLink" id="jumplink-ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106"></span><a href="javascript:;" reveal-id="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" data-open="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" class="link link-ref link-reveal xref-bibr">1100–1106</a></sup>

- (b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)<sup><span class="xrefLink" id="jumplink-ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110"></span><a href="javascript:;" reveal-id="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" data-open="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" class="link link-ref link-reveal xref-bibr">1107–1110</a></sup>

- (c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)<sup><span class="xrefLink" id="jumplink-ehae176-B1111"></span><a href="javascript:;" reveal-id="ehae176-B1111" data-open="ehae176-B1111" class="link link-ref link-reveal xref-bibr">1111</a></sup>

- (d) Contactless video plethysmography (through video monitoring)<sup><span class="xrefLink" id="jumplink-ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115"></span><a href="javascript:;" reveal-id="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" data-open="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" class="link link-ref link-reveal xref-bibr">1112–1115</a></sup>

- (e) Smart speakers (through the identification of abnormal heart rate patterns)<sup><span class="xrefLink" id="jumplink-ehae176-B1116"></span><a href="javascript:;" reveal-id="ehae176-B1116" data-open="ehae176-B1116" class="link link-ref link-reveal xref-bibr">1116</a></sup>


 |

| Tools for AF screening .  |
| --- |
| 
- (i) Pulse palpation<sup><span class="xrefLink" id="jumplink-ehae176-B1045"></span><a href="javascript:;" reveal-id="ehae176-B1045" data-open="ehae176-B1045" class="link link-ref link-reveal xref-bibr">1045</a></sup>

- (ii) Use of artificial intelligence algorithms to identify patients at risk<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup>

- (iii) ECG-based devices

- (a) Conventional ECG devices

- (1) Classic 12-lead ECG <sup><span class="xrefLink" id="jumplink-ehae176-B1047"></span><a href="javascript:;" reveal-id="ehae176-B1047" data-open="ehae176-B1047" class="link link-ref link-reveal xref-bibr">1047</a></sup>

- (2) Holter monitoring (from 24 h to a week or more)<sup><span class="xrefLink" id="jumplink-ehae176-B1048"></span><a href="javascript:;" reveal-id="ehae176-B1048" data-open="ehae176-B1048" class="link link-ref link-reveal xref-bibr">1048</a></sup>

- (3) Mobile cardiac telemetry (during hospitalization)<sup><span class="xrefLink" id="jumplink-ehae176-B1049"></span><a href="javascript:;" reveal-id="ehae176-B1049" data-open="ehae176-B1049" class="link link-ref link-reveal xref-bibr">1049</a></sup>

- (4) Handheld devices<sup><span class="xrefLink" id="jumplink-ehae176-B1050 ehae176-B1051 ehae176-B1052"></span><a href="javascript:;" reveal-id="ehae176-B1050 ehae176-B1051 ehae176-B1052" data-open="ehae176-B1050 ehae176-B1051 ehae176-B1052" class="link link-ref link-reveal xref-bibr">1050–1052</a></sup>

- (5) Wearable patches (up to 14 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067"></span><a href="javascript:;" reveal-id="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" data-open="ehae176-B1053 ehae176-B1054 ehae176-B1055 ehae176-B1056 ehae176-B1057 ehae176-B1058 ehae176-B1059 ehae176-B1060 ehae176-B1061 ehae176-B1062 ehae176-B1063 ehae176-B1064 ehae176-B1065 ehae176-B1066 ehae176-B1067" class="link link-ref link-reveal xref-bibr">1053–1067</a></sup>

- (6) Biotextiles (up to 30 days)<sup><span class="xrefLink" id="jumplink-ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072"></span><a href="javascript:;" reveal-id="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" data-open="ehae176-B1068 ehae176-B1069 ehae176-B1070 ehae176-B1071 ehae176-B1072" class="link link-ref link-reveal xref-bibr">1068–1072</a></sup>

- (7) Smart devices (30 s)<sup><span class="xrefLink" id="jumplink-ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" data-open="ehae176-B1073 ehae176-B1074 ehae176-B1075 ehae176-B1076 ehae176-B1077 ehae176-B1078 ehae176-B1079 ehae176-B1080 ehae176-B1081 ehae176-B1082 ehae176-B1083 ehae176-B1084 ehae176-B1085 ehae176-B1086 ehae176-B1087 ehae176-B1088 ehae176-B1089 ehae176-B1090 ehae176-B1091" class="link link-ref link-reveal xref-bibr">1073–1091</a></sup>

- (b) Implantable loop recorders (3–5 years)<sup><span class="xrefLink" id="jumplink-ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099"></span><a href="javascript:;" reveal-id="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" data-open="ehae176-B1092 ehae176-B1093 ehae176-B1094 ehae176-B1095 ehae176-B1096 ehae176-B1097 ehae176-B1098 ehae176-B1099" class="link link-ref link-reveal xref-bibr">1092–1099</a></sup>

- (iv) Non-ECG-based devices

- (a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)<sup><span class="xrefLink" id="jumplink-ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106"></span><a href="javascript:;" reveal-id="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" data-open="ehae176-B1100 ehae176-B1101 ehae176-B1102 ehae176-B1103 ehae176-B1104 ehae176-B1105 ehae176-B1106" class="link link-ref link-reveal xref-bibr">1100–1106</a></sup>

- (b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)<sup><span class="xrefLink" id="jumplink-ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110"></span><a href="javascript:;" reveal-id="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" data-open="ehae176-B1107 ehae176-B1108 ehae176-B1109 ehae176-B1110" class="link link-ref link-reveal xref-bibr">1107–1110</a></sup>

- (c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)<sup><span class="xrefLink" id="jumplink-ehae176-B1111"></span><a href="javascript:;" reveal-id="ehae176-B1111" data-open="ehae176-B1111" class="link link-ref link-reveal xref-bibr">1111</a></sup>

- (d) Contactless video plethysmography (through video monitoring)<sup><span class="xrefLink" id="jumplink-ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115"></span><a href="javascript:;" reveal-id="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" data-open="ehae176-B1112 ehae176-B1113 ehae176-B1114 ehae176-B1115" class="link link-ref link-reveal xref-bibr">1112–1115</a></sup>

- (e) Smart speakers (through the identification of abnormal heart rate patterns)<sup><span class="xrefLink" id="jumplink-ehae176-B1116"></span><a href="javascript:;" reveal-id="ehae176-B1116" data-open="ehae176-B1116" class="link link-ref link-reveal xref-bibr">1116</a></sup>


 |

ECG, electrocardiogram.

© ESC 2024

Most consumer-based devices use photoplethysmography, and several large studies have been performed typically in low-risk individuals.<sup><span class="xrefLink" id="jumplink-ehae176-B633"></span><a href="javascript:;" reveal-id="ehae176-B633" data-open="ehae176-B633" class="link link-ref link-reveal xref-bibr">633</a>,<span class="xrefLink" id="jumplink-ehae176-B1076"></span><a href="javascript:;" reveal-id="ehae176-B1076" data-open="ehae176-B1076" class="link link-ref link-reveal xref-bibr">1076</a>,<span class="xrefLink" id="jumplink-ehae176-B1117"></span><a href="javascript:;" reveal-id="ehae176-B1117" data-open="ehae176-B1117" class="link link-ref link-reveal xref-bibr">1117</a>,<span class="xrefLink" id="jumplink-ehae176-B1118"></span><a href="javascript:;" reveal-id="ehae176-B1118" data-open="ehae176-B1118" class="link link-ref link-reveal xref-bibr">1118</a></sup> In an RCT of 5551 participants invited by their health insurer, smartphone-based photoplethysmography increased the odds of OAC-treated new AF by 2.12 (95% CI, 1.19–3.76; _P_ = .01) compared with usual care.<sup><span class="xrefLink" id="jumplink-ehae176-B605"></span><a href="javascript:;" reveal-id="ehae176-B605" data-open="ehae176-B605" class="link link-ref link-reveal xref-bibr">605</a></sup> RCTs powered for assessment of clinical outcomes are still lacking for consumer-based AF screening. Further head-to-head comparisons between novel digital devices and those commonly used in healthcare settings are needed to establish their comparative effectiveness in the clinical setting and account for different populations and settings.<sup><span class="xrefLink" id="jumplink-ehae176-B1119"></span><a href="javascript:;" reveal-id="ehae176-B1119" data-open="ehae176-B1119" class="link link-ref link-reveal xref-bibr">1119</a></sup> In a systematic review of smartphone-based photoplethysmography compared with a reference ECG, unrealistically high sensitivity and specificity were noted, likely due to small, low-quality studies with a high degree of patient selection bias.<sup><span class="xrefLink" id="jumplink-ehae176-B1120"></span><a href="javascript:;" reveal-id="ehae176-B1120" data-open="ehae176-B1120" class="link link-ref link-reveal xref-bibr">1120</a></sup> Hence, when AF is suggested by a photoplethysmography device or any other screening tool, a single-lead or continuous ECG tracing of >30 s or 12-lead ECG showing AF analysed by a physician with expertise in ECG rhythm interpretation is recommended to establish a definitive diagnosis of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1091"></span><a href="javascript:;" reveal-id="ehae176-B1091" data-open="ehae176-B1091" class="link link-ref link-reveal xref-bibr">1091</a>,<span class="xrefLink" id="jumplink-ehae176-B1121 ehae176-B1122 ehae176-B1123 ehae176-B1124 ehae176-B1125"></span><a href="javascript:;" reveal-id="ehae176-B1121 ehae176-B1122 ehae176-B1123 ehae176-B1124 ehae176-B1125" data-open="ehae176-B1121 ehae176-B1122 ehae176-B1123 ehae176-B1124 ehae176-B1125" class="link link-ref link-reveal xref-bibr">1121–1125</a></sup>

The combination of big data and artificial intelligence (AI) is having an increasing impact on the field of electrophysiology. Algorithms have been created to improve automated AF diagnosis and several algorithms to aid diagnostics are being investigated.<sup><span class="xrefLink" id="jumplink-ehae176-B1046"></span><a href="javascript:;" reveal-id="ehae176-B1046" data-open="ehae176-B1046" class="link link-ref link-reveal xref-bibr">1046</a></sup> However, the clinical performance and broad applicability of these solutions are not yet known. The use of AI may enable future treatment changes to be assessed with dynamic and continuous patient-directed monitoring using wearable devices.<sup><span class="xrefLink" id="jumplink-ehae176-B1126"></span><a href="javascript:;" reveal-id="ehae176-B1126" data-open="ehae176-B1126" class="link link-ref link-reveal xref-bibr">1126</a></sup> There are still challenges in the field that need clarification, such as data acquisition, model performance, external validity, clinical implementation, algorithm interpretation, and confidence, as well as the ethical aspects.<sup><span class="xrefLink" id="jumplink-ehae176-B1127"></span><a href="javascript:;" reveal-id="ehae176-B1127" data-open="ehae176-B1127" class="link link-ref link-reveal xref-bibr">1127</a></sup>

### 10.3. Screening strategies for AF

Screening can be performed systematically, with an invitation issued to a patient, or opportunistically, at the time of an _ad hoc_ meeting with a healthcare professional. Regardless of the mode of invitation, screening should be part of a structured programme<sup><span class="xrefLink" id="jumplink-ehae176-B1128"></span><a href="javascript:;" reveal-id="ehae176-B1128" data-open="ehae176-B1128" class="link link-ref link-reveal xref-bibr">1128</a></sup> and is not the same as identification of AF during a routine healthcare visit or secondary to arrhythmia symptoms.

Screening can be done at a single timepoint (snapshot of the heart rhythm), e.g. using pulse palpation or a 12-lead ECG. Screening can also be of an extended duration, i.e. prolonged, using either intermittent or continuous monitoring of heart rhythm. Most studies using an opportunistic strategy have screened for AF at a single timepoint with short duration (such as a single timepoint ECG), compared with systematic screening studies that have mainly used prolonged (repeated or continuous) rhythm assessment.<sup><span class="xrefLink" id="jumplink-ehae176-B1129"></span><a href="javascript:;" reveal-id="ehae176-B1129" data-open="ehae176-B1129" class="link link-ref link-reveal xref-bibr">1129</a></sup> The optimal screening method will vary depending on the population being studied (_[Figure 16](javascript:;)_) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S32](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). More sensitive methods will detect more AF but may lead to an increased risk of false positives and an increased detection of low burden AF, whereas more specific methods result in less false positives, at the risk of missing AF.

![Approaches to screening for AF.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176f16.jpeg?Expires=1728478929&Signature=GnX9hvDuMJMjCN54e~pPiD6LPdW8r3m5EmK0wHqx9Lh12X7ug07Q6VpT3OQPXFYJYaZO2ckqTLZjkqOlQURtyPilLRNBjxax-8E~Yf7d6~8n5PEaO5bmnGfyqwHYStPEoovXjx1O-ioSwQEl~jBUeGu9yImJNS0Xv4h4ZrGXGmykzMlrXSpHr7uLOeuynqSaZ-f40kt6GSwAWggxn6onNQUPtpmPmFBTobTtV3yXNquAUiKlW58O3WQd4smRSRx-v9jIlf~2aNjBPvPng-K79LcLdANnlyTfPork52Nb9P40craWOBQSPmPjA6HOXyOgd-uM8JOgh7UrkkHfHRp4oA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 16

Approaches to screening for AF.

AF, atrial fibrillation; AF-CARE, atrial fibrillation—\[C\] Comorbidity and risk factor management, \[A\] Avoid stroke and thromboembolism, \[R\] Reduce symptoms by rate and rhythm control, \[E\] Evaluation and dynamic reassessment; CHA<sub>2</sub>DS<sub>2</sub>\-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/TIA/arterial thromboembolism (2 points), vascular disease, age 65–74 years; ECG, electrocardiogram. See [Figure 15](javascript:;) for non-invasive ECG methods.

[Open in new tab](https://academic.oup.com/view-large/figure/479884441/ehae176f16.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176f16.jpeg?Expires=1728478929&Signature=th7HndLdIrBczWLxqYHbpWAVwn6-amGHE~12EZVibrMz~Xqcu4IQPOU5ZSr14gyKjFWLp5tnIhcURRY~4oYdS58pDwDiGVtDyPyHwW-dvqeTGwXIM7KZDxyiSi1zwgIjS~Qt9MjQGc5RnYBposZbz4AuoWSkPCDpCh9~QmcTWpyYT9FCoPvY73AdwQblHDVNTH0Y55xOQAHJs7SliYQtx7RHSGayAmhDShIDzzP5myO5YECFwqE0OqDBSdi~t5JrxQJYcUI70fzgLUSUmTjl3KV5x6nxBycvGD8Oog9duhQaZXe0DbDmPhXLwG0MIwTxTtzj~KEAaRtW8t5KXTVZAA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479884441&ar=7738779&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Invasive monitoring of heart rhythm in high-risk populations extended for several years has been shown to result in device-detected AF prevalence of around 30%, albeit most of whom have a low burden of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B857"></span><a href="javascript:;" reveal-id="ehae176-B857" data-open="ehae176-B857" class="link link-ref link-reveal xref-bibr">857</a>,<span class="xrefLink" id="jumplink-ehae176-B1130"></span><a href="javascript:;" reveal-id="ehae176-B1130" data-open="ehae176-B1130" class="link link-ref link-reveal xref-bibr">1130</a>,<span class="xrefLink" id="jumplink-ehae176-B1131"></span><a href="javascript:;" reveal-id="ehae176-B1131" data-open="ehae176-B1131" class="link link-ref link-reveal xref-bibr">1131</a></sup> Pacemaker studies have shown that patients with a low burden of device-detected subclinical AF have a lower risk of ischaemic stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B24"></span><a href="javascript:;" reveal-id="ehae176-B24" data-open="ehae176-B24" class="link link-ref link-reveal xref-bibr">24</a>,<span class="xrefLink" id="jumplink-ehae176-B1131"></span><a href="javascript:;" reveal-id="ehae176-B1131" data-open="ehae176-B1131" class="link link-ref link-reveal xref-bibr">1131</a>,<span class="xrefLink" id="jumplink-ehae176-B1132"></span><a href="javascript:;" reveal-id="ehae176-B1132" data-open="ehae176-B1132" class="link link-ref link-reveal xref-bibr">1132</a></sup> This has been confirmed in RCTs assessing DOAC use in patients with device-detected subclinical AF (see _Section [6.1.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false#ehae176-s5.1.1)_).<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B281"></span><a href="javascript:;" reveal-id="ehae176-B281" data-open="ehae176-B281" class="link link-ref link-reveal xref-bibr">281</a>,<span class="xrefLink" id="jumplink-ehae176-B282"></span><a href="javascript:;" reveal-id="ehae176-B282" data-open="ehae176-B282" class="link link-ref link-reveal xref-bibr">282</a></sup> The burden needed for device-detected subclinical AF to translate into stroke risk is not known, and further studies are clearly needed.<sup><span class="xrefLink" id="jumplink-ehae176-B1133"></span><a href="javascript:;" reveal-id="ehae176-B1133" data-open="ehae176-B1133" class="link link-ref link-reveal xref-bibr">1133</a>,<span class="xrefLink" id="jumplink-ehae176-B1134"></span><a href="javascript:;" reveal-id="ehae176-B1134" data-open="ehae176-B1134" class="link link-ref link-reveal xref-bibr">1134</a></sup> Benefit and cost-effectiveness of screening are discussed in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA).

Recommendation Table 31

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884443)

Recommendations for screening for AF (see also Evidence Table 31)

![Recommendations for screening for AF (see also Evidence Table 31)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt31.jpeg?Expires=1728478929&Signature=bo6aXkxV26MTJXzmZ9BsqUH6AdkoznbpZmliYOTF-4thM4WHGIFf1e1Vp~~WZPAPnfKcfMQ0voCwhEbhm~NL406vXfOm-3yb6PAUFxwiUQeQyZmdEo1DmO7grjGAVbo~h2L1kJrc6u8r01UHwu5gzxhDJ4x~RMOjg6NZP6qCVYM7ro4bDeSiqd0TY8vN9DIw9qsPVPvRTd8SH-6psXdMH4rQsSpWH056XSTtpwML43DpEj0TGSjUEoDwHzTNBF0h7cEqfhVWXfbACtCtj7t74GnlBleydorhVKvjoHVVw4s4y9kSiNti~7f5nTO3SXHs3Yl5A8jjJLznKNt4JM8zng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 31

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884443)

Recommendations for screening for AF (see also Evidence Table 31)

![Recommendations for screening for AF (see also Evidence Table 31)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt31.jpeg?Expires=1728478929&Signature=bo6aXkxV26MTJXzmZ9BsqUH6AdkoznbpZmliYOTF-4thM4WHGIFf1e1Vp~~WZPAPnfKcfMQ0voCwhEbhm~NL406vXfOm-3yb6PAUFxwiUQeQyZmdEo1DmO7grjGAVbo~h2L1kJrc6u8r01UHwu5gzxhDJ4x~RMOjg6NZP6qCVYM7ro4bDeSiqd0TY8vN9DIw9qsPVPvRTd8SH-6psXdMH4rQsSpWH056XSTtpwML43DpEj0TGSjUEoDwHzTNBF0h7cEqfhVWXfbACtCtj7t74GnlBleydorhVKvjoHVVw4s4y9kSiNti~7f5nTO3SXHs3Yl5A8jjJLznKNt4JM8zng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 10.3.1. Single timepoint screening ‘snapshot’

Several cluster RCTs in primary care settings have explored whether screening performed as a snapshot of the heart rhythm at one timepoint can detect more AF compared with usual care in individuals aged ≥65 years.<sup><span class="xrefLink" id="jumplink-ehae176-B1138 ehae176-B1139 ehae176-B1140"></span><a href="javascript:;" reveal-id="ehae176-B1138 ehae176-B1139 ehae176-B1140" data-open="ehae176-B1138 ehae176-B1139 ehae176-B1140" class="link link-ref link-reveal xref-bibr">1138–1140</a></sup> No increased detection of AF was seen in groups randomized to single timepoint screening.<sup><span class="xrefLink" id="jumplink-ehae176-B1138 ehae176-B1139 ehae176-B1140"></span><a href="javascript:;" reveal-id="ehae176-B1138 ehae176-B1139 ehae176-B1140" data-open="ehae176-B1138 ehae176-B1139 ehae176-B1140" class="link link-ref link-reveal xref-bibr">1138–1140</a></sup> These findings were confirmed in a meta-analysis of RCTs showing that screening as a one-time event did not increase detection of AF compared with usual care.<sup><span class="xrefLink" id="jumplink-ehae176-B1135"></span><a href="javascript:;" reveal-id="ehae176-B1135" data-open="ehae176-B1135" class="link link-ref link-reveal xref-bibr">1135</a></sup> Notably, these studies were performed in healthcare settings where the detection of AF in the population might be high, hence the results might not be generalizable to healthcare settings with a lower spontaneous AF detection. There are no RCTs addressing clinical outcomes in patients with AF detected by single timepoint screening.<sup><span class="xrefLink" id="jumplink-ehae176-B1123"></span><a href="javascript:;" reveal-id="ehae176-B1123" data-open="ehae176-B1123" class="link link-ref link-reveal xref-bibr">1123</a>,<span class="xrefLink" id="jumplink-ehae176-B1135"></span><a href="javascript:;" reveal-id="ehae176-B1135" data-open="ehae176-B1135" class="link link-ref link-reveal xref-bibr">1135</a></sup>

#### 10.3.2. Prolonged screening

Studies using prolonged screening have shown an increased detection of AF leading to initiation of OAC.<sup><span class="xrefLink" id="jumplink-ehae176-B1129"></span><a href="javascript:;" reveal-id="ehae176-B1129" data-open="ehae176-B1129" class="link link-ref link-reveal xref-bibr">1129</a>,<span class="xrefLink" id="jumplink-ehae176-B1135"></span><a href="javascript:;" reveal-id="ehae176-B1135" data-open="ehae176-B1135" class="link link-ref link-reveal xref-bibr">1135</a>,<span class="xrefLink" id="jumplink-ehae176-B1141"></span><a href="javascript:;" reveal-id="ehae176-B1141" data-open="ehae176-B1141" class="link link-ref link-reveal xref-bibr">1141</a></sup> Two RCTs have investigated the effect on clinical outcomes in prolonged screening for AF.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a>,<span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> In the STROKESTOP trial (Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden), 75- and 76-year-olds were randomized to be invited to prolonged screening for AF using single-lead ECGs twice daily for 2 weeks, or to standard of care. After a median of 6.9 years there was a small reduction in the primary combined endpoint of all-cause mortality, stroke, systematic embolism, and severe bleeding in favour of prolonged screening (HR, 0.96; 95% CI, 0.92–1.00; _P_ = .045).<sup><span class="xrefLink" id="jumplink-ehae176-B6"></span><a href="javascript:;" reveal-id="ehae176-B6" data-open="ehae176-B6" class="link link-ref link-reveal xref-bibr">6</a></sup> In the LOOP (Atrial Fibrillation Detected by Continuous ECG Monitoring) trial, individuals at increased risk of stroke were randomized to receive an implantable loop recorder that monitored heart rhythm for an average of 3.3 years, or to a control group receiving standard of care. Although there was a higher detection of AF (31.8%) and subsequent initiation of OAC in the loop recorder group compared with standard of care (12.2%), this was not accompanied by a difference in the primary outcome of stroke or systemic embolism.<sup><span class="xrefLink" id="jumplink-ehae176-B5"></span><a href="javascript:;" reveal-id="ehae176-B5" data-open="ehae176-B5" class="link link-ref link-reveal xref-bibr">5</a></sup> In a meta-analysis of recent RCTs on the outcome of stroke, a small but significant benefit was seen in favour of prolonged screening (RR, 0.91; 95% CI, 0.84–0.99).<sup><span class="xrefLink" id="jumplink-ehae176-B1136"></span><a href="javascript:;" reveal-id="ehae176-B1136" data-open="ehae176-B1136" class="link link-ref link-reveal xref-bibr">1136</a></sup> This was not repeated in a second meta-analysis including older RCTs, where no risk reduction was seen with regard to mortality or stroke.<sup><span class="xrefLink" id="jumplink-ehae176-B1135"></span><a href="javascript:;" reveal-id="ehae176-B1135" data-open="ehae176-B1135" class="link link-ref link-reveal xref-bibr">1135</a></sup> Notably, both these meta-analyses are likely underpowered to assess clinical outcomes.

### 10.4. Factors associated with incident AF

The most common risk predictors for incident (new-onset) AF are shown in _[Table 16](javascript:;)_. While the factors listed are robustly associated with incident AF in observational studies, it is not known whether the relationships are causal. Studies using Mendelian randomization (genetic proxies for risk factors to estimate causal effects) robustly implicate systolic BP and higher BMI as causal risk factors for incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1142"></span><a href="javascript:;" reveal-id="ehae176-B1142" data-open="ehae176-B1142" class="link link-ref link-reveal xref-bibr">1142</a></sup>

Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884450)

Factors associated with incident AF

<table role="presentation" aria-labelledby="
label-20501" aria-describedby="
caption-20501"><tbody><tr><td rowspan="4">Demographic factors</td><td>Age<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Male sex<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" class="link link-ref link-reveal xref-bibr">1149–1152</a></sup></td></tr><tr><td>European ancestry<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Lower socioeconomic status<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td rowspan="6">Lifestyle behaviours</td><td>Smoking/tobacco use<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Alcohol intake<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Physical inactivity<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Vigorous exercise<sup><span class="xrefLink" id="jumplink-ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156"></span><a href="javascript:;" reveal-id="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" data-open="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" class="link link-ref link-reveal xref-bibr">1153–1156</a></sup></td></tr><tr><td>Competitive or athlete-level endurance sports<sup><span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1157"></span><a href="javascript:;" reveal-id="ehae176-B1157" data-open="ehae176-B1157" class="link link-ref link-reveal xref-bibr">1157</a></sup></td></tr><tr><td>Caffeine<sup><span class="xrefLink" id="jumplink-ehae176-B1158 ehae176-B1159 ehae176-B1160"></span><a href="javascript:;" reveal-id="ehae176-B1158 ehae176-B1159 ehae176-B1160" data-open="ehae176-B1158 ehae176-B1159 ehae176-B1160" class="link link-ref link-reveal xref-bibr">1158–1160</a></sup></td></tr><tr><td rowspan="18">Comorbidities and risk factors</td><td>Hypertension<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Heart failure<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a></sup></td></tr><tr><td>Valvular disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1162 ehae176-B1163 ehae176-B1164"></span><a href="javascript:;" reveal-id="ehae176-B1162 ehae176-B1163 ehae176-B1164" data-open="ehae176-B1162 ehae176-B1163 ehae176-B1164" class="link link-ref link-reveal xref-bibr">1162–1164</a></sup></td></tr><tr><td>Coronary artery disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<span class="xrefLink" id="jumplink-ehae176-B1165"></span><a href="javascript:;" reveal-id="ehae176-B1165" data-open="ehae176-B1165" class="link link-ref link-reveal xref-bibr">1165</a></sup></td></tr><tr><td>Peripheral arterial disease<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup></td></tr><tr><td>Congenital heart disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1166"></span><a href="javascript:;" reveal-id="ehae176-B1166" data-open="ehae176-B1166" class="link link-ref link-reveal xref-bibr">1166</a></sup></td></tr><tr><td>Heart rate, heart rate variability<sup><span class="xrefLink" id="jumplink-ehae176-B1167"></span><a href="javascript:;" reveal-id="ehae176-B1167" data-open="ehae176-B1167" class="link link-ref link-reveal xref-bibr">1167</a>,<span class="xrefLink" id="jumplink-ehae176-B1168"></span><a href="javascript:;" reveal-id="ehae176-B1168" data-open="ehae176-B1168" class="link link-ref link-reveal xref-bibr">1168</a></sup></td></tr><tr><td>Total cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Low-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>High-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Triglycerides<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Impaired glucose tolerance,<sup><span class="xrefLink" id="jumplink-ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172"></span><a href="javascript:;" reveal-id="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" data-open="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" class="link link-ref link-reveal xref-bibr">1169–1172</a></sup>diabetes mellitus<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1169"></span><a href="javascript:;" reveal-id="ehae176-B1169" data-open="ehae176-B1169" class="link link-ref link-reveal xref-bibr">1169</a></sup></td></tr><tr><td>Renal dysfunction/CKD<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1173"></span><a href="javascript:;" reveal-id="ehae176-B1173" data-open="ehae176-B1173" class="link link-ref link-reveal xref-bibr">1173</a>,<span class="xrefLink" id="jumplink-ehae176-B1174"></span><a href="javascript:;" reveal-id="ehae176-B1174" data-open="ehae176-B1174" class="link link-ref link-reveal xref-bibr">1174</a></sup></td></tr><tr><td>Obesity<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1175"></span><a href="javascript:;" reveal-id="ehae176-B1175" data-open="ehae176-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<span class="xrefLink" id="jumplink-ehae176-B1176"></span><a href="javascript:;" reveal-id="ehae176-B1176" data-open="ehae176-B1176" class="link link-ref link-reveal xref-bibr">1176</a></sup></td></tr><tr><td>Body mass index, weight<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Height<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Sleep apnoea<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1177"></span><a href="javascript:;" reveal-id="ehae176-B1177" data-open="ehae176-B1177" class="link link-ref link-reveal xref-bibr">1177</a>,<span class="xrefLink" id="jumplink-ehae176-B1178"></span><a href="javascript:;" reveal-id="ehae176-B1178" data-open="ehae176-B1178" class="link link-ref link-reveal xref-bibr">1178</a></sup></td></tr><tr><td>Chronic obstructive pulmonary disease<sup><span class="xrefLink" id="jumplink-ehae176-B1179"></span><a href="javascript:;" reveal-id="ehae176-B1179" data-open="ehae176-B1179" class="link link-ref link-reveal xref-bibr">1179</a></sup></td></tr><tr><td rowspan="2">Subclinical atherosclerosis</td><td>Coronary artery calcification<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1180"></span><a href="javascript:;" reveal-id="ehae176-B1180" data-open="ehae176-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup></td></tr><tr><td>Carotid IMT and carotid plaque<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1181"></span><a href="javascript:;" reveal-id="ehae176-B1181" data-open="ehae176-B1181" class="link link-ref link-reveal xref-bibr">1181</a>,<span class="xrefLink" id="jumplink-ehae176-B1182"></span><a href="javascript:;" reveal-id="ehae176-B1182" data-open="ehae176-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup></td></tr><tr><td rowspan="3">ECG abnormalities</td><td>PR interval prolongation<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1183"></span><a href="javascript:;" reveal-id="ehae176-B1183" data-open="ehae176-B1183" class="link link-ref link-reveal xref-bibr">1183</a></sup></td></tr><tr><td>Sick sinus syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1184"></span><a href="javascript:;" reveal-id="ehae176-B1184" data-open="ehae176-B1184" class="link link-ref link-reveal xref-bibr">1184</a>,<span class="xrefLink" id="jumplink-ehae176-B1185"></span><a href="javascript:;" reveal-id="ehae176-B1185" data-open="ehae176-B1185" class="link link-ref link-reveal xref-bibr">1185</a></sup></td></tr><tr><td>Wolff–Parkinson–White<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1186"></span><a href="javascript:;" reveal-id="ehae176-B1186" data-open="ehae176-B1186" class="link link-ref link-reveal xref-bibr">1186</a></sup></td></tr><tr><td rowspan="4">Genetic factors</td><td>Family history of AF<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190"></span><a href="javascript:;" reveal-id="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" data-open="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" class="link link-ref link-reveal xref-bibr">1187–1190</a></sup></td></tr><tr><td>AF-susceptible loci identified by GWAS<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1191"></span><a href="javascript:;" reveal-id="ehae176-B1191" data-open="ehae176-B1191" class="link link-ref link-reveal xref-bibr">1191</a>,<span class="xrefLink" id="jumplink-ehae176-B1192"></span><a href="javascript:;" reveal-id="ehae176-B1192" data-open="ehae176-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup></td></tr><tr><td>Short QT syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a></sup></td></tr><tr><td>Genetic cardiomyopathies<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a>,<span class="xrefLink" id="jumplink-ehae176-B1193"></span><a href="javascript:;" reveal-id="ehae176-B1193" data-open="ehae176-B1193" class="link link-ref link-reveal xref-bibr">1193</a></sup></td></tr><tr><td rowspan="6">Biomarkers</td><td>C-reactive protein<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td>Fibrinogen<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Growth differentiation factor-15<sup><span class="xrefLink" id="jumplink-ehae176-B1194"></span><a href="javascript:;" reveal-id="ehae176-B1194" data-open="ehae176-B1194" class="link link-ref link-reveal xref-bibr">1194</a></sup></td></tr><tr><td>Natriuretic peptides (atrial and B-type)<sup><span class="xrefLink" id="jumplink-ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200"></span><a href="javascript:;" reveal-id="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" data-open="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" class="link link-ref link-reveal xref-bibr">1195–1200</a></sup></td></tr><tr><td>Cardiac troponins<sup><span class="xrefLink" id="jumplink-ehae176-B1199"></span><a href="javascript:;" reveal-id="ehae176-B1199" data-open="ehae176-B1199" class="link link-ref link-reveal xref-bibr">1199</a></sup></td></tr><tr><td>Inflammatory biomarkers <sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td rowspan="5">Others</td><td>Thyroid dysfunction<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Autoimmune diseases<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Air pollution<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1201"></span><a href="javascript:;" reveal-id="ehae176-B1201" data-open="ehae176-B1201" class="link link-ref link-reveal xref-bibr">1201</a></sup></td></tr><tr><td>Sepsis<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1202"></span><a href="javascript:;" reveal-id="ehae176-B1202" data-open="ehae176-B1202" class="link link-ref link-reveal xref-bibr">1202</a></sup></td></tr><tr><td>Psychological factors <sup><span class="xrefLink" id="jumplink-ehae176-B1203"></span><a href="javascript:;" reveal-id="ehae176-B1203" data-open="ehae176-B1203" class="link link-ref link-reveal xref-bibr">1203</a>,<span class="xrefLink" id="jumplink-ehae176-B1204"></span><a href="javascript:;" reveal-id="ehae176-B1204" data-open="ehae176-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup></td></tr></tbody></table>

<table><tbody><tr><td rowspan="4">Demographic factors</td><td>Age<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Male sex<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" class="link link-ref link-reveal xref-bibr">1149–1152</a></sup></td></tr><tr><td>European ancestry<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Lower socioeconomic status<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td rowspan="6">Lifestyle behaviours</td><td>Smoking/tobacco use<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Alcohol intake<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Physical inactivity<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Vigorous exercise<sup><span class="xrefLink" id="jumplink-ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156"></span><a href="javascript:;" reveal-id="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" data-open="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" class="link link-ref link-reveal xref-bibr">1153–1156</a></sup></td></tr><tr><td>Competitive or athlete-level endurance sports<sup><span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1157"></span><a href="javascript:;" reveal-id="ehae176-B1157" data-open="ehae176-B1157" class="link link-ref link-reveal xref-bibr">1157</a></sup></td></tr><tr><td>Caffeine<sup><span class="xrefLink" id="jumplink-ehae176-B1158 ehae176-B1159 ehae176-B1160"></span><a href="javascript:;" reveal-id="ehae176-B1158 ehae176-B1159 ehae176-B1160" data-open="ehae176-B1158 ehae176-B1159 ehae176-B1160" class="link link-ref link-reveal xref-bibr">1158–1160</a></sup></td></tr><tr><td rowspan="18">Comorbidities and risk factors</td><td>Hypertension<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Heart failure<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a></sup></td></tr><tr><td>Valvular disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1162 ehae176-B1163 ehae176-B1164"></span><a href="javascript:;" reveal-id="ehae176-B1162 ehae176-B1163 ehae176-B1164" data-open="ehae176-B1162 ehae176-B1163 ehae176-B1164" class="link link-ref link-reveal xref-bibr">1162–1164</a></sup></td></tr><tr><td>Coronary artery disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<span class="xrefLink" id="jumplink-ehae176-B1165"></span><a href="javascript:;" reveal-id="ehae176-B1165" data-open="ehae176-B1165" class="link link-ref link-reveal xref-bibr">1165</a></sup></td></tr><tr><td>Peripheral arterial disease<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup></td></tr><tr><td>Congenital heart disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1166"></span><a href="javascript:;" reveal-id="ehae176-B1166" data-open="ehae176-B1166" class="link link-ref link-reveal xref-bibr">1166</a></sup></td></tr><tr><td>Heart rate, heart rate variability<sup><span class="xrefLink" id="jumplink-ehae176-B1167"></span><a href="javascript:;" reveal-id="ehae176-B1167" data-open="ehae176-B1167" class="link link-ref link-reveal xref-bibr">1167</a>,<span class="xrefLink" id="jumplink-ehae176-B1168"></span><a href="javascript:;" reveal-id="ehae176-B1168" data-open="ehae176-B1168" class="link link-ref link-reveal xref-bibr">1168</a></sup></td></tr><tr><td>Total cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Low-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>High-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Triglycerides<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Impaired glucose tolerance,<sup><span class="xrefLink" id="jumplink-ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172"></span><a href="javascript:;" reveal-id="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" data-open="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" class="link link-ref link-reveal xref-bibr">1169–1172</a></sup>diabetes mellitus<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1169"></span><a href="javascript:;" reveal-id="ehae176-B1169" data-open="ehae176-B1169" class="link link-ref link-reveal xref-bibr">1169</a></sup></td></tr><tr><td>Renal dysfunction/CKD<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1173"></span><a href="javascript:;" reveal-id="ehae176-B1173" data-open="ehae176-B1173" class="link link-ref link-reveal xref-bibr">1173</a>,<span class="xrefLink" id="jumplink-ehae176-B1174"></span><a href="javascript:;" reveal-id="ehae176-B1174" data-open="ehae176-B1174" class="link link-ref link-reveal xref-bibr">1174</a></sup></td></tr><tr><td>Obesity<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1175"></span><a href="javascript:;" reveal-id="ehae176-B1175" data-open="ehae176-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<span class="xrefLink" id="jumplink-ehae176-B1176"></span><a href="javascript:;" reveal-id="ehae176-B1176" data-open="ehae176-B1176" class="link link-ref link-reveal xref-bibr">1176</a></sup></td></tr><tr><td>Body mass index, weight<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Height<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Sleep apnoea<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1177"></span><a href="javascript:;" reveal-id="ehae176-B1177" data-open="ehae176-B1177" class="link link-ref link-reveal xref-bibr">1177</a>,<span class="xrefLink" id="jumplink-ehae176-B1178"></span><a href="javascript:;" reveal-id="ehae176-B1178" data-open="ehae176-B1178" class="link link-ref link-reveal xref-bibr">1178</a></sup></td></tr><tr><td>Chronic obstructive pulmonary disease<sup><span class="xrefLink" id="jumplink-ehae176-B1179"></span><a href="javascript:;" reveal-id="ehae176-B1179" data-open="ehae176-B1179" class="link link-ref link-reveal xref-bibr">1179</a></sup></td></tr><tr><td rowspan="2">Subclinical atherosclerosis</td><td>Coronary artery calcification<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1180"></span><a href="javascript:;" reveal-id="ehae176-B1180" data-open="ehae176-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup></td></tr><tr><td>Carotid IMT and carotid plaque<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1181"></span><a href="javascript:;" reveal-id="ehae176-B1181" data-open="ehae176-B1181" class="link link-ref link-reveal xref-bibr">1181</a>,<span class="xrefLink" id="jumplink-ehae176-B1182"></span><a href="javascript:;" reveal-id="ehae176-B1182" data-open="ehae176-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup></td></tr><tr><td rowspan="3">ECG abnormalities</td><td>PR interval prolongation<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1183"></span><a href="javascript:;" reveal-id="ehae176-B1183" data-open="ehae176-B1183" class="link link-ref link-reveal xref-bibr">1183</a></sup></td></tr><tr><td>Sick sinus syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1184"></span><a href="javascript:;" reveal-id="ehae176-B1184" data-open="ehae176-B1184" class="link link-ref link-reveal xref-bibr">1184</a>,<span class="xrefLink" id="jumplink-ehae176-B1185"></span><a href="javascript:;" reveal-id="ehae176-B1185" data-open="ehae176-B1185" class="link link-ref link-reveal xref-bibr">1185</a></sup></td></tr><tr><td>Wolff–Parkinson–White<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1186"></span><a href="javascript:;" reveal-id="ehae176-B1186" data-open="ehae176-B1186" class="link link-ref link-reveal xref-bibr">1186</a></sup></td></tr><tr><td rowspan="4">Genetic factors</td><td>Family history of AF<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190"></span><a href="javascript:;" reveal-id="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" data-open="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" class="link link-ref link-reveal xref-bibr">1187–1190</a></sup></td></tr><tr><td>AF-susceptible loci identified by GWAS<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1191"></span><a href="javascript:;" reveal-id="ehae176-B1191" data-open="ehae176-B1191" class="link link-ref link-reveal xref-bibr">1191</a>,<span class="xrefLink" id="jumplink-ehae176-B1192"></span><a href="javascript:;" reveal-id="ehae176-B1192" data-open="ehae176-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup></td></tr><tr><td>Short QT syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a></sup></td></tr><tr><td>Genetic cardiomyopathies<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a>,<span class="xrefLink" id="jumplink-ehae176-B1193"></span><a href="javascript:;" reveal-id="ehae176-B1193" data-open="ehae176-B1193" class="link link-ref link-reveal xref-bibr">1193</a></sup></td></tr><tr><td rowspan="6">Biomarkers</td><td>C-reactive protein<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td>Fibrinogen<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Growth differentiation factor-15<sup><span class="xrefLink" id="jumplink-ehae176-B1194"></span><a href="javascript:;" reveal-id="ehae176-B1194" data-open="ehae176-B1194" class="link link-ref link-reveal xref-bibr">1194</a></sup></td></tr><tr><td>Natriuretic peptides (atrial and B-type)<sup><span class="xrefLink" id="jumplink-ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200"></span><a href="javascript:;" reveal-id="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" data-open="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" class="link link-ref link-reveal xref-bibr">1195–1200</a></sup></td></tr><tr><td>Cardiac troponins<sup><span class="xrefLink" id="jumplink-ehae176-B1199"></span><a href="javascript:;" reveal-id="ehae176-B1199" data-open="ehae176-B1199" class="link link-ref link-reveal xref-bibr">1199</a></sup></td></tr><tr><td>Inflammatory biomarkers <sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td rowspan="5">Others</td><td>Thyroid dysfunction<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Autoimmune diseases<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Air pollution<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1201"></span><a href="javascript:;" reveal-id="ehae176-B1201" data-open="ehae176-B1201" class="link link-ref link-reveal xref-bibr">1201</a></sup></td></tr><tr><td>Sepsis<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1202"></span><a href="javascript:;" reveal-id="ehae176-B1202" data-open="ehae176-B1202" class="link link-ref link-reveal xref-bibr">1202</a></sup></td></tr><tr><td>Psychological factors <sup><span class="xrefLink" id="jumplink-ehae176-B1203"></span><a href="javascript:;" reveal-id="ehae176-B1203" data-open="ehae176-B1203" class="link link-ref link-reveal xref-bibr">1203</a>,<span class="xrefLink" id="jumplink-ehae176-B1204"></span><a href="javascript:;" reveal-id="ehae176-B1204" data-open="ehae176-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup></td></tr></tbody></table>

AF, atrial fibrillation; CKD, chronic kidney disease; GWAS, genome-wide association studies; HF, heart failure; IMT, intima-media thickness.

© ESC 2024

Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884450)

Factors associated with incident AF

<table role="presentation" aria-labelledby="
label-20501" aria-describedby="
caption-20501"><tbody><tr><td rowspan="4">Demographic factors</td><td>Age<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Male sex<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" class="link link-ref link-reveal xref-bibr">1149–1152</a></sup></td></tr><tr><td>European ancestry<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Lower socioeconomic status<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td rowspan="6">Lifestyle behaviours</td><td>Smoking/tobacco use<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Alcohol intake<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Physical inactivity<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Vigorous exercise<sup><span class="xrefLink" id="jumplink-ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156"></span><a href="javascript:;" reveal-id="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" data-open="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" class="link link-ref link-reveal xref-bibr">1153–1156</a></sup></td></tr><tr><td>Competitive or athlete-level endurance sports<sup><span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1157"></span><a href="javascript:;" reveal-id="ehae176-B1157" data-open="ehae176-B1157" class="link link-ref link-reveal xref-bibr">1157</a></sup></td></tr><tr><td>Caffeine<sup><span class="xrefLink" id="jumplink-ehae176-B1158 ehae176-B1159 ehae176-B1160"></span><a href="javascript:;" reveal-id="ehae176-B1158 ehae176-B1159 ehae176-B1160" data-open="ehae176-B1158 ehae176-B1159 ehae176-B1160" class="link link-ref link-reveal xref-bibr">1158–1160</a></sup></td></tr><tr><td rowspan="18">Comorbidities and risk factors</td><td>Hypertension<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Heart failure<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a></sup></td></tr><tr><td>Valvular disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1162 ehae176-B1163 ehae176-B1164"></span><a href="javascript:;" reveal-id="ehae176-B1162 ehae176-B1163 ehae176-B1164" data-open="ehae176-B1162 ehae176-B1163 ehae176-B1164" class="link link-ref link-reveal xref-bibr">1162–1164</a></sup></td></tr><tr><td>Coronary artery disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<span class="xrefLink" id="jumplink-ehae176-B1165"></span><a href="javascript:;" reveal-id="ehae176-B1165" data-open="ehae176-B1165" class="link link-ref link-reveal xref-bibr">1165</a></sup></td></tr><tr><td>Peripheral arterial disease<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup></td></tr><tr><td>Congenital heart disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1166"></span><a href="javascript:;" reveal-id="ehae176-B1166" data-open="ehae176-B1166" class="link link-ref link-reveal xref-bibr">1166</a></sup></td></tr><tr><td>Heart rate, heart rate variability<sup><span class="xrefLink" id="jumplink-ehae176-B1167"></span><a href="javascript:;" reveal-id="ehae176-B1167" data-open="ehae176-B1167" class="link link-ref link-reveal xref-bibr">1167</a>,<span class="xrefLink" id="jumplink-ehae176-B1168"></span><a href="javascript:;" reveal-id="ehae176-B1168" data-open="ehae176-B1168" class="link link-ref link-reveal xref-bibr">1168</a></sup></td></tr><tr><td>Total cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Low-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>High-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Triglycerides<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Impaired glucose tolerance,<sup><span class="xrefLink" id="jumplink-ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172"></span><a href="javascript:;" reveal-id="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" data-open="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" class="link link-ref link-reveal xref-bibr">1169–1172</a></sup>diabetes mellitus<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1169"></span><a href="javascript:;" reveal-id="ehae176-B1169" data-open="ehae176-B1169" class="link link-ref link-reveal xref-bibr">1169</a></sup></td></tr><tr><td>Renal dysfunction/CKD<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1173"></span><a href="javascript:;" reveal-id="ehae176-B1173" data-open="ehae176-B1173" class="link link-ref link-reveal xref-bibr">1173</a>,<span class="xrefLink" id="jumplink-ehae176-B1174"></span><a href="javascript:;" reveal-id="ehae176-B1174" data-open="ehae176-B1174" class="link link-ref link-reveal xref-bibr">1174</a></sup></td></tr><tr><td>Obesity<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1175"></span><a href="javascript:;" reveal-id="ehae176-B1175" data-open="ehae176-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<span class="xrefLink" id="jumplink-ehae176-B1176"></span><a href="javascript:;" reveal-id="ehae176-B1176" data-open="ehae176-B1176" class="link link-ref link-reveal xref-bibr">1176</a></sup></td></tr><tr><td>Body mass index, weight<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Height<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Sleep apnoea<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1177"></span><a href="javascript:;" reveal-id="ehae176-B1177" data-open="ehae176-B1177" class="link link-ref link-reveal xref-bibr">1177</a>,<span class="xrefLink" id="jumplink-ehae176-B1178"></span><a href="javascript:;" reveal-id="ehae176-B1178" data-open="ehae176-B1178" class="link link-ref link-reveal xref-bibr">1178</a></sup></td></tr><tr><td>Chronic obstructive pulmonary disease<sup><span class="xrefLink" id="jumplink-ehae176-B1179"></span><a href="javascript:;" reveal-id="ehae176-B1179" data-open="ehae176-B1179" class="link link-ref link-reveal xref-bibr">1179</a></sup></td></tr><tr><td rowspan="2">Subclinical atherosclerosis</td><td>Coronary artery calcification<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1180"></span><a href="javascript:;" reveal-id="ehae176-B1180" data-open="ehae176-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup></td></tr><tr><td>Carotid IMT and carotid plaque<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1181"></span><a href="javascript:;" reveal-id="ehae176-B1181" data-open="ehae176-B1181" class="link link-ref link-reveal xref-bibr">1181</a>,<span class="xrefLink" id="jumplink-ehae176-B1182"></span><a href="javascript:;" reveal-id="ehae176-B1182" data-open="ehae176-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup></td></tr><tr><td rowspan="3">ECG abnormalities</td><td>PR interval prolongation<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1183"></span><a href="javascript:;" reveal-id="ehae176-B1183" data-open="ehae176-B1183" class="link link-ref link-reveal xref-bibr">1183</a></sup></td></tr><tr><td>Sick sinus syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1184"></span><a href="javascript:;" reveal-id="ehae176-B1184" data-open="ehae176-B1184" class="link link-ref link-reveal xref-bibr">1184</a>,<span class="xrefLink" id="jumplink-ehae176-B1185"></span><a href="javascript:;" reveal-id="ehae176-B1185" data-open="ehae176-B1185" class="link link-ref link-reveal xref-bibr">1185</a></sup></td></tr><tr><td>Wolff–Parkinson–White<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1186"></span><a href="javascript:;" reveal-id="ehae176-B1186" data-open="ehae176-B1186" class="link link-ref link-reveal xref-bibr">1186</a></sup></td></tr><tr><td rowspan="4">Genetic factors</td><td>Family history of AF<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190"></span><a href="javascript:;" reveal-id="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" data-open="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" class="link link-ref link-reveal xref-bibr">1187–1190</a></sup></td></tr><tr><td>AF-susceptible loci identified by GWAS<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1191"></span><a href="javascript:;" reveal-id="ehae176-B1191" data-open="ehae176-B1191" class="link link-ref link-reveal xref-bibr">1191</a>,<span class="xrefLink" id="jumplink-ehae176-B1192"></span><a href="javascript:;" reveal-id="ehae176-B1192" data-open="ehae176-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup></td></tr><tr><td>Short QT syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a></sup></td></tr><tr><td>Genetic cardiomyopathies<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a>,<span class="xrefLink" id="jumplink-ehae176-B1193"></span><a href="javascript:;" reveal-id="ehae176-B1193" data-open="ehae176-B1193" class="link link-ref link-reveal xref-bibr">1193</a></sup></td></tr><tr><td rowspan="6">Biomarkers</td><td>C-reactive protein<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td>Fibrinogen<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Growth differentiation factor-15<sup><span class="xrefLink" id="jumplink-ehae176-B1194"></span><a href="javascript:;" reveal-id="ehae176-B1194" data-open="ehae176-B1194" class="link link-ref link-reveal xref-bibr">1194</a></sup></td></tr><tr><td>Natriuretic peptides (atrial and B-type)<sup><span class="xrefLink" id="jumplink-ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200"></span><a href="javascript:;" reveal-id="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" data-open="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" class="link link-ref link-reveal xref-bibr">1195–1200</a></sup></td></tr><tr><td>Cardiac troponins<sup><span class="xrefLink" id="jumplink-ehae176-B1199"></span><a href="javascript:;" reveal-id="ehae176-B1199" data-open="ehae176-B1199" class="link link-ref link-reveal xref-bibr">1199</a></sup></td></tr><tr><td>Inflammatory biomarkers <sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td rowspan="5">Others</td><td>Thyroid dysfunction<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Autoimmune diseases<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Air pollution<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1201"></span><a href="javascript:;" reveal-id="ehae176-B1201" data-open="ehae176-B1201" class="link link-ref link-reveal xref-bibr">1201</a></sup></td></tr><tr><td>Sepsis<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1202"></span><a href="javascript:;" reveal-id="ehae176-B1202" data-open="ehae176-B1202" class="link link-ref link-reveal xref-bibr">1202</a></sup></td></tr><tr><td>Psychological factors <sup><span class="xrefLink" id="jumplink-ehae176-B1203"></span><a href="javascript:;" reveal-id="ehae176-B1203" data-open="ehae176-B1203" class="link link-ref link-reveal xref-bibr">1203</a>,<span class="xrefLink" id="jumplink-ehae176-B1204"></span><a href="javascript:;" reveal-id="ehae176-B1204" data-open="ehae176-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup></td></tr></tbody></table>

<table><tbody><tr><td rowspan="4">Demographic factors</td><td>Age<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Male sex<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151 ehae176-B1152" class="link link-ref link-reveal xref-bibr">1149–1152</a></sup></td></tr><tr><td>European ancestry<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Lower socioeconomic status<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td rowspan="6">Lifestyle behaviours</td><td>Smoking/tobacco use<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Alcohol intake<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Physical inactivity<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Vigorous exercise<sup><span class="xrefLink" id="jumplink-ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156"></span><a href="javascript:;" reveal-id="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" data-open="ehae176-B1153 ehae176-B1154 ehae176-B1155 ehae176-B1156" class="link link-ref link-reveal xref-bibr">1153–1156</a></sup></td></tr><tr><td>Competitive or athlete-level endurance sports<sup><span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1157"></span><a href="javascript:;" reveal-id="ehae176-B1157" data-open="ehae176-B1157" class="link link-ref link-reveal xref-bibr">1157</a></sup></td></tr><tr><td>Caffeine<sup><span class="xrefLink" id="jumplink-ehae176-B1158 ehae176-B1159 ehae176-B1160"></span><a href="javascript:;" reveal-id="ehae176-B1158 ehae176-B1159 ehae176-B1160" data-open="ehae176-B1158 ehae176-B1159 ehae176-B1160" class="link link-ref link-reveal xref-bibr">1158–1160</a></sup></td></tr><tr><td rowspan="18">Comorbidities and risk factors</td><td>Hypertension<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Heart failure<sup><span class="xrefLink" id="jumplink-ehae176-B178"></span><a href="javascript:;" reveal-id="ehae176-B178" data-open="ehae176-B178" class="link link-ref link-reveal xref-bibr">178</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a></sup></td></tr><tr><td>Valvular disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1162 ehae176-B1163 ehae176-B1164"></span><a href="javascript:;" reveal-id="ehae176-B1162 ehae176-B1163 ehae176-B1164" data-open="ehae176-B1162 ehae176-B1163 ehae176-B1164" class="link link-ref link-reveal xref-bibr">1162–1164</a></sup></td></tr><tr><td>Coronary artery disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1161"></span><a href="javascript:;" reveal-id="ehae176-B1161" data-open="ehae176-B1161" class="link link-ref link-reveal xref-bibr">1161</a>,<span class="xrefLink" id="jumplink-ehae176-B1165"></span><a href="javascript:;" reveal-id="ehae176-B1165" data-open="ehae176-B1165" class="link link-ref link-reveal xref-bibr">1165</a></sup></td></tr><tr><td>Peripheral arterial disease<sup><span class="xrefLink" id="jumplink-ehae176-B785"></span><a href="javascript:;" reveal-id="ehae176-B785" data-open="ehae176-B785" class="link link-ref link-reveal xref-bibr">785</a></sup></td></tr><tr><td>Congenital heart disease<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1166"></span><a href="javascript:;" reveal-id="ehae176-B1166" data-open="ehae176-B1166" class="link link-ref link-reveal xref-bibr">1166</a></sup></td></tr><tr><td>Heart rate, heart rate variability<sup><span class="xrefLink" id="jumplink-ehae176-B1167"></span><a href="javascript:;" reveal-id="ehae176-B1167" data-open="ehae176-B1167" class="link link-ref link-reveal xref-bibr">1167</a>,<span class="xrefLink" id="jumplink-ehae176-B1168"></span><a href="javascript:;" reveal-id="ehae176-B1168" data-open="ehae176-B1168" class="link link-ref link-reveal xref-bibr">1168</a></sup></td></tr><tr><td>Total cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Low-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>High-density lipoprotein cholesterol<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Triglycerides<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Impaired glucose tolerance,<sup><span class="xrefLink" id="jumplink-ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172"></span><a href="javascript:;" reveal-id="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" data-open="ehae176-B1169 ehae176-B1170 ehae176-B1171 ehae176-B1172" class="link link-ref link-reveal xref-bibr">1169–1172</a></sup>diabetes mellitus<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1169"></span><a href="javascript:;" reveal-id="ehae176-B1169" data-open="ehae176-B1169" class="link link-ref link-reveal xref-bibr">1169</a></sup></td></tr><tr><td>Renal dysfunction/CKD<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1173"></span><a href="javascript:;" reveal-id="ehae176-B1173" data-open="ehae176-B1173" class="link link-ref link-reveal xref-bibr">1173</a>,<span class="xrefLink" id="jumplink-ehae176-B1174"></span><a href="javascript:;" reveal-id="ehae176-B1174" data-open="ehae176-B1174" class="link link-ref link-reveal xref-bibr">1174</a></sup></td></tr><tr><td>Obesity<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1175"></span><a href="javascript:;" reveal-id="ehae176-B1175" data-open="ehae176-B1175" class="link link-ref link-reveal xref-bibr">1175</a>,<span class="xrefLink" id="jumplink-ehae176-B1176"></span><a href="javascript:;" reveal-id="ehae176-B1176" data-open="ehae176-B1176" class="link link-ref link-reveal xref-bibr">1176</a></sup></td></tr><tr><td>Body mass index, weight<sup><span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Height<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Sleep apnoea<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1177"></span><a href="javascript:;" reveal-id="ehae176-B1177" data-open="ehae176-B1177" class="link link-ref link-reveal xref-bibr">1177</a>,<span class="xrefLink" id="jumplink-ehae176-B1178"></span><a href="javascript:;" reveal-id="ehae176-B1178" data-open="ehae176-B1178" class="link link-ref link-reveal xref-bibr">1178</a></sup></td></tr><tr><td>Chronic obstructive pulmonary disease<sup><span class="xrefLink" id="jumplink-ehae176-B1179"></span><a href="javascript:;" reveal-id="ehae176-B1179" data-open="ehae176-B1179" class="link link-ref link-reveal xref-bibr">1179</a></sup></td></tr><tr><td rowspan="2">Subclinical atherosclerosis</td><td>Coronary artery calcification<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1180"></span><a href="javascript:;" reveal-id="ehae176-B1180" data-open="ehae176-B1180" class="link link-ref link-reveal xref-bibr">1180</a></sup></td></tr><tr><td>Carotid IMT and carotid plaque<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1181"></span><a href="javascript:;" reveal-id="ehae176-B1181" data-open="ehae176-B1181" class="link link-ref link-reveal xref-bibr">1181</a>,<span class="xrefLink" id="jumplink-ehae176-B1182"></span><a href="javascript:;" reveal-id="ehae176-B1182" data-open="ehae176-B1182" class="link link-ref link-reveal xref-bibr">1182</a></sup></td></tr><tr><td rowspan="3">ECG abnormalities</td><td>PR interval prolongation<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1183"></span><a href="javascript:;" reveal-id="ehae176-B1183" data-open="ehae176-B1183" class="link link-ref link-reveal xref-bibr">1183</a></sup></td></tr><tr><td>Sick sinus syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1184"></span><a href="javascript:;" reveal-id="ehae176-B1184" data-open="ehae176-B1184" class="link link-ref link-reveal xref-bibr">1184</a>,<span class="xrefLink" id="jumplink-ehae176-B1185"></span><a href="javascript:;" reveal-id="ehae176-B1185" data-open="ehae176-B1185" class="link link-ref link-reveal xref-bibr">1185</a></sup></td></tr><tr><td>Wolff–Parkinson–White<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1186"></span><a href="javascript:;" reveal-id="ehae176-B1186" data-open="ehae176-B1186" class="link link-ref link-reveal xref-bibr">1186</a></sup></td></tr><tr><td rowspan="4">Genetic factors</td><td>Family history of AF<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190"></span><a href="javascript:;" reveal-id="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" data-open="ehae176-B1187 ehae176-B1188 ehae176-B1189 ehae176-B1190" class="link link-ref link-reveal xref-bibr">1187–1190</a></sup></td></tr><tr><td>AF-susceptible loci identified by GWAS<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a>,<span class="xrefLink" id="jumplink-ehae176-B1191"></span><a href="javascript:;" reveal-id="ehae176-B1191" data-open="ehae176-B1191" class="link link-ref link-reveal xref-bibr">1191</a>,<span class="xrefLink" id="jumplink-ehae176-B1192"></span><a href="javascript:;" reveal-id="ehae176-B1192" data-open="ehae176-B1192" class="link link-ref link-reveal xref-bibr">1192</a></sup></td></tr><tr><td>Short QT syndrome<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a></sup></td></tr><tr><td>Genetic cardiomyopathies<sup><span class="xrefLink" id="jumplink-ehae176-B990"></span><a href="javascript:;" reveal-id="ehae176-B990" data-open="ehae176-B990" class="link link-ref link-reveal xref-bibr">990</a>,<span class="xrefLink" id="jumplink-ehae176-B1193"></span><a href="javascript:;" reveal-id="ehae176-B1193" data-open="ehae176-B1193" class="link link-ref link-reveal xref-bibr">1193</a></sup></td></tr><tr><td rowspan="6">Biomarkers</td><td>C-reactive protein<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td>Fibrinogen<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Growth differentiation factor-15<sup><span class="xrefLink" id="jumplink-ehae176-B1194"></span><a href="javascript:;" reveal-id="ehae176-B1194" data-open="ehae176-B1194" class="link link-ref link-reveal xref-bibr">1194</a></sup></td></tr><tr><td>Natriuretic peptides (atrial and B-type)<sup><span class="xrefLink" id="jumplink-ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200"></span><a href="javascript:;" reveal-id="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" data-open="ehae176-B1195 ehae176-B1196 ehae176-B1197 ehae176-B1198 ehae176-B1199 ehae176-B1200" class="link link-ref link-reveal xref-bibr">1195–1200</a></sup></td></tr><tr><td>Cardiac troponins<sup><span class="xrefLink" id="jumplink-ehae176-B1199"></span><a href="javascript:;" reveal-id="ehae176-B1199" data-open="ehae176-B1199" class="link link-ref link-reveal xref-bibr">1199</a></sup></td></tr><tr><td>Inflammatory biomarkers <sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1151" data-open="ehae176-B1151" class="link link-ref link-reveal xref-bibr">1151</a></sup></td></tr><tr><td rowspan="5">Others</td><td>Thyroid dysfunction<sup><span class="xrefLink" id="jumplink-ehae176-B912"></span><a href="javascript:;" reveal-id="ehae176-B912" data-open="ehae176-B912" class="link link-ref link-reveal xref-bibr">912</a>,<span class="xrefLink" id="jumplink-ehae176-B1149 ehae176-B1150 ehae176-B1151"></span><a href="javascript:;" reveal-id="ehae176-B1149 ehae176-B1150 ehae176-B1151" data-open="ehae176-B1149 ehae176-B1150 ehae176-B1151" class="link link-ref link-reveal xref-bibr">1149–1151</a></sup></td></tr><tr><td>Autoimmune diseases<sup><span class="xrefLink" id="jumplink-ehae176-B1150"></span><a href="javascript:;" reveal-id="ehae176-B1150" data-open="ehae176-B1150" class="link link-ref link-reveal xref-bibr">1150</a></sup></td></tr><tr><td>Air pollution<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1201"></span><a href="javascript:;" reveal-id="ehae176-B1201" data-open="ehae176-B1201" class="link link-ref link-reveal xref-bibr">1201</a></sup></td></tr><tr><td>Sepsis<sup><span class="xrefLink" id="jumplink-ehae176-B1149"></span><a href="javascript:;" reveal-id="ehae176-B1149" data-open="ehae176-B1149" class="link link-ref link-reveal xref-bibr">1149</a>,<span class="xrefLink" id="jumplink-ehae176-B1202"></span><a href="javascript:;" reveal-id="ehae176-B1202" data-open="ehae176-B1202" class="link link-ref link-reveal xref-bibr">1202</a></sup></td></tr><tr><td>Psychological factors <sup><span class="xrefLink" id="jumplink-ehae176-B1203"></span><a href="javascript:;" reveal-id="ehae176-B1203" data-open="ehae176-B1203" class="link link-ref link-reveal xref-bibr">1203</a>,<span class="xrefLink" id="jumplink-ehae176-B1204"></span><a href="javascript:;" reveal-id="ehae176-B1204" data-open="ehae176-B1204" class="link link-ref link-reveal xref-bibr">1204</a></sup></td></tr></tbody></table>

AF, atrial fibrillation; CKD, chronic kidney disease; GWAS, genome-wide association studies; HF, heart failure; IMT, intima-media thickness.

© ESC 2024

A high degree of interaction occurs between all factors related to AF development (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Additional Evidence Table S33](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B1038"></span><a href="javascript:;" reveal-id="ehae176-B1038" data-open="ehae176-B1038" class="link link-ref link-reveal xref-bibr">1038</a>,<span class="xrefLink" id="jumplink-ehae176-B1039"></span><a href="javascript:;" reveal-id="ehae176-B1039" data-open="ehae176-B1039" class="link link-ref link-reveal xref-bibr">1039</a>,<span class="xrefLink" id="jumplink-ehae176-B1143 ehae176-B1144 ehae176-B1145"></span><a href="javascript:;" reveal-id="ehae176-B1143 ehae176-B1144 ehae176-B1145" data-open="ehae176-B1143 ehae176-B1144 ehae176-B1145" class="link link-ref link-reveal xref-bibr">1143–1145</a></sup> For ease of clinical application, risk prediction tools have combined various factors, and have recently employed machine learning algorithms for prediction.<sup><span class="xrefLink" id="jumplink-ehae176-B1146"></span><a href="javascript:;" reveal-id="ehae176-B1146" data-open="ehae176-B1146" class="link link-ref link-reveal xref-bibr">1146</a>,<span class="xrefLink" id="jumplink-ehae176-B1147"></span><a href="javascript:;" reveal-id="ehae176-B1147" data-open="ehae176-B1147" class="link link-ref link-reveal xref-bibr">1147</a></sup> Classical risk scores are also available with variable predictive ability and model performance (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S7](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><span class="xrefLink" id="jumplink-ehae176-B1148"></span><a href="javascript:;" reveal-id="ehae176-B1148" data-open="ehae176-B1148" class="link link-ref link-reveal xref-bibr">1148</a></sup> Improved outcomes when using these risk scores have yet to be demonstrated. Although knowledge is rapidly increasing about the genetic basis for AF in some patients, the value of genetic screening is limited at the present time (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

### 10.5. Primary prevention of AF

Preventing the onset of AF before clinical manifestation has clear potential to improve the lives of the general population and reduce the considerable health and social care costs associated with development of AF. Whereas the \[C\] in AF-CARE is focused on the effective management of risk factors and comorbidities to limit AF recurrence and progression, there is also evidence they can be targeted to prevent AF. Available data are presented below for hypertension, heart failure, type 2 diabetes mellitus, obesity, sleep apnoea syndrome, physical activity, and alcohol, although many other risk markers can also be targeted. Further information on each factor's attributable risk for AF is provided in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Evidence Table 32](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[Additional Evidence Tables S34–S39](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

Recommendation Table 32

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884454)

Recommendations for primary prevention of AF (see also Evidence Table 32)

![Recommendations for primary prevention of AF (see also Evidence Table 32)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt32.jpeg?Expires=1728478929&Signature=i4GYu1g7SI9nhGSq4-5JHgNuoEtP3Zca8AgqjF9~Jm0Os9aEV9ryCtgOBc9VEbaYfQNu7XMdUJc5djhzff9e5F6rhFNOMW-LjG17r3LDo7P7gVH0Vid~JocPuzQl9H9UdELMgJhV~ALXxZB-i88lcTnthps3dl2vQH1-Fo8mko0E6axTDdIEgAvFjW5fCDcYx7El8zRdixtpTSFkEq6tUIGCcpOUe3PHblWq7~30x1NL5wBBtwIcGFFucm5BB90C0sx2Nlydmd3jI-otMhkLOFYboKcTq~oVjH0kZySOsv2ZUyPiNIJWlm0IBYfkvwbuJ6Il4zsMJtUNSQEaJYDY5A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Recommendation Table 32

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884454)

Recommendations for primary prevention of AF (see also Evidence Table 32)

![Recommendations for primary prevention of AF (see also Evidence Table 32)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176ilt32.jpeg?Expires=1728478929&Signature=i4GYu1g7SI9nhGSq4-5JHgNuoEtP3Zca8AgqjF9~Jm0Os9aEV9ryCtgOBc9VEbaYfQNu7XMdUJc5djhzff9e5F6rhFNOMW-LjG17r3LDo7P7gVH0Vid~JocPuzQl9H9UdELMgJhV~ALXxZB-i88lcTnthps3dl2vQH1-Fo8mko0E6axTDdIEgAvFjW5fCDcYx7El8zRdixtpTSFkEq6tUIGCcpOUe3PHblWq7~30x1NL5wBBtwIcGFFucm5BB90C0sx2Nlydmd3jI-otMhkLOFYboKcTq~oVjH0kZySOsv2ZUyPiNIJWlm0IBYfkvwbuJ6Il4zsMJtUNSQEaJYDY5A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 10.5.1. Hypertension

Management of hypertension has been associated with a reduction in incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1205 ehae176-B1206 ehae176-B1207"></span><a href="javascript:;" reveal-id="ehae176-B1205 ehae176-B1206 ehae176-B1207" data-open="ehae176-B1205 ehae176-B1206 ehae176-B1207" class="link link-ref link-reveal xref-bibr">1205–1207</a>,<span class="xrefLink" id="jumplink-ehae176-B1232"></span><a href="javascript:;" reveal-id="ehae176-B1232" data-open="ehae176-B1232" class="link link-ref link-reveal xref-bibr">1232</a></sup> In the LIFE (Losartan Intervention for End point reduction in hypertension) trial, a 10 mmHg reduction in systolic BP was associated with a 17% reduction in incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1207"></span><a href="javascript:;" reveal-id="ehae176-B1207" data-open="ehae176-B1207" class="link link-ref link-reveal xref-bibr">1207</a></sup> Secondary analysis of RCTs and observational studies suggest that ACE inhibitors or ARBs may be superior to beta-blockers, calcium channel blockers, or diuretics for the prevention of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1233 ehae176-B1234 ehae176-B1235 ehae176-B1236"></span><a href="javascript:;" reveal-id="ehae176-B1233 ehae176-B1234 ehae176-B1235 ehae176-B1236" data-open="ehae176-B1233 ehae176-B1234 ehae176-B1235 ehae176-B1236" class="link link-ref link-reveal xref-bibr">1233–1236</a></sup>

#### 10.5.2. Heart failure

Long-standing established pharmacological treatments for HFrEF have been associated with a reduction in incident AF. The use of ACE inhibitors or ARBs in patients with known HFrEF was associated with a 44% reduction in incidence of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1208"></span><a href="javascript:;" reveal-id="ehae176-B1208" data-open="ehae176-B1208" class="link link-ref link-reveal xref-bibr">1208</a></sup> Similarly, beta-blockers in HFrEF led to a 33% reduction in the odds of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B133"></span><a href="javascript:;" reveal-id="ehae176-B133" data-open="ehae176-B133" class="link link-ref link-reveal xref-bibr">133</a></sup> Mineralocorticoid receptor antagonists have also been shown to reduce the risk of new-onset AF by 42% in patients with HFrEF.<sup><span class="xrefLink" id="jumplink-ehae176-B1209"></span><a href="javascript:;" reveal-id="ehae176-B1209" data-open="ehae176-B1209" class="link link-ref link-reveal xref-bibr">1209</a></sup> Although there have been variable effects of SGLT2 inhibitors on incident AF, several meta-analyses have demonstrated that there is an 18%–37% reduction in incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B136"></span><a href="javascript:;" reveal-id="ehae176-B136" data-open="ehae176-B136" class="link link-ref link-reveal xref-bibr">136</a>,<span class="xrefLink" id="jumplink-ehae176-B1210"></span><a href="javascript:;" reveal-id="ehae176-B1210" data-open="ehae176-B1210" class="link link-ref link-reveal xref-bibr">1210</a>,<span class="xrefLink" id="jumplink-ehae176-B1211"></span><a href="javascript:;" reveal-id="ehae176-B1211" data-open="ehae176-B1211" class="link link-ref link-reveal xref-bibr">1211</a>,<span class="xrefLink" id="jumplink-ehae176-B1237"></span><a href="javascript:;" reveal-id="ehae176-B1237" data-open="ehae176-B1237" class="link link-ref link-reveal xref-bibr">1237</a></sup> However, treatment of HFrEF with sacubitril/valsartan has not yet been shown to confer any adjunctive benefit in reducing new-onset AF when compared with ACE inhibitors/ARBs alone.<sup><span class="xrefLink" id="jumplink-ehae176-B1238"></span><a href="javascript:;" reveal-id="ehae176-B1238" data-open="ehae176-B1238" class="link link-ref link-reveal xref-bibr">1238</a></sup> There is some evidence to suggest that effective CRT in eligible patients with HFrEF reduces the risk of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1239"></span><a href="javascript:;" reveal-id="ehae176-B1239" data-open="ehae176-B1239" class="link link-ref link-reveal xref-bibr">1239</a></sup> To date, no treatments in HFpEF have been shown to reduce incident AF.

#### 10.5.3. Type 2 diabetes mellitus

The integrated care of type 2 diabetes, based on lifestyle and pharmacological treatments for comorbidities such as obesity, hypertension, and dyslipidaemia, are useful steps in preventing atrial remodelling and subsequent AF. Intensive glucose-lowering therapy targeting an HbA1c level of <6.0% (<42 mmol/mol) failed to show a protective effect on incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1240"></span><a href="javascript:;" reveal-id="ehae176-B1240" data-open="ehae176-B1240" class="link link-ref link-reveal xref-bibr">1240</a></sup> More than glycaemic control _per se_, the class of glucose-lowering agent may influence the risk of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1240"></span><a href="javascript:;" reveal-id="ehae176-B1240" data-open="ehae176-B1240" class="link link-ref link-reveal xref-bibr">1240</a></sup> Insulin promotes adipogenesis and cardiac fibrosis, and sulfonylureas have been consistently associated with an increased risk of AF.<sup><span class="xrefLink" id="jumplink-ehae176-B193"></span><a href="javascript:;" reveal-id="ehae176-B193" data-open="ehae176-B193" class="link link-ref link-reveal xref-bibr">193</a></sup> Observational studies have associated metformin with lower rates of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1224"></span><a href="javascript:;" reveal-id="ehae176-B1224" data-open="ehae176-B1224" class="link link-ref link-reveal xref-bibr">1224</a>,<span class="xrefLink" id="jumplink-ehae176-B1225"></span><a href="javascript:;" reveal-id="ehae176-B1225" data-open="ehae176-B1225" class="link link-ref link-reveal xref-bibr">1225</a>,<span class="xrefLink" id="jumplink-ehae176-B1241 ehae176-B1242 ehae176-B1243"></span><a href="javascript:;" reveal-id="ehae176-B1241 ehae176-B1242 ehae176-B1243" data-open="ehae176-B1241 ehae176-B1242 ehae176-B1243" class="link link-ref link-reveal xref-bibr">1241–1243</a></sup> Various recent studies and meta-analyses point to the positive role of SGLT2 inhibitors to reduce the risk of incident AF in diabetic and non-diabetic patients.<sup><span class="xrefLink" id="jumplink-ehae176-B136"></span><a href="javascript:;" reveal-id="ehae176-B136" data-open="ehae176-B136" class="link link-ref link-reveal xref-bibr">136</a>,<span class="xrefLink" id="jumplink-ehae176-B1226"></span><a href="javascript:;" reveal-id="ehae176-B1226" data-open="ehae176-B1226" class="link link-ref link-reveal xref-bibr">1226</a>,<span class="xrefLink" id="jumplink-ehae176-B1244 ehae176-B1245 ehae176-B1246"></span><a href="javascript:;" reveal-id="ehae176-B1244 ehae176-B1245 ehae176-B1246" data-open="ehae176-B1244 ehae176-B1245 ehae176-B1246" class="link link-ref link-reveal xref-bibr">1244–1246</a></sup> Pooled data from 22 trials including 52 951 patients with type 2 diabetes and heart failure showed that SGLT2 inhibitors compared with placebo can significantly reduce the incidence of AF by 18% in studies on diabetes, and up to 37% in heart failure with or without type 2 diabetes.<sup><span class="xrefLink" id="jumplink-ehae176-B1210"></span><a href="javascript:;" reveal-id="ehae176-B1210" data-open="ehae176-B1210" class="link link-ref link-reveal xref-bibr">1210</a>,<span class="xrefLink" id="jumplink-ehae176-B1211"></span><a href="javascript:;" reveal-id="ehae176-B1211" data-open="ehae176-B1211" class="link link-ref link-reveal xref-bibr">1211</a></sup>

#### 10.5.4. Obesity

Management of weight is important in the prevention of AF. In a large population-based cohort study, normal weight was associated with a reduced risk of incident AF compared with those who were obese (4.7% increase in the risk of incident AF for each 1 kg/m<sup>2</sup> increase of BMI).<sup><span class="xrefLink" id="jumplink-ehae176-B208"></span><a href="javascript:;" reveal-id="ehae176-B208" data-open="ehae176-B208" class="link link-ref link-reveal xref-bibr">208</a></sup> In the Women's Health Study, participants who became obese had a 41% increased risk of incident AF compared with those who maintained their BMI <30 kg/m<sup>2</sup>.<sup><span class="xrefLink" id="jumplink-ehae176-B1212"></span><a href="javascript:;" reveal-id="ehae176-B1212" data-open="ehae176-B1212" class="link link-ref link-reveal xref-bibr">1212</a></sup> Similarly, observational studies in populations using bariatric surgery for weight loss in morbidly obese individuals (BMI ≥40 kg/m<sup>2</sup>) have observed a lower risk of incident AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1227 ehae176-B1228 ehae176-B1229 ehae176-B1230 ehae176-B1231"></span><a href="javascript:;" reveal-id="ehae176-B1227 ehae176-B1228 ehae176-B1229 ehae176-B1230 ehae176-B1231" data-open="ehae176-B1227 ehae176-B1228 ehae176-B1229 ehae176-B1230 ehae176-B1231" class="link link-ref link-reveal xref-bibr">1227–1231</a></sup>

#### 10.5.5. Sleep apnoea syndrome

Although it would seem rational to optimize sleep habits, to date there is no conclusive evidence to support this for the primary prevention of AF. The SAVE (Sleep Apnea cardioVascular Endpoints) trial failed to demonstrate a difference in clinical outcomes in those randomized to CPAP therapy or placebo.<sup><span class="xrefLink" id="jumplink-ehae176-B230"></span><a href="javascript:;" reveal-id="ehae176-B230" data-open="ehae176-B230" class="link link-ref link-reveal xref-bibr">230</a></sup> There was no difference in incident AF, albeit the analysis of AF was not based on systematic screening but rather on clinically documented AF.

#### 10.5.6. Physical activity

Several studies have demonstrated beneficial effects of moderate physical activity on cardiovascular health.<sup><span class="xrefLink" id="jumplink-ehae176-B1247"></span><a href="javascript:;" reveal-id="ehae176-B1247" data-open="ehae176-B1247" class="link link-ref link-reveal xref-bibr">1247</a></sup> Moderate aerobic exercise may also reduce the risk of new-onset AF.<sup><span class="xrefLink" id="jumplink-ehae176-B1214 ehae176-B1215 ehae176-B1216 ehae176-B1217 ehae176-B1218 ehae176-B1219"></span><a href="javascript:;" reveal-id="ehae176-B1214 ehae176-B1215 ehae176-B1216 ehae176-B1217 ehae176-B1218 ehae176-B1219" data-open="ehae176-B1214 ehae176-B1215 ehae176-B1216 ehae176-B1217 ehae176-B1218 ehae176-B1219" class="link link-ref link-reveal xref-bibr">1214–1219</a></sup> It should be noted that the incidence of AF appears to be increased among athletes, with a meta-analysis of observational studies showing a 2.5-fold increased risk of AF compared with non-athlete controls.<sup><span class="xrefLink" id="jumplink-ehae176-B1248"></span><a href="javascript:;" reveal-id="ehae176-B1248" data-open="ehae176-B1248" class="link link-ref link-reveal xref-bibr">1248</a></sup>

#### 10.5.7. Alcohol intake

The premise that reducing alcohol intake can prevent AF is based on observational studies linking alcohol to an excess risk of incident AF in a dose-dependent manner (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478929&Signature=gD8mn9S8DxHqTtexxcVwrI-4PNcxLJ-EzF~qFqRXgn4aivGG6JUCFkST6XQqfCeFSP6uOHkg5BgPiIkDlXbAsQikZb97vDNYJ-yOmhnwlZdMHo42uPiQoQsNMkgsFDR~6~FLkWnr24OsYPFy41ygD0d1J1~0v7qTJsdBa9KXxToAcQ0PQ7lL5nEfaB3fl~mp4AZ776Fzo2XhT13Gr16LgqrCGkwgfujF8GRXLifzwAcms1asg3ksIXVxE2OwOy~6XtS4Muky-Ljx2Y2ytjg~LGlG8ZAeaEpr-JgTpQY9EVmyStd7jPKr1JO2PBiiniQIQoBQT7PGyovPTOH4nwXLhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><span class="xrefLink" id="jumplink-ehae176-B1220 ehae176-B1221 ehae176-B1222"></span><a href="javascript:;" reveal-id="ehae176-B1220 ehae176-B1221 ehae176-B1222" data-open="ehae176-B1220 ehae176-B1221 ehae176-B1222" class="link link-ref link-reveal xref-bibr">1220–1222</a></sup> In addition, a population cohort study of those with high alcohol consumption (>60 g/day for men and >40 g/day for women) found that abstinence from alcohol was associated with a lower incidence of AF compared with patients who continued heavy drinking.<sup><span class="xrefLink" id="jumplink-ehae176-B1223"></span><a href="javascript:;" reveal-id="ehae176-B1223" data-open="ehae176-B1223" class="link link-ref link-reveal xref-bibr">1223</a></sup>

## 11\. Key messages

1.General management: optimal treatment according to the AF-CARE pathway, which includes: \[C\] Comorbidity and risk factor management; \[A\] Avoid stroke and thromboembolism; \[R\] Reduce symptoms by rate and rhythm control; and \[E\] Evaluation and dynamic reassessment.

2.Shared care: patient-centred AF management with joint decision-making and a multidisciplinary team.

3.Equal care: avoid health inequalities based on gender, ethnicity, disability, and socioeconomic factors.

4.Education: for patients, family members, caregivers, and healthcare professionals to aid shared decision-making.

5.Diagnosis: clinical AF requires confirmation on an ECG device to initiate risk stratification and AF management.

6.Initial evaluation: medical history, assessment of symptoms and their impact, blood tests, echocardiography/other imaging, patient-reported outcome measures, and risk factors for thromboembolism and bleeding.

7.Comorbidities and risk factors: thorough evaluation and management critical to all aspects of care for patients with AF to avoid recurrence and progression of AF, improve success of AF treatments, and prevent AF-related adverse outcomes.

8.Focus on conditions associated with AF: including hypertension, heart failure, diabetes mellitus, obesity, obstructive sleep apnoea, physical inactivity, and high alcohol intake.

9.Assessing the risk of thromboembolism: use locally validated risk tools or the CHA<sub>2</sub>DS<sub>2</sub>\-VA score and assessment of other risk factors, with reassessment at periodic intervals to assist in decisions on anticoagulant prescription.

10.Oral anticoagulants: recommended for all eligible patients, except those at low risk of incident stroke or thromboembolism (CHA<sub>2</sub>DS<sub>2</sub>\-VA = 1 anticoagulation should be considered; CHA<sub>2</sub>DS<sub>2</sub>\-VA ≥2 anticoagulation recommended).

11.Choice of anticoagulant: DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are preferred over VKAs (warfarin and others), except in patients with mechanical heart valves and mitral stenosis.

12.Dose/range of anticoagulant: use full standard doses for DOACs unless the patient meets specific dose-reduction criteria; for VKAs, keep INR generally 2.0–3.0, and in range for >70% of the time.

13.Switching anticoagulants: switch from a VKA to DOAC if risk of intracranial haemorrhage or poor control of INR levels.

14.Bleeding risk: modifiable bleeding risk factors should be managed to improve safety; bleeding risk scores should not be used to decide on starting or withdrawing anticoagulants.

15.Antiplatelet therapy: avoid combining anticoagulants and antiplatelet agents, unless the patient has an acute vascular event or needs interim treatment for procedures.

16.Rate control therapy: use beta-blockers (any ejection fraction), digoxin (any ejection fraction), or diltiazem/verapamil (LVEF >40%) as initial therapy in the acute setting, an adjunct to rhythm control therapies, or as a sole treatment strategy to control heart rate and symptoms.

17.Rhythm control: consider in all suitable AF patients, explicitly discussing with patients all potential benefits and risks of cardioversion, antiarrhythmic drugs, and catheter or surgical ablation to reduce symptoms and morbidity.

18.Safety first: keep safety and anticoagulation in mind when considering rhythm control; e.g. delay cardioversion and provide at least 3 weeks of anticoagulation beforehand if AF duration >24 h, and consider toxicity and drug interactions for antiarrhythmic therapy.

19.Cardioversion: use electrical cardioversion in cases of haemodynamic instability; otherwise choose electrical or pharmacological cardioversion based on patient characteristics and preferences.

20.Indication for long-term rhythm control: the primary indication should be reduction in AF-related symptoms and improvement in quality of life; for selected patient groups, sinus rhythm maintenance can be pursued to reduce morbidity and mortality.

21.Success or failure of rhythm control: continue anticoagulation according to the patient's individual risk of thromboembolism, irrespective of whether they are in AF or sinus rhythm.

22.Catheter ablation: consider as second-line option if antiarrhythmic drugs fail to control AF, or first-line option in patients with paroxysmal AF.

23.Endoscopic or hybrid ablation: consider if catheter ablation fails, or an alternative to catheter ablation in persistent AF despite antiarrhythmic drugs.

24.Atrial fibrillation ablation during cardiac surgery: perform in centres with experienced teams, especially for patients undergoing mitral valve surgery.

25.Dynamic evaluation: periodically reassess therapy and give attention to new modifiable risk factors that could slow/reverse the progression of AF, increase quality of life, and prevent adverse outcomes.


## 12\. Gaps in evidence

The following bullet list gives the most important gaps in evidence where new clinical trials could substantially aid the patient pathway:

**Definition and clinical impact of AF**

- Paroxysmal AF is not one entity, and patterns of AF progression and regression are highly variable. It is uncertain what the relevance is for treatment strategies and management decisions.

- Thirty seconds as definition for clinical AF needs validation and evaluation whether it is related to AF-related outcomes.

- Definition, clinical features, diagnosis, and implementation for treatment choices of atrial cardiomyopathy in patients with AF is unsettled.

- Diversity in AF presentation, underlying pathophysiological mechanisms, and associated comorbidities is incompletely understood with regard to differences in sex, gender, race/ethnicity, socioeconomic state, education, and differences between low-, moderate-, and high-income countries.

- Personalized risk prediction for AF incidence, AF progression, and associated outcomes remains challenging.

- Insights into psychosocial and environmental factors and risk of AF and adverse outcomes in AF are understudied.


**Patient-centred, multidisciplinary AF management**

- The benefit of additional education directed to patients, to family members, and to healthcare professionals in order to optimize shared decision-making still needs to be proved.

- Access to patient-centred management according to the AF-CARE principles to ensure equality in healthcare provision and improve outcomes warrants evidence.

- The place of remote monitoring and telemedicine for identification and follow-up of patients with AF, or its subgroups is non-established, though widely applied.


**\[C\] Comorbidity and risk factor management**

- Methods to achieve consistent and reproducible weight loss in patients with AF requires substantial improvement. Despite some evidence demonstrating the benefits of weight loss, widespread adoption has been limited by the need for reproducible strategies.

- The importance of sleep apnoea syndrome and its treatment on AF-related outcomes remains to be elucidated.


**\[A\] Avoid stroke and thromboembolism**

- Data are lacking on how to treat patients with low risk of stroke (with a CHA<sub>2</sub>DS<sub>2</sub>\-VA score of 0 or 1), as these patients were excluded from large RCTs.

- Not enough evidence is available for OAC in elderly patients, frail polypharmacy patients, those with cognitive impairment/dementia, recent bleeding, previous ICH, severe end-stage renal failure, liver impairment, cancer, or severe obesity.

- In elderly patients, routinely switching VKAs to DOACs is associated with increased bleeding risk; however, the reasons why this happens are unclear.

- The selection of which patients with asymptomatic device-detected subclinical AF benefit from OAC therapy needs to be defined.

- There is a lack of evidence whether and when to (re)start anticoagulation after intracranial haemorrhage.

- There is lack of evidence about optimal anticoagulation in patients with ischaemic stroke or left atrial thrombus while being treated with OAC.

- There is uncertainty about the place of LAA closure and how to manage antithrombotic post-procedural management when LAAO is performed.

- Balance of thromboembolism and bleeding is unclear in patients with AF and incidental cerebral artery aneurysms identified on brain MRI.


**\[R\] Reduce symptoms by rate and rhythm control**

- In some patients, AF can be benign in terms of symptoms and outcomes. In which patients rhythm control is not needed warrants investigation.

- Application of antiarrhythmic drugs has been hampered by poor effectiveness and side effects; however, new antiarrhythmic drugs are needed to increase the therapeutic arsenal for AF patients.

- The amount of AF reduction obtained by rhythm control to improve outcomes is unknown.

- Large catheter ablation studies showed no improved outcome of patients with AF. Some small studies in specific subpopulations have observed an improved outcome. This warrants further investigation to provide each patient with AF with personalized treatment goals.

- Uncertainty exists on the time of duration of AF and risk of stroke when performing a cardioversion.

- The value of diagnostic cardioversion for persistent AF in steering management of AF is unknown.

- Decisions on continuation of OAC are completely based on stroke risk scores and irrespective of having (episodes) of AF; whether this holds for patients undergoing successful catheter ablation is uncertain.

- Large variability in ablation strategies and techniques exist for patients with persistent AF, or after first failed catheter ablation for paroxysmal AF. The optimal catheter ablation strategy and techniques, however, are unknown.

- Sham-controlled intervention studies are lacking to determine the effects on AF symptoms, quality of life, and PROMS, accounting for the placebo effect that is associated with interventions.


**The AF-CARE pathway in specific clinical settings**

- The optimal duration of triple therapy in patients with AF at high risk of recurrent coronary events after acute coronary syndrome is unclear.

- The role of the coronary vessel involved and whether this should impact on the duration of combined OAC and antiplatelet treatment needs further study.

- The role of antiplatelet therapy in patients with AF and peripheral artery disease on OAC is uncertain.

- The use of DOACs in patients with congenital heart disease, particularly in patients with complex corrected congenital defects, is poorly studied.

- Improved risk stratification for stroke in patients with AF and cancer, or with post-operative or trigger-induced AF is needed to inform on OAC treatment decisions.


**Screening and prevention of AF**

- There are a lack of adequately powered randomized controlled studies on ischaemic stroke rate in patients screened for AF, both in the primary prevention setting and in secondary prevention (post-stroke), and its cost-effectiveness.

- Population selection that might benefit the most from screening, the optimal duration of screening, and the burden of AF that might increase the risk for patients with screening-detected AF are uncertain.

- Evaluation of strategies to support longer-term use of technologies for AF detection are awaited.

- The role of photoplethysmography technology for AF screening in an effort to assess AF burden and reduce stroke is still unclear.

- How new consumer devices and wearable technology can be used for diagnostic and monitoring purposes in routine clinical practice needs to be clarified.


## 13\. ‘What to do’ and ‘What not to do’ messages from the guidelines

_[Table 17](javascript:;)_ lists all Class I and Class III recommendations from the text alongside their level of evidence.

Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884489)

‘What to do’ and ‘what not to do’

![‘What to do’ and ‘what not to do’](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t17.jpeg?Expires=1728478929&Signature=2Q-OXh7gcnSvLhb~elpZuvwPcWUoP19mETbvgOyDeM2i-qgNZsrDuCvzczGHJlFE~wD5eqqUIIWtNahwIf2EX-I5XE4Ftu97Tw4r6B8N87Ac8HwbvpOHttsxAmRpfO9LjIJGeT93v0htjJZnZ756kvAzkIfzOx8gqXd10vK6zyO-czEegDJwsD2Dal8Bms10U66MpRr8QhNS5~09xOaJHht6KUuxIqDg~Akxb5k5SkosOmo6euCxoz2ccJaSJ2wrZTMJqez4qBk~7yddBTiDWkSPwAhSkZSUtGhiMMpVN9ToiX5Nq9R2zEqiuVRTI-Mw-Qm8~79mbjyHt3qcPWzBwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae176/7738779?login=false
/view-large/479884489)

‘What to do’ and ‘what not to do’

![‘What to do’ and ‘what not to do’](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176t17.jpeg?Expires=1728478929&Signature=2Q-OXh7gcnSvLhb~elpZuvwPcWUoP19mETbvgOyDeM2i-qgNZsrDuCvzczGHJlFE~wD5eqqUIIWtNahwIf2EX-I5XE4Ftu97Tw4r6B8N87Ac8HwbvpOHttsxAmRpfO9LjIJGeT93v0htjJZnZ756kvAzkIfzOx8gqXd10vK6zyO-czEegDJwsD2Dal8Bms10U66MpRr8QhNS5~09xOaJHht6KUuxIqDg~Akxb5k5SkosOmo6euCxoz2ccJaSJ2wrZTMJqez4qBk~7yddBTiDWkSPwAhSkZSUtGhiMMpVN9ToiX5Nq9R2zEqiuVRTI-Mw-Qm8~79mbjyHt3qcPWzBwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 14\. Evidence tables

[Evidence tables](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478929&Signature=2Awpp-KSQvAwcYVnlXvYAuBopKy9F2TOXCDN1xlr-dM8BBBBxiPun7BHi8K33tb5YvSfmP7A1X1~btFTmz~~K0H8vaKDsb7OE0bnz5q~2pt1TX6mTjfuRv4e1kVbRDQjH~X7-MqiuTvl6nO~Eoxh~ErBVSjkuRCnXG88Ok~4wxGe8be-Q1bHIrAVQVHvaHxUZIs6R-KFDuVwtL8uuN23JMiFHhk65JF8D-V-f7D6rg~E2OtgCinvPP-gChsJfZ0Y9VRmkhujjP~JbJpebgpHnjAX12VWU1SlQFxMp8Fz2WLZPJ55pcxP5udgHD~XYgJs3YUxnioV4AdaCqIiqMiB2Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) are available at _European Heart Journal_ online.

## 15\. Data availability statement

No new data were generated or analysed in support of this research.

## 16\. Author information

**Author/Task Force Member Affiliations: Michiel Rienstra**, Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands; **Karina V. Bunting**, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom, Cardiology Department, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; **Ruben Casado-Arroyo**, Department of Cardiology, H.U.B.-Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; **Valeria Caso**, Stroke Unit, Santa della Misericordia Hospital, Perugia, Italy; **Harry J.G.M. Crijns**, Cardiology Maastricht University Medical Centre, Maastricht, Netherlands, Cardiology Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands; **Tom J. R. De Potter**, Department of Cardiology, OLV Hospital, Aalst, Belgium; **Jeremy Dwight** (United Kingdom), ESC Patient Forum, Sophia Antipolis, France; **Luigina Guasti**, Department of Medicine and Surgery, University of Insubria, Varese, Italy, Division of Geriatrics and Clinical Gerontology, ASST-Settelaghi, Varese, Italy; **Thorsten Hanke**, Clinic For Cardiac Surgery, Asklepios Klinikum, Harburg, Hamburg, Germany; **Tiny Jaarsma**, Department of Cardiology, Linkoping University, Linkoping, Sweden, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; **Maddalena Lettino**, Department for Cardiac, Thoracic and Vascular Diseases, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; **Maja-Lisa Løchen**, Deparment of Clincal Medicine UiT, The Arctic University of Norway, Tromsø, Norway, Department of Cardiology, University Hospital of North Norway, Tromsø, Norway; **R. Thomas Lumbers**, Institute of Health Informatics, University College London, London, United Kingdom, Saint Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom, University College Hospital, University College London Hospitals NHS Trust, London, United Kingdom; **Bart Maesen**, Department of Cardiothoracic Surgery, Maastricht University Medical Centre+, Maastricht, Netherlands, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands; **Inge Mølgaard** (Denmark), ESC Patient Forum, Sophia Antipolis, France; **Giuseppe M.C. Rosano**, Department of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome, Rome, Italy, Cardiology, San Raffaele Cassino Hospital, Cassino, Italy, Cardiovascular Academic Group, St George's University Medical School, London, United Kingdom; **Prashanthan Sanders**, Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, Australia, Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia; **Renate B. Schnabel**, Cardiology University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, German Center for Cardiovascular Research (DZHK) Partner site Hamburg/Kiel/Lübeck, Germany; **Piotr Suwalski**, Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Centre of Postgraduate Medical Education, Warsaw, Poland; **Emma Svennberg**, Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden; **Juan Tamargo**, Pharmacology and Toxicology School of Medicine, Universidad Complutense, Madrid, Spain; **Otilia Tica**, Department of Cardiology, Emergency County Clinical Hospital of Bihor, Oradea, Romania, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; **Vassil Traykov**, Department of Invasive Electrophysiology, Acibadem City Clinic Tokuda University Hospital, Sofia, Bulgaria; and **Stylianos Tzeis**, Cardiology Department, Mitera Hospital, Athens, Greece.

### 17\. Appendix

**ESC Scientific Document Group**

Includes Document Reviewers and ESC National Cardiac Societies.

**Document Reviewers:** Nikolaos Dagres (CPG Review Co-ordinator) (Germany), Bianca Rocca (CPG Review Co-ordinator) (Italy), Syed Ahsan (United Kingdom), Pietro Ameri (Italy), Elena Arbelo (Spain), Axel Bauer (Austria), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Barbara Casadei (United Kingdom), Ovidiu Chioncel (Romania), Dobromir Dobrev (Germany), Laurent Fauchier (France), Bruna Gigante (Sweden), Michael Glikson (Israel), Ziad Hijazi (Sweden), Gerhard Hindricks (Germany), Daniela Husser (Germany), Borja Ibanez (Spain), Stefan James (Sweden), Stefan Kaab (Germany), Paulus Kirchhof (Germany), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Thomas Kumler (Denmark), Gregory Y.H. Lip (United Kingdom), John Mandrola (United States of America), Nikolaus Marx (Germany), John William Mcevoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Denisa Muraru (Italy), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Jonas Oldgren (Sweden), Maurizio Paciaroni (Italy), Agnes A. Pasquet (Belgium), Eva Prescott (Denmark), Filip Rega (Belgium), Francisco Javier Rossello (Spain), Marcin Rucinski (Poland), Sacha P. Salzberg (Switzerland), Sam Schulman (Canada), Philipp Sommer (Germany), Jesper Hastrup Svendsen (Denmark), Jurrien M. ten Berg (Netherlands), Hugo Ten Cate (Netherlands), Ilonca Vaartjes (Netherlands), Christiaan Jm. Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands).

**ESC National Cardiac Societies** actively involved in the review process of the 2024 ESC Guidelines for the management of atrial fibrillation:

**Albania**: Albanian Society of Cardiology, Leonard Simoni; **Algeria**: Algerian Society of Cardiology, Brahim Kichou; **Armenia**: Armenian Cardiologists Association, Hamayak S. Sisakian; **Austria**: Austrian Society of Cardiology, Daniel Scherr; **Belgium**: Belgian Society of Cardiology, Frank Cools; **Bosnia and Herzegovina**: Association of Cardiologists of Bosnia and Herzegovina, Elnur Smajić; **Bulgaria**: Bulgarian Society of Cardiology, Tchavdar Shalganov; **Croatia**: Croatian Cardiac Society, Sime Manola; **Cyprus**: Cyprus Society of Cardiology, Panayiotis Avraamides; **Czechia**: Czech Society of Cardiology, Milos Taborsky; **Denmark**: Danish Society of Cardiology, Axel Brandes; **Egypt**: Egyptian Society of Cardiology, Ahmed M. El-Damaty; **Estonia**: Estonian Society of Cardiology, Priit Kampus; **Finland**: Finnish Cardiac Society, Pekka Raatikainen; **France**: French Society of Cardiology, Rodrigue Garcia; **Georgia**: Georgian Society of Cardiology, Kakhaber Etsadashvili; **Germany**: German Cardiac Society, Lars Eckardt; **Greece**: Hellenic Society of Cardiology, Eleftherios Kallergis; **Hungary**: Hungarian Society of Cardiology, László Gellér; **Iceland**: Icelandic Society of Cardiology, Kristján Guðmundsson; **Ireland**: Irish Cardiac Society, Jonathan Lyne; **Israel**: Israel Heart Society, Ibrahim Marai; **Italy**: Italian Federation of Cardiology, Furio Colivicchi; **Kazakhstan**: Association of Cardiologists of Kazakhstan, Ayan Suleimenovich Abdrakhmanov; **Kosovo (Republic of)**: Kosovo Society of Cardiology, Ibadete Bytyci; **Kyrgyzstan**: Kyrgyz Society of Cardiology, Alina Kerimkulova; **Latvia**: Latvian Society of Cardiology, Kaspars Kupics; **Lebanon**: Lebanese Society of Cardiology, Marwan Refaat; **Libya**: Libyan Cardiac Society, Osama Abdulmajed Bheleel; **Lithuania**: Lithuanian Society of Cardiology, Jūratė Barysienė; **Luxembourg**: Luxembourg Society of Cardiology, Patrick Leitz; **Malta**: Maltese Cardiac Society, Mark A. Sammut; **Moldova (Republic of)**: Moldavian Society of Cardiology, Aurel Grosu; **Montenegro**: Montenegro Society of Cardiology, Nikola Pavlovic; **Morocco**: Moroccan Society of Cardiology, Abdelhamid Moustaghfir; **Netherlands**: Netherlands Society of Cardiology, Sing-Chien Yap; **North Macedonia**: National Society of Cardiology of North Macedonia, Jane Taleski; **Norway**: Norwegian Society of Cardiology, Trine Fink; **Poland**: Polish Cardiac Society, Jaroslaw Kazmierczak; **Portugal**: Portuguese Society of Cardiology, Victor M. Sanfins; **Romania**: Romanian Society of Cardiology, Dragos Cozma; **San Marino**: San Marino Society of Cardiology, Marco Zavatta; **Serbia**: Cardiology Society of Serbia, Dragan V. Kovačević; **Slovakia**: Slovak Society of Cardiology, Peter Hlivak; **Slovenia**: Slovenian Society of Cardiology, Igor Zupan; **Spain**: Spanish Society of Cardiology, David Calvo; **Sweden**: Swedish Society of Cardiology, Anna Björkenheim; **Switzerland:** Swiss Society of Cardiology, Michael Kühne; **Tunisia**: Tunisian Society of Cardiology and Cardiovascular Surgery, Sana Ouali; **Turkey**: Turkish Society of Cardiology, Sabri Demircan; **Ukraine**: Ukrainian Association of Cardiology, Oleg S. Sychov; **United Kingdom of Great Britain and Northern Ireland**: British Cardiovascular Society, Andre Ng; and **Uzbekistan**: Association of Cardiologists of Uzbekistan, Husniddin Kuchkarov.

**ESC Clinical Practice Guidelines (CPG) Committee:** Eva Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) (Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands). Andrea Sarkozy\* (Belgium) _\*Contributor either stepped down or was engaged in only a part of the review process._

## 18\. References

## Author notes

Isabelle C Van Gelder and Dipak Kotecha Chairpersons contributed equally to the document and are joint corresponding authors.

Michiel Rienstra and Karina V Bunting Task Force Co-ordinators contributed equally to the document.

**Author/Task Force Member affiliations are listed in author information.**

Representing European Stroke Organisation (ESO).

Representing European Association for Cardio-Thoracic Surgery (EACTS).

**ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.**

**ESC subspecialty communities having participated in the development of this document:**

**Associations:** Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

**Councils:** Council for Cardiology Practice, Council of Cardio-Oncology, Council on Cardiovascular Genomics, Council on Stroke.

**Working Groups:** Cardiac Cellular Electrophysiology, Cardiovascular Pharmacotherapy, E-Cardiology, Thrombosis.

**Patient Forum**

  ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/m_ehae176il3.jpeg?Expires=1728478928&Signature=b8EXSSoYiZSs2eV1M4JryJE~7183OIpBkS5PJCvFlDevadWt~6Lmxl1yWaKA2qr0PLinxPFFd3eGNSx5gwdV35a8VOF7kA-lkiBW-eYEEtyUOyNldz~J-rMWD52FuvkGmW8Yh1MDBkwKtnoeOq2NeHzxgbL8usJLibzceXgSv4HbzUjn2NraEI8mvHerlaSKar6oJxrJkb024JxxVJmjCaD46CXtWDfXP51bzWBLdi9k0gStSwHmtU75BiAQ10XBUWFyDR165QNn380cws3wt4Z1ge5lsIvyyorFl5Ldc3rECMR0V4XGEcJJ0v7ZtCEfi-CGaHZMfTzuB4Ss-qkwKw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  **All experts involved in the development of these guidelines have submitted declarations of interest which are reported in a supplementary document to the guidelines. See the _European Heart Journal_ online or [www.escardio.org/guidelines](https://www.escardio.org/Guidelines) for supplementary documents as well as evidence tables.**

**Disclaimer.** The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.

**Permissions.** The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the _European Heart Journal_ and the party authorized to handle such permissions on behalf of the ESC ([journals.permissions@oup.com](mailto:journals.permissions@oup.com)).

© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ([https://academic.oup.com/pages/standard-publication-reuse-rights](https://academic.oup.com/pages/standard-publication-reuse-rights))

[Download all slides](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=&PPTtype=SlideSet&ar=7738779&xsltPath=~/UI/app/XSLT&siteId=5375)

## Supplementary data

[ehae176\_Supplementary\_Data](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/ehae176_supplementary_data.pdf?Expires=1728478930&Signature=ghcq3T3R~y6OPFOt-UD-LShlzfsAGhfuHZSZR1iskTZp0kP9wFQHo9MM1QQpDT4DO2cFrvlH7UNpu0bf8zfwx1mgS2IDOJ35Uczula2cgRPnYA-WELhJkeefITYNM0pYArtKASszKBFSkZWz2hrILtLqnsgFwcgJwzkTf3WCN64k1ORC5zHr0emEDNcekP71YyFICwqimiGRbm2a2dDD8~yjRzYsvyS928cR04ZnN4-kqIa4AuGNTlG4TAixpL1ieydrE5nPherSLSwhgT2h2V8R4Pr1RIy5R6gbqVR~Lci8vCdKyOX76uXnauntnoFBanKF8-ATIVmSqiYBbAwYow__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[2024\_AFIB\_GIs\_Evidence\_tables\_Final](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/2024_afib_gis_evidence_tables_final.pdf?Expires=1728478930&Signature=2xU1cCFUkxr7sZEA3tsnMZFkibl1YCqDeTJFKZkoDdYK7cqQIq5H7gZ7aHxuIr8TVuGNIpqtHMkRNhO~Z1-lsSYCC92h6SQMJss2LUnUv~mLwLTxqX4vu-izXqwxMCnbRnoaYx6vWmB6ySqUicmx1i4jPZLqJTa7x7IIjRaU0RDlr7joMhd5rw2pFuOipIC6LdSUJurmjRRg-oZwZ3jqRr1F89js5f6stN-IKScNxEUF6DtJ2nklV~nZ8WAqXTpLI3IpvjKo8W5cMGPcpXfhur2NpYT4ggIPpj4c5oYy~cX-y90-UCNKBH5ZHWPv9qDY~JPkycYOO8cEOdUpGatD8Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[DOI\_summary\_2024\_ESC\_Guidelines\_AFIB\_EHAE176](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae176/4/doi_summary_2024_esc_guidelines_afib_ehae176.pdf?Expires=1728478930&Signature=FSDZdGNR9z9VL2sjnN7vy5XuyaCwcDyrwtbrEgdPQ5tyXdO9SrDlLoFjz~PimnFUG0jJMY~jd83YQ7H5wvh7-UVmjeIShb204SUhjMXWZXeob88S~rp6I76B2233Yz3VrnjI4JpUHaQeUPyeiMO4OiCRPoHSJbVxwN4xSD8ujaTeORRBgmavOe9axyMPbmz5kHWA8vzS6K74sSKRLScgcNUoQ~2AnfcHci3uMmdXLn2b5uPBjHVAs64i2gjojdblniXeZqy~fISw-KdpeEnlLxoNKzVN9iNbf~RCtZYJzRrcl19RUY9-H3qe9ZSVO7vjTDHEs11aAdGSfpf6P~Sfug__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file
